
<html lang="en"     class="pb-page"  data-request-id="2219e423-7ec5-4709-8c23-30c3d9a5dca4"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2018.61.issue-6;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/acs.jmedchem.7b01712"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton’s Tyrosine Kinase Inhibitor in Early Clinical Development" /></meta><meta name="dc.Creator" content="James J.  Crawford" /></meta><meta name="dc.Creator" content="Adam R.  Johnson" /></meta><meta name="dc.Creator" content="Dinah L.  Misner" /></meta><meta name="dc.Creator" content="Lisa D.  Belmont" /></meta><meta name="dc.Creator" content="Georgette  Castanedo" /></meta><meta name="dc.Creator" content="Regina  Choy" /></meta><meta name="dc.Creator" content="Melis  Coraggio" /></meta><meta name="dc.Creator" content="Liming  Dong" /></meta><meta name="dc.Creator" content="Charles  Eigenbrot" /></meta><meta name="dc.Creator" content="Rebecca  Erickson" /></meta><meta name="dc.Creator" content="Nico  Ghilardi" /></meta><meta name="dc.Creator" content="Jonathan  Hau" /></meta><meta name="dc.Creator" content="Arna  Katewa" /></meta><meta name="dc.Creator" content="Pawan Bir  Kohli" /></meta><meta name="dc.Creator" content="Wendy  Lee" /></meta><meta name="dc.Creator" content="Joseph W.  Lubach" /></meta><meta name="dc.Creator" content="Brent S.  McKenzie" /></meta><meta name="dc.Creator" content="Daniel F.  Ortwine" /></meta><meta name="dc.Creator" content="Leah  Schutt" /></meta><meta name="dc.Creator" content="Suzanne  Tay" /></meta><meta name="dc.Creator" content="BinQing  Wei" /></meta><meta name="dc.Creator" content="Karin  Reif" /></meta><meta name="dc.Creator" content="Lichuan  Liu" /></meta><meta name="dc.Creator" content="Harvey  Wong" /></meta><meta name="dc.Creator" content="Wendy B.  Young" /></meta><meta name="dc.Description" content="Bruton’s tyrosine kinase (Btk) is a nonreceptor cytoplasmic tyrosine kinase involved in B-cell and myeloid cell activation, downstream of B-cell and Fcγ receptors, respectively. Preclinical studies..." /></meta><meta name="Description" content="Bruton’s tyrosine kinase (Btk) is a nonreceptor cytoplasmic tyrosine kinase involved in B-cell and myeloid cell activation, downstream of B-cell and Fcγ receptors, respectively. Preclinical studies..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="February 19, 2018" /></meta><meta name="dc.Type" content="news" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.7b01712" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2018 American Chemical Society" /></meta><meta name="citation_fulltext_world_readable" content=""/></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b01712" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.7b01712" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b01712" /></link>
        
    
    

<title>Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton’s Tyrosine Kinase Inhibitor in Early Clinical Development | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.7b01712" /></meta><meta property="og:title" content="Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton’s Tyrosine Kinase Inhibitor in Early Clinical Development" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/large/jm-2017-017125_0024.jpeg" /></meta><meta property="og:description" content="Bruton’s tyrosine kinase (Btk) is a nonreceptor cytoplasmic tyrosine kinase involved in B-cell and myeloid cell activation, downstream of B-cell and Fcγ receptors, respectively. Preclinical studies have indicated that inhibition of Btk activity might offer a potential therapy in autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus. Here we disclose the discovery and preclinical characterization of a potent, selective, and noncovalent Btk inhibitor currently in clinical development. GDC-0853 (29) suppresses B cell- and myeloid cell-mediated components of disease and demonstrates dose-dependent activity in an in vivo rat model of inflammatory arthritis. It demonstrates highly favorable safety, pharmacokinetic (PK), and pharmacodynamic (PD) profiles in preclinical and Phase 2 studies ongoing in patients with rheumatoid arthritis, lupus, and chronic spontaneous urticaria. On the basis of its potency, selectivity, long target residence time, and noncovalent mode of inhibition, 29 has the potential to be a best-in-class Btk inhibitor for a wide range of immunological indications." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.7b01712"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b01712">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.7b01712&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.7b01712&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.7b01712&amp;href=/doi/10.1021/acs.jmedchem.7b01712" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2018</span><span class="cit-fg-volume">, 61</span><span class="cit-fg-issue">, 6</span><span class="cit-fg-pageRange">, 2227-2245</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/61/6" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.7b00734" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Drug Annotation</span><a href="/doi/10.1021/acs.jmedchem.7b01285" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton’s Tyrosine Kinase Inhibitor in Early Clinical Development</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">James J. Crawford</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">James J. Crawford</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#d9baabb8aebfb6abbdf7b3b8b4bcaa99bebcb7bcf7bab6b4"><span class="__cf_email__" data-cfemail="eb88998a9c8d84998fc5818a868e98ab8c8e858ec5888486">[email protected]</span></a></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=James+J.++Crawford">James J. Crawford</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-6408-8246" title="Orcid link">http://orcid.org/0000-0002-6408-8246</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Adam R. Johnson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Adam R. Johnson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Adam+R.++Johnson">Adam R. Johnson</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dinah L. Misner</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dinah L. Misner</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dinah+L.++Misner">Dinah L. Misner</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Lisa D. Belmont</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lisa D. Belmont</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lisa+D.++Belmont">Lisa D. Belmont</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Georgette Castanedo</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Georgette Castanedo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Georgette++Castanedo">Georgette Castanedo</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-4584-6715" title="Orcid link">http://orcid.org/0000-0003-4584-6715</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Regina Choy</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Regina Choy</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Regina++Choy">Regina Choy</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Melis Coraggio</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Melis Coraggio</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Melis++Coraggio">Melis Coraggio</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Liming Dong</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Liming Dong</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Liming++Dong">Liming Dong</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Charles Eigenbrot</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Charles Eigenbrot</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Charles++Eigenbrot">Charles Eigenbrot</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Rebecca Erickson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rebecca Erickson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rebecca++Erickson">Rebecca Erickson</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Nico Ghilardi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Nico Ghilardi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Nico++Ghilardi">Nico Ghilardi</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jonathan Hau</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jonathan Hau</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jonathan++Hau">Jonathan Hau</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Arna Katewa</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Arna Katewa</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Arna++Katewa">Arna Katewa</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Pawan Bir Kohli</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Pawan Bir Kohli</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Pawan+Bir++Kohli">Pawan Bir Kohli</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Wendy Lee</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wendy Lee</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wendy++Lee">Wendy Lee</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Joseph W. Lubach</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Joseph W. Lubach</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Joseph+W.++Lubach">Joseph W. Lubach</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5806-0204" title="Orcid link">http://orcid.org/0000-0002-5806-0204</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Brent S. McKenzie</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Brent S. McKenzie</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Brent+S.++McKenzie">Brent S. McKenzie</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Daniel F. Ortwine</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Daniel F. Ortwine</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Daniel+F.++Ortwine">Daniel F. Ortwine</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Leah Schutt</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Leah Schutt</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Leah++Schutt">Leah Schutt</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Suzanne Tay</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Suzanne Tay</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Suzanne++Tay">Suzanne Tay</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">BinQing Wei</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">BinQing Wei</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=BinQing++Wei">BinQing Wei</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Karin Reif</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Karin Reif</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Karin++Reif">Karin Reif</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Lichuan Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lichuan Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lichuan++Liu">Lichuan Liu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Harvey Wong</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Harvey Wong</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Harvey++Wong">Harvey Wong</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Wendy B. Young</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wendy B. Young</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#d9a0b6acb7bef7aebcb7bda099bebcb7bcf7bab6b4"><span class="__cf_email__" data-cfemail="6910061c070e471e0c070d10290e0c070c470a0604">[email protected]</span></a></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wendy+B.++Young">Wendy B. Young</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1575-3227" title="Orcid link">http://orcid.org/0000-0003-1575-3227</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b01712&amp;href=/doi/10.1021%2Facs.jmedchem.7b01712" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2018</span></span><span class="cit-volume">, 61</span><span class="cit-issue">, 6</span><span class="cit-pageRange">, 2227–2245</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">February 19, 2018</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>20 November 2017</li><li><span class="item_label"><b>Published</b> online</span>19 February 2018</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 22 March 2018</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.7b01712" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01712</a></div><div class="article_header-article-copyright"><strong>Copyright © 2018 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D2227%26pageCount%3D19%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DJames%2BJ.%2BCrawford%252C%2BAdam%2BR.%2BJohnson%252C%2BDinah%2BL.%2BMisner%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D61%26issueNum%3D6%26contentID%3Dacs.jmedchem.7b01712%26title%3DDiscovery%2Bof%2BGDC-0853%253A%2BA%2BPotent%252C%2BSelective%252C%2Band%2BNoncovalent%2BBruton%25E2%2580%2599s%2BTyrosine%2BKinase%2BInhibitor%2Bin%2BEarly%2BClinical%2BDevelopment%26numPages%3D19%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D2245%26publicationDate%3DMarch%2B2018">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.7b01712"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">17400</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">87</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.7b01712" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton’s Tyrosine Kinase Inhibitor in Early Clinical Development&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;James&quot;,&quot;last_name&quot;:&quot;J. Crawford&quot;},{&quot;first_name&quot;:&quot;Adam&quot;,&quot;last_name&quot;:&quot;R. Johnson&quot;},{&quot;first_name&quot;:&quot;Dinah&quot;,&quot;last_name&quot;:&quot;L. Misner&quot;},{&quot;first_name&quot;:&quot;Lisa&quot;,&quot;last_name&quot;:&quot;D. Belmont&quot;},{&quot;first_name&quot;:&quot;Georgette&quot;,&quot;last_name&quot;:&quot;Castanedo&quot;},{&quot;first_name&quot;:&quot;Regina&quot;,&quot;last_name&quot;:&quot;Choy&quot;},{&quot;first_name&quot;:&quot;Melis&quot;,&quot;last_name&quot;:&quot;Coraggio&quot;},{&quot;first_name&quot;:&quot;Liming&quot;,&quot;last_name&quot;:&quot;Dong&quot;},{&quot;first_name&quot;:&quot;Charles&quot;,&quot;last_name&quot;:&quot;Eigenbrot&quot;},{&quot;first_name&quot;:&quot;Rebecca&quot;,&quot;last_name&quot;:&quot;Erickson&quot;},{&quot;first_name&quot;:&quot;Nico&quot;,&quot;last_name&quot;:&quot;Ghilardi&quot;},{&quot;first_name&quot;:&quot;Jonathan&quot;,&quot;last_name&quot;:&quot;Hau&quot;},{&quot;first_name&quot;:&quot;Arna&quot;,&quot;last_name&quot;:&quot;Katewa&quot;},{&quot;first_name&quot;:&quot;Pawan&quot;,&quot;last_name&quot;:&quot;Bir Kohli&quot;},{&quot;first_name&quot;:&quot;Wendy&quot;,&quot;last_name&quot;:&quot;Lee&quot;},{&quot;first_name&quot;:&quot;Joseph&quot;,&quot;last_name&quot;:&quot;W. Lubach&quot;},{&quot;first_name&quot;:&quot;Brent&quot;,&quot;last_name&quot;:&quot;S. McKenzie&quot;},{&quot;first_name&quot;:&quot;Daniel&quot;,&quot;last_name&quot;:&quot;F. Ortwine&quot;},{&quot;first_name&quot;:&quot;Leah&quot;,&quot;last_name&quot;:&quot;Schutt&quot;},{&quot;first_name&quot;:&quot;Suzanne&quot;,&quot;last_name&quot;:&quot;Tay&quot;},{&quot;first_name&quot;:&quot;BinQing&quot;,&quot;last_name&quot;:&quot;Wei&quot;},{&quot;first_name&quot;:&quot;Karin&quot;,&quot;last_name&quot;:&quot;Reif&quot;},{&quot;first_name&quot;:&quot;Lichuan&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Harvey&quot;,&quot;last_name&quot;:&quot;Wong&quot;},{&quot;first_name&quot;:&quot;Wendy&quot;,&quot;last_name&quot;:&quot;B. Young&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2018&quot;,&quot;month&quot;:&quot;02&quot;,&quot;day&quot;:&quot;19&quot;,&quot;issue&quot;:&quot;6&quot;,&quot;volume&quot;:&quot;61&quot;,&quot;pages&quot;:&quot;2227-2245&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.7b01712&quot;},&quot;abstract&quot;:&quot;Bruton’s tyrosine kinase (Btk) is a nonreceptor cytoplasmic tyrosine kinase involved in B-cell and myeloid cell activation, downstream of B-cell and Fcγ receptors, respectively. Preclinical studies have indicated that inhibition of Btk activity might offer a potential therapy in autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus. Here we disclose the discovery and preclinical characterization of a potent, selective, and noncovalent Btk inhibitor currently in clinical development. GDC-0853 (29) suppresses B cell- and myeloid cell-mediated components of disease and demonstrates dose-dependent activity in an in vivo rat model of inflammatory arthritis. It demonstrates highly favorable safety, pharmacokinetic (PK), and pharmacodynamic (PD) profiles in preclinical and Phase 2 studies ongoing in patients with rheumatoid arthritis, lupus, and chronic spontaneous urticaria. On the basis of its potency, selectivity, long target residence time, and noncovalent mode of inhibition, 29 has t&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01712&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01712" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01712&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01712" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b01712&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01712" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b01712&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b01712&amp;href=/doi/10.1021/acs.jmedchem.7b01712" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.7b01712" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.7b01712" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (5 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01712&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.7b01712%26sid%3Dliteratum%253Aachs%26pmid%3D29457982%26genre%3Darticle%26aulast%3DCrawford%26date%3D2018%26atitle%3DDiscovery%2Bof%2BGDC-0853%253A%2BA%2BPotent%252C%2BSelective%252C%2Band%2BNoncovalent%2BBruton%25E2%2580%2599s%2BTyrosine%2BKinase%2BInhibitor%2Bin%2BEarly%2BClinical%2BDevelopment%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D61%26issue%3D6%26spage%3D2227%26epage%3D2245%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290758" title="Anatomy">Anatomy</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/61/6" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/jmcmar.2018.61.issue-6/20180322/jmcmar.2018.61.issue-6.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/medium/jm-2017-017125_0024.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/large/jm-2017-017125_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01712&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Bruton’s tyrosine kinase (Btk) is a nonreceptor cytoplasmic tyrosine kinase involved in B-cell and myeloid cell activation, downstream of B-cell and Fcγ receptors, respectively. Preclinical studies have indicated that inhibition of Btk activity might offer a potential therapy in autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus. Here we disclose the discovery and preclinical characterization of a potent, selective, and noncovalent Btk inhibitor currently in clinical development. GDC-0853 (<b>29</b>) suppresses B cell- and myeloid cell-mediated components of disease and demonstrates dose-dependent activity in an <i>in vivo</i> rat model of inflammatory arthritis. It demonstrates highly favorable safety, pharmacokinetic (PK), and pharmacodynamic (PD) profiles in preclinical and Phase 2 studies ongoing in patients with rheumatoid arthritis, lupus, and chronic spontaneous urticaria. On the basis of its potency, selectivity, long target residence time, and noncovalent mode of inhibition, <b>29</b> has the potential to be a best-in-class Btk inhibitor for a wide range of immunological indications.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_73504" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_73504" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Bruton’s tyrosine kinase (Btk) is a nonreceptor Tec family tyrosine kinase that is broadly expressed in hematopoietic cells, with the exception of T cells.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> Btk plays a crucial role in signaling through the B-cell antigen receptor (BCR) and the Fcγ receptor (FcγR) in B cells and myeloid cells, respectively.<a onclick="showRef(event, 'ref1 ref3 ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref1 ref3 ref4 ref5">(1,3−5)</a> Spontaneous mutations in the pleckstrin homology domain of the <i>Btk</i> gene found in <i>xid</i> mice<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> and targeted mutations in Btk knockout mice both result in B-cell development and proliferation defects.<a onclick="showRef(event, 'ref2 ref7'); return false;" href="javascript:void(0);" class="ref ref2 ref7">(2,7)</a> These deficiencies are manifested by reduced numbers of mature circulating B cells, greatly reduced serum titers of certain immunoglobulin (Ig) isotypes, particularly IgM and IgG3, and poor T-independent antibody responses. X-linked agammaglobulinemia (XLA) is a human congenital immunodeficiency condition that occurs in males,<a onclick="showRef(event, 'ref2 ref7'); return false;" href="javascript:void(0);" class="ref ref2 ref7">(2,7)</a> which is associated with low to undetectable <i>btk</i> mRNA levels and Btk protein expression and, as a consequence, low to no Btk kinase activity.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> In contrast to the phenotype observed in <i>xid</i> mice, B-cell development in XLA patients is almost completely blocked at the pro-B-cell to pre-B-cell transition leading to extremely low to undetectable levels of mature B cells and, in turn, immunoglobulins.<a onclick="showRef(event, 'ref2 ref7'); return false;" href="javascript:void(0);" class="ref ref2 ref7">(2,7)</a> Left untreated, XLA patients succumb to recurring infections but can be treated with Ig replacement therapy.<a onclick="showRef(event, 'ref9 ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref9 ref10 ref11">(9−11)</a> Taken together, these factors indicate that inhibition of Btk represents an attractive potential therapeutic approach for the treatment of immunological disorders in which B cells and myeloid cells induce or sustain an excessive autoimmune response such as rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE).<a onclick="showRef(event, 'ref4 ref5 ref7 ref12 ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref4 ref5 ref7 ref12 ref13 ref14">(4,5,7,12−14)</a> For over a decade, there have been significant efforts expended toward the goal of identifying Btk inhibitors for clinical application in chronic inflammatory diseases as well as hematologic malignancies.<a onclick="showRef(event, 'ref15 ref16 ref17 ref18 ref19 ref20 ref21 ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref15 ref16 ref17 ref18 ref19 ref20 ref21 ref22 ref23">(15−23)</a> While the irreversible Btk inhibitor ibrutinib (PCI-32765, Imbruvica)<a onclick="showRef(event, 'ref15 ref24'); return false;" href="javascript:void(0);" class="ref ref15 ref24">(15,24)</a> has been successful in treating B-cell malignancies and is approved for chronic lymphocytic leukemia (CLL),<a onclick="showRef(event, 'ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref25 ref26">(25,26)</a> relapsed or refractory mantle-cell lymphoma (MCL),<a onclick="showRef(event, 'ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref27 ref28">(27,28)</a> and Waldenström’s macroglobulinemia (WM),<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> there is currently no approved Btk-targeted therapy for chronic autoimmune indications. A number of Btk inhibitors have shown efficacy in several preclinical models of inflammatory or autoimmune diseases that are driven by pathogenic B cells or myeloid cells,<a onclick="showRef(event, 'ref5 ref14 ref24 ref30 ref31 ref32 ref33 ref34 ref35 ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref5 ref14 ref24 ref30 ref31 ref32 ref33 ref34 ref35 ref36 ref37">(5,14,24,30−37)</a> but thus far none of these has progressed into advanced clinical trials for the treatment of autoimmune diseases. This slow progress in the autoimmune/inflammatory arena may, at least in part, be due to the stringent safety requirements these indications demand.</div><div class="NLM_p">There continues to be significant interest in the pursuit of Btk inhibitors and the leading inhibitors to date are covalent: ibrutinib (<b>1</b>), spebrutinib<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> (<b>2</b>) (CC-292, AVL-292), tirabrutinib<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> (<b>3</b>) (GS-4059, ONO-4059), and acalabrutinib<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> (<b>4</b>) (ACP-196) (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). All of these compounds react covalently and irreversibly with cysteine-481 in the ATP binding site of Btk. This dependence on irreversible inhibition poses a selectivity risk, since 10 other human kinases possess an equivalent cysteine residue in their active site,<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> and raises the spectre of unwanted off-target inhibition of these kinases. Indeed, the limited kinase selectivity data published so far for these covalent inhibitors align with this expectation, as off targets include some or all of these 10 kinases that contain an analogous cysteine residue.<a onclick="showRef(event, 'ref24 ref31'); return false;" href="javascript:void(0);" class="ref ref24 ref31">(24,31)</a> Furthermore, due to their ATP-like binding mode, these covalent molecules can also bind noncovalently to and inhibit even more kinases, further increasing safety concerns due to selectivity. Finally, the reactive groups on covalent compounds may lead to haptenization of serum proteins, potentially leading in rare cases to serum sickness-like reactions in patients. Together, these off-target effects could theoretically erode the safety profiles of these molecules. Because autoimmune indications such as RA and SLE require exquisitely safe drugs, our strategy was to develop noncovalent inhibitors that interact with Btk in a different manner than existing ATP-mimetic covalent inhibitors.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/medium/jm-2017-017125_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/large/jm-2017-017125_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Selected examples of clinical stage Btk inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/large/jm-2017-017125_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01712&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_31814" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_31814" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">We previously reported the discovery and structure–activity relationships (SAR) of our first clinical-stage inhibitor, GDC-0834, <b>5</b>,<a onclick="showRef(event, 'ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref20 ref21">(20,21)</a> which suffered from rapid amide bond hydrolysis in humans<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> but which we evolved into more advanced compounds including G-278, <b>6</b> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> With a Btk enzyme IC<sub>50</sub> of 4 nM and a BCR-induced CD69 IC<sub>50</sub> of 35 nM in human whole blood, <b>6</b> had a desirable profile. This, in addition to good kinase selectivity and an acceptable preclinical pharmacokinetic profile, allowed us to evaluate <b>6</b> in rat and dog tolerability studies with the intent of advancing this compound into the clinic. Unfortunately, <b>6</b> induced dose-limiting toxicities with unacceptably low safety margins in both species. In Sprague–Dawley rats, an unusual pancreatic toxicity was also observed with this as well as a number of other Btk inhibitors, and this was the subject of previously reported investigations (<i>vide infra</i>),<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> whereas in dogs liver toxicity was observed with <b>6</b> (as well as related analogues). The observed hepatotoxicity in dogs was characterized by increases in ALT and AST liver enzymes, as well as other findings in the liver such as perivascular mixed cell infiltrates, Kupffer cell hypertrophy, and hepatocellular degeneration. In addition, increased circulating neutrophils were observed at higher dose levels (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01712/suppl_file/jm7b01712_si_002.pdf" class="ext-link">Supporting Information</a>). As a result, hepatotoxicity was the primary issue that we sought to eliminate in next generation analogues.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/medium/jm-2017-017125_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/large/jm-2017-017125_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Progression of Genentech’s published Btk inhibitors from GDC-0834 to G-278.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/large/jm-2017-017125_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01712&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In an attempt to better understand the hepatotoxicity that was primarily observed in dogs, a cell viability (cytotoxicity) assay using cryopreserved human hepatocytes was used to identify high-risk compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01712/suppl_file/jm7b01712_si_002.pdf" class="ext-link">Supporting Information</a>).<a onclick="showRef(event, 'ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref42 ref43">(42,43)</a> Compounds with an IC<sub>50</sub> < 50 μM in this assay were classified as having potentially high risk for cytotoxicity while compounds with IC<sub>50</sub> > 100 μM were considered low risk. Once a sufficient data set was obtained in this assay, we set out to develop an <i>in silico</i> model for the prediction of hepatocyte cytotoxicity to be applied prior to compound synthesis and to flag any possible causative factors (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01712/suppl_file/jm7b01712_si_002.pdf" class="ext-link">Figure S-1</a>, Supporting Information). A training data set consisting of 70 Btk inhibitors was used, with their cytotoxicity classified into three toxicity risk bins: high (IC<sub>50</sub> < 50 μM), medium (IC<sub>50</sub> = 50–100 μM), or low (IC<sub>50</sub> > 100 μM). We explored a wide range of commonly used structural and physicochemical descriptors and a variety of modeling algorithms. A decision tree model was chosen based on its performance in 5-fold cross-validation as well as its easy interpretability. It was subsequently tested using the data for 121 molecules outside the training set, including some compounds that originated from other internal discovery projects. The model performed well on this more structurally diverse set of molecules (see details in the <a href="/doi/suppl/10.1021/acs.jmedchem.7b01712/suppl_file/jm7b01712_si_002.pdf" class="ext-link">Supporting Information</a>), which supported its application on this program.</div><div class="NLM_p">The model relied on only three calculated properties (p<i>K</i><sub>a</sub> of the most basic nitrogen, plasma protein binding (PPB), and log <i>P</i>)<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> and assigned a predicted hepatocyte IC<sub>50</sub> range of a given molecule into one of the three defined toxicity risk categories. While we had previously hypothesized basicity (i.e., high p<i>K</i><sub>a</sub>) to be a major risk factor for cytotoxicity, the decision tree model identified log <i>P</i> and PPB as two additional predictive factors and defined specific thresholds for each of them. Although often related, log <i>P</i> and PPB within this set of compounds were linked enough to give a modest correlation (<i>R</i><sup>2</sup> = 0.55), removing either parameter significantly reduced the performance of the model. Interestingly, inclusion of structure descriptors did not improve the accuracy of predictions. This suggested that, within this series of Btk inhibitors, physicochemical properties rather than particular substructures were the likely drivers of hepatocyte cytotoxicity (for more details, see the <a href="/doi/suppl/10.1021/acs.jmedchem.7b01712/suppl_file/jm7b01712_si_002.pdf" class="ext-link">Supporting Information</a>). Given the influence of basicity and log <i>P</i>, moving forward we focused our efforts on avoiding the incorporation of strongly basic groups, and lowering log <i>D</i> (i.e., taking into account the combined impact of p<i>K</i><sub>a</sub> and log <i>P</i>), while aiming to maintain or improve whole blood potency and pharmacokinetic (PK) properties.</div><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> SAR: Increasing Potency, Improving Metabolic Stability, and Minimizing Toxicity</h3><div class="NLM_p">One region of this Btk inhibitor scaffold that we sought to optimize was the hydroxymethyl-substituted aryl ring that links the pyridone hinge-binding motif to the selectivity pocket (or “H3”) motif. While hydroxymethyl and F substitution had been shown to improve potency,<a onclick="showRef(event, 'ref22 ref45'); return false;" href="javascript:void(0);" class="ref ref22 ref45">(22,45)</a> changes to the ring itself had not.</div><div class="NLM_p">We sought to lower log <i>D</i> by replacing the aryl ring with a heterocycle such as pyridine. The three isomeric pyridyl analogues were prepared and tested (<b>7</b>–<b>9</b>, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). In all cases, incorporation of the nitrogen reduced the calculated and measured log <i>D</i> by at least one unit and resulted in improved metabolic stability in human liver microsomes as compared to the benzene analogue <b>6</b>. Examples <b>7</b> and <b>8</b> maintained whole blood potency within 2-fold of the benzene analogue <b>6</b>; however, the isomer with the pyridyl nitrogen ortho to the H3 motif (<b>7</b>) retained the most intrinsic potency with a Btk <i>K</i><sub>i</sub> of 1.8 nM and thus was regarded as the preferred isomer.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Initial SAR around the Core Aryl Ring</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/medium/jm-2017-017125_0014.gif" alt="" id="GRAPHIC-d49e700-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/medium/jm-2017-017125_0015.gif" alt="" id="gr14" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Inhibitor <i>K</i><sub>i</sub> values were determined in at least triplicate in an assay that monitors Btk-catalyzed phosphorylation of a synthetic peptide substrate. See <a href="/doi/suppl/10.1021/acs.jmedchem.7b01712/suppl_file/jm7b01712_si_002.pdf" class="ext-link">Supporting Information</a> for assay details.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">CD69 expression on CD19<sup>+</sup> B cells in human whole blood was measured after stimulation with anti-IgM (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01712/suppl_file/jm7b01712_si_002.pdf" class="ext-link">Supporting Information</a>).</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">Human liver microsome-predicted hepatic clearance.</p></div><div class="footnote" id="t1fn4"><sup><sup>d</sup></sup><p class="last">Calculated log <i>D</i> (log <i>D</i> was calculated using v2 of the MoKa program, available from Molecular Discovery Ltd. (<a href="http://www.moldiscovery.com" class="extLink">www.moldiscovery.com</a>)).</p></div><div class="footnote" id="t1fn5"><sup><sup>e</sup></sup><p class="last">Log <i>D</i> measured using a high-throughput microscale shake flask with liquid chromatography–tandem mass spectrometry quantitation.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a></p></div></div><div></div></div><div class="NLM_p">Over time, many additional pyridyl compounds were prepared and the same trends toward improved metabolic stability and LLE were apparent as illustrated in matched pair plot analyses (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>).<a onclick="showRef(event, 'ref47 ref48'); return false;" href="javascript:void(0);" class="ref ref47 ref48">(47,48)</a></div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/medium/jm-2017-017125_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/large/jm-2017-017125_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Matched pair plots for Btk inhibitors containing an Ar–F (l) or pyridyl (r) linker. Lines join matched pairs: (a) HLM stability (mL/min/kg) and (b) LLE = p<i>K</i><sub>i</sub> – clogD.<a onclick="showRef(event, 'ref47 ref48'); return false;" href="javascript:void(0);" class="ref ref47 ref48">(47,48)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/large/jm-2017-017125_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01712&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As previously noted, much of the potency and selectivity of our chemical scaffold results from the ability of these compounds to stabilize and interact with a binding site in Btk that is generated via a conformational rearrangement of the activation loop of the kinase domain.<a onclick="showRef(event, 'ref5 ref22 ref50'); return false;" href="javascript:void(0);" class="ref ref5 ref22 ref50">(5,22,50)</a> It is instructive to note that, given our induced-fit binding mode, we used our whole blood assay as the main driver of SAR in this program since it could encompass the effects of a combination of therapeutically relevant parameters, including Btk affinity, cell permeability, PPB, and favorable target-binding kinetics. In this respect, potency in whole human blood was determined as previously described<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> and monitored via either Btk Y223 phosphorylation or anti-IgM-induced CD69 expression on B cells.</div><div class="NLM_p">The generally lipophilic groups at the tricyclic H3 motif termini present hydrophobic surfaces that interact with Y551 of the activation loop of Btk (among other residues), ultimately occupying a lipophilic specificity/selectivity pocket. We decided to synthesize a set of inhibitors with a variety of H3 groups in combination with the pyridyl linker to see if we could take advantage of improved LLE, allowing us to incorporate groups that might afford improved whole blood potency. In the case of thiophene-containing examples <b>10</b> and <b>11</b>, the resulting increase in lipophilicity relative to pyrrole analogue <b>7</b> led to increased log <i>D</i> and a drop in metabolic stability in human liver microsomes (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). The dimethyl substituted cyclopentyl (<b>11</b>) offered improved whole blood potency relative to the corresponding cyclohexyl analogue (<b>10</b>), so the next compound prepared was the corresponding pyrrole-containing derivative, <b>12</b>. This molecule displayed improved whole blood potency (IC<sub>50</sub> = 15.4 nM) and maintained the metabolic stability and physicochemical property profile of <b>6</b> (kinetic solubility = 79.8 μM for <b>12</b> vs 12 μM for <b>6</b>). Small changes such as unsaturation of the lactam ring or fluoro substitution of the pyrrole ring, albeit not in tandem, as was subsequently reported to be beneficial,<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> did not afford any appreciable whole blood potency benefits in our series. Lastly, although the <i>tert</i>-butyl-substituted bicyclic thiophene lactam <b>15</b> was a potent inhibitor, it had an unfavorable high measured log <i>D</i> (>3) like the other thiophene-containing examples. From this exploration, compound <b>12</b> offered the best balance of properties and was not cytotoxic in primary human hepatocytes (IC<sub>50</sub> > 100 μM). However, when dosed in a cassette rat PK study, <b>12</b> exhibited high plasma clearance (CL<sub>p</sub> = 165 mL/min/kg) and a relatively short half-life (0.4 h), so SAR efforts continued in order to improve the metabolic stability of this scaffold.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Selectivity Pocket/H3 SAR<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/medium/jm-2017-017125_0016.gif" alt="" id="GRAPHIC-d49e864-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/medium/jm-2017-017125_0017.gif" alt="" id="gr15" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">See footnotes from <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> for experimental details.</p></div></div><div></div></div><div class="NLM_p">We previously reported that a pyridopiperazine moiety, such as <b>12</b> (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>), that spans a flat, lipophilic channel leading to a partially solvent exposed region of the protein (“H2 pocket”), optionally as the <i>N</i>-oxetanyl derivative, displayed improved kinetic solubility and pharmacokinetic properties.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> With a preference for compounds with a lower p<i>K</i><sub>a</sub>, we next set out to examine the SAR around the H2 region of our inhibitors. Moving the oxetanylpiperazine ortho to the pyridyl nitrogen (<b>16</b>) was tolerated with respect to Btk inhibition (<i>K</i><sub>i</sub> maintained relative to <b>12</b>) but resulted in a significant drop in whole blood potency and metabolic stability (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Structural modeling suggested that substitution at the other ring positions would not be tolerated, so our subsequent efforts focused on 2,5-disubstituted pyridyl inhibitors. Replacement of the oxetane with an acyl group, either as the piperazine (<b>17</b>) or the bis-azetidine isostere thereof (<b>18</b>), was tolerated but offered no advantage. Similarly, while the introduction of other substituents that allowed for modulation of the piperazine nitrogen p<i>K</i><sub>a</sub> (<b>19</b>–<b>22</b>) did not result in a significant loss in potency (with the exception of <b>21</b>, with a whole blood potency of 116 nM), each of these suffered from decreased metabolic stability in human liver microsomes (CL<sub>hep</sub> of 12–16 mL/min/kg) relative to <b>12</b>. A close-in analogue of <b>12</b> was prepared in the form of oxetanylazetidine <b>23</b>. While <b>23</b> maintained much of the Btk affinity and whole blood potency relative to <b>12</b>, it suffered from poor metabolic stability and a higher measured log <i>D</i> value and, therefore, was not advanced.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Piperazine Replacements<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/medium/jm-2017-017125_0018.gif" alt="" id="GRAPHIC-d49e962-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/medium/jm-2017-017125_0019.gif" alt="" id="gr16" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">See footnotes from <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">Permeability in Madin-Darby Canine Kidney (MDCKI) cells, apical-to-basolateral (AB), and efflux ratio (ER).</p></div></div><div></div></div><div class="NLM_p">One aspect of the piperazine SAR that remained relatively unexplored was substitution of the piperazine ring itself. Modeling suggested that we might be able to increase van der Waals contacts with the edge of the protein and/or perhaps influence the conformation of the ring itself using small alkyl substituents, e.g., methyl (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A). We subsequently synthesized and tested a set of such compounds, with a methyl group in the four possible positions on the ring, using available intermediates containing the F-aryl linker motif (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>).</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/medium/jm-2017-017125_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/large/jm-2017-017125_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Solvent exposed surface of Btk around the oxetanylpiperazine motifs: (A) model of oxetanylpiperazine.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> and (B) from the X-ray cocrystal structure of <b>29</b> bound to Btk (see <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/large/jm-2017-017125_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01712&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. SAR for Piperazine Ring Substitution<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/medium/jm-2017-017125_0020.gif" alt="" id="GRAPHIC-d49e1013-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/medium/jm-2017-017125_0021.gif" alt="" id="gr17" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">See footnotes from <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>.</p></div></div><div></div></div><div class="NLM_p">In each case, whole blood potency improved without any negative impact on other properties. Most significantly, in the case of (<i>S</i>)-2,4-dimethyl-1-(pyridin-3-yl)piperazine <b>26</b> (as in an X-ray cocrystal structure of <b>29</b>, <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B), we observed a 5-fold improvement in CD69 whole blood potency relative to <b>24</b>. Since this particular example had a higher log <i>D</i> and p<i>K</i><sub>a</sub> than desired (per our <i>in silico</i> model for prediction of human hepatotoxicity), we applied this change to compound <b>12</b>.</div><div class="NLM_p">We chose to transfer the (S)-methyl group of <b>26</b> onto <b>12</b>, which afforded a compound with an overall excellent profile. This resulting compound, GDC-0853, <b>29</b> (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>), had a ∼2-fold improvement in whole blood B cell CD69 potency (IC<sub>50</sub> = 8.4 nM) relative to <b>12</b> (IC<sub>50</sub> = 15.4 nM) and greater than 4-fold relative to <b>6</b> (IC<sub>50</sub> = 36.5 nM). The corresponding enantiomer of <b>29</b> (<b>30</b>) suffered from poor metabolic stability and had whole blood potency of only 40 nM. Increasing the size of the substituent to an ethyl group (<b>31</b>) resulted in an expected log <i>D</i> increase and eroded stability in human liver microsomes and hepatocytes. Adding an additional methyl to the ring as in <b>32</b> gave a similar result, albeit with excellent whole blood potency. Finally, incorporation of nitrogen atoms as in hinge motif pyridazinone <b>33</b> and H2 pyrazine <b>34</b> yielded no further benefit. Compound <b>29</b> exhibited the best overall profile of any compound prepared and as such was further characterized. When tested for cytotoxicity in primary human hepatocytes, <b>29</b> had a clean profile with an IC<sub>50</sub> > 300 μM, in contrast to <b>6</b>, which had an IC<sub>50</sub> of 39 μM.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Combination of Core Aryl Ring, H3, Piperazine, and Late Stage SAR<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/medium/jm-2017-017125_0022.gif" alt="" id="GRAPHIC-d49e1134-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/medium/jm-2017-017125_0023.gif" alt="" id="gr18" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">See footnotes from <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> and <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>.</p></div></div><div></div></div><div class="NLM_p">We obtained a 1.59-Å resolution X-ray cocrystal structure of GDC-0853 (<b>29</b>) bound to Btk (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). Within the Btk kinase domain, <b>29</b> shows the expected hinge binding by the central pyridone, with hydrogen bonding between the pyridone carbonyl and pendant aniline NH hydrogen and the protein backbone atoms of Met477. Consistent with other previously solved crystal structures with earlier molecules, Tyr551 in the activation loop has moved 18 Å from its position in apo-Btk to pack against the hydrophobic right-hand side of the tricyclic ring system, forming part of the H3 site that confers substantial potency and kinase selectivity. Additionally, the gem-dimethyl cyclopentane presents nonplanar structure that complements the shape of the pocket in this area, in a similar vein to <i>tert</i>-butyl analogues. The hydoxymethyl projects into an interior water-filled cavity, forming hydrogen bonds with Lys430 and Asp539. The pyridyl ring occupies part of the active site cleft and packs against Gly480 and Leu408 while its nitrogen atom accepts a nontraditional H-bond from an aromatic hydrogen on the adjacent pyridone ring, contributing to the molecule’s rigidity. The 2-Me substituent on the piperazine ring imparts a restricted rotation relative to the unsubstituted analogue, favoring a more out-of-plane orientation of the piperazine ring. Energetics from a quantum torsion scan of the piperazine-to-pyridyl bond support this observation (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01712/suppl_file/jm7b01712_si_002.pdf" class="ext-link">Supporting Information</a>). The unsubstituted piperazine is calculated to have relatively free rotation about this bond, while the 2-Me substituent on the piperazine ring imparts a more restricted rotation. The conformation observed in the structure of <b>29</b> lies essentially at the calculated global minimum. Thus, in addition to being conformationally rigid, it presents a more nonplanar motif at each end of its structure, which aids in conferring favorable physiochemical, cellular potency, and ultimately pharmacokinetic properties. Detailed physicochemical properties of <b>29</b> are included in the <a href="/doi/suppl/10.1021/acs.jmedchem.7b01712/suppl_file/jm7b01712_si_002.pdf" class="ext-link">Supporting Information</a>. The most stable known crystalline form has a very high melting point of 274 °C, which contributes to the relatively low water solubility of 0.003 mg/mL. When protonated in 0.1 N HCl, aqueous solubility jumps to 35.9 mg/mL, affording excellent solubility and dissolution in the, typically acidic, mammalian stomach.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/medium/jm-2017-017125_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/large/jm-2017-017125_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. X-ray cocrystal structure of the <b>29</b>/Btk kinase domain complex (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5VFI">5VFI</a>) with key residues labeled. The molecular surface of <b>29</b> is in blue and protein–ligand H-bonds are shown as dashed lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/large/jm-2017-017125_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01712&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Preclinical PK Profile</h3><div class="NLM_p">We assessed the <i>in vivo</i> pharmacokinetic properties of <b>29</b> (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>) in cassette studies in both rats (0.2 mg/kg IV and 1.0 mg/kg PO) and dogs (0.2 mg/kg IV and 0.5 mg/kg PO). In rats, <b>29</b> had moderate clearance of 27.4 mL/min/kg and excellent bioavailability (<i>F</i> = 65%) relative to the des-methyl analogue <b>12</b>. The plasma clearance was reduced 6-fold, from 165 to 27.4 mL/min/kg, while the volume of distribution (<i>V</i><sub>d</sub>) and oral bioavailability were relatively unchanged, which resulted in a 5.5-fold improvement in plasma half-life from 0.4 to 2.2 h. Because efficacy in the collagen-induced arthritis model in rat likely requires chronic inhibition of Btk throughout the study,<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> this improvement enabled adequate exposures following oral dosing such that preclinical efficacy could be assessed. Compound <b>29</b> also demonstrated favorable PK properties in dogs. The 3.8-h half-life (Cl<sub>p</sub> 10.9 mL/min/kg, <i>V</i><sub>d</sub> 2.96 L/kg) and high oral bioavailability (85%) also enabled attainment of sufficient exposures in dog toxicology studies. Overall, these enhancements in the <i>in vivo</i> pharmacokinetics provided adequate exposures to enable rat and dog preclinical toxicology studies.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Rat Pharmacokinetic Parameters Estimated from Single-Dose Intravenous (0.2 mg/kg) and Oral (1 mg/kg) Cassette Pharmacokinetic Study</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"><b>12</b></th><th class="colsep0 rowsep0" align="center"><b>29</b> (GDC-0853)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CL (mL/min/kg)</td><td class="colsep0 rowsep0" align="left">165</td><td class="colsep0 rowsep0" align="left">27.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>V</i><sub>d</sub> (L/kg)</td><td class="colsep0 rowsep0" align="left">4.97</td><td class="colsep0 rowsep0" align="left">5.42</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="left">0.4</td><td class="colsep0 rowsep0" align="left">2.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>F</i> (%)</td><td class="colsep0 rowsep0" align="left">65.8</td><td class="colsep0 rowsep0" align="left">65.1</td></tr></tbody></table></div></div><div class="NLM_p"><b>29</b> was tested for off-target activity against a panel of <i>in vitro</i> safety assays and was found to have a clean off-target profile (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>), was negative in the <i>in vitro</i> Ames and MNT assays, indicating a low risk for genotoxicity, and has low potential cardiovascular risk liability as indicated in the <i>in vitro</i> hERG assay (IC<sub>50</sub> > 30 μM).</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. <i>In Vitro</i> Safety Profile of <b>29</b> (GDC-0853)<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">assay</th><th class="colsep0 rowsep0" align="center">result</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">receptor binding profile (41 targets)</td><td class="colsep0 rowsep0" align="left">no binding >50% at 10 μM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hERG channel inhibition (functional)</td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> > 30 μM (>1500-fold window)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hNa<sub><i>v</i></sub>1.5 channel inhibition (functional)</td><td class="colsep0 rowsep0" align="left">0.6% at 1 μM, 1.9% at 10 μM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hCa<sub><i>v</i></sub>1.2 channel inhibition (functional)</td><td class="colsep0 rowsep0" align="left">1.5% at 1 μM, 3.8% at 10 μM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Ames</td><td class="colsep0 rowsep0" align="left">negative</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MNT (HPBLs)</td><td class="colsep0 rowsep0" align="left">negative</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cytotoxicity in human hepatocytes</td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> > 300 μM</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CYP 3A4, 1A2, 2C19, 2D6, 2D9 inhibition</td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub>s > 5 μM</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup><sup>a</sup></sup><p class="last">See the <a href="/doi/suppl/10.1021/acs.jmedchem.7b01712/suppl_file/jm7b01712_si_002.pdf" class="ext-link">Supporting Information</a> for assay methods and details.</p></div></div></div><div class="NLM_p">Like other structurally related molecules that bind in the H3 region of Btk, <b>29</b> is an extremely selective Btk inhibitor. When compared with six other clinical stage Btk inhibitors, each tested at 1 μM against a broad panel of human kinase biochemical assays, <b>29</b> was found to be the most Btk-selective molecule and inhibited only 3 of 286 off-target kinases (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>a). On the basis of the determined IC<sub>50</sub> values, the selectivity for Btk was >100-fold against each of these 3 off-targets: Bmx (153-fold), Fgr (168-fold), and Src (131-fold) (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>b and the <a href="/doi/suppl/10.1021/acs.jmedchem.7b01712/suppl_file/jm7b01712_si_002.pdf" class="ext-link">Supporting Information</a>). In contrast, BMS-986142<a onclick="showRef(event, 'ref23 ref51'); return false;" href="javascript:void(0);" class="ref ref23 ref51">(23,51)</a> showed >50% inhibition of 20 of 219 off-target kinases tested and ibrutinib (<b>1</b>) inhibited 31 of 221 off-target kinases by >50% (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>b and the <a href="/doi/suppl/10.1021/acs.jmedchem.7b01712/suppl_file/jm7b01712_si_002.pdf" class="ext-link">Supporting Information</a>). The IC<sub>50</sub> values (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>b and the <a href="/doi/suppl/10.1021/acs.jmedchem.7b01712/suppl_file/jm7b01712_si_002.pdf" class="ext-link">Supporting Information</a>) demonstrate that ibrutinib is rather nonselective, being <100-fold selective against 18 other kinases, while BMS-986142 is <100-fold selective for 6 kinases. Although spebrutinib (<b>2</b>), tirabrutinib (<b>3</b>), and acalabrutinib (<b>4</b>) inhibit fewer total off-targets than ibrutinib or BMS-986142 at the same 1-μM test concentration, for the additional targets they do inhibit, the IC<sub>50</sub> values are quite close in magnitude to the activity they display against Btk [spebrutinib: Bmx (1-fold selectivity ratio), Tec (1-fold), Txk (5-fold), JAK3 (6-fold), and STK16 (7-fold); tirabrutinib: Bmx (2-fold) and Tec (12-fold); acalabrutinib: ErbB4 (4-fold), Bmx (22-fold), and RIPK2 (47-fold)] (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>b and the <a href="/doi/suppl/10.1021/acs.jmedchem.7b01712/suppl_file/jm7b01712_si_002.pdf" class="ext-link">Supporting Information</a>). Evobrutinib<a onclick="showRef(event, 'ref52 ref53'); return false;" href="javascript:void(0);" class="ref ref52 ref53">(52,53)</a> inhibited 3 of 221 off-targets (Bmx, Tec, and ErbB4), but it was also the weakest Btk inhibitor tested (IC<sub>50</sub> = 37.9 nM) (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01712/suppl_file/jm7b01712_si_002.pdf" class="ext-link">Supporting Information</a>). As noted above, 10 other human kinases have a Cys residue in the analogous location as Cys-481 of Btk and as such may be particularly sensitive to inhibition by covalent inhibitors.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> When these clinical stage Btk inhibitors were tested against 10 of the Cys-containing kinases, <b>29</b> was clearly more selective for Btk than any of the covalent Btk inhibitors, or even the noncovalent inhibitor, BMS-986142 (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>c). Thus, on the basis of these <i>in vitro</i> kinase profiles, <b>29</b> is overall a more selective Btk inhibitor than any of these other molecules. The complete kinase selectivity profiles of <b>29</b> and the six other clinical stage Btk inhibitors (tested at the 1-μM test concentration and in IC<sub>50</sub> titrations) are provided in the <a href="/doi/suppl/10.1021/acs.jmedchem.7b01712/suppl_file/jm7b01712_si_002.pdf" class="ext-link">Supporting Information</a>.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/medium/jm-2017-017125_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/large/jm-2017-017125_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (a) Kinase selectivity of Btk inhibitors ibrutinib <b>1</b>, spebrutinib <b>2</b>, tirabrutinib <b>3</b>, acalabrutinib <b>4</b>, evobrutinib, BMS-986142, and GDC-0853 <b>29</b>. <i>In vitro</i> kinase selectivity for Btk inhibitors was determined in the SelectScreen panel (ThermoFisher, Madison, WI) comprised of activity assays and ATP site competitive binding assays. Percent (%) inhibition was assessed at a 1-μM test concentration: red, ≥80% inhibition; yellow, 50–80% inhibition; green, ≤50% inhibition or not tested. Compound <b>29</b> was tested in 287 total kinase assays, whereas the other 6 inhibitors were tested against a subset of approximately 220 of these kinases, and only those kinases that were tested against all 7 inhibitors are represented (see the <a href="/doi/suppl/10.1021/acs.jmedchem.7b01712/suppl_file/jm7b01712_si_002.pdf" class="ext-link">Supporting Information</a> for all of the % inhibition data against all kinases). (b) Potency of Btk inhibitors against off-target kinases. IC<sub>50</sub> values were determined as described in the methods against kinases that were inhibited by >50% at 1 μM. The IC<sub>50</sub> values for <b>29</b> and six other clinical stage Btk inhibitors are provided in the <a href="/doi/suppl/10.1021/acs.jmedchem.7b01712/suppl_file/jm7b01712_si_002.pdf" class="ext-link">Supporting Information</a>. Because of its low potency toward inhibition of Btk (IC<sub>50</sub> = 37.9 nM), no off-target IC<sub>50</sub> values were collected for evobrutinib. (c) Inhibition of kinases that have a cysteine that is analogous to Btk Cys-481. Inhibitors were tested at 1 μM as described above for <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>a and the % inhibition is shown.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/large/jm-2017-017125_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01712&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> GDC-0853 Inhibits Human BCR and FcγR Signaling</h3><div class="NLM_p">Since Btk plays a critical role in signal transduction of BCR and FcγR, we evaluated the cellular potency of <b>29</b> in isolated primary human B cells and monocytes.<a onclick="showRef(event, 'ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref12 ref13">(12,13)</a> Specifically, we evaluated inhibition of anti-IgM induced Btk phosphorylation as well as anti-IgM or CD40L stimulated proliferation in B cells and FcγR-dependent TNFα production in human monocytes.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a></div><div class="NLM_p">In isolated primary human B cells, <b>29</b> potently inhibited anti-IgM-induced Btk Y223 tyrosine phosphorylation (IC<sub>50</sub> = 3.1 nM) and anti-IgM and CD40L-induced B-cell proliferation (IC<sub>50</sub> = 1.2 nM and 1.4 nM, respectively) (<a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>). Consistent with the previously reported role of Btk in Fc receptor function,<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Btk inhibition by <b>29</b> prevented FcγRIII-triggered TNFα production in human monocytes (IC<sub>50</sub> = 1.3 nM). As previously mentioned, in human blood <b>29</b> potently inhibited up-regulation of the early activation marker CD69 on B cells after overnight anti-IgM stimulation (IC<sub>50</sub> = 8 nM). Furthermore, GDC-0853 also suppressed anti-IgM induced Btk Y223 autophosphorylation in human whole blood (IC<sub>50</sub> = 11 nM). Taken together, these data demonstrate that <b>29</b> is a highly selective Btk inhibitor that blocks both B-cell BCR and monocyte FcγR signaling.</div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Potency of <b>29</b> in Human Whole Blood and Isolated Primary Cell Assays</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" colspan="2" align="center">blood</th><th class="colsep0 rowsep0" colspan="3" align="center">B cells</th><th class="colsep0 rowsep0" align="center">monocytes</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">stimulus</td><td class="colsep0 rowsep0" colspan="2" align="center">anti-IgM</td><td class="colsep0 rowsep0" colspan="2" align="center">anti-IgM</td><td class="colsep0 rowsep0" align="left">rhCD40L</td><td class="colsep0 rowsep0" align="left">anti-FCγRIII</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">readout</td><td class="colsep0 rowsep0" align="left">pBtk</td><td class="colsep0 rowsep0" align="left">CD69</td><td class="colsep0 rowsep0" align="left">pBtk</td><td class="colsep0 rowsep0" align="left">proliferation</td><td class="colsep0 rowsep0" align="left">proliferation</td><td class="colsep0 rowsep0" align="left">TNFα</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">donors</td><td class="colsep0 rowsep0" align="left">(<i>n</i> = 6)</td><td class="colsep0 rowsep0" align="left">(<i>n</i> = 6)</td><td class="colsep0 rowsep0" align="left">(<i>n</i> = 4)</td><td class="colsep0 rowsep0" align="left">(<i>n</i> = 3)</td><td class="colsep0 rowsep0" align="left">(<i>n</i> = 3)</td><td class="colsep0 rowsep0" align="left">(<i>n</i> = 3)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> ± SD (nM)</td><td class="colsep0 rowsep0" align="left">11 ± 4.2</td><td class="colsep0 rowsep0" align="left">8.0 ± 6.0</td><td class="colsep0 rowsep0" align="left">3.1 ± 0.7</td><td class="colsep0 rowsep0" align="left">1.2 ± 0.9</td><td class="colsep0 rowsep0" align="left">1.4 ± 0.6</td><td class="colsep0 rowsep0" align="left">1.3 ± 0.8</td></tr></tbody></table></div></div><div class="NLM_p">In the course of our SAR efforts, we wondered if our H3-pocket binding compounds might show time-dependent inhibition of Btk. We found that some inhibitors did show an increase in potency after preincubation with the enzyme. As just one example, <b>29</b> showed an 8-fold increase in potency in the enzyme assay after a 2-h preincubation with Btk. We were interested to determine whether this time-dependent inhibition would be accompanied by slow dissociation of <b>29</b> from Btk and an extended target residence time, as this feature could lead to an extended duration of pharmacological action <i>in vivo</i>.<a onclick="showRef(event, 'ref54 ref55'); return false;" href="javascript:void(0);" class="ref ref54 ref55">(54,55)</a></div><div class="NLM_p">In order to quantify the kinetics of dissociation of GDC-0853 from Btk and to determine the Btk residence time for <b>29</b>, we adapted our standard <i>in vitro</i> biochemical Btk enzyme assay conditions<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> to a “jump dilution” experiment (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01712/suppl_file/jm7b01712_si_002.pdf" class="ext-link">Supporting Information</a>). Btk that had been incubated with DMSO vehicle before being extensively diluted into the assay mixture rapidly catalyzed the phosphorylation of the peptide substrate to form a phospho-peptide product in a nearly linear fashion over time (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>, blue circles). On the other hand, Btk that had been preincubated with <b>29</b> and then diluted into the assay mixture showed a lag in product formation that extended for several hours (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>, red circles). This delayed recovery of activity suggests that <b>29</b> dissociates extremely slowly from Btk. The product formation time course data were fitted to an equation<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> that describes the first-order dissociation of E·I into free enzyme and inhibitor with an observed rate constant, <i>k</i><sub>off</sub> (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01712/suppl_file/jm7b01712_si_002.pdf" class="ext-link">Supporting Information</a>). The residence time is defined as 1/<i>k</i><sub>off</sub>.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> In three experiments <b>29</b> displayed an average residence time with Btk of 18.3 ± 2.8 h (<i>k</i><sub>off</sub> = 1.52 × 10<sup>–5</sup> s<sup>–1</sup>).</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/medium/jm-2017-017125_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/large/jm-2017-017125_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. An <i>in vitro</i> biochemical jump dilution experiment illustrates the long Btk residence time of <b>29</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/large/jm-2017-017125_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01712&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Interestingly, however, not all H3-binding inhibitors showed time-dependent inhibition or such a long residence time, and investigations are ongoing to clarify the mechanistic basis of these kinetic differences. Given the approximately 12-h half-life of the Btk protein (36–63% Btk protein degraded in 8–17 h),<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> and the slow resynthesis rate of new Btk protein (43–71% recovery of Btk protein levels over 24–48 h),<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> the 18-h residence time of <b>29</b> with Btk is impressive. If this long residence time translates to the <i>in vivo</i> setting, the functional duration of action of <b>29</b> could match that of covalent Btk inhibitors. Thus, the long residence time for <b>29</b> that we measured <i>in vitro</i> is a feature that may enhance its cell based, <i>in vivo</i>, and even clinical efficacy.</div><div class="NLM_p">Since the known clinical stage and approved Btk inhibitors use a variety of binding and inhibition modes, we compared the potency of <b>29</b> and a subset of these molecules (both covalent and noncovalent) in human whole blood assays. Specifically, we studied both the aforementioned anti-IgM-induced expression of CD69 on B cells and IgE-driven and FcεR mediated basophil activation as assessed by surface expression of CD63. Of the five molecules tested, GDC-0853 had the best whole blood potency in both assays (<a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>).</div><div class="NLM_table-wrap" id="tbl9"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 9. Comparison of the Potency of <b>29</b> and Other Clinical Stage Btk Inhibitors in Human Whole Blood CD69 and CD63 Assays</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Btk inhibitor</th><th class="colsep0 rowsep0" align="center">CD69 IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t9fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">CD63 IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t9fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>29</b>, GDC-0853</td><td class="colsep0 rowsep0" align="left">8.4 ± 5.6</td><td class="colsep0 rowsep0" align="left">30.7 ± 4.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BMS-986142</td><td class="colsep0 rowsep0" align="left">88.3 ± 21.8</td><td class="colsep0 rowsep0" align="left">374.3 ± 131.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b>, acalabrutinib</td><td class="colsep0 rowsep0" align="left">198.0 ± 7.1</td><td class="colsep0 rowsep0" align="left">296.9 ± 56.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b>, tirabrutinib</td><td class="colsep0 rowsep0" align="left">103.0 ± 56.2</td><td class="colsep0 rowsep0" align="left">312.3 ± 33.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b>, ibrutinib</td><td class="colsep0 rowsep0" align="left">12.0 ± 1.4</td><td class="colsep0 rowsep0" align="left">171.0 ± 15.0</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t9fn1"><div class="footnote" id="t9fn1"><sup><sup>a</sup></sup><p class="last">CD69 expression on CD19<sup>+</sup> B cells in human whole blood was measured after stimulation with anti-IgM.</p></div><div class="footnote" id="t9fn2"><sup><sup>b</sup></sup><p class="last">CD63 expression on basophils upon activation by IgE mediated-FcεR ligation. Each entry represents the mean IC<sub>50</sub> and standard deviation determined using blood from at least three donors.</p></div></div></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Preclinical Efficacy in Rheumatoid Arthritis and Lupus</h3><div class="NLM_p">To evaluate the <i>in vivo</i> efficacy of <b>29</b>, we tested it in a B and myeloid cell-dependent inflammatory arthritis model. Female Lewis rats with developing collagen-induced arthritis<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> were dosed orally for 16 days with <b>29</b> at a range of doses once (0.06, 0.25, 1, 4, and 16 mg/kg QD) (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>A) or twice (0.125, 0.5, and 2 mg/kg BID) daily (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>B). <b>29</b> dose-dependently reduced ankle thickness following QD (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>A) and BID (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>B) dosing regimens. Furthermore, <b>29</b> showed a dose responsive beneficial effect on a panel of ankle histopathology parameters (inflammation, pannus, cartilage damage, bone resorption; data not shown). We also assessed the ankle diameter expressed as area under the curve (AUC) as an efficacy parameter. Ankle diameter AUC was significantly reduced toward normal for rats treated QD with 16 mg/kg (99% reduction), 4 mg/kg (89%), 1 mg/kg (71%), and 0.25 mg/kg <b>29</b> (26%) or BID with 2 mg/kg (96%), 0.5 mg/kg (79%), and 0.125 mg/kg <b>29</b> (50%) as compared with the respective disease controls. The QD 16 mg/kg dose and the BID 2 mg/kg dose of <b>29</b> showed comparable (to slightly improved) efficacy relative to dexamethasone. In naı̈ve rats treated with vehicle, the ankle diameters did not change over the course of the study and ankle diameters from normal rats were significantly smaller (<i>P</i> <  0.05) than those of the rats with CIA that were treated with vehicle.</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/medium/jm-2017-017125_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/large/jm-2017-017125_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Efficacy of GDC-0853 (<b>29</b>) in rat type II collagen-induced arthritis (CIA). Female Lewis rats with developing CIA (<i>n</i> = 10 per group) were dosed orally either once (A) or twice (B) daily for 16 days (study days 0–15) with vehicle [HPMCT (pH 3): 1% HPMC E4M, 100 mM citrate buffer (pH 3), and 0.2% Tween 80], the indicated doses of <b>29</b> or the reference compound dexamethasone (0.05 mg/kg QD). Daily ankle diameter measurements are shown as mean ± SEM and were significantly (by ANOVA) reduced toward normal for all drug-treated rats as compared with the respective disease control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/large/jm-2017-017125_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01712&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Oral dosing with <b>29</b> at 1, 4, and 16 mg/kg QD (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>A) maintained plasma concentrations above the rat whole blood pBtk potency, as determined by inhibition of Btk Y223 autophosphorylation (IC<sub>50</sub> = 9 nM, IC<sub>70</sub> = 27 nM, IC<sub>90</sub> = 135 nM), for a minimum of 12 h of the 24-h dosing period. BID dosing at 0.125, 0.5, and 2 mg/kg (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>B) also maintained plasma concentrations above the IC<sub>50</sub>, IC<sub>70</sub>, and IC<sub>90</sub> levels for a minimum of 6 h of the 12-h dosing period. Doses of 1 mg/kg QD and 0.5 mg/kg BID were associated with plasma concentrations that, at a minimum, exceeded the whole blood pBtk IC<sub>70</sub> (27 nM) for approximately 12 h in a 24-h period. This exposure-efficacy relationship suggests that plasma concentrations of <b>29</b> in excess of the IC<sub>70</sub> for 12 h were required to achieve efficacy, defined as a reduction of ∼75% of ankle swelling. Increased target coverage, as seen at the 4 mg/kg QD dose covered the IC<sub>90</sub> for 24 h and offered further efficacy improvement. The efficacy of Btk inhibition by noncovalent inhibitors has also been assessed in mouse models of SLE.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Taken together, these impressive <i>in vivo</i> efficacy results with our noncovalent Btk inhibitors, combined with the excellent preclinical pharmacologic, pharmacokinetic and <i>in vitro</i> safety profile of <b>29</b>, gave us confidence to progress this molecule into tolerability studies.</div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/medium/jm-2017-017125_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/large/jm-2017-017125_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Plasma concentration of <b>29</b> vs time plots for female Lewis rats with developing CIA. Graphical representation of the pharmacokinetic profile of <b>29</b> after 6 days of once daily (A) or twice daily (B) oral dosing (i.e., study day 14 in <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). Each concentration represents a mean concentration from three rats from a satellite group designated for pharmacokinetic collections. For BID dosing (B), doses were given 12 h apart and concentrations were collected only for a 12-h period. Dotted lines denote the mean IC<sub>50</sub> = 9 nM, IC<sub>70</sub> = 27 nM, and IC<sub>90</sub> = 135 nM levels, as determined by inhibition of Btk Y223 autophosphorylation in rat whole blood.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/large/jm-2017-017125_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01712&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> GDC-0853: Preclinical Tolerability and Toxicity</h3><div class="NLM_p last">In studies designed to assess the safety of the molecule, <b>29</b> was well tolerated in both rats and dogs and displayed an overall favorable safety profile. The no observed adverse effect level (NOAEL) in dogs, the most sensitive preclinical species, was >80-fold higher than the targeted efficacious exposure, i.e., exceeding for 12 h the IC<sub>70</sub> concentration (from the human whole blood CD69 assay). In Sprague–Dawley rats, <b>29</b> and other structurally distinct Btk inhibitors have been shown to be associated with islet-centric pancreatic lesions at clinically relevant doses.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> After a thorough investigation involving evaluation of strain and species sensitivity differences, Btk knockout (KO) mice, and literature reports of humans with XLA mutations, we concluded that the GDC-0853-related pancreas findings in the Sprague–Dawley strain were the result of a rat-specific, strain-variable, on-target effect of Btk inhibition that is not relevant for humans.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> These conclusions have been supported by a histologic evaluation of the pancreas of untreated <i>Btk</i> KO Sprague–Dawley rats, that demonstrated the presence of identical pancreatic pathology.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> With a favorable safety profile and evidence that the observed pancreatic toxicity was a rat-specific phenomenon, we selected <b>29</b> as our lead candidate for clinical development.</div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> GDC-0853: Tackling Btk Mutations in Oncology</h3><div class="NLM_p">We have previously reported that our inhibitors bind to Btk in an orientation that is essentially orthogonal to that of the reported clinical covalent inhibitors. While our inhibitors do bind the hinge region, they do not encroach or interact with either the gatekeeper T474 or the C481 residue that is responsible for covalent interaction with Btk (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>).<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a></div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/medium/jm-2017-017125_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/large/jm-2017-017125_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Superposition of the X-ray structures of <b>29 (</b>GDC-0853) (cyan) and <b>1</b> (ibrutinib)<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> (purple) bound in the kinase domain of Btk. The orthogonal binding modes of these inhibitors are apparent: <b>1</b> (ibrutinib) occupies the kinase back pocket behind the gatekeeper T474 and also interacts with C481; <b>29</b> does neither.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/large/jm-2017-017125_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01712&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We hypothesized that if drug resistance appeared in patients being treated with ibrutinib, our unique inhibitors could retain activity against certain mutant forms of Btk. Thus, we proactively generated nine potential Btk mutant proteins and tested the potency of <b>29</b> against them. We have previously reported that our Btk inhibitors retain activity against clinically occurring mutant forms of Btk, most notably the C481S active site mutation.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> We extended these studies to <b>29</b> and assessed the effect of it and <b>1</b> (ibrutinib) on Y223 phosphorylation of wild type Btk and of the C481S mutant in HEK293T cells transiently expressing these proteins.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> Whereas no Btk protein was detected in nontransfected cells (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>a, lane 1), transient transfection with WT Btk or Btk C481S-encoding plasmids (lanes 2 and 3, respectively) yielded similar total Btk protein levels and pY223 tyrosine phosphorylation levels as assessed by Western blotting with anti-total or anti-pY223 Btk antibodies. In cells that were transfected with either WT Btk or Btk C481S plasmids and treated with vehicle alone, robust levels of pY223 were observed for both WT (lane 1) and C481S (lane 4) mutant Btk. Treatment of WT Btk-transfected cells with 1 μM of either <b>1</b> (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>b, lane 2) or <b>29</b> (lane 3) ablated Y223 phosphorylation. In contrast, in C481S Btk-transfected cells, treatment with 1 μM <b>1</b> failed to block autophosphorylation of the Btk C481S protein on Y223 (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>b, lane 5), whereas 1 μΜ GDC-0853 fully inhibited Y223 autophosphorylation of the Btk-C481S protein (lane 6). Likewise, in biochemical testing <b>29</b> maintained its inhibitory activity against four Btk enzyme mutants at either the active site C481 or the gatekeeper threonine residues: C481S, C481R, T474I, and T474 M (<a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">Table <a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">10</a></a>). Similarly, six of our other H3-binding Btk inhibitors also showed equivalent inhibitory activity against WT Btk and the C481S and T474 M mutants, while being slightly less active against the T474I mutant (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01712/suppl_file/jm7b01712_si_002.pdf" class="ext-link">Table S-1</a>, Supporting Information).</div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/medium/jm-2017-017125_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/large/jm-2017-017125_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. <b>29</b> (GDC-0853) blocked cellular autophosphorylation of WT Btk and the C481S mutant: (a) Btk protein levels and Btk Y223 autophosphorylation was assessed by western blotting, with anti-total or anti-pY223 Btk antibodies, respectively, of HEK293T cells transiently transfected with plasmids encoding WT (lane 2) or C481S Btk (lane 3) or nontransfected cells (lane 1). (b) <b>1</b> and <b>29</b> both blocked cellular autophosphorylation of Y223 in WT Btk. However, only <b>29</b> was able to inhibit cellular autophosphorylation of Y223 of the C481S Btk mutant protein. Ibrutinib (<b>1</b>) was unable to block cellular Y223 autophosphorylation of Btk C481S. The effect of <b>29</b> or <b>1</b> (ibrutinib) on WT Btk and Btk-C481S mutant phosphorylation on Y223 was assessed and quantified as previously described.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/large/jm-2017-017125_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01712&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl10"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 10. Biochemical Potency of <b>29</b> against WT Btk and the C481S, C481R, T474I, and T474M Mutants<a class="ref internalNav" href="#tbl10-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="5" align="center"><i>K</i><sub>i</sub> (nM) against Btk enzyme form</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">inhibitor</th><th class="colsep0 rowsep0" align="center">WT</th><th class="colsep0 rowsep0" align="center">C481S</th><th class="colsep0 rowsep0" align="center">C481R</th><th class="colsep0 rowsep0" align="center">T474I</th><th class="colsep0 rowsep0" align="center">T474M</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>29</b>, GDC-0853</td><td class="colsep0 rowsep0" align="left">0.91 ± 0.34</td><td class="colsep0 rowsep0" align="left">1.6 ± 0.9</td><td class="colsep0 rowsep0" align="left">1.3 ± 0.6</td><td class="colsep0 rowsep0" align="left">12.6 ± 4.8</td><td class="colsep0 rowsep0" align="left">3.4 ± 0.6</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl10-fn1"><div class="footnote" id="tbl10-fn1"><sup><sup>a</sup></sup><p class="last">Each <i>K</i><sub>i</sub> is the mean ± SD of at least three inhibitor titrations.</p></div></div></div><div class="NLM_p last">In 2013, Chang and co-workers reported the first cases of NHL or CLL patients relapsing on ibrutinib.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> Genomic sequencing of these lymphomas showed that the <i>BTK</i><sup><i>C481S</i></sup> mutation was prevalent in these patients. Because <b>29</b> has the potential to treat ibrutinib relapsed patients harboring the <i>BTK</i><sup><i>C481S</i></sup> mutation, we are currently conducting a first-in-human Phase 1 study in patients with relapsed or refractory B cell NHL and CLL that had relapsed on ibrutinib, and in particular those that were identified to be <i>BTK</i><sup><i>C481S</i></sup> positive. Initial results of this study will be reported shortly.</div></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Synthesis of GDC-0853 (<b>29</b>)</h3><div class="NLM_p">GDC-0853 (<b>29</b>) was synthesized in a highly convergent manner as shown in <a class="ref internalNav" href="#sch1" aria-label="Schemes 1">Schemes 1</a> and <a class="ref internalNav" href="#sch2" aria-label="2">2</a>. <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a> shows the synthesis of the left portion of the molecule, intermediate <b>41</b>. Wittig olefination of chlorovinyl aldehyde <b>35</b><a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> gave olefin intermediate <b>36</b>. Treatment with sodium azide and subsequent heating gave rise to pyrrole <b>37</b> following denitrogenative cyclization via the nitrene. The tricylic lactam <b>40</b> was then accessed via a three-step sequence: N-alkylation with bromoacetonitrile, nitrile reduction, and base-mediated saponification/lactam cyclization. Finally, palladium catalyzed C–N coupling gave the desired H3-linker intermediate <b>41</b> via coupling with bromo-pyridine aldehyde <b>42</b> in the presence of Pd<sub>2</sub>(dba)<sub>3</sub> and xantphos in 32% yield.</div><figure id="sch1" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/medium/jm-2017-017125_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/large/jm-2017-017125_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of <b>29</b> Part 1: Synthesis of Intermediate <b>42</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/large/jm-2017-017125_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01712&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Ethoxycarbonylmethylene triphenylphosphoran, benzene, 14 h, 37%; (b) NaN<sub>3</sub>, DMSO, 75 °C, 8 h, 37%; (c) NaH, DMF, bromoacetonitrile, 14 h, 95%; (d) 10% Pd/C, 12% HCl in EtOH/EtOAc, H<sub>2</sub> (50 psi), 6 h; (e) NaOEt, EtOH, 55 °C, overnight, 61%, 2 steps; (f) 2-bromo-4-chloronicotinaldehyde (<b>42</b>), Pd<sub>2</sub>(dba)<sub>3</sub>, Xantphos, Cs<sub>2</sub>CO<sub>3</sub>, dioxane, 100 °C, 5 h, 63%.</p></p></figure><figure id="sch2" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/medium/jm-2017-017125_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/large/jm-2017-017125_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of <b>29</b> Part 2<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/large/jm-2017-017125_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01712&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Pd<sub>2</sub>(dba)<sub>3</sub>, BINAP, Cs<sub>2</sub>CO<sub>3</sub>, dioxane, 100 °C, 15 h, 63%; (b) H<sub>2</sub>, Pd/C, MeOH, 16 h, 93%; (c) 3,5-dibromo-1-methylpyridin-2(1<i>H</i>)-one, Pd<sub>2</sub>(dba)<sub>3</sub>, Xantphos, Cs<sub>2</sub>CO<sub>3</sub>, dioxane, 100 °C, 16 h, 61%; (d) HCl in dioxane, DCM, 4 h, 95%; (e) oxetan-3-one, NaBH<sub>3</sub>CN, ZnCl<sub>2</sub>, MeOH, 50 °C, 4 h, 73%; (f) bis(pinacolato)diboron, Pd<sub>2</sub>(dba)3, Xphos, KOAc, dioxane, 70 °C, 2 h, 90%; (g) Pd(dppf)Cl<sub>2</sub>, K<sub>3</sub>PO<sub>4</sub>, THF, H<sub>2</sub>O, reflux, 3 h, 31%; (h) NaBH<sub>4</sub>, MeOH, 1 h, 44%.</p></p></figure><div class="NLM_p last">The synthesis of <b>29</b> was completed as shown in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. The H2 motif was assembled via two C–N coupling reactions, first between bromopyridine <b>43</b><a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> and Boc-protected piperazine <b>44</b> to afford intermediate <b>45</b>. Subsequent nitro reduction (to <b>46</b>) set up the second coupling, this time with 3,5-dibromo-1-methylpyridin-2(1<i>H</i>)-one to give <b>47</b>. Boc deprotection followed by reductive amination with oxetan-3-one in the presence of ZnCl<sub>2</sub> afforded the fully formed right-hand side of the molecule in the form of <b>49</b>. Borylation of <b>49</b> with bis(pinacolato)diboron set up the penultimate step of the synthesis, Suzuki coupling with H3-linker aldehyde <b>41</b> to give <b>51</b> in 31% yield. Finally, aldehyde reduction of <b>51</b> with NaBH<sub>4</sub> gave GDC-0853, <b>29</b>. Analogues <b>7</b>–<b>10</b>, <b>12</b>–<b>15</b>, and <b>30</b>–<b>32</b> were prepared in a similar manner using the appropriate left-hand moiety and H2 motif (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01712/suppl_file/jm7b01712_si_002.pdf" class="ext-link">Supporting Information</a>). The synthetic details of additional intermediates and characterization details are provided in the <a class="ref internalNav" href="#sec3" aria-label="Experimental Section">Experimental Section</a> and <a href="/doi/suppl/10.1021/acs.jmedchem.7b01712/suppl_file/jm7b01712_si_002.pdf" class="ext-link">Supporting Information</a>.</div></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Conclusion and Clinical Evaluation in Immunology Indications</h3><div class="NLM_p last">In summary, we have discovered a potential best-in-class Btk inhibitor, GDC-0853 (<b>29</b>), that is currently in clinical investigation for several immune disorders. It is highly potent and is the most selective Btk inhibitor reported to date. Its preclinical pharmacokinetic characteristics are favorable, indicating the potential for QD oral dosing. In addition, the supporting efficacy data reported here suggest that it could have utility in treating rheumatoid arthritis and other B-cell or myeloid cell mediated autoimmune diseases. These findings, combined with a very desirable tolerability and safety profile in multiple species, encouraged us to progress <b>29</b> into clinical studies in autoimmune diseases. In a single ascending dose (SAD) study (0.5 mg to 600 mg) and multiple ascending dose (MAD) study for 14 days (250 mg of BID to 500 mg of QD) in healthy volunteers, GDC-0853 was very well tolerated with no severe adverse events, no safety signals, and no dose limiting toxicities. Additionally, <b>29</b> was well absorbed and had linear, dose-proportional PK. Target engagement (CD63, CD69, pBTK) was assessed and complete suppression of PD markers was maintained over 24 h. With favorable Phase 1 results, <b>29</b> entered Phase 2 clinical studies in rheumatoid arthritis, lupus, and chronic urticaria.<a onclick="showRef(event, 'ref61 ref62 ref63'); return false;" href="javascript:void(0);" class="ref ref61 ref62 ref63">(61−63)</a> Further details and clinical results will be reported in due course.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i24">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71866" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71866" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">All chemicals were purchased from commercial suppliers and used as received. <sup>1</sup>H NMR spectra were recorded on Bruker Avance 400 or 500 spectrometers. Chemical shifts are expressed in δ ppm referenced to an internal standard, tetramethylsilane (δ = 0 ppm). Abbreviations used in describing peak signals are br = broad signal, s = singlet, d = doublet, dd = doublet of doublets, t = triplet, q = quartet, m = multiplet. All final compounds were purified to have purity higher than 95% by reverse phase high-performance liquid chromatography (HPLC), supercritical fluid chromatography (SFC) or normal phase silica gel flash chromatography. The purity was assessed by reverse phase HPLC with an isocratic gradient of 5–95% acetonitrile in water (with either acid or base modifier) and monitored by diode array ultraviolet detection at 254 nm. Low-resolution mass spectra were recorded on a liquid chromatography–mass spectrometer in electrospray positive (ES+) mode. HRMS experiments were performed on a Dionex LC Ultimate3000 coupled with a ThermoScientific Q Exactive orbitrap mass spectrometer using ESI as the ionization source and a Phenomenex XB-C18, 1.7 mm, 50 mm × 2.1 mm column with a 0.7 mL/min flow rate at 40 °C for LC separation. Solvent A was 0.1% FA in water and solvent B was 0.1% FA in acetonitrile. The gradient consisted of 2–98% solvent B over 7 min and held at 98% B for 1.5 min following equilibration for 1.0 min. The LC was monitored by UV absorbance at 220 and 254 nm. MS full scans with 10 000 resolution were applied to all experiments.</div><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> (<i>S</i>)-2-(3′-(Hydroxymethyl)-1-methyl-5-((5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)-6-oxo-1,6-dihydro-[3,4′-bipyridin]-2′-yl)-7,7-dimethyl-3,4,7,8-tetrahydro-2<i>H</i>-cyclopenta[4,5]pyrrolo[1,2-<i>a</i>]pyrazin-1(6<i>H</i>)-one (<b>29</b>)</h3><div class="NLM_p">Step 1: A 100 mL single-neck round-bottomed flask equipped with a magnetic stirrer and a reflux condenser was charged with <b>49</b> (1.0 g, 2.3 mmol), Pin<sub>2</sub>B<sub>2</sub> (1.4 g, 5.7 mmol), Pd<sub>2</sub>(dba)<sub>3</sub> (105 mg, 0.13 mmol), XPhos (93 mg, 0.23 mmol), KOAc (680 mg, 6.9 mmol), and dioxane (50 mL). After three vacuum purge/argon fill cycles, the mixture was heated to 70 °C and stirred for 2 h. It was then cooled to room temperature and filtered. The filtrate was concentrated under reduced pressure, and the resulting residue was washed with 3:1 petroleum ether/EtOAc (80 mL) to obtain the boronate ester <b>50</b> as a yellow solid (1.0 g, 90% yield) without further purification. [ES-MS] (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>25</sub>H<sub>37</sub>BN<sub>5</sub>O<sub>4</sub> [M + H]<sup>+</sup>, 482; found, 482.</div><div class="NLM_p">Step 2: A 50 mL single-neck round-bottomed flask equipped with a magnetic stirrer and a reflux condenser was charged with <b>50</b> (420 mg, 0.44 mmol), <b>41</b> (200 mg, 0.88 mmol), Pd(dppf)Cl<sub>2</sub> (36 mg, 0.044 mmol), K<sub>3</sub>PO<sub>4</sub> (279 mg, 1.32 mmol), and THF (20 mL). After three vacuum purge/argon fill cycles, the mixture was heated at reflux for 3 h. It was then cooled to room temperature and filtered. The filtrate was concentrated under reduced pressure, and the resulting residue was washed with 3:1 petroleum ether/EtOAc (80 mL) to give (<i>S</i>)-2′-(7,7-dimethyl-1-oxo-1,3,4,6,7,8-hexahydro-2<i>H</i>-cyclopenta[4,5]pyrrolo[1,2-<i>a</i>]pyrazin-2-yl)-1-methyl-5-((5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)-6-oxo-1,6-dihydro-[3,4′-bipyridine]-3′-carbaldehyde <b>51</b> (90 mg, 31% yield) as a solid without further purification. [ES-MS] (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>37</sub>H<sub>43</sub>N<sub>8</sub>O<sub>4</sub> [M + H]<sup>+</sup>, 663; found, 663.</div><div class="NLM_p last">Step 3: A 50 mL single-neck round-bottomed flask equipped with a magnetic stirrer was charged with <b>51</b> (90 mg, 0.11 mmol), NaBH<sub>4</sub> (13 mg, 0.33 mmol), and MeOH (10 mL). The mixture was stirred at room temperature for 1 h. It was then filtered and the filtrate concentrated under reduced pressure. The residue was purified by reversed-phase prep-HPLC to afford 40 mg of the title compound <b>29</b> as a yellow solid. Yield: 44%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.62 (d, <i>J</i> = 2.4 Hz, 1H), 8.48 (d, <i>J</i> = 5.0 Hz, 1H), 8.43 (s, 1H), 7.83 (d, <i>J</i> = 2.9 Hz, 1H), 7.47 (d, <i>J</i> = 2.4 Hz, 1H), 7.41–7.31 (m, 2H), 7.24 (d, <i>J</i> = 9.0 Hz, 1H), 6.56 (s, 1H), 4.96 (t, <i>J</i> = 5.2 Hz, 1H), 4.59–4.52 (m, 2H), 4.51–4.35 (m, 4H), 4.29–4.15 (m, 3H), 3.89–3.80 (m, 1H), 3.72–3.63 (m, 1H), 3.60 (s, 3H), 3.44–3.35 (m, 1H), 3.14–3.04 (m, 1H), 2.99–2.90 (m, 1H), 2.65–2.52 (m, 3H), 2.43 (s, 2H), 2.39–2.23 (m, 2H), 2.24–2.14 (m, 1H), 1.22 (s, 6H), 0.93 (d, <i>J</i> = 6.3 Hz, 3H). <sup>13</sup>C NMR (101 MHz, DMSO) δ 159.75, 157.20, 155.30, 149.47, 149.19, 148.36, 141.31, 140.13, 137.08, 131.36, 131.21, 129.11, 127.81, 126.27, 126.00, 124.20, 116.83, 116.26, 113.47, 109.29, 74.93, 74.80, 58.87, 57.65, 55.63, 51.23, 49.83, 48.33, 46.02, 46.01, 42.41, 41.19, 39.44, 38.01, 30.64, 30.52, 14.03. HRMS (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>37</sub>H<sub>45</sub>N<sub>8</sub>O<sub>4</sub> [M + H]<sup>+</sup>, 665.3564; found, <i>m</i>/<i>z</i> 665.3550</div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> 7,7-Dimethyl-3,4,7,8-tetrahydro-2<i>H</i>-cyclopenta[4,5]pyrrolo[1,2-<i>a</i>]pyrazin-1(6<i>H</i>)-one (<b>40</b>)</h3><div class="NLM_p">Step 1: A 500 mL single neck round bottomed flask equipped with a magnetic stirrer and nitrogen inlet was charged with 2-chloro-4,4-dimethylcyclopent-1-enecarbaldehyde (38 g, 240 mmol) in benzene (240 mL). To the solution was added ethoxycarbonylmethylene triphenylphosphorane (84 g, 240 mmol, 1 equiv). The mixture was stirred for 14 h. After that time, the solvent was evaporated and the residue was triturated with hexanes (2 L) to extract the product away from the triphenylphosphine byproducts. The organic layer was dried over sodium sulfate and concentrated <i>in vacuo</i>. The residue was purified by column chromatography (SiO<sub>2</sub>: ethyl acetate/hexane) to afford (<i>E</i>)-ethyl 3-(2-chloro-4,4-dimethylcyclopent-1-enyl)acrylate <b>36</b> (20 g, 37% yield).</div><div class="NLM_p">Step 2: A 250 mL single neck round bottomed flask equipped with a magnetic stirrer and nitrogen inlet was charged with <b>36</b> (17 g, 74 mmol) in DMSO (100 mL). To the solution was added sodium azide (9.6 g, 150 mmol, 2 equiv). The mixture was then heated to 75 °C and stirred for 8 h. After cooling to room temperature, H<sub>2</sub>O (100 mL) and DCM (200 mL) were added and the organic layer was separated. The aqueous layer was extracted with DCM (50 mL). The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated <i>in vacuo</i>. The residue was purified by column chromatography (SiO<sub>2</sub>: ethyl acetate/hexane) to afford ethyl 5,5-dimethyl-1,4,5,6-tetrahydrocyclopenta[<i>b</i>]pyrrole-2-carboxylate <b>37</b> (5.7 g, 37% yield).</div><div class="NLM_p">Step 3: A 250 mL single neck round bottomed flask equipped with a magnetic stirrer and nitrogen inlet was charged with <b>37</b> (6.2 g, 30 mmol) in DMF (57 mL). To the solution was added NaH (80% dispersion in mineral oil, 1.3 g, 42 mmol, 1.4 equiv). The resulting mixture was stirred at room temperature for 90 min. After that time, bromoacetonitrile (2.9 mL, 42 mmol, 1.4 equiv) was added. The mixture was stirred for 14 h. After that time, water (100 mL) and ethyl acetate (200 mL) were added and the organic layer was separated. The aqueous layer was extracted with ethyl acetate (2 × 50 mL). The combined organic layers were washed with brine, dried over sodium sulfate and concentrated <i>in vacuo</i>. The residue was purified by column chromatography (SiO<sub>2</sub>: ethyl acetate/hexane) to yield ethyl 1-(cyanomethyl)-5,5-dimethyl-1,4,5,6-tetrahydrocyclopenta[<i>b</i>]pyrrole-2-carboxylate <b>38</b> (7 g, 95% yield).</div><div class="NLM_p">Step 4: A 500 mL Parr reactor bottle was purged with nitrogen and charged with 10% palladium on carbon (50% wet, 2 g dry weight), <b>38</b> (4.5 g, 18 mmol), 12% hydrochloric acid (9.2 mL, 37 mmol) in ethyl acetate (80 mL) and ethanol (52 mL). The bottle was attached to a Parr hydrogenator, evacuated, charged with hydrogen gas to a pressure of 50 psi, and shaken for 6 h. After this time, the hydrogen was evacuated, and nitrogen was charged into the bottle. CELITE (10.0 g) was added and the mixture was filtered through a pad of CELITE. The filter cake was washed with ethanol (2 × 50 mL), and the combined filtrates were concentrated to dryness under reduced pressure. The crude residue ethyl 1-(2-aminoethyl)-5,5-dimethyl-1,4,5,6-tetrahydrocyclo-penta[<i>b</i>]pyrrole-2-carboxylate hydrochloride <b>39</b> was carried onto the next step without further purification.</div><div class="NLM_p last">Step 5: A 100 mL single-neck round-bottomed flask equipped with a magnetic stirrer and nitrogen inlet was purged with nitrogen and charged with crude <b>39</b> (∼18 mmol), sodium ethoxide (6.2 g, 92 mmol), and ethanol (120 mL). The mixture was stirred at 55 °C overnight. After that time, the reaction mixture was concentrated under reduced pressure, and the residue was partitioned between ethyl acetate (200 mL) and water (100 mL). The solution was filtered. The solid was washed with ethyl acetate (15 mL) to give 850 mg of desired product <b>40</b>. The organic layer was then separated and the aqueous layer extracted with ethyl acetate (2 × 100 mL). The combined organic layers were dried over sodium sulfate and concentrated under reduced pressure to near dryness. The solution was filtered and the additional solid <b>40</b> (1.44 g) was washed with ethyl acetate (15 mL). The combined solids were dried under vacuum to yield the title compound <b>40</b> as a yellow solid (2.3 g, 61% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 6.70 (s, 1H), 5.82 (s, 1H), 3.96–3.93 (m, 2H), 3.65 (s, 2H), 2.50 (s, 2H), 2.47 (s, 2H), 1.23 (s, 6H). [ES-MS] (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>12</sub>H<sub>17</sub>N<sub>2</sub>O [M + H]<sup>+</sup>, 205.1; found, 205.</div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> 4-Chloro-2-(7,7-dimethyl-1-oxo-1,3,4,6,7,8-hexahydro-2<i>H</i>-cyclopenta[4,5]pyrrolo[1,2-<i>a</i>]pyrazin-2-yl)nicotinaldehyde (<b>41</b>)</h3><div class="NLM_p last">A flask equipped with a magnetic stirrer and a reflux condenser was charged with 2-bromo-4-chloronicotinaldehyde (25.0 g, 115 mmol), <b>40</b> (24.5 g, 120.0 mmol), Pd<sub>2</sub>(dba)<sub>3</sub> (9.2 mg, 10.0 mmol), XantPhos (5.7 g, 10 mmol), Cs<sub>2</sub>CO<sub>3</sub> (74.7 g, 230.0 mmol), and 1,4-dioxane (1 L). After three cycles of vacuum/argon flush, the mixture was heated at 90 °C for 5 h. It was then cooled to room temperature and filtered, then partitioned between ethyl acetate (500 mL) and water (100 mL). The aqueous layer was separated and extracted with ethyl acetate (500 mL × 3). The combined organic layers were washed with brine (500 mL) and dried over sodium sulfate, filtered, and concentrated. The residue was purified by silica gel chromatography (DCM/MeOH = 40/1) to give the title compound (25 g, 63% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.84 (s, 1H), 8.58 (d, <i>J</i> = 5.5 Hz, 1H), 7.53 (d, <i>J</i> = 5.4 Hz, 1H), 6.61 (s, 1H), 4.30–4.17 (m, 4H), 2.58 (s, 2H), 2.42 (s, 2H), 1.21 (s, 6H). [ES-MS] (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>18</sub>H<sub>18</sub>ClN<sub>3</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 344.1; found, 344.0.</div></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> (3<i>S</i>)-<i>tert</i>-Butyl-4-(6-aminopyridin-3-yl)-3-methylpiperazine-1-carboxylate (<b>46</b>)</h3><div class="NLM_p">Step 1: A 3-L single-neck round-bottomed flask equipped with a magnetic stirrer and reflux condenser was charged with 5-bromo-2-nitropyridine (100 g, 0.49 mol), (<i>S</i>)-<i>tert</i>-butyl 3-methylpiperazine-1-carboxylate (99.5 g, 0.49 mol), cesium carbonate (332 g, 1 mol), and 1,4-dioxane (1.5 L). After bubbling nitrogen through the resulting solution for 30 min, BINAP (24 g, 0.039 mmol) and Pd<sub>2</sub>(dba)<sub>3</sub> (35.6 g, 0.039 mmol) were added, and the reaction mixture was stirred at 100 °C for 15 h. After this time, the reaction was cooled to room temperature, partitioned between ethyl acetate (1 L) and water (300 mL), and filtered. The aqueous layer was separated and extracted with ethyl acetate (3 × 500 mL). The combined organic layer was washed with brine (500 mL) and dried over sodium sulfate. The drying agent was removed by filtration, and the filtrate was concentrated under reduced pressure. The residue was purified on flash column chromatography (SiO<sub>2</sub>: petroleum ether/ethyl acetate) to give (3<i>S</i>)-<i>tert</i>-butyl 3-methyl-4-(6-nitropyridin-3-yl)piperazine-1-carboxylate <b>45</b> (100 g, 63% yield). [ES-MS] (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>15</sub>H<sub>23</sub>N<sub>4</sub>O<sub>4</sub>, [M + H]<sup>+</sup>, 323; found, 323.</div><div class="NLM_p last">Step 2: A 2-L flask was purged with nitrogen and charged with <b>45</b> (100 g, 0.31 mol), 10% palladium on carbon (50% wet, 8 g), and ethanol (1 L). It was then evacuated, charged with hydrogen gas, and stirred at room temperature for 16 h. Hydrogen was evacuated and nitrogen was charged into the flask. The catalyst was removed by filtration through a pad of Celite and the filtrate was concentrated under reduced pressure to give the title compound <b>46</b> (85 g, 93% yield). [ES-MS] (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>15</sub>H<sub>25</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 293; found, 293.</div></div><div id="sec3_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> (3<i>S</i>)-5-Bromo-1-methyl-3-(5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridine-2-ylamino)pyridin-2(1<i>H</i>)-one (<b>49</b>)</h3><div class="NLM_p">Step 1: A 2-L single-neck round-bottomed flask equipped with a magnetic stirrer and reflux condenser was charged with 1,4-dioxane (1 L), <b>46</b> (60 g, 210 mmol), 3,5-dibromo-1-methylpyridin-2(1<i>H</i>)-one (56 g, 210 mmol), and cesium carbonate (139 g, 427 mmol). After bubbling nitrogen through the resulting solution for 30 min, Xantphos (9.7 g, 16.8 mmol) and Pd<sub>2</sub>(dba)<sub>3</sub> (15.1 g, 16.8 mmol) were added, and the reaction mixture was heated at reflux for 15 h. After this time, the reaction was cooled to room temperature, partitioned between ethyl acetate (500 mL) and water (100 mL), and filtered. The aqueous layer was separated and extracted with ethyl acetate (3 × 500 mL). The combined organic layer was washed with brine (500 mL) and dried over sodium sulfate. The drying agent was removed by filtration, and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (SiO<sub>2</sub>: DCM/MeOH) to afford <b>(</b>3<i>S</i>)-<i>tert</i>-butyl-4-(6-(5-bromo-1-methyl-2-oxo-1,2-dihydropyridin-3-ylamino)pyridine-3-yl)-3-methylpiperazine-1-carboxylate <b>47</b> (60 g, 61%). [ES-MS] (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>29</sub>BrN<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 478; found, 478.</div><div class="NLM_p">Step 2: To a solution of <b>47</b> (55 g, 115 mmol) in DCM (500 mL) was added 3.0 M HCl in dioxane (150 mL). The reaction mixture was stirred at room temperature for 4 h and filtered. The filtrate was reduced under reduced pressure. The residue was basified with aqueous 1.0 M NaOH and extracted with methylene chloride to obtain (3<i>S</i>)-5-bromo-1-methyl-3-(5-(2-methylpiperazin-1-yl)pyridin-2-ylamino)pyridine-2(1<i>H</i>)-one <b>48 (</b>42 g, 95% yield). [ES-MS] (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>21</sub>BrN<sub>5</sub>O [M + H]<sup>+</sup>, 378; found, 378.</div><div class="NLM_p last">Step 3: A mixture of <b>48</b> (40 g, 106 mmol), oxetan-3-one (11.4 g, 159 mmol), NaBH<sub>3</sub>CN (10.0 g, 159 mmol), and zinc chloride (21.3 g, 159 mmol) in methanol (700 mL) was stirred at 50 °C for 4 h. The mixture was added to H<sub>2</sub>O (50 mL) and extracted with DCM three times (200 mL × 3). The combined organic layers were concentrated under reduced pressure. The residue was purified by column chromatography (SiO<sub>2</sub>: DCM/MeOH) to give the title compound <b>49</b> (35 g, 73% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.60 (d, <i>J</i> = 2.5 Hz, 1 H), 8.03 (d, <i>J</i> = 3.0 Hz, 1 H), 7.80 (s, 1 H), 7.30 (dd, <i>J</i> = 9.0 Hz, <i>J</i> = 2.5 Hz, 1 H), 6.95 (d, <i>J</i> = 2.5 Hz, 1 H), 6.76 (d, <i>J</i> = 8.5 Hz, 1 H), 4.72–4.62 (m, 4 H), 3.60 (s, 3 H), 3.54–3.48 (m, 2 H), 3.09 (t, <i>J</i> = 5.5 Hz, 2 H), 2.56–2.43 (m, 3 H), 2.25–2.22 (m, 1 H), 1.00 (d, <i>J</i> = 6.0 Hz, 3 H). [ES-MS] (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>19</sub>H<sub>25</sub>BrN<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 434; found, 434.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="NOTES-d49e3412-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i30"><a href="/doi/suppl/10.1021/acs.jmedchem.7b01712" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02041" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02041" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.7b01712" class="ext-link">10.1021/acs.jmedchem.7b01712</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01712/suppl_file/jm7b01712_si_001.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Chemistry; assay conditions; metabolic stability assays; biochemical potency of inhibitors against WT Btk and the C481S, C481R, T474I, and T474M mutants; kinase selectivity of Btk inhibitors; GDC-0853 residence time assay; developing rat collagen induced arthritis study (CIA); cytotoxicity prediction computational model; quantum torsion scan of the GDC-0853 piperazine-to-pyridyl bond; physicochemical properties of GDC-0853; <i>in vitro</i> safety profiling methods; protein purification, crystallographic methods, and crystallographic parameters of X-ray structure of <b>29</b>, GDC-0853, bound to Btk) (<a href="/doi/suppl/10.1021/acs.jmedchem.7b01712/suppl_file/jm7b01712_si_002.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01712/suppl_file/jm7b01712_si_001.csv">jm7b01712_si_001.csv (3.03 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01712/suppl_file/jm7b01712_si_002.pdf">jm7b01712_si_002.pdf (945.63 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">The authors will release the coordinates and experimental data upon article publication, PDB accession code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5VFI">5VFI</a></p><div class="testing" data-doi="10.1021/acs.jmedchem.7b01712" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35501" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35501" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">James J. Crawford</span> - <span class="hlFld-Affiliation affiliation">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-6408-8246" title="Orcid link">http://orcid.org/0000-0002-6408-8246</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#771405160011180513591d161a120437101219125914181a"><span class="__cf_email__" data-cfemail="ed8e9f8c9a8b829f89c3878c80889ead8a888388c38e8280">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wendy B. Young</span> - <span class="hlFld-Affiliation affiliation">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-1575-3227" title="Orcid link">http://orcid.org/0000-0003-1575-3227</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#c3baacb6ada4edb4a6ada7ba83a4a6ada6eda0acae"><span class="__cf_email__" data-cfemail="b9c0d6ccd7de97cedcd7ddc0f9dedcd7dc97dad6d4">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Adam R. Johnson</span> - <span class="hlFld-Affiliation affiliation">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dinah L. Misner</span> - <span class="hlFld-Affiliation affiliation">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>; 
    <span>Present Address:
                        D.L.M.: Alios BioPharma Inc., 260 East Grand Avenue, South San Francisco, CA, 94080</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lisa D. Belmont</span> - <span class="hlFld-Affiliation affiliation">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Georgette Castanedo</span> - <span class="hlFld-Affiliation affiliation">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-4584-6715" title="Orcid link">http://orcid.org/0000-0003-4584-6715</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Regina Choy</span> - <span class="hlFld-Affiliation affiliation">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Melis Coraggio</span> - <span class="hlFld-Affiliation affiliation">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>; 
    <span>Present Address:
                        M.C.: Food and Drug Administration (FDA), 10903 New Hampshire Avenue, Silver Springs, MD 20903</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Liming Dong</span> - <span class="hlFld-Affiliation affiliation">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Charles Eigenbrot</span> - <span class="hlFld-Affiliation affiliation">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rebecca Erickson</span> - <span class="hlFld-Affiliation affiliation">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nico Ghilardi</span> - <span class="hlFld-Affiliation affiliation">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jonathan Hau</span> - <span class="hlFld-Affiliation affiliation">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Arna Katewa</span> - <span class="hlFld-Affiliation affiliation">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Pawan Bir Kohli</span> - <span class="hlFld-Affiliation affiliation">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wendy Lee</span> - <span class="hlFld-Affiliation affiliation">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Joseph W. Lubach</span> - <span class="hlFld-Affiliation affiliation">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-5806-0204" title="Orcid link">http://orcid.org/0000-0002-5806-0204</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brent S. McKenzie</span> - <span class="hlFld-Affiliation affiliation">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Daniel F. Ortwine</span> - <span class="hlFld-Affiliation affiliation">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Leah Schutt</span> - <span class="hlFld-Affiliation affiliation">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Suzanne Tay</span> - <span class="hlFld-Affiliation affiliation">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">BinQing Wei</span> - <span class="hlFld-Affiliation affiliation">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Karin Reif</span> - <span class="hlFld-Affiliation affiliation">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lichuan Liu</span> - <span class="hlFld-Affiliation affiliation">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Harvey Wong</span> - <span class="hlFld-Affiliation affiliation">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</span>; 
    <span>Present Address:
                        H.W.: Faculty of Pharmaceutical Sciences, University of British Columbia, 2405 Wesbrook Mall, Vancouver, BC, Canada, V6T 1Z3</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.</p></li><li><span class="author-information-subsection-header">Funding</span><p>Thanks to Genentech, a member of the Roche Group, for the research funds.</p></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): The authors are employees of Genentech, part of the Roche Group.<br /></br><p class="inlineNote">Not a Genentech employee. Liming Dong was an employee of ChemPartner, No. 1 Building, 998 Halei Road, Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai, China 201203.</p></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i37">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_17114" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_17114" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We would like to thank the members of our synthetic chemistry team at Shanghai Chempartner and, in particular, Yu Nan, Deng Wei, Zhou Fusheng, and Shi (Stone) Xiaoyong. We would also like to thank Proteros Biostructures GmbH, who performed crystallographic analysis of BTK/GDC-0853, Rama Pai and Patricia Chang for <i>in vitro</i> cytotoxicity data in primary human hepatocytes, and Sergei Romanov (Nanosyn, Inc.) for assistance with the residence time assay. Finally, we would like to acknowledge the Genentech analytical and purification teams, Seth Harris for assistance with graphics, and Joachim Rudolph for helpful comments and insights.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">ALT</td><td class="NLM_def"><p class="first last">alanine aminotransferase</p></td></tr><tr><td class="NLM_term">AST</td><td class="NLM_def"><p class="first last">aspartate aminotransferase</p></td></tr><tr><td class="NLM_term">BID</td><td class="NLM_def"><p class="first last">twice a day</p></td></tr><tr><td class="NLM_term">Btk</td><td class="NLM_def"><p class="first last">Bruton’s tyrosine kinase</p></td></tr><tr><td class="NLM_term">CLL</td><td class="NLM_def"><p class="first last">chronic lymphocytic leukemia</p></td></tr><tr><td class="NLM_term">DMPK</td><td class="NLM_def"><p class="first last">drug metabolism and pharmacokinetics</p></td></tr><tr><td class="NLM_term">MS</td><td class="NLM_def"><p class="first last">multiple sclerosis</p></td></tr><tr><td class="NLM_term">MCL</td><td class="NLM_def"><p class="first last">Mantle cell lymphoma</p></td></tr><tr><td class="NLM_term">NHL</td><td class="NLM_def"><p class="first last">non-Hodgkin lymphoma</p></td></tr><tr><td class="NLM_term">NOAEL</td><td class="NLM_def"><p class="first last">no observed adverse effect level</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetic</p></td></tr><tr><td class="NLM_term">RA</td><td class="NLM_def"><p class="first last">rheumatoid arthritis</p></td></tr><tr><td class="NLM_term">SLE</td><td class="NLM_def"><p class="first last">systemic lupus erythematosus</p></td></tr><tr><td class="NLM_term"><i>V</i><sub>d</sub></td><td class="NLM_def"><p class="first last">volume of distribution</p></td></tr><tr><td class="NLM_term">WT</td><td class="NLM_def"><p class="first last">wild type.</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i39">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47273" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47273" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 63 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Satterthwaite, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witte, O. N.</span></span> <span> </span><span class="NLM_article-title">Btk Function In B Cell Development and Response</span>. <i>Semin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">309</span>– <span class="NLM_lpage">316</span>, <span class="refDoi"> DOI: 10.1006/smim.1998.0123</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1006%2Fsmim.1998.0123" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=9695187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADyaK1cXltlCiuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1998&pages=309-316&author=A.+B.+Satterthwaiteauthor=Z.+Liauthor=O.+N.+Witte&title=Btk+Function+In+B+Cell+Development+and+Response&doi=10.1006%2Fsmim.1998.0123"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Btk function in B cell development and response</span></div><div class="casAuthors">Satterthwaite, Anne B.; Li, Zuomei; Witte, Owen N.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Immunology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">309-316</span>CODEN:
                <span class="NLM_cas:coden">SEIME2</span>;
        ISSN:<span class="NLM_cas:issn">1044-5323</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">A review with 85 refs.  Mutations in Bruton's tyrosine kinase (Btk) result in the B cell immunodeficiencies XLA (X-linked agammaglobulinemia) in humans and Xid (X-linked immunodeficiency) in mice.  Both the maintenance of peripheral B cell nos. and their response to B cell antigen receptor (BCR) crosslinking depend on Btk.  Btk integrates signals from multiple cell surface receptors, including BCR and G-protein coupled receptors.  These Btk dependent signals control B cell proliferation and survival by mediating Ca2+ flux, activating JNK and p38 and inducing cell cycle regulatory genes.  (c) 1998 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVrVOyUeT25bVg90H21EOLACvtfcHk0liP9HAstviVAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXltlCiuro%253D&md5=f03605bc9f39d663d28794c7b7e40138</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1006%2Fsmim.1998.0123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fsmim.1998.0123%26sid%3Dliteratum%253Aachs%26aulast%3DSatterthwaite%26aufirst%3DA.%2BB.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DWitte%26aufirst%3DO.%2BN.%26atitle%3DBtk%2520Function%2520In%2520B%2520Cell%2520Development%2520and%2520Response%26jtitle%3DSemin.%2520Immunol.%26date%3D1998%26volume%3D10%26spage%3D309%26epage%3D316%26doi%3D10.1006%2Fsmim.1998.0123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khan, W. N.</span></span> <span> </span><span class="NLM_article-title">Regulation of B Lymphocyte Development and Activation by Bruton’s Tyrosine Kinase</span>. <i>Immunol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">147</span>– <span class="NLM_lpage">156</span>, <span class="refDoi"> DOI: 10.1385/IR:23:2-3:147</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1385%2FIR%3A23%3A2-3%3A147" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=11444380" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BD3MXltFWqsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2001&pages=147-156&author=W.+N.+Khan&title=Regulation+of+B+Lymphocyte+Development+and+Activation+by+Bruton%E2%80%99s+Tyrosine+Kinase&doi=10.1385%2FIR%3A23%3A2-3%3A147"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of B lymphocyte development and activation by Bruton's tyrosine kinase</span></div><div class="casAuthors">Khan, Wasif N.</div><div class="citationInfo"><span class="NLM_cas:title">Immunologic Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">2 & 3</span>),
    <span class="NLM_cas:pages">147-156</span>CODEN:
                <span class="NLM_cas:coden">IMRSEB</span>;
        ISSN:<span class="NLM_cas:issn">0257-277X</span>.
    
            (<span class="NLM_cas:orgname">Humana Press Inc.</span>)
        </div><div class="casAbstract">A review discussed the role of Bruton's tyrosine kinase in B lymphocyte development and activation.  The generation and maintenance of B lymphocytes is controlled by biochem. signals transmitted by the B cell antigen receptor (BCR) complex.  These signals are transduced by multiple cytoplasmic protein tyrosine kinases (PTKs) including Lyn, Syk, and Bruton's tyrosine kinase (BTK).  Upon BCR engagement, these PTKs activate downstream effectors, including transcription factors that modulate gene expression.  In turn, activation of downstream effectors is crit. for B cell survival, cell cycle progression, and antibody prodn.  Our studies focus on the role of BTK in these biol. responses.  We have discovered that BTK is required for activation of the BCR-responsive transcription factor, NF-κB.  Furthermore, BTK-dependent activation of NF-κB is essential for reprogramming the expression of genes that control B cell survival and proliferation.  The biochem. mechanisms by which BTK regulates signaling components that activate NF-κB, and the identification of BTK-responsive genes are under investigation.  Elucidation of these regulatory mechanisms is expected to reveal new therapeutic targets for B cell pathologies involving defects in BTK, including X-linked agammaglobulinemia (XLA).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrx0btKIFSX9LVg90H21EOLACvtfcHk0liP9HAstviVAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXltFWqsb0%253D&md5=564d950f06ab14daff2b45f5a3d863f4</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1385%2FIR%3A23%3A2-3%3A147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1385%252FIR%253A23%253A2-3%253A147%26sid%3Dliteratum%253Aachs%26aulast%3DKhan%26aufirst%3DW.%2BN.%26atitle%3DRegulation%2520of%2520B%2520Lymphocyte%2520Development%2520and%2520Activation%2520by%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%26jtitle%3DImmunol.%2520Res.%26date%3D2001%26volume%3D23%26spage%3D147%26epage%3D156%26doi%3D10.1385%2FIR%3A23%3A2-3%3A147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boucheron, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unger, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellmeier, W.</span></span> <span> </span><span class="NLM_article-title">The Role of Tec Family Kinases in Myeloid Cells</span>. <i>Int. Arch. Allergy Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>134</i></span>,  <span class="NLM_fpage">65</span>– <span class="NLM_lpage">78</span>, <span class="refDoi"> DOI: 10.1159/000078339</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1159%2F000078339" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=15133303" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BD2cXktFKlsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2004&pages=65-78&author=U.+Schmidtauthor=N.+Boucheronauthor=B.+Ungerauthor=W.+Ellmeier&title=The+Role+of+Tec+Family+Kinases+in+Myeloid+Cells&doi=10.1159%2F000078339"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The Role of Tec Family Kinases in Myeloid Cells</span></div><div class="casAuthors">Schmidt, Uwe; Boucheron, Nicole; Unger, Bernd; Ellmeier, Wilfried</div><div class="citationInfo"><span class="NLM_cas:title">International Archives of Allergy and Immunology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">134</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">65-78</span>CODEN:
                <span class="NLM_cas:coden">IAAIEG</span>;
        ISSN:<span class="NLM_cas:issn">1018-2438</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">A review.  Members of the Tec kinase family (Bmx, Btk, Itk, Rlk and Tec) are primarily expressed in the hematopoietic system and form, after the Src kinase family, the second largest class of non-receptor protein tyrosine kinases.  During lymphocyte development and activation Tec kinases have important functions in signaling pathways downstream of the antigen receptors.  Tec family kinases are also expressed in cells of the myeloid lineage.  However, with the exception of mast cells and platelets, their biol. role in the myeloid system is only poorly understood.  This review summarizes the current knowledge about the function of Tec family kinases in hematopoietic cells of the myeloid lineage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpewxKP7kBxe7Vg90H21EOLACvtfcHk0likNcBxRcX1DA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXktFKlsr8%253D&md5=e6e88b9b59049d9e55e95b6621a27453</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1159%2F000078339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000078339%26sid%3Dliteratum%253Aachs%26aulast%3DSchmidt%26aufirst%3DU.%26aulast%3DBoucheron%26aufirst%3DN.%26aulast%3DUnger%26aufirst%3DB.%26aulast%3DEllmeier%26aufirst%3DW.%26atitle%3DThe%2520Role%2520of%2520Tec%2520Family%2520Kinases%2520in%2520Myeloid%2520Cells%26jtitle%3DInt.%2520Arch.%2520Allergy%2520Immunol.%26date%3D2004%26volume%3D134%26spage%3D65%26epage%3D78%26doi%3D10.1159%2F000078339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brunner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirth, T.</span></span> <span> </span><span class="NLM_article-title">Bruton’s Tyrosine Kinase is Involved in Innate and Adaptive Immunity</span>. <i>Histol. Histopathol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">945</span>– <span class="NLM_lpage">955</span>, <span class="refDoi"> DOI: 10.14670/HH-20.945</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.14670%2FHH-20.945" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=15944945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpsFKjtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2005&pages=945-955&author=C.+Brunnerauthor=B.+M%C3%BCllerauthor=T.+Wirth&title=Bruton%E2%80%99s+Tyrosine+Kinase+is+Involved+in+Innate+and+Adaptive+Immunity&doi=10.14670%2FHH-20.945"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Bruton's Tyrosine Kinase is involved in innate and adaptive immunity</span></div><div class="casAuthors">Brunner, C.; Mueller, B.; Wirth, T.</div><div class="citationInfo"><span class="NLM_cas:title">Histology and Histopathology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">945-955</span>CODEN:
                <span class="NLM_cas:coden">HIHIES</span>;
        ISSN:<span class="NLM_cas:issn">0213-3911</span>.
    
            (<span class="NLM_cas:orgname">Jimenez Godoy, S.A.</span>)
        </div><div class="casAbstract">A review.  Btk is a cytoplasmic tyrosine kinase, which is mainly involved in B cell receptor signaling.  Gene targeting expts. revealed that Btk is important for B cell development and function.  However, Btk is not only expressed in B cells, but also in most other hematopoietic lineages except for T cells and plasma cells.  Recently we found that Btk is involved in Toll-like receptor signaling.  Toll-like receptors play an important role in innate immunity.  They are highly expressed on mast cells, macrophages and dendritic cells, which are essential for the recognition and consequently for the elimination of microbial pathogens.  Therefore Btk might play an important role for the function of immunocompetent cells of innate as well as adaptive immunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQA-9NFdeNr7Vg90H21EOLACvtfcHk0likNcBxRcX1DA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpsFKjtL4%253D&md5=97cbcc5df2704d4b58933085ab8ff929</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.14670%2FHH-20.945&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.14670%252FHH-20.945%26sid%3Dliteratum%253Aachs%26aulast%3DBrunner%26aufirst%3DC.%26aulast%3DM%25C3%25BCller%26aufirst%3DB.%26aulast%3DWirth%26aufirst%3DT.%26atitle%3DBruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520is%2520Involved%2520in%2520Innate%2520and%2520Adaptive%2520Immunity%26jtitle%3DHistol.%2520Histopathol.%26date%3D2005%26volume%3D20%26spage%3D945%26epage%3D955%26doi%3D10.14670%2FHH-20.945" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di
Paolo, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balazs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbosa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barck, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bravo, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carano, R. A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darrow, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeForge, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diehl, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrando, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallion, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giannetti, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gribling, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hymowitz, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kropf, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maciejewski, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staker, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitney, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currie, K. S.</span></span> <span> </span><span class="NLM_article-title">Specific Btk Inhibition Suppresses B Cell- And Myeloid Cell-Mediated Arthritis</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">50</span>, <span class="refDoi"> DOI: 10.1038/nchembio.481</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1038%2Fnchembio.481" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=21113169" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVOrsLjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=41-50&author=J.+A.+Di%0APaoloauthor=T.+Huangauthor=M.+Balazsauthor=J.+Barbosaauthor=K.+H.+Barckauthor=B.+J.+Bravoauthor=R.+A.+D.+Caranoauthor=J.+Darrowauthor=D.+R.+Daviesauthor=L.+E.+DeForgeauthor=L.+Diehlauthor=R.+Ferrandoauthor=S.+L.+Gallionauthor=A.+M.+Giannettiauthor=P.+Griblingauthor=V.+Hurezauthor=S.+G.+Hymowitzauthor=R.+Jonesauthor=J.+E.+Kropfauthor=W.+P.+Leeauthor=P.+M.+Maciejewskiauthor=S.+A.+Mitchellauthor=H.+Rongauthor=B.+L.+Stakerauthor=J.+A.+Whitneyauthor=S.+Yehauthor=W.+B.+Youngauthor=C.+Yuauthor=J.+Zhangauthor=K.+Reifauthor=K.+S.+Currie&title=Specific+Btk+Inhibition+Suppresses+B+Cell-+And+Myeloid+Cell-Mediated+Arthritis&doi=10.1038%2Fnchembio.481"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis</span></div><div class="casAuthors">Di Paolo, Julie A.; Huang, Tao; Balazs, Mercedesz; Barbosa, James; Barck, Kai H.; Bravo, Brandon J.; Carano, Richard A. D.; Darrow, James; Davies, Douglas R.; DeForge, Laura E.; Diehl, Lauri; Ferrando, Ronald; Gallion, Steven L.; Giannetti, Anthony M.; Gribling, Peter; Hurez, Vincent; Hymowitz, Sarah G.; Jones, Randall; Kropf, Jeffrey E.; Lee, Wyne P.; Maciejewski, Patricia M.; Mitchell, Scott A.; Rong, Hong; Staker, Bart L.; Whitney, J. Andrew; Yeh, Sherry; Young, Wendy B.; Yu, Christine; Zhang, Juan; Reif, Karin; Currie, Kevin S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-50</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (Btk) is a therapeutic target for rheumatoid arthritis, but the cellular and mol. mechanisms by which Btk mediates inflammation are poorly understood.  Here we describe the discovery of CGI1746, a small-mol. Btk inhibitor chemotype with a new binding mode that stabilizes an inactive nonphosphorylated enzyme conformation.  CGI1746 has exquisite selectivity for Btk and inhibits both auto- and transphosphorylation steps necessary for enzyme activation.  Using CGI1746, we demonstrate that Btk regulates inflammatory arthritis by two distinct mechanisms.  CGI1746 blocks B cell receptor-dependent B cell proliferation and in prophylactic regimens reduces autoantibody levels in collagen-induced arthritis.  In macrophages, Btk inhibition abolishes FcγRIII-induced TNFα, IL-1β and IL-6 prodn.  Accordingly, in myeloid- and FcγR-dependent autoantibody-induced arthritis, CGI1746 decreases cytokine levels within joints and ameliorates disease.  These results provide new understanding of the function of Btk in both B cell- or myeloid cell-driven disease processes and provide a compelling rationale for targeting Btk in rheumatoid arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoegiZYoitP57Vg90H21EOLACvtfcHk0likNcBxRcX1DA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVOrsLjP&md5=99d925c71bc1b201191ebde0f1c0b50f</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.481&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.481%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BPaolo%26aufirst%3DJ.%2BA.%26aulast%3DHuang%26aufirst%3DT.%26aulast%3DBalazs%26aufirst%3DM.%26aulast%3DBarbosa%26aufirst%3DJ.%26aulast%3DBarck%26aufirst%3DK.%2BH.%26aulast%3DBravo%26aufirst%3DB.%2BJ.%26aulast%3DCarano%26aufirst%3DR.%2BA.%2BD.%26aulast%3DDarrow%26aufirst%3DJ.%26aulast%3DDavies%26aufirst%3DD.%2BR.%26aulast%3DDeForge%26aufirst%3DL.%2BE.%26aulast%3DDiehl%26aufirst%3DL.%26aulast%3DFerrando%26aufirst%3DR.%26aulast%3DGallion%26aufirst%3DS.%2BL.%26aulast%3DGiannetti%26aufirst%3DA.%2BM.%26aulast%3DGribling%26aufirst%3DP.%26aulast%3DHurez%26aufirst%3DV.%26aulast%3DHymowitz%26aufirst%3DS.%2BG.%26aulast%3DJones%26aufirst%3DR.%26aulast%3DKropf%26aufirst%3DJ.%2BE.%26aulast%3DLee%26aufirst%3DW.%2BP.%26aulast%3DMaciejewski%26aufirst%3DP.%2BM.%26aulast%3DMitchell%26aufirst%3DS.%2BA.%26aulast%3DRong%26aufirst%3DH.%26aulast%3DStaker%26aufirst%3DB.%2BL.%26aulast%3DWhitney%26aufirst%3DJ.%2BA.%26aulast%3DYeh%26aufirst%3DS.%26aulast%3DYoung%26aufirst%3DW.%2BB.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26atitle%3DSpecific%2520Btk%2520Inhibition%2520Suppresses%2520B%2520Cell-%2520And%2520Myeloid%2520Cell-Mediated%2520Arthritis%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2011%26volume%3D7%26spage%3D41%26epage%3D50%26doi%3D10.1038%2Fnchembio.481" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rawlings, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saffran, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukada, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Largaespada, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimaldi, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohr, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bazan, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witte, O. N.</span></span> <span> </span><span class="NLM_article-title">Mutation of Unique Region of Bruton’s Tyrosine Kinase in Immunodeficient XID Mice</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>261</i></span>,  <span class="NLM_fpage">358</span>– <span class="NLM_lpage">361</span>, <span class="refDoi"> DOI: 10.1126/science.8332901</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1126%2Fscience.8332901" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=261&publication_year=1993&pages=358-361&author=D.+J.+Rawlingsauthor=D.+C.+Saffranauthor=S.+Tsukadaauthor=D.+A.+Largaespadaauthor=J.+C.+Grimaldiauthor=L.+Cohenauthor=R.+N.+Mohrauthor=J.+F.+Bazanauthor=M.+Howardauthor=N.+G.+Copelandauthor=N.+A.+Jenkinsauthor=O.+N.+Witte&title=Mutation+of+Unique+Region+of+Bruton%E2%80%99s+Tyrosine+Kinase+in+Immunodeficient+XID+Mice&doi=10.1126%2Fscience.8332901"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1126%2Fscience.8332901&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.8332901%26sid%3Dliteratum%253Aachs%26aulast%3DRawlings%26aufirst%3DD.%2BJ.%26aulast%3DSaffran%26aufirst%3DD.%2BC.%26aulast%3DTsukada%26aufirst%3DS.%26aulast%3DLargaespada%26aufirst%3DD.%2BA.%26aulast%3DGrimaldi%26aufirst%3DJ.%2BC.%26aulast%3DCohen%26aufirst%3DL.%26aulast%3DMohr%26aufirst%3DR.%2BN.%26aulast%3DBazan%26aufirst%3DJ.%2BF.%26aulast%3DHoward%26aufirst%3DM.%26aulast%3DCopeland%26aufirst%3DN.%2BG.%26aulast%3DJenkins%26aufirst%3DN.%2BA.%26aulast%3DWitte%26aufirst%3DO.%2BN.%26atitle%3DMutation%2520of%2520Unique%2520Region%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520in%2520Immunodeficient%2520XID%2520Mice%26jtitle%3DScience%26date%3D1993%26volume%3D261%26spage%3D358%26epage%3D361%26doi%3D10.1126%2Fscience.8332901" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Satterthwaite, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witte, O. N.</span></span> <span> </span><span class="NLM_article-title">The Role of Bruton’s Tyrosine Kinase in B-cell Development and Function: a Genetic Perspective,</span>. <i>Immunol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>175</i></span>,  <span class="NLM_fpage">120</span>– <span class="NLM_lpage">127</span>, <span class="refDoi"> DOI: 10.1111/j.1600-065X.2000.imr017504.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1111%2Fj.1600-065X.2000.imr017504.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10933597" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BD3cXls12gs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=2000&pages=120-127&author=A.+B.+Satterthwaiteauthor=O.+N.+Witte&title=The+Role+of+Bruton%E2%80%99s+Tyrosine+Kinase+in+B-cell+Development+and+Function%3A+a+Genetic+Perspective%2C&doi=10.1111%2Fj.1600-065X.2000.imr017504.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The role of Bruton's tyrosine kinase in B-cell development and function: A genetic perspective</span></div><div class="casAuthors">Satterthwaite, Anne B.; Witte, Owen N.</div><div class="citationInfo"><span class="NLM_cas:title">Immunological Reviews</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">175</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">120-127</span>CODEN:
                <span class="NLM_cas:coden">IMRED2</span>;
        ISSN:<span class="NLM_cas:issn">0105-2896</span>.
    
            (<span class="NLM_cas:orgname">Munksgaard International Publishers Ltd.</span>)
        </div><div class="casAbstract">A review with 95 refs.  Mutations in Bruton's tyrosine kinase (Btk) result in the B-cell immunodeficiencies X-linked agammaglobulinemia in humans and X-linked immunodeficiency in mice.  These diseases are characterized by blocks in B-cell development at multiple stages and impaired function of residual mature B cells.  The authors focus here on a series of in vivo genetic studies that have begun to define the mechanism by which Btk regulates B-cell development and function.  The functional interactions between Btk and other signaling mols. defined by this approach are more complex than initially appreciated from in vitro biochem. and cell culture studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpysAcsASekh7Vg90H21EOLACvtfcHk0lh9FXQyfyOqxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXls12gs7g%253D&md5=8fb36554501b75b645cc2a807c29d6ac</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-065X.2000.imr017504.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-065X.2000.imr017504.x%26sid%3Dliteratum%253Aachs%26aulast%3DSatterthwaite%26aufirst%3DA.%2BB.%26aulast%3DWitte%26aufirst%3DO.%2BN.%26atitle%3DThe%2520Role%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520in%2520B-cell%2520Development%2520and%2520Function%253A%2520a%2520Genetic%2520Perspective%252C%26jtitle%3DImmunol.%2520Rev.%26date%3D2000%26volume%3D175%26spage%3D120%26epage%3D127%26doi%3D10.1111%2Fj.1600-065X.2000.imr017504.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Genevier, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinshelwood, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaspar, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rigley, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saeland, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rousset, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levinsky, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callard, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinnon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovering, R. C.</span></span> <span> </span><span class="NLM_article-title">Expression of Bruton’s Tyrosine Kinase Protein Within the B Cell Lineage</span>. <i>Eur. J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">3100</span>– <span class="NLM_lpage">3105</span>, <span class="refDoi"> DOI: 10.1002/eji.1830241228</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1002%2Feji.1830241228" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=1994&pages=3100-3105&author=H.+C.+Genevierauthor=S.+Hinshelwoodauthor=H.+B.+Gasparauthor=K.+P.+Rigleyauthor=D.+Brownauthor=S.+Saelandauthor=F.+Roussetauthor=R.+J.+Levinskyauthor=R.+E.+Callardauthor=C.+Kinnonauthor=R.+C.+Lovering&title=Expression+of+Bruton%E2%80%99s+Tyrosine+Kinase+Protein+Within+the+B+Cell+Lineage&doi=10.1002%2Feji.1830241228"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1002%2Feji.1830241228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Feji.1830241228%26sid%3Dliteratum%253Aachs%26aulast%3DGenevier%26aufirst%3DH.%2BC.%26aulast%3DHinshelwood%26aufirst%3DS.%26aulast%3DGaspar%26aufirst%3DH.%2BB.%26aulast%3DRigley%26aufirst%3DK.%2BP.%26aulast%3DBrown%26aufirst%3DD.%26aulast%3DSaeland%26aufirst%3DS.%26aulast%3DRousset%26aufirst%3DF.%26aulast%3DLevinsky%26aufirst%3DR.%2BJ.%26aulast%3DCallard%26aufirst%3DR.%2BE.%26aulast%3DKinnon%26aufirst%3DC.%26aulast%3DLovering%26aufirst%3DR.%2BC.%26atitle%3DExpression%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520Protein%2520Within%2520the%2520B%2520Cell%2520Lineage%26jtitle%3DEur.%2520J.%2520Immunol.%26date%3D1994%26volume%3D24%26spage%3D3100%26epage%3D3105%26doi%3D10.1002%2Feji.1830241228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bruton, O. C.</span></span> <span> </span><span class="NLM_article-title">Agammaglobulinemia</span>. <i>Pediatrics</i> <span class="NLM_year" style="font-weight: bold;">1952</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">722</span>– <span class="NLM_lpage">729</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=14929630" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A280%3ADyaG38%252FlvFOnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1952&pages=722-729&author=O.+C.+Bruton&title=Agammaglobulinemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Agammaglobulinemia</span></div><div class="casAuthors">BRUTON O C</div><div class="citationInfo"><span class="NLM_cas:title">Pediatrics</span>
        (<span class="NLM_cas:date">1952</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">722-8</span>
        ISSN:<span class="NLM_cas:issn">0031-4005</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ99IDXIc3tbqqcneEtCi92fW6udTcc2eYNzZMVc0U_JLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaG38%252FlvFOnsg%253D%253D&md5=737a40c8a7c8f591efca619f2ba894aa</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBruton%26aufirst%3DO.%2BC.%26atitle%3DAgammaglobulinemia%26jtitle%3DPediatrics%26date%3D1952%26volume%3D9%26spage%3D722%26epage%3D729" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaveri, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maddur, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegde, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacroix-Desmazes, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayry, J.</span></span> <span> </span><span class="NLM_article-title">Intravenous Immunoglobulins in Immunodeficiencies: More Than Mere Replacement Therapy</span>. <i>Clin. Exp. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>164</i></span> (<span class="NLM_issue">Suppl 2</span>),  <span class="NLM_fpage">2</span>– <span class="NLM_lpage">5</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2249.2011.04387.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1111%2Fj.1365-2249.2011.04387.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=21466545" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnvVehtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=164&publication_year=2011&pages=2-5&issue=Suppl+2&author=S.+V.+Kaveriauthor=M.+S.+Maddurauthor=P.+Hegdeauthor=S.+Lacroix-Desmazesauthor=J.+Bayry&title=Intravenous+Immunoglobulins+in+Immunodeficiencies%3A+More+Than+Mere+Replacement+Therapy&doi=10.1111%2Fj.1365-2249.2011.04387.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Intravenous immunoglobulins in immunodeficiencies: more than mere replacement therapy</span></div><div class="casAuthors">Kaveri, S. V.; Maddur, M. S.; Hegde, P.; Lacroix-Desmazes, S.; Bayry, J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and Experimental Immunology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">164</span>
        (<span class="NLM_cas:issue">Suppl. 2</span>),
    <span class="NLM_cas:pages">2-5</span>CODEN:
                <span class="NLM_cas:coden">CEXIAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-9104</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  I.v. Ig (IVIG) is a therapeutic compd. prepd. from pools of plasma obtained from several thousand healthy blood donors.  For more than 20 years, IVIG has been used in the treatment of a wide range of primary and secondary immunodeficiencies.  IVIG now represents a std. therapeutic option for most antibody deficiencies.  Routinely, IVIG is used in patients with X-linked agammaglobulinemia (XLA), common variable immunodeficiency (CVID), X-linked hyper-IgM, severe combined immunodeficiency, Wiskott-Aldrich syndrome, and selective IgG class deficiency.  In addn., IVIG is used extensively in the treatment of a wide variety of autoimmune disorders.  IVIG is administered at distinct doses in the two clin. settings: whereas immunodeficient patients are treated with replacement levels of IVIG, patients with autoimmune and inflammatory diseases are administered with very high doses of IVIG.  Several lines of exptl. evidence gathered in the recent years suggest that the therapeutic beneficial effect of IVIG in immunodeficiencies reflects an active role for IVIG, rather than a mere passive transfer of antibodies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCxnh_OFe14bVg90H21EOLACvtfcHk0lg8Qkmlz5gMzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnvVehtLs%253D&md5=483fc8a4b947e21a248a66c148d9075f</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2249.2011.04387.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2249.2011.04387.x%26sid%3Dliteratum%253Aachs%26aulast%3DKaveri%26aufirst%3DS.%2BV.%26aulast%3DMaddur%26aufirst%3DM.%2BS.%26aulast%3DHegde%26aufirst%3DP.%26aulast%3DLacroix-Desmazes%26aufirst%3DS.%26aulast%3DBayry%26aufirst%3DJ.%26atitle%3DIntravenous%2520Immunoglobulins%2520in%2520Immunodeficiencies%253A%2520More%2520Than%2520Mere%2520Replacement%2520Therapy%26jtitle%3DClin.%2520Exp.%2520Immunol.%26date%3D2011%26volume%3D164%26issue%3DSuppl%25202%26spage%3D2%26epage%3D5%26doi%3D10.1111%2Fj.1365-2249.2011.04387.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ochs, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. I.</span></span> <span> </span><span class="NLM_article-title">X-linked Agammaglobulinemia. A Clinical and Molecular Analysis</span>. <i>Medicine</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">287</span>– <span class="NLM_lpage">299</span>, <span class="refDoi"> DOI: 10.1097/00005792-199611000-00001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1097%2F00005792-199611000-00001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=8982147" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A280%3ADyaK2s7js1Oksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=1996&pages=287-299&author=H.+D.+Ochsauthor=C.+I.+Smith&title=X-linked+Agammaglobulinemia.+A+Clinical+and+Molecular+Analysis&doi=10.1097%2F00005792-199611000-00001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">X-linked agammaglobulinemia. A clinical and molecular analysis</span></div><div class="casAuthors">Ochs H D; Smith C I</div><div class="citationInfo"><span class="NLM_cas:title">Medicine</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">287-99</span>
        ISSN:<span class="NLM_cas:issn">0025-7974</span>.
    </div><div class="casAbstract">X-linked agammaglobulinemia (XLA), characterized by a profound deficiency of B lymphocytes due to an arrest in B lymphocyte development, is caused by mutations in the gene encoding Btk (Bruton tyrosine kinase).  The BTK gene has been cloned and the genomic organization determined.  BTK codes for 19 exons and is expressed in all hematopoietic cell lineages but is selectively down-regulated in T lymphocytes and plasma cells.  The different Btk domains include PH, TH, SH3, SH2, and the kinase (SH1) domains.  Btk, a cytoplasmic protein tyrosine kinase, is involved in cell signaling, although the precise pathway remains elusive.  Mutation analysis has been performed in 236 families representing 282 patients.  Mutations are scattered throughout the gene and consist of missense, nonsense, and splice site mutations as well as deletions and insertions.  The major consequence of nonfunctional Btk appears to be a delay or block of the development of pro-B cells to pre-B cells and then to mature lymphocytes.  Because IgG is actively transported across the placenta, affected newborns have normal levels of serum IgG at birth followed by gradually decreasing IgG levels and development of hypogammaglobulinemia and increased susceptibility to infections.  Bacterial infections are the most common clinical manifestation.  Resistance to viral infection is intact, except for an unusual susceptibility to infections with enteroviruses that may result in vaccine-related paralytic poliomyelitis or a dermatomyositis-meningoencephalitis syndrome.  The diagnosis of XLA is based on the presence of lymphoid hypoplasia, markedly reduced serum levels of all 3 major classes of immunoglobulins, failure to make antibody to antigenic stimulation, and almost complete absence of B lymphocytes in the peripheral blood.  Carrier detection and prenatal diagnosis are possible.  The prophylactic infusion of high-dose intravenous immunoglobulin (IVIG) and the use of antibiotics have markedly improved the long-term prognosis of patients with XLA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTcFX6ocpNz4tts4TFFB11gfW6udTcc2eYv2XxA3tq837ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2s7js1Oksg%253D%253D&md5=a8f9be39459087b1de4975aa6067eee5</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1097%2F00005792-199611000-00001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00005792-199611000-00001%26sid%3Dliteratum%253Aachs%26aulast%3DOchs%26aufirst%3DH.%2BD.%26aulast%3DSmith%26aufirst%3DC.%2BI.%26atitle%3DX-linked%2520Agammaglobulinemia.%2520A%2520Clinical%2520and%2520Molecular%2520Analysis%26jtitle%3DMedicine%26date%3D1996%26volume%3D75%26spage%3D287%26epage%3D299%26doi%3D10.1097%2F00005792-199611000-00001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">So, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fruman, D. A.</span></span> <span> </span><span class="NLM_article-title">PI3K Signalling In B- and T-Lymphocytes: New Developments and Therapeutic Advances</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>442</i></span>,  <span class="NLM_fpage">465</span>– <span class="NLM_lpage">481</span>, <span class="refDoi"> DOI: 10.1042/BJ20112092</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1042%2FBJ20112092" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=442&publication_year=2012&pages=465-481&author=L.+Soauthor=D.+A.+Fruman&title=PI3K+Signalling+In+B-+and+T-Lymphocytes%3A+New+Developments+and+Therapeutic+Advances&doi=10.1042%2FBJ20112092"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1042%2FBJ20112092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20112092%26sid%3Dliteratum%253Aachs%26aulast%3DSo%26aufirst%3DL.%26aulast%3DFruman%26aufirst%3DD.%2BA.%26atitle%3DPI3K%2520Signalling%2520In%2520B-%2520and%2520T-Lymphocytes%253A%2520New%2520Developments%2520and%2520Therapeutic%2520Advances%26jtitle%3DBiochem.%2520J.%26date%3D2012%26volume%3D442%26spage%3D465%26epage%3D481%26doi%3D10.1042%2FBJ20112092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Puri, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Paolo, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gold, M. R.</span></span> <span> </span><span class="NLM_article-title">B-cell Receptor Signaling Inhibitors for Treatment of Autoimmune Inflammatory Diseases and B-cell Malignancies</span>. <i>Int. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">397</span>– <span class="NLM_lpage">427</span>, <span class="refDoi"> DOI: 10.3109/08830185.2013.818140</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.3109%2F08830185.2013.818140" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=23886342" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFygsrrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2013&pages=397-427&author=K.+D.+Puriauthor=J.+A.+Di+Paoloauthor=M.+R.+Gold&title=B-cell+Receptor+Signaling+Inhibitors+for+Treatment+of+Autoimmune+Inflammatory+Diseases+and+B-cell+Malignancies&doi=10.3109%2F08830185.2013.818140"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">B-Cell Receptor Signaling Inhibitors for Treatment of Autoimmune Inflammatory Diseases and B-Cell Malignancies</span></div><div class="casAuthors">Puri, Kamal D.; Di Paolo, Julie A.; Gold, Michael R.</div><div class="citationInfo"><span class="NLM_cas:title">International Reviews of Immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">397-427</span>CODEN:
                <span class="NLM_cas:coden">IRIMEH</span>;
        ISSN:<span class="NLM_cas:issn">0883-0185</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  B-cell receptor (BCR) signaling is essential for normal B-cell development, selection, survival, proliferation, and differentiation into antibody-secreting cells.  Similarly, this pathway plays a key role in the pathogenesis of multiple B-cell malignancies.  Genetic and pharmacol. approaches have established an important role for the Spleen tyrosine kinase (Syk), Bruton's tyrosine kinase (Btk), and phosphatidylinositol 3-kinase isoform p110delta (PI3Kδ) in coupling the BCR and other BCRs to B-cell survival, migration, and activation.  In the past few years, several small-mol. inhibitory drugs that target PI3Kδ, Btk, and Syk have been developed and shown to have efficacy in clin. trials for the treatment of several types of B-cell malignancies.  Emerging preclin. data have also shown a crit. role of BCR signaling in the activation and function of self-reactive B cells that contribute to autoimmune diseases.  Because BCR signaling plays a major role in both B-cell-mediated autoimmune inflammation and B-cell malignancies, inhibition of this pathway may represent a promising new strategy for treating these diseases.  This review summarizes recent achievements in the mechanism of action, pharmacol. properties, and clin. activity and toxicity of these BCR signaling inhibitors, with a focus on their emerging role in treating lymphoid malignancies and autoimmune disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpLDUjmfDEurVg90H21EOLACvtfcHk0lg8Qkmlz5gMzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFygsrrO&md5=85ace1d58bb75405311bfe4a613ae2a7</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.3109%2F08830185.2013.818140&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F08830185.2013.818140%26sid%3Dliteratum%253Aachs%26aulast%3DPuri%26aufirst%3DK.%2BD.%26aulast%3DDi%2BPaolo%26aufirst%3DJ.%2BA.%26aulast%3DGold%26aufirst%3DM.%2BR.%26atitle%3DB-cell%2520Receptor%2520Signaling%2520Inhibitors%2520for%2520Treatment%2520of%2520Autoimmune%2520Inflammatory%2520Diseases%2520and%2520B-cell%2520Malignancies%26jtitle%3DInt.%2520Rev.%2520Immunol.%26date%3D2013%26volume%3D32%26spage%3D397%26epage%3D427%26doi%3D10.3109%2F08830185.2013.818140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katewa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hackney, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suto, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramamoorthi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bremer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currie, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blomgren, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeVoss, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiPaolo, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesch, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeForge, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liimatta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubach, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McVay, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modrusan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Townsend, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, K.</span></span> <span> </span><span class="NLM_article-title">Btk-Specific Inhibition Blocks Pathogenic Plasma Cell Signatures and Myeloid Cell-Associated Damage in IFN-α Driven Lupus Nephritis</span>. <i>JCI Insight</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">e90111</span>, <span class="refDoi"> DOI: 10.1172/jci.insight.90111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1172%2Fjci.insight.90111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=28405610" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2017&pages=e90111&author=A.+Katewaauthor=Y.+Wangauthor=J.+A.+Hackneyauthor=T.+Huangauthor=E.+Sutoauthor=N.+Ramamoorthiauthor=C.+D.+Austinauthor=M.+Bremerauthor=J.+Z.+Chenauthor=J.+J.+Crawfordauthor=K.+S.+Currieauthor=P.+Blomgrenauthor=J.+DeVossauthor=J.+A.+DiPaoloauthor=J.+Hauauthor=A.+Johnsonauthor=J.+Leschauthor=L.+E.+DeForgeauthor=Z.+Linauthor=M.+Liimattaauthor=J.+W.+Lubachauthor=S.+McVayauthor=Z.+Modrusanauthor=A.+Nguyenauthor=C.+Poonauthor=J.+Wangauthor=L.+Liuauthor=W.+P.+Leeauthor=H.+Wongauthor=W.+B.+Youngauthor=M.+J.+Townsendauthor=K.+Reif&title=Btk-Specific+Inhibition+Blocks+Pathogenic+Plasma+Cell+Signatures+and+Myeloid+Cell-Associated+Damage+in+IFN-%CE%B1+Driven+Lupus+Nephritis&doi=10.1172%2Fjci.insight.90111"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1172%2Fjci.insight.90111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252Fjci.insight.90111%26sid%3Dliteratum%253Aachs%26aulast%3DKatewa%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DHackney%26aufirst%3DJ.%2BA.%26aulast%3DHuang%26aufirst%3DT.%26aulast%3DSuto%26aufirst%3DE.%26aulast%3DRamamoorthi%26aufirst%3DN.%26aulast%3DAustin%26aufirst%3DC.%2BD.%26aulast%3DBremer%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DJ.%2BZ.%26aulast%3DCrawford%26aufirst%3DJ.%2BJ.%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26aulast%3DBlomgren%26aufirst%3DP.%26aulast%3DDeVoss%26aufirst%3DJ.%26aulast%3DDiPaolo%26aufirst%3DJ.%2BA.%26aulast%3DHau%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DA.%26aulast%3DLesch%26aufirst%3DJ.%26aulast%3DDeForge%26aufirst%3DL.%2BE.%26aulast%3DLin%26aufirst%3DZ.%26aulast%3DLiimatta%26aufirst%3DM.%26aulast%3DLubach%26aufirst%3DJ.%2BW.%26aulast%3DMcVay%26aufirst%3DS.%26aulast%3DModrusan%26aufirst%3DZ.%26aulast%3DNguyen%26aufirst%3DA.%26aulast%3DPoon%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DLee%26aufirst%3DW.%2BP.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DYoung%26aufirst%3DW.%2BB.%26aulast%3DTownsend%26aufirst%3DM.%2BJ.%26aulast%3DReif%26aufirst%3DK.%26atitle%3DBtk-Specific%2520Inhibition%2520Blocks%2520Pathogenic%2520Plasma%2520Cell%2520Signatures%2520and%2520Myeloid%2520Cell-Associated%2520Damage%2520in%2520IFN-%25CE%25B1%2520Driven%2520Lupus%2520Nephritis%26jtitle%3DJCI%2520Insight%26date%3D2017%26volume%3D2%26spage%3De90111%26doi%3D10.1172%2Fjci.insight.90111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheerens, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sprengeler, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrill, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendonca, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, K. C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grothaus, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeffery, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spoerke, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honigberg, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalrymple, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, J. T.</span></span> <span> </span><span class="NLM_article-title">Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">58</span>– <span class="NLM_lpage">61</span>, <span class="refDoi"> DOI: 10.1002/cmdc.200600221</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1002%2Fcmdc.200600221" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=17154430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsVWjsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=58-61&author=Z.+Panauthor=H.+Scheerensauthor=S.-J.+Liauthor=B.+E.+Schultzauthor=P.+A.+Sprengelerauthor=L.+C.+Burrillauthor=R.+V.+Mendoncaauthor=M.+D.+Sweeneyauthor=K.+C.+K.+Scottauthor=P.+G.+Grothausauthor=D.+A.+Jefferyauthor=J.+M.+Spoerkeauthor=L.+A.+Honigbergauthor=P.+R.+Youngauthor=S.+A.+Dalrympleauthor=J.+T.+Palmer&title=Discovery+of+Selective+Irreversible+Inhibitors+for+Bruton%E2%80%99s+Tyrosine+Kinase&doi=10.1002%2Fcmdc.200600221"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of selective irreversible inhibitors for bruton's tyrosine kinase</span></div><div class="casAuthors">Pan, Zhengying; Scheerens, Heleen; Li, Shyr-Jiann; Schultz, Brian E.; Sprengeler, Paul A.; Burrill, L. Chuck; Mendonca, Rohan V.; Sweeney, Michael D.; Scott, Keana C. K.; Grothaus, Paul G.; Jeffery, Douglas A.; Spoerke, Jill M.; Honigberg, Lee A.; Young, Peter R.; Dalrymple, Stacie A.; Palmer, James T.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">58-61</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Synthesis and pharmacol. evaluation of a series of peptidomimetic quinoline derivs. was undertaken to evaluate their efficacy in acting as selective irreversible inhibitors of Bruton's tyrosine kinase (Btk).  With the relative scarcity of knowledge on the inhibition of Btk it is crucial to discover a potent and selective tool compd. for this kinase.  Herein is described the discovery of selective irreversible Btk inhibitors and their efficacy in a mouse RA model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovT3kBCYECdbVg90H21EOLACvtfcHk0lglzttGhvrgvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsVWjsbg%253D&md5=023ba8bca9942ad0127d7cf32293e9d2</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200600221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200600221%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DZ.%26aulast%3DScheerens%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DS.-J.%26aulast%3DSchultz%26aufirst%3DB.%2BE.%26aulast%3DSprengeler%26aufirst%3DP.%2BA.%26aulast%3DBurrill%26aufirst%3DL.%2BC.%26aulast%3DMendonca%26aufirst%3DR.%2BV.%26aulast%3DSweeney%26aufirst%3DM.%2BD.%26aulast%3DScott%26aufirst%3DK.%2BC.%2BK.%26aulast%3DGrothaus%26aufirst%3DP.%2BG.%26aulast%3DJeffery%26aufirst%3DD.%2BA.%26aulast%3DSpoerke%26aufirst%3DJ.%2BM.%26aulast%3DHonigberg%26aufirst%3DL.%2BA.%26aulast%3DYoung%26aufirst%3DP.%2BR.%26aulast%3DDalrymple%26aufirst%3DS.%2BA.%26aulast%3DPalmer%26aufirst%3DJ.%2BT.%26atitle%3DDiscovery%2520of%2520Selective%2520Irreversible%2520Inhibitors%2520for%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%26jtitle%3DChemMedChem%26date%3D2007%26volume%3D2%26spage%3D58%26epage%3D61%26doi%3D10.1002%2Fcmdc.200600221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robak, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robak, E.</span></span> <span> </span><span class="NLM_article-title">Tyrosine Kinase Inhibitors as Potential Drugs for B-cell Lymphoid Malignancies and Autoimmune Disorders</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">921</span>– <span class="NLM_lpage">947</span>, <span class="refDoi"> DOI: 10.1517/13543784.2012.685650</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1517%2F13543784.2012.685650" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2012&pages=921-947&author=T.+Robakauthor=E.+Robak&title=Tyrosine+Kinase+Inhibitors+as+Potential+Drugs+for+B-cell+Lymphoid+Malignancies+and+Autoimmune+Disorders&doi=10.1517%2F13543784.2012.685650"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1517%2F13543784.2012.685650&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2012.685650%26sid%3Dliteratum%253Aachs%26aulast%3DRobak%26aufirst%3DT.%26aulast%3DRobak%26aufirst%3DE.%26atitle%3DTyrosine%2520Kinase%2520Inhibitors%2520as%2520Potential%2520Drugs%2520for%2520B-cell%2520Lymphoid%2520Malignancies%2520and%2520Autoimmune%2520Disorders%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2012%26volume%3D21%26spage%3D921%26epage%3D947%26doi%3D10.1517%2F13543784.2012.685650" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuglstatter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondru, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, D. M.</span></span> <span> </span><span class="NLM_article-title">Bruton’s Tyrosine Kinase Inhibitors: Approaches to Potent and Selective Inhibition, Pre-clinical and Clinical Evaluation for Inflammatory Diseases and B Cell Malignancies</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">4539</span>– <span class="NLM_lpage">4550</span>, <span class="refDoi"> DOI: 10.1021/jm300035p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300035p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=4539-4550&author=Y.+Louauthor=T.+D.+Owensauthor=A.+Kuglstatterauthor=R.+K.+Kondruauthor=D.+M.+Goldstein&title=Bruton%E2%80%99s+Tyrosine+Kinase+Inhibitors%3A+Approaches+to+Potent+and+Selective+Inhibition%2C+Pre-clinical+and+Clinical+Evaluation+for+Inflammatory+Diseases+and+B+Cell+Malignancies&doi=10.1021%2Fjm300035p"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm300035p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300035p%26sid%3Dliteratum%253Aachs%26aulast%3DLou%26aufirst%3DY.%26aulast%3DOwens%26aufirst%3DT.%2BD.%26aulast%3DKuglstatter%26aufirst%3DA.%26aulast%3DKondru%26aufirst%3DR.%2BK.%26aulast%3DGoldstein%26aufirst%3DD.%2BM.%26atitle%3DBruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520Inhibitors%253A%2520Approaches%2520to%2520Potent%2520and%2520Selective%2520Inhibition%252C%2520Pre-clinical%2520and%2520Clinical%2520Evaluation%2520for%2520Inflammatory%2520Diseases%2520and%2520B%2520Cell%2520Malignancies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D4539%26epage%3D4550%26doi%3D10.1021%2Fjm300035p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Currie, K. S.</span></span> Targeting the B-cell Receptor Pathway in Hematological Maligancies. In  <i>2015 Medicinal Chemistry Reviews</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, M. C.</span></span>, Ed.; <span class="NLM_publisher-name">American Chemical Society Division of Medicinal Chemistry</span>: <span class="NLM_publisher-loc">Washington, DC</span>, <span class="NLM_year">2016</span>; pp  <span class="NLM_fpage">225</span>– <span class="NLM_lpage">234</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&pages=225-234&author=K.+S.+Currieauthor=M.+C.+Desai&title=2015+Medicinal+Chemistry+Reviews"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26btitle%3D2015%2520Medicinal%2520Chemistry%2520Reviews%26aulast%3DDesai%26aufirst%3DM.%2BC.%26pub%3DAmerican%2520Chemical%2520Society%2520Division%2520of%2520Medicinal%2520Chemistry%26date%3D2016%26spage%3D225%26epage%3D234" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dougan, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komandla, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanouni, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knight, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawson, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabat, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyrick, C.</span></span> <span> </span><span class="NLM_article-title">Fragment-Based Discovery of a Small Molecule Inhibitor of Bruton’s Tyrosine Kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">5437</span>– <span class="NLM_lpage">5444</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00734</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00734" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVans7rF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=5437-5444&author=C.+R.+Smithauthor=D.+R.+Douganauthor=M.+Komandlaauthor=T.+Kanouniauthor=B.+Knightauthor=J.+D.+Lawsonauthor=M.+Sabatauthor=E.+R.+Taylorauthor=P.+Vuauthor=C.+Wyrick&title=Fragment-Based+Discovery+of+a+Small+Molecule+Inhibitor+of+Bruton%E2%80%99s+Tyrosine+Kinase&doi=10.1021%2Facs.jmedchem.5b00734"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Fragment-Based Discovery of a Small Molecule Inhibitor of Bruton's Tyrosine Kinase</span></div><div class="casAuthors">Smith, Christopher R.; Dougan, Douglas R.; Komandla, Mallareddy; Kanouni, Toufike; Knight, Beverly; Lawson, J. David; Sabat, Mark; Taylor, Ewan R.; Vu, Phong; Wyrick, Corey</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5437-5444</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery and optimization of a series of 4-aminocinnoline-3-carboxamide inhibitors of Bruton's tyrosine kinase are reported.  A fragment-based screening approach incorporating x-ray cocrystallog. was used to identify a cinnoline fragment and characterize its binding mode in the ATP binding site of Btk.  Optimization of the fragment hit resulted in the identification of a lead compd. I which reduced paw swelling in a dose- and exposure-dependent fashion in a rat model of collagen-induced arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozENTW7pHlFrVg90H21EOLACvtfcHk0lii51cLGxuqqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVans7rF&md5=d6626fabcc3e2aa6a9180dc702a5030c</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00734&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00734%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DC.%2BR.%26aulast%3DDougan%26aufirst%3DD.%2BR.%26aulast%3DKomandla%26aufirst%3DM.%26aulast%3DKanouni%26aufirst%3DT.%26aulast%3DKnight%26aufirst%3DB.%26aulast%3DLawson%26aufirst%3DJ.%2BD.%26aulast%3DSabat%26aufirst%3DM.%26aulast%3DTaylor%26aufirst%3DE.%2BR.%26aulast%3DVu%26aufirst%3DP.%26aulast%3DWyrick%26aufirst%3DC.%26atitle%3DFragment-Based%2520Discovery%2520of%2520a%2520Small%2520Molecule%2520Inhibitor%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D5437%26epage%3D5444%26doi%3D10.1021%2Facs.jmedchem.5b00734" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Young, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbosa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blomgren, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bremer, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dambach, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallion, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hymowitz, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kropf, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubach, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macaluso, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maciejewski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortwine, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Paolo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheerens, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sowell, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currie, K. S.</span></span> <span> </span><span class="NLM_article-title">Potent and Selective Bruton’s Tyrosine Kinase Inhibitors: Discovery of GDC-0834</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1333</span>– <span class="NLM_lpage">1337</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.01.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1016%2Fj.bmcl.2015.01.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=25701252" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BC2MXisVSit7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=1333-1337&author=W.+B.+Youngauthor=J.+Barbosaauthor=P.+Blomgrenauthor=M.+C.+Bremerauthor=J.+J.+Crawfordauthor=D.+Dambachauthor=S.+Gallionauthor=S.+G.+Hymowitzauthor=J.+E.+Kropfauthor=S.+H.+Leeauthor=L.+Liuauthor=J.+W.+Lubachauthor=J.+Macalusoauthor=P.+Maciejewskiauthor=B.+Maurerauthor=S.+A.+Mitchellauthor=D.+F.+Ortwineauthor=J.+Di+Paoloauthor=K.+Reifauthor=H.+Scheerensauthor=A.+Schmittauthor=C.+G.+Sowellauthor=X.+Wangauthor=H.+Wongauthor=J.-M.+Xiongauthor=J.+Xuauthor=Z.+Zhaoauthor=K.+S.+Currie&title=Potent+and+Selective+Bruton%E2%80%99s+Tyrosine+Kinase+Inhibitors%3A+Discovery+of+GDC-0834&doi=10.1016%2Fj.bmcl.2015.01.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Potent and selective Bruton's tyrosine kinase inhibitors: Discovery of GDC-0834</span></div><div class="casAuthors">Young, Wendy B.; Barbosa, James; Blomgren, Peter; Bremer, Meire C.; Crawford, James J.; Dambach, Donna; Gallion, Steve; Hymowitz, Sarah G.; Kropf, Jeffrey E.; Lee, Seung H.; Liu, Lichuan; Lubach, Joseph W.; Macaluso, Jen; Maciejewski, Pat; Maurer, Brigitte; Mitchell, Scott A.; Ortwine, Daniel F.; Di Paolo, Julie; Reif, Karin; Scheerens, Heleen; Schmitt, Aaron; Sowell, C. Gregory; Wang, Xiaojing; Wong, Harvey; Xiong, Jin-Ming; Xu, Jianjun; Zhao, Zhongdong; Currie, Kevin S.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1333-1337</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">SAR studies focused on improving the pharmacokinetic (PK) properties of the previously reported potent and selective Btk inhibitor CGI-1746 resulted in the clin. candidate GDC-0834, which retained the potency and selectivity of CGI-1746, but with much improved PK in preclin. animal models.  Structure based design efforts drove this work as modifications to CGI-1746 were investigated at both the solvent exposed region as well as 'H3 binding pocket'.  However, in vitro metabolic evaluation of GDC-0834 revealed a non CYP-mediated metabolic process that was more prevalent in human than preclin. species (mouse, rat, dog, cyno), leading to a high-level of uncertainly in predicting human pharmacokinetics.  Due to its promising potency, selectivity, and preclin. efficacy, a single dose IND was filed and GDC-0834 was taken in to a single dose phase I trial in healthy volunteers to quickly evaluate the human pharmacokinetics.  In human, GDC-0834 was found to be highly labile at the exo-cyclic amide bond that links the tetrahydrobenzothiophene moiety to the central aniline ring, resulting in insufficient parent drug exposure.  This information informed the back-up program and discovery of improved inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhL04eYDiT3bVg90H21EOLACvtfcHk0lii51cLGxuqqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXisVSit7w%253D&md5=fdebc0199c8222e093cfb9583244bce3</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.01.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.01.032%26sid%3Dliteratum%253Aachs%26aulast%3DYoung%26aufirst%3DW.%2BB.%26aulast%3DBarbosa%26aufirst%3DJ.%26aulast%3DBlomgren%26aufirst%3DP.%26aulast%3DBremer%26aufirst%3DM.%2BC.%26aulast%3DCrawford%26aufirst%3DJ.%2BJ.%26aulast%3DDambach%26aufirst%3DD.%26aulast%3DGallion%26aufirst%3DS.%26aulast%3DHymowitz%26aufirst%3DS.%2BG.%26aulast%3DKropf%26aufirst%3DJ.%2BE.%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DLubach%26aufirst%3DJ.%2BW.%26aulast%3DMacaluso%26aufirst%3DJ.%26aulast%3DMaciejewski%26aufirst%3DP.%26aulast%3DMaurer%26aufirst%3DB.%26aulast%3DMitchell%26aufirst%3DS.%2BA.%26aulast%3DOrtwine%26aufirst%3DD.%2BF.%26aulast%3DDi%2BPaolo%26aufirst%3DJ.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DScheerens%26aufirst%3DH.%26aulast%3DSchmitt%26aufirst%3DA.%26aulast%3DSowell%26aufirst%3DC.%2BG.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DXiong%26aufirst%3DJ.-M.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26atitle%3DPotent%2520and%2520Selective%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520Inhibitors%253A%2520Discovery%2520of%2520GDC-0834%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D1333%26epage%3D1337%26doi%3D10.1016%2Fj.bmcl.2015.01.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Young, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbosa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blomgren, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bremer, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dambach, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallion, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kropf, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubach, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macaluso, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maciejewski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortwine, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Paolo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheerens, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currie, K. S.</span></span> <span> </span><span class="NLM_article-title">Discovery of Highly Potent and Selective Bruton’s Tyrosine Kinase Inhibitors: Pyridazinone Analogs With Improved Metabolic Stability</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">575</span>– <span class="NLM_lpage">579</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.11.076</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1016%2Fj.bmcl.2015.11.076" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=26675441" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvF2ms77M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=575-579&author=W.+B.+Youngauthor=J.+Barbosaauthor=P.+Blomgrenauthor=M.+C.+Bremerauthor=J.+J.+Crawfordauthor=D.+Dambachauthor=C.+Eigenbrotauthor=S.+Gallionauthor=A.+R.+Johnsonauthor=J.+E.+Kropfauthor=S.+H.+Leeauthor=L.+Liuauthor=J.+W.+Lubachauthor=J.+Macalusoauthor=P.+Maciejewskiauthor=S.+A.+Mitchellauthor=D.+F.+Ortwineauthor=J.+Di+Paoloauthor=K.+Reifauthor=H.+Scheerensauthor=A.+Schmittauthor=X.+Wangauthor=H.+Wongauthor=J.-M.+Xiongauthor=J.+Xuauthor=C.+Yuauthor=Z.+Zhaoauthor=K.+S.+Currie&title=Discovery+of+Highly+Potent+and+Selective+Bruton%E2%80%99s+Tyrosine+Kinase+Inhibitors%3A+Pyridazinone+Analogs+With+Improved+Metabolic+Stability&doi=10.1016%2Fj.bmcl.2015.11.076"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of highly potent and selective Bruton's tyrosine kinase inhibitors: Pyridazinone analogs with improved metabolic stability</span></div><div class="casAuthors">Young, Wendy B.; Barbosa, James; Blomgren, Peter; Bremer, Meire C.; Crawford, James J.; Dambach, Donna; Eigenbrot, Charles; Gallion, Steve; Johnson, Adam R.; Kropf, Jeffrey E.; Lee, Seung H.; Liu, Lichuan; Lubach, Joseph W.; Macaluso, Jen; Maciejewski, Pat; Mitchell, Scott A.; Ortwine, Daniel F.; Di Paolo, Julie; Reif, Karin; Scheerens, Heleen; Schmitt, Aaron; Wang, Xiaojing; Wong, Harvey; Xiong, Jin-Ming; Xu, Jianjun; Yu, Christine; Zhao, Zhongdong; Currie, Kevin S.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">575-579</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">BTK inhibitor GDC-0834 was found to be rapidly metabolized in human studies, resulting in a suspension of clin. trials.  The primary route of metab. was through cleavage of the acyclic amide bond connecting the terminal tetrahydrobenzothiophene with the central linker aryl ring.  SAR studies were focused on reducing metabolic cleavage of this amide, and resulted in the identification of several central aryl linker substituents that conferred improved stability.  The most promising substituted aryl linkers were then incorporated into an optimized pyridazinone scaffold, resulting in the identification of lead analog I, possessing improved potency, metabolic stability and preclin. properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWhbh3H4N2ErVg90H21EOLACvtfcHk0lirfAWMIw_9Pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvF2ms77M&md5=ff074fc16518d072ccb9b7b5d8520a03</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.11.076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.11.076%26sid%3Dliteratum%253Aachs%26aulast%3DYoung%26aufirst%3DW.%2BB.%26aulast%3DBarbosa%26aufirst%3DJ.%26aulast%3DBlomgren%26aufirst%3DP.%26aulast%3DBremer%26aufirst%3DM.%2BC.%26aulast%3DCrawford%26aufirst%3DJ.%2BJ.%26aulast%3DDambach%26aufirst%3DD.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DGallion%26aufirst%3DS.%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DKropf%26aufirst%3DJ.%2BE.%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DLubach%26aufirst%3DJ.%2BW.%26aulast%3DMacaluso%26aufirst%3DJ.%26aulast%3DMaciejewski%26aufirst%3DP.%26aulast%3DMitchell%26aufirst%3DS.%2BA.%26aulast%3DOrtwine%26aufirst%3DD.%2BF.%26aulast%3DDi%2BPaolo%26aufirst%3DJ.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DScheerens%26aufirst%3DH.%26aulast%3DSchmitt%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DXiong%26aufirst%3DJ.-M.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26atitle%3DDiscovery%2520of%2520Highly%2520Potent%2520and%2520Selective%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520Inhibitors%253A%2520Pyridazinone%2520Analogs%2520With%2520Improved%2520Metabolic%2520Stability%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D575%26epage%3D579%26doi%3D10.1016%2Fj.bmcl.2015.11.076" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbosa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blomgren, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bremer, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallion, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katewa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kropf, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubach, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macaluso, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maciejewski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortwine, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiPaolo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheerens, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currie, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, W. B.</span></span> <span> </span><span class="NLM_article-title">Discovery of Potent and Selective Tricyclic Inhibitors of Bruton’s Tyrosine Kinase with Improved Druglike Properties</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">608</span>– <span class="NLM_lpage">613</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00103</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00103" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BC2sXntVGgs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=608-613&author=X.+Wangauthor=J.+Barbosaauthor=P.+Blomgrenauthor=M.+C.+Bremerauthor=J.+Chenauthor=J.+J.+Crawfordauthor=W.+Dengauthor=L.+Dongauthor=C.+Eigenbrotauthor=S.+Gallionauthor=J.+Hauauthor=H.+Huauthor=A.+R.+Johnsonauthor=A.+Katewaauthor=J.+E.+Kropfauthor=S.+H.+Leeauthor=L.+Liuauthor=J.+W.+Lubachauthor=J.+Macalusoauthor=P.+Maciejewskiauthor=S.+A.+Mitchellauthor=D.+F.+Ortwineauthor=J.+DiPaoloauthor=K.+Reifauthor=H.+Scheerensauthor=A.+Schmittauthor=H.+Wongauthor=J.+M.+Xiongauthor=J.+Xuauthor=Z.+Zhaoauthor=F.+Zhouauthor=K.+S.+Currieauthor=W.+B.+Young&title=Discovery+of+Potent+and+Selective+Tricyclic+Inhibitors+of+Bruton%E2%80%99s+Tyrosine+Kinase+with+Improved+Druglike+Properties&doi=10.1021%2Facsmedchemlett.7b00103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent and Selective Tricyclic Inhibitors of Bruton's Tyrosine Kinase with Improved Druglike Properties</span></div><div class="casAuthors">Wang, Xiaojing; Barbosa, James; Blomgren, Peter; Bremer, Meire C.; Chen, Jacob; Crawford, James J.; Deng, Wei; Dong, Liming; Eigenbrot, Charles; Gallion, Steve; Hau, Jonathon; Hu, Huiyong; Johnson, Adam R.; Katewa, Arna; Kropf, Jeffrey E.; Lee, Seung H.; Liu, Lichuan; Lubach, Joseph W.; Macaluso, Jen; Maciejewski, Pat; Mitchell, Scott A.; Ortwine, Daniel F.; DiPaolo, Julie; Reif, Karin; Scheerens, Heleen; Schmitt, Aaron; Wong, Harvey; Xiong, Jin-Ming; Xu, Jianjun; Zhao, Zhongdong; Zhou, Fusheng; Currie, Kevin S.; Young, Wendy B.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">608-613</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In our continued effort to discover and develop best-in-class Bruton's tyrosine kinase (Btk) inhibitors for the treatment of B-cell lymphomas, rheumatoid arthritis, and systemic lupus erythematosus, we devised a series of novel tricyclic compds. that improved upon the druglike properties of our previous chem. matter.  Compds. exemplified by G-744 are highly potent, selective for Btk, metabolically stable, well tolerated, and efficacious in an animal model of arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooogQZhchmHrVg90H21EOLACvtfcHk0lirfAWMIw_9Pg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXntVGgs7o%253D&md5=81e9b9c5cc497fc88e033a9de88090be</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00103%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DBarbosa%26aufirst%3DJ.%26aulast%3DBlomgren%26aufirst%3DP.%26aulast%3DBremer%26aufirst%3DM.%2BC.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DCrawford%26aufirst%3DJ.%2BJ.%26aulast%3DDeng%26aufirst%3DW.%26aulast%3DDong%26aufirst%3DL.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DGallion%26aufirst%3DS.%26aulast%3DHau%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DH.%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DKatewa%26aufirst%3DA.%26aulast%3DKropf%26aufirst%3DJ.%2BE.%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DLubach%26aufirst%3DJ.%2BW.%26aulast%3DMacaluso%26aufirst%3DJ.%26aulast%3DMaciejewski%26aufirst%3DP.%26aulast%3DMitchell%26aufirst%3DS.%2BA.%26aulast%3DOrtwine%26aufirst%3DD.%2BF.%26aulast%3DDiPaolo%26aufirst%3DJ.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DScheerens%26aufirst%3DH.%26aulast%3DSchmitt%26aufirst%3DA.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DXiong%26aufirst%3DJ.%2BM.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DF.%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26aulast%3DYoung%26aufirst%3DW.%2BB.%26atitle%3DDiscovery%2520of%2520Potent%2520and%2520Selective%2520Tricyclic%2520Inhibitors%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520with%2520Improved%2520Druglike%2520Properties%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D608%26epage%3D613%26doi%3D10.1021%2Facsmedchemlett.7b00103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Lucca, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langevine, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batt, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertrand, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yip, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traeger, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattoli, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obermeier, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vickery, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Discenza, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arienzo, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimrich, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillooly, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulicicchio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galella, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tebben, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muckelbauer, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rampulla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter-Cid, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrish, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tino, J. A.</span></span> <span> </span><span class="NLM_article-title">Discovery of 6-Fluoro-5-(R)-(3-(S)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-2-methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (BMS-986142): A Reversible Inhibitor of Bruton’s Tyrosine Kinase (BTK) Conformationally Constrained by Two Locked Atropisomers</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">9173</span>– <span class="NLM_lpage">9200</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01088</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01088" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVKjsrfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=9173-9200&author=S.+H.+Wattersonauthor=G.+V.+De+Luccaauthor=Q.+Shiauthor=C.+M.+Langevineauthor=Q.+Liuauthor=D.+G.+Battauthor=M.+B.+Bertrandauthor=H.+Gongauthor=J.+Daiauthor=S.+Yipauthor=P.+Liauthor=D.+Sunauthor=D.-R.+Wuauthor=C.+Wangauthor=Y.+Zhangauthor=S.+C.+Traegerauthor=M.+A.+Pattoliauthor=S.+Skalaauthor=L.+Chengauthor=M.+T.+Obermeierauthor=R.+Vickeryauthor=L.+N.+Discenzaauthor=C.+J.+D%E2%80%99Arienzoauthor=Y.+Zhangauthor=E.+Heimrichauthor=K.+M.+Gilloolyauthor=T.+L.+Taylorauthor=C.+Pulicicchioauthor=K.+W.+McIntyreauthor=M.+A.+Galellaauthor=A.+J.+Tebbenauthor=J.+K.+Muckelbauerauthor=C.+Changauthor=R.+Rampullaauthor=A.+Mathurauthor=L.+Salter-Cidauthor=J.+C.+Barrishauthor=P.+H.+Carterauthor=A.+Furaauthor=J.+R.+Burkeauthor=J.+A.+Tino&title=Discovery+of+6-Fluoro-5-%28R%29-%283-%28S%29-%288-fluoro-1-methyl-2%2C4-dioxo-1%2C2-dihydroquinazolin-3%284H%29-yl%29-2-methylphenyl%29-2-%28S%29-%282-hydroxypropan-2-yl%29-2%2C3%2C4%2C9-tetrahydro-1H-carbazole-8-carboxamide+%28BMS-986142%29%3A+A+Reversible+Inhibitor+of+Bruton%E2%80%99s+Tyrosine+Kinase+%28BTK%29+Conformationally+Constrained+by+Two+Locked+Atropisomers&doi=10.1021%2Facs.jmedchem.6b01088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 6-Fluoro-5-(R)-(3-(S)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-2-methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (BMS-986142): A Reversible Inhibitor of Bruton's Tyrosine Kinase (BTK) Conformationally Constrained by Two Locked Atropisomers</span></div><div class="casAuthors">Watterson, Scott H.; De Lucca, George V.; Shi, Qing; Langevine, Charles M.; Liu, Qingjie; Batt, Douglas G.; Beaudoin Bertrand, Myra; Gong, Hua; Dai, Jun; Yip, Shiuhang; Li, Peng; Sun, Dawn; Wu, Dauh-Rurng; Wang, Chunlei; Zhang, Yingru; Traeger, Sarah C.; Pattoli, Mark A.; Skala, Stacey; Cheng, Lihong; Obermeier, Mary T.; Vickery, Rodney; Discenza, Lorell N.; D'Arienzo, Celia J.; Zhang, Yifan; Heimrich, Elizabeth; Gillooly, Kathleen M.; Taylor, Tracy L.; Pulicicchio, Claudine; McIntyre, Kim W.; Galella, Michael A.; Tebben, Andy J.; Muckelbauer, Jodi K.; Chang, ChiehYing; Rampulla, Richard; Mathur, Arvind; Salter-Cid, Luisa; Barrish, Joel C.; Carter, Percy H.; Fura, Aberra; Burke, James R.; Tino, Joseph A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">9173-9200</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK), a nonreceptor tyrosine kinase, is a member of the Tec family of kinases.  BTK plays an essential role in B cell receptor (BCR)-mediated signaling as well as Fcγ receptor signaling in monocytes and Fcε receptor signaling in mast cells and basophils, all of which have been implicated in the pathophysiol. of autoimmune disease.  As a result, inhibition of BTK is anticipated to provide an effective strategy for the clin. treatment of autoimmune diseases such as lupus and rheumatoid arthritis.  This article details the structure-activity relationships (SAR) leading to a novel series of highly potent and selective carbazole and tetrahydrocarbazole based, reversible inhibitors of BTK.  Of particular interest is that two atropisomeric centers were rotationally locked to provide a single, stable atropisomer, resulting in enhanced potency and selectivity as well as a redn. in safety liabilities.  With significantly enhanced potency and selectivity, excellent in vivo properties and efficacy, and a very desirable tolerability and safety profile, 14f (BMS-986142) was advanced into clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmpBAygRAsYrVg90H21EOLACvtfcHk0li8zgq6I7I8JQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVKjsrfF&md5=91098abc802521b9ad91563d20ac5893</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01088%26sid%3Dliteratum%253Aachs%26aulast%3DWatterson%26aufirst%3DS.%2BH.%26aulast%3DDe%2BLucca%26aufirst%3DG.%2BV.%26aulast%3DShi%26aufirst%3DQ.%26aulast%3DLangevine%26aufirst%3DC.%2BM.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DBatt%26aufirst%3DD.%2BG.%26aulast%3DBertrand%26aufirst%3DM.%2BB.%26aulast%3DGong%26aufirst%3DH.%26aulast%3DDai%26aufirst%3DJ.%26aulast%3DYip%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DWu%26aufirst%3DD.-R.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DTraeger%26aufirst%3DS.%2BC.%26aulast%3DPattoli%26aufirst%3DM.%2BA.%26aulast%3DSkala%26aufirst%3DS.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DObermeier%26aufirst%3DM.%2BT.%26aulast%3DVickery%26aufirst%3DR.%26aulast%3DDiscenza%26aufirst%3DL.%2BN.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%2BJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHeimrich%26aufirst%3DE.%26aulast%3DGillooly%26aufirst%3DK.%2BM.%26aulast%3DTaylor%26aufirst%3DT.%2BL.%26aulast%3DPulicicchio%26aufirst%3DC.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DGalella%26aufirst%3DM.%2BA.%26aulast%3DTebben%26aufirst%3DA.%2BJ.%26aulast%3DMuckelbauer%26aufirst%3DJ.%2BK.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DRampulla%26aufirst%3DR.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DSalter-Cid%26aufirst%3DL.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DFura%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DTino%26aufirst%3DJ.%2BA.%26atitle%3DDiscovery%2520of%25206-Fluoro-5-%2528R%2529-%25283-%2528S%2529-%25288-fluoro-1-methyl-2%252C4-dioxo-1%252C2-dihydroquinazolin-3%25284H%2529-yl%2529-2-methylphenyl%2529-2-%2528S%2529-%25282-hydroxypropan-2-yl%2529-2%252C3%252C4%252C9-tetrahydro-1H-carbazole-8-carboxamide%2520%2528BMS-986142%2529%253A%2520A%2520Reversible%2520Inhibitor%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520%2528BTK%2529%2520Conformationally%2520Constrained%2520by%2520Two%2520Locked%2520Atropisomers%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D9173%26epage%3D9200%26doi%3D10.1021%2Facs.jmedchem.6b01088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Honigberg, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sirisawad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loury, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thamm, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buggy, J. J.</span></span> <span> </span><span class="NLM_article-title">The Bruton Tyrosine Kinase Inhibitor PCI-32765 Blocks B Cell Activation and is Efficacious in Models of Autoimmune Disease and B-cell Malignancy</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">13075</span>– <span class="NLM_lpage">13080</span>, <span class="refDoi"> DOI: 10.1073/pnas.1004594107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1073%2Fpnas.1004594107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=20615965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsVCrsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=13075-13080&author=L.+A.+Honigbergauthor=A.+M.+Smithauthor=M.+Sirisawadauthor=E.+Vernerauthor=D.+Louryauthor=B.+Changauthor=S.+Liauthor=Z.+Panauthor=D.+H.+Thammauthor=R.+A.+Millerauthor=J.+J.+Buggy&title=The+Bruton+Tyrosine+Kinase+Inhibitor+PCI-32765+Blocks+B+Cell+Activation+and+is+Efficacious+in+Models+of+Autoimmune+Disease+and+B-cell+Malignancy&doi=10.1073%2Fpnas.1004594107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy</span></div><div class="casAuthors">Honigberg, Lee A.; Smith, Ashley M.; Sirisawad, Mint; Verner, Erik; Loury, David; Chang, Betty; Li, Shyr; Pan, Zhengying; Thamm, Douglas H.; Miller, Richard A.; Buggy, Joseph J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">13075-13080, S13075/1-S13075/3</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Activation of the B-cell antigen receptor (BCR) signaling pathway contributes to the initiation and maintenance of B-cell malignancies and autoimmune diseases.  The Bruton tyrosine kinase (Btk) is specifically required for BCR signaling as demonstrated by human and mouse mutations that disrupt Btk function and prevent B-cell maturation at steps that require a functional BCR pathway.  Herein we describe a selective and irreversible Btk inhibitor, PCI-32765, that is currently under clin. development in patients with B-cell non-Hodgkin lymphoma.  We have used this inhibitor to investigate the biol. effects of Btk inhibition on mature B-cell function and the progression of B cell-assocd. diseases in vivo.  PCI-32765 blocked BCR signaling in human peripheral B cells at concns. that did not affect T cell receptor signaling.  In mice with collagen-induced arthritis, orally administered PCI-32765 reduced the level of circulating autoantibodies and completely suppressed disease.  PCI-32765 also inhibited autoantibody prodn. and the development of kidney disease in the MRL-Fas(lpr) lupus model.  Occupancy of the Btk active site by PCI-32765 was monitored in vitro and in vivo using a fluorescent affinity probe for Btk.  Active site occupancy of Btk was tightly correlated with the blockade of BCR signaling and in vivo efficacy.  Finally, PCI-32765 induced objective clin. responses in dogs with spontaneous B-cell non-Hodgkin lymphoma.  These findings support Btk inhibition as a therapeutic approach for the treatment of human diseases assocd. with activation of the BCR pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoT4OQHme7oHLVg90H21EOLACvtfcHk0lhBgI_G73wgYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsVCrsbk%253D&md5=196ce4a05bb9c622c49cb7e908682e63</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1004594107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1004594107%26sid%3Dliteratum%253Aachs%26aulast%3DHonigberg%26aufirst%3DL.%2BA.%26aulast%3DSmith%26aufirst%3DA.%2BM.%26aulast%3DSirisawad%26aufirst%3DM.%26aulast%3DVerner%26aufirst%3DE.%26aulast%3DLoury%26aufirst%3DD.%26aulast%3DChang%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DPan%26aufirst%3DZ.%26aulast%3DThamm%26aufirst%3DD.%2BH.%26aulast%3DMiller%26aufirst%3DR.%2BA.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26atitle%3DThe%2520Bruton%2520Tyrosine%2520Kinase%2520Inhibitor%2520PCI-32765%2520Blocks%2520B%2520Cell%2520Activation%2520and%2520is%2520Efficacious%2520in%2520Models%2520of%2520Autoimmune%2520Disease%2520and%2520B-cell%2520Malignancy%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2010%26volume%3D107%26spage%3D13075%26epage%3D13080%26doi%3D10.1073%2Fpnas.1004594107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Advani, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buggy, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharman, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyd, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolibaba, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sukbuntherng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izumi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamdy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedrick, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fowler, N. H.</span></span> <span> </span><span class="NLM_article-title">Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) has Significant Activity in Patients with Relapsed/Refractory B-cell Malignancies</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">88</span>– <span class="NLM_lpage">94</span>, <span class="refDoi"> DOI: 10.1200/JCO.2012.42.7906</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1200%2FJCO.2012.42.7906" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=23045577" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BC3sXitFaltLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=88-94&author=R.+H.+Advaniauthor=J.+J.+Buggyauthor=J.+P.+Sharmanauthor=S.+M.+Smithauthor=T.+E.+Boydauthor=B.+Grantauthor=K.+S.+Kolibabaauthor=R.+R.+Furmanauthor=S.+Rodriguezauthor=B.+Y.+Changauthor=J.+Sukbuntherngauthor=R.+Izumiauthor=A.+Hamdyauthor=E.+Hedrickauthor=N.+H.+Fowler&title=Bruton+Tyrosine+Kinase+Inhibitor+Ibrutinib+%28PCI-32765%29+has+Significant+Activity+in+Patients+with+Relapsed%2FRefractory+B-cell+Malignancies&doi=10.1200%2FJCO.2012.42.7906"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies</span></div><div class="casAuthors">Advani, Ranjana H.; Buggy, Joseph J.; Sharman, Jeff P.; Smith, Sonali M.; Boyd, Thomas E.; Grant, Barbara; Kolibaba, Kathryn S.; Furman, Richard R.; Rodriguez, Sara; Chang, Betty Y.; Sukbuntherng, Juthamas; Izumi, Raquel; Hamdy, Ahmed; Hedrick, Eric; Fowler, Nathan H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">88-94</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose Survival and progression of mature B-cell malignancies depend on signals from the B-cell antigen receptor, and Bruton tyrosine kinase (BTK) is a crit. signaling kinase in this pathway.  We evaluated ibrutinib (PCI-32765), a small-mol. irreversible inhibitor of BTK, in patients with B-cell malignancies.  Patients and Methods Patients with relapsed or refractory B-cell lymphoma and chronic lymphocytic leukemia received escalating oral doses of ibrutinib.  Two schedules were evaluated: one, 28 days on, 7 days off; and two, once-daily continuous dosing.  Occupancy of BTK by ibrutinib in peripheral blood was monitored using a fluorescent affinity probe.  Dose escalation proceeded until either the max.-tolerated dose (MTD) was achieved or, in the absence of MTD, until three dose levels above full BTK occupancy by ibrutinib.  Response was evaluated every two cycles.  Results Fifty-six patients with a variety of B-cell malignancies were treated over seven cohorts.  Most adverse events were grade 1 and 2 in severity and self-limited.  Dose-limiting events were not obsd., even with prolonged dosing.  Full occupancy of the BTK active site occurred at 2.5 mg/kg per day, and dose escalation continued to 12.5 mg/kg per day without reaching MTD.  Pharmacokinetic data indicated rapid absorption and elimination, yet BTK occupancy was maintained for at least 24 h, consistent with the irreversible mechanism.  Objective response rate in 50 evaluable patients was 60%, including complete response of 16%.  Median progression-free survival in all patients was 13.6 mo.  Conclusion Ibrutinib, a novel BTK-targeting inhibitor, is well tolerated, with substantial activity across B-cell histologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqj_UZPM0nBrVg90H21EOLACvtfcHk0lhBgI_G73wgYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXitFaltLg%253D&md5=e955490a02af9a321823033b9e258cb6</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1200%2FJCO.2012.42.7906&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2012.42.7906%26sid%3Dliteratum%253Aachs%26aulast%3DAdvani%26aufirst%3DR.%2BH.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26aulast%3DSharman%26aufirst%3DJ.%2BP.%26aulast%3DSmith%26aufirst%3DS.%2BM.%26aulast%3DBoyd%26aufirst%3DT.%2BE.%26aulast%3DGrant%26aufirst%3DB.%26aulast%3DKolibaba%26aufirst%3DK.%2BS.%26aulast%3DFurman%26aufirst%3DR.%2BR.%26aulast%3DRodriguez%26aufirst%3DS.%26aulast%3DChang%26aufirst%3DB.%2BY.%26aulast%3DSukbuntherng%26aufirst%3DJ.%26aulast%3DIzumi%26aufirst%3DR.%26aulast%3DHamdy%26aufirst%3DA.%26aulast%3DHedrick%26aufirst%3DE.%26aulast%3DFowler%26aufirst%3DN.%2BH.%26atitle%3DBruton%2520Tyrosine%2520Kinase%2520Inhibitor%2520Ibrutinib%2520%2528PCI-32765%2529%2520has%2520Significant%2520Activity%2520in%2520Patients%2520with%2520Relapsed%252FRefractory%2520B-cell%2520Malignancies%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D31%26spage%3D88%26epage%3D94%26doi%3D10.1200%2FJCO.2012.42.7906" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Byrd, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coutre, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flinn, I. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharman, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wierda, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heerema, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sukbuntherng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clow, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedrick, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buggy, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S.</span></span> <span> </span><span class="NLM_article-title">Targeting Btk with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>369</i></span>,  <span class="NLM_fpage">32</span>– <span class="NLM_lpage">42</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1215637</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1056%2FNEJMoa1215637" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=23782158" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFygu7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=369&publication_year=2013&pages=32-42&author=J.+C.+Byrdauthor=R.+R.+Furmanauthor=S.+E.+Coutreauthor=I.+W.+Flinnauthor=J.+A.+Burgerauthor=K.+A.+Blumauthor=B.+Grantauthor=J.+P.+Sharmanauthor=M.+Colemanauthor=W.+G.+Wierdaauthor=J.+A.+Jonesauthor=W.+Zhaoauthor=N.+A.+Heeremaauthor=A.+J.+Johnsonauthor=J.+Sukbuntherngauthor=B.+Y.+Changauthor=F.+Clowauthor=E.+Hedrickauthor=J.+J.+Buggyauthor=D.+F.+Jamesauthor=S.+O%E2%80%99Brien&title=Targeting+Btk+with+Ibrutinib+in+Relapsed+Chronic+Lymphocytic+Leukemia&doi=10.1056%2FNEJMoa1215637"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia</span></div><div class="casAuthors">Byrd, John C.; Furman, Richard R.; Coutre, Steven E.; Flinn, Ian W.; Burger, Jan A.; Blum, Kristie A.; Grant, Barbara; Sharman, Jeff P.; Coleman, Morton; Wierda, William G.; Jones, Jeffrey A.; Zhao, Weiqiang; Heerema, Nyla A.; Johnson, Amy J.; Sukbuntherng, Juthamas; Chang, Betty Y.; Clow, Fong; Hedrick, Eric; Buggy, Joseph J.; James, Danelle F.; O'Brien, Susan</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">369</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">32-42</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background The treatment of relapsed chronic lymphocytic leukemia (CLL) has resulted in few durable remissions.  Bruton's tyrosine kinase (BTK), an essential component of B-cell-receptor signaling, mediates interactions with the tumor microenvironment and promotes the survival and proliferation of CLL cells.  Methods We conducted a phase 1b-2 multicenter study to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of ibrutinib (PCI-32765), a first-in-class, oral covalent inhibitor of BTK designed for treatment of B-cell cancers, in patients with relapsed or refractory CLL or small lymphocytic lymphoma.  A total of 85 patients, the majority of whom were considered to have high-risk disease, received ibrutinib orally once daily; 51 received 420 mg, and 34 received 840 mg.  Results Toxic effects were predominantly grade 1 or 2 and included transient diarrhea, fatigue, and upper respiratory tract infection; thus, patients could receive extended treatment with minimal hematol. toxic effects.  The overall response rate was the same in the group that received 420 mg and the group that received 840 mg (71%), and an addnl. 20% and 15% of patients in the resp. groups had a partial response with lymphocytosis.  The response was independent of clin. and genomic risk factors present before treatment, including advanced-stage disease, the no. of previous therapies, and the 17p13.1 deletion.  At 26 mo, the estd. progression-free survival rate was 75% and the rate of overall survival was 83%.  Conclusions Ibrutinib was assocd. with a high frequency of durable remissions in patients with relapsed or refractory CLL and small lymphocytic lymphoma, including patients with high-risk genetic lesions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1EhPQxMRz7rVg90H21EOLACvtfcHk0lhBgI_G73wgYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFygu7zN&md5=32a5eb6ab06beeecf64d9ada84139925</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1215637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1215637%26sid%3Dliteratum%253Aachs%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DFurman%26aufirst%3DR.%2BR.%26aulast%3DCoutre%26aufirst%3DS.%2BE.%26aulast%3DFlinn%26aufirst%3DI.%2BW.%26aulast%3DBurger%26aufirst%3DJ.%2BA.%26aulast%3DBlum%26aufirst%3DK.%2BA.%26aulast%3DGrant%26aufirst%3DB.%26aulast%3DSharman%26aufirst%3DJ.%2BP.%26aulast%3DColeman%26aufirst%3DM.%26aulast%3DWierda%26aufirst%3DW.%2BG.%26aulast%3DJones%26aufirst%3DJ.%2BA.%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DHeerema%26aufirst%3DN.%2BA.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26aulast%3DSukbuntherng%26aufirst%3DJ.%26aulast%3DChang%26aufirst%3DB.%2BY.%26aulast%3DClow%26aufirst%3DF.%26aulast%3DHedrick%26aufirst%3DE.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26aulast%3DJames%26aufirst%3DD.%2BF.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%26atitle%3DTargeting%2520Btk%2520with%2520Ibrutinib%2520in%2520Relapsed%2520Chronic%2520Lymphocytic%2520Leukemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D369%26spage%3D32%26epage%3D42%26doi%3D10.1056%2FNEJMoa1215637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rule, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahl, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jurczak, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Advani, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romaguera, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrientos, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chmielowska, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radford, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stilgenbauer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dreyling, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jedzejczak, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spurgeon, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newberry, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGreivy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clow, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buggy, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaupre, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunkel, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, K. A.</span></span> <span> </span><span class="NLM_article-title">Targeting Btk with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>369</i></span>,  <span class="NLM_fpage">507</span>– <span class="NLM_lpage">516</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1306220</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1056%2FNEJMoa1306220" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=23782157" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1OgtL%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=369&publication_year=2013&pages=507-516&author=M.+L.+Wangauthor=S.+Ruleauthor=P.+Martinauthor=A.+Goyauthor=R.+Auerauthor=B.+S.+Kahlauthor=W.+Jurczakauthor=R.+H.+Advaniauthor=J.+E.+Romagueraauthor=M.+E.+Williamsauthor=J.+C.+Barrientosauthor=E.+Chmielowskaauthor=J.+Radfordauthor=S.+Stilgenbauerauthor=M.+Dreylingauthor=W.+W.+Jedzejczakauthor=P.+Johnsonauthor=S.+E.+Spurgeonauthor=L.+Liauthor=L.+Zhangauthor=K.+Newberryauthor=Z.+Ouauthor=N.+Chengauthor=B.+Fangauthor=J.+McGreivyauthor=F.+Clowauthor=J.+J.+Buggyauthor=B.+Y.+Changauthor=D.+M.+Beaupreauthor=L.+A.+Kunkelauthor=K.+A.+Blum&title=Targeting+Btk+with+Ibrutinib+in+Relapsed+or+Refractory+Mantle-Cell+Lymphoma&doi=10.1056%2FNEJMoa1306220"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma</span></div><div class="casAuthors">Wang, Michael L.; Rule, Simon; Martin, Peter; Goy, Andre; Auer, Rebecca; Kahl, Brad S.; Jurczak, Wojciech; Advani, Ranjana H.; Romaguera, Jorge E.; Williams, Michael E.; Barrientos, Jacqueline C.; Chmielowska, Ewa; Radford, John; Stilgenbauer, Stephan; Dreyling, Martin; Jedrzejczak, Wieslaw Wiktor; Johnson, Peter; Spurgeon, Stephen E.; Li, Lei; Zhang, Liang; Newberry, Kate; Ou, Zhishuo; Cheng, Nancy; Fang, Bingliang; McGreivy, Jesse; Clow, Fong; Buggy, Joseph J.; Chang, Betty Y.; Beaupre, Darrin M.; Kunkel, Lori A.; Blum, Kristie A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">369</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">507-516</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Bruton's tyrosine kinase (BTK) is a mediator of the B-cell-receptor signaling pathway implicated in the pathogenesis of B-cell cancers.  In a phase 1 study, ibrutinib, a BTK inhibitor, showed antitumor activity in several types of non-Hodgkin's lymphoma, including mantle-cell lymphoma.  METHODS: In this phase 2 study, we investigated oral ibrutinib, at a daily dose of 560 mg, in 111 patients with relapsed or refractory mantle-cell lymphoma.  Patients were enrolled into two groups: those who had previously received at least 2 cycles of bortezomib therapy and those who had received less than 2 complete cycles of bortezomib or had received no prior bortezomib therapy.  The primary end point was the overall response rate.  Secondary end points were duration of response, progression-free survival, overall survival, and safety.  RESULTS: The median age was 68 years, and 86% of patients had intermediate-risk or high-risk mantle-cell lymphoma according to clin. prognostic factors.  Patients had received a median of three prior therapies.  The most common treatment-related adverse events were mild or moderate diarrhea, fatigue, and nausea.  Grade 3 or higher hematol. events were infrequent and included neutropenia (in 16% of patients), thrombocytopenia (in 11%), and anemia (in 10%).  A response rate of 68% (75 patients) was obsd., with a complete response rate of 21% and a partial response rate of 47%; prior treatment with bortezomib had no effect on the response rate.  With an estd. median follow-up of 15.3 mo, the estd. median response duration was 17.5 mo (95% confidence interval [CI], 15.8 to not reached), the estd. median progression-free survival was 13.9 mo (95% CI, 7.0 to not reached), and the median overall survival was not reached.  The estd. rate of overall survival was 58% at 18 mo.  CONCLUSIONS: Ibrutinib shows durable single-agent efficacy in relapsed or refractory mantle-cell lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovUuOKvHS0NrVg90H21EOLACvtfcHk0lhWe5rMoEvJKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1OgtL%252FF&md5=7a92bbd5acf86e614cea96f44503e12b</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1306220&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1306220%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DM.%2BL.%26aulast%3DRule%26aufirst%3DS.%26aulast%3DMartin%26aufirst%3DP.%26aulast%3DGoy%26aufirst%3DA.%26aulast%3DAuer%26aufirst%3DR.%26aulast%3DKahl%26aufirst%3DB.%2BS.%26aulast%3DJurczak%26aufirst%3DW.%26aulast%3DAdvani%26aufirst%3DR.%2BH.%26aulast%3DRomaguera%26aufirst%3DJ.%2BE.%26aulast%3DWilliams%26aufirst%3DM.%2BE.%26aulast%3DBarrientos%26aufirst%3DJ.%2BC.%26aulast%3DChmielowska%26aufirst%3DE.%26aulast%3DRadford%26aufirst%3DJ.%26aulast%3DStilgenbauer%26aufirst%3DS.%26aulast%3DDreyling%26aufirst%3DM.%26aulast%3DJedzejczak%26aufirst%3DW.%2BW.%26aulast%3DJohnson%26aufirst%3DP.%26aulast%3DSpurgeon%26aufirst%3DS.%2BE.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DNewberry%26aufirst%3DK.%26aulast%3DOu%26aufirst%3DZ.%26aulast%3DCheng%26aufirst%3DN.%26aulast%3DFang%26aufirst%3DB.%26aulast%3DMcGreivy%26aufirst%3DJ.%26aulast%3DClow%26aufirst%3DF.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26aulast%3DChang%26aufirst%3DB.%2BY.%26aulast%3DBeaupre%26aufirst%3DD.%2BM.%26aulast%3DKunkel%26aufirst%3DL.%2BA.%26aulast%3DBlum%26aufirst%3DK.%2BA.%26atitle%3DTargeting%2520Btk%2520with%2520Ibrutinib%2520in%2520Relapsed%2520or%2520Refractory%2520Mantle-Cell%2520Lymphoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D369%26spage%3D507%26epage%3D516%26doi%3D10.1056%2FNEJMoa1306220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Noy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vos, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thieblemont, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flowers, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morschhauser, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peles, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrientos, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munneke, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimery, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaupre, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, R.</span></span> <span> </span><span class="NLM_article-title">Targeting BTK with Ibrutinib in Relapsed/Refractory Marginal Zone Lymphoma</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">2224</span>– <span class="NLM_lpage">2232</span>, <span class="refDoi"> DOI: 10.1182/blood-2016-10-747345</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1182%2Fblood-2016-10-747345" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2017&pages=2224-2232&author=A.+Noyauthor=S.+de+Vosauthor=C.+Thieblemontauthor=P.+Martinauthor=C.+R.+Flowersauthor=F.+Morschhauserauthor=G.+P.+Collinsauthor=S.+Maauthor=M.+Colemanauthor=S.+Pelesauthor=S.+Smithauthor=J.+C.+Barrientosauthor=A.+Smithauthor=B.+Munnekeauthor=I.+Dimeryauthor=D.+M.+Beaupreauthor=R.+Chen&title=Targeting+BTK+with+Ibrutinib+in+Relapsed%2FRefractory+Marginal+Zone+Lymphoma&doi=10.1182%2Fblood-2016-10-747345"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1182%2Fblood-2016-10-747345&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2016-10-747345%26sid%3Dliteratum%253Aachs%26aulast%3DNoy%26aufirst%3DA.%26aulast%3Dde%2BVos%26aufirst%3DS.%26aulast%3DThieblemont%26aufirst%3DC.%26aulast%3DMartin%26aufirst%3DP.%26aulast%3DFlowers%26aufirst%3DC.%2BR.%26aulast%3DMorschhauser%26aufirst%3DF.%26aulast%3DCollins%26aufirst%3DG.%2BP.%26aulast%3DMa%26aufirst%3DS.%26aulast%3DColeman%26aufirst%3DM.%26aulast%3DPeles%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DS.%26aulast%3DBarrientos%26aufirst%3DJ.%2BC.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DMunneke%26aufirst%3DB.%26aulast%3DDimery%26aufirst%3DI.%26aulast%3DBeaupre%26aufirst%3DD.%2BM.%26aulast%3DChen%26aufirst%3DR.%26atitle%3DTargeting%2520BTK%2520with%2520Ibrutinib%2520in%2520Relapsed%252FRefractory%2520Marginal%2520Zone%2520Lymphoma%26jtitle%3DBlood%26date%3D2017%26volume%3D129%26spage%3D2224%26epage%3D2232%26doi%3D10.1182%2Fblood-2016-10-747345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Treon, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tripsas, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meid, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warren, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varma, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Argyropolous, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodig, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zehnder, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aster, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghobrial, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castillo, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laubach, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, Z. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salman, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clow, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graef, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palomba, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Advani, R. H.</span></span> <span> </span><span class="NLM_article-title">Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>372</i></span>,  <span class="NLM_fpage">1430</span>– <span class="NLM_lpage">1440</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1501548</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1056%2FNEJMoa1501548" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=25853747" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BC2MXns1Wrt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2015&pages=1430-1440&author=S.+P.+Treonauthor=C.+K.+Tripsasauthor=K.+Meidauthor=D.+Warrenauthor=G.+Varmaauthor=R.+Greenauthor=K.+V.+Argyropolousauthor=G.+Yangauthor=Y.+Caoauthor=L.+Xuauthor=C.+J.+Pattersonauthor=S.+Rodigauthor=J.+L.+Zehnderauthor=J.+C.+Asterauthor=N.+L.+Harrisauthor=S.+Kananauthor=I.+Ghobrialauthor=J.+J.+Castilloauthor=J.+P.+Laubachauthor=Z.+R.+Hunterauthor=Z.+Salmanauthor=J.+Liauthor=M.+Chengauthor=F.+Clowauthor=T.+Graefauthor=M.+L.+Palombaauthor=R.+H.+Advani&title=Ibrutinib+in+Previously+Treated+Waldenstr%C3%B6m%E2%80%99s+Macroglobulinemia&doi=10.1056%2FNEJMoa1501548"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Ibrutinib in previously treated waldenstrom's macroglobulinemia</span></div><div class="casAuthors">Treon, Steven P.; Tripsas, Christina K.; Meid, Kirsten; Warren, Diane; Varma, Gaurav; Green, Rebecca; Argyropoulos, Kimon V.; Yang, Guang; Cao, Yang; Xu, Lian; Patterson, Christopher J.; Rodig, Scott; Zehnder, James L.; Aster, Jon C.; Harris, Nancy Lee; Kanan, Sandra; Ghobrial, Irene; Castillo, Jorge J.; Laubach, Jacob P.; Hunter, Zachary R.; Salman, Zeena; Li, Jianling; Cheng, Mei; Clow, Fong; Graef, Thorsten; Palomba, M. Lia; Advani, Ranjana H.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">372</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1430-1440</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">MYD88L265P and CXCR4WHIM mutations are highly prevalent in Waldenstrom's macroglobulinemia.  MYD88L265P triggers tumor-cell growth through Bruton's tyrosine kinase, a target of ibrutinib.  CXCR4WHIM mutations confer in vitro resistance to ibrutinib.  We performed a prospective study of ibrutinib in 63 symptomatic patients with Waldenstrom's macroglobulinemia who had received at least one previous treatment, and we investigated the effect of MYD88 and CXCR4 mutations on outcomes.  Ibrutinib at a daily dose of 420 mg was administered orally until disease progression or the development of unacceptable toxic effects.  After the patients received ibrutinib, median serum IgM levels decreased from 3520 mg per dL to 880 mg per dL, median Hb levels increased from 10.5 g per dL to 13.8 g per dL, and bone marrow involvement decreased from 60% to 25% (P<0.01 for all comparisons).  The median time to at least a minor response was 4 wk.  The overall response rate was 90.5%, and the major response rate was 73.0%; these rates were highest among patients with MYD88L265PCXCR4WT (with WT indicating wild-type) (100% overall response rate and 91.2% major response rate), followed by patients with MYD88L265PCXCR4WHIM (85.7% and 61.9%, resp.) and patients with MYD88WTCXCR4WT (71.4% and 28.6%).  The estd. 2-yr progression-free and overall survival rates among all patients were 69.1% and 95.2%, resp.  Treatment-related toxic effects of grade 2 or higher included neutropenia (in 22% of the patients) and thrombocytopenia (in 14%), which were more common in heavily pretreated patients; postprocedural bleeding (in 3%); epistaxis assocd. with the use of fish-oil supplements (in 3%); and atrial fibrillation assocd. with a history of arrhythmia (5%).  Ibrutinib was highly active, assocd. with durable responses, and safe in pretreated patients with Waldenstrom's macroglobulinemia.  MYD88 and CXCR4 mutation status affected responses to this drug. (Funded by Pharmacyclics and others; ClinicalTrials.gov no., NCT01614821.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoifbEcGkxnFrVg90H21EOLACvtfcHk0ljo97oaen1kVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXns1Wrt7w%253D&md5=00d1d3dd9be87801725d8c161afa899c</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1501548&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1501548%26sid%3Dliteratum%253Aachs%26aulast%3DTreon%26aufirst%3DS.%2BP.%26aulast%3DTripsas%26aufirst%3DC.%2BK.%26aulast%3DMeid%26aufirst%3DK.%26aulast%3DWarren%26aufirst%3DD.%26aulast%3DVarma%26aufirst%3DG.%26aulast%3DGreen%26aufirst%3DR.%26aulast%3DArgyropolous%26aufirst%3DK.%2BV.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DPatterson%26aufirst%3DC.%2BJ.%26aulast%3DRodig%26aufirst%3DS.%26aulast%3DZehnder%26aufirst%3DJ.%2BL.%26aulast%3DAster%26aufirst%3DJ.%2BC.%26aulast%3DHarris%26aufirst%3DN.%2BL.%26aulast%3DKanan%26aufirst%3DS.%26aulast%3DGhobrial%26aufirst%3DI.%26aulast%3DCastillo%26aufirst%3DJ.%2BJ.%26aulast%3DLaubach%26aufirst%3DJ.%2BP.%26aulast%3DHunter%26aufirst%3DZ.%2BR.%26aulast%3DSalman%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DClow%26aufirst%3DF.%26aulast%3DGraef%26aufirst%3DT.%26aulast%3DPalomba%26aufirst%3DM.%2BL.%26aulast%3DAdvani%26aufirst%3DR.%2BH.%26atitle%3DIbrutinib%2520in%2520Previously%2520Treated%2520Waldenstr%25C3%25B6m%25E2%2580%2599s%2520Macroglobulinemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D372%26spage%3D1430%26epage%3D1440%26doi%3D10.1056%2FNEJMoa1501548" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Paolo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbosa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, H.</span></span> <span> </span><span class="NLM_article-title">Antiarthritis Effect of a Novel Bruton’s Tyrosine Kinase (BTK) Inhibitor in Rat Collagen-Induced Arthritis and Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling: Relationships Between Inhibition of BTK Phosphorylation and Efficacy</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>338</i></span>,  <span class="NLM_fpage">154</span>– <span class="NLM_lpage">163</span>, <span class="refDoi"> DOI: 10.1124/jpet.111.181545</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1124%2Fjpet.111.181545" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=21521773" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosFCiu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=338&publication_year=2011&pages=154-163&author=L.+Liuauthor=J.+Di+Paoloauthor=J.+Barbosaauthor=H.+Rongauthor=K.+Reifauthor=H.+Wong&title=Antiarthritis+Effect+of+a+Novel+Bruton%E2%80%99s+Tyrosine+Kinase+%28BTK%29+Inhibitor+in+Rat+Collagen-Induced+Arthritis+and+Mechanism-Based+Pharmacokinetic%2FPharmacodynamic+Modeling%3A+Relationships+Between+Inhibition+of+BTK+Phosphorylation+and+Efficacy&doi=10.1124%2Fjpet.111.181545"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Antiarthritis effect of a novel Bruton's tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy</span></div><div class="casAuthors">Liu, Lichuan; Di Paolo, Julie; Barbosa, Jim; Rong, Hong; Reif, Karin; Wong, Harvey</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">338</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">154-163</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK) plays a crit. role in the development, differentiation, and proliferation of B-lineage cells, making it an attractive target for the treatment of rheumatoid arthritis.  The objective of this study was to evaluate the antiarthritis effect of GDC-0834 [R-N-(3-(6-(4-(1,4-dimethyl-3-oxopiperazin-2-yl)phenylamino)-4-methyl-5-oxo-4,5-dihydropyrazin-2-yl)-2-methylphenyl)-4,5,6,7-tetrahydrobenzo[b]thiophene-2-carboxamide], a potent and selective BTK inhibitor, and characterize the relationship between inhibition of BTK phosphorylation (pBTK) and efficacy.  GDC-0834 inhibited BTK with an in vitro IC50 of 5.9 and 6.4 nM in biochem. and cellular assays, resp., and in vivo IC50 of 1.1 and 5.6 μM in mouse and rat, resp.  Administration of GDC-0834 (30-100 mg/kg) in a rat collagen-induced arthritis (CIA) model resulted in a dose-dependent decrease of ankle swelling and redn. of morphol. pathol.  An integrated disease progression pharmacokinetic/pharmacodynamic model where efficacy is driven by pBTK inhibition was fit to ankle-diam. time-course data.  This model incorporated a transit model to characterize nondrug-related decreases in ankle swelling occurring at later stages of disease progression in CIA rats.  The time course of ankle swelling in vehicle animals was described well by the base model.  Simultaneous fitting of data from vehicle- and GDC-0834-treated groups showed that overall 73% inhibition of pBTK was needed to decrease the rate const. describing the ankle swelling increase (kin) by half.  These findings suggest a high degree of pBTK inhibition is required for maximal activity of the pathway on inflammatory arthritis in rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUtceutx0oDrVg90H21EOLACvtfcHk0ljo97oaen1kVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosFCiu7w%253D&md5=52ec6f33d9fc743036baea87a2d6bce1</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1124%2Fjpet.111.181545&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.111.181545%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DDi%2BPaolo%26aufirst%3DJ.%26aulast%3DBarbosa%26aufirst%3DJ.%26aulast%3DRong%26aufirst%3DH.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DWong%26aufirst%3DH.%26atitle%3DAntiarthritis%2520Effect%2520of%2520a%2520Novel%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520%2528BTK%2529%2520Inhibitor%2520in%2520Rat%2520Collagen-Induced%2520Arthritis%2520and%2520Mechanism-Based%2520Pharmacokinetic%252FPharmacodynamic%2520Modeling%253A%2520Relationships%2520Between%2520Inhibition%2520of%2520BTK%2520Phosphorylation%2520and%2520Efficacy%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2011%26volume%3D338%26spage%3D154%26epage%3D163%26doi%3D10.1124%2Fjpet.111.181545" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Evans, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tester, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aslanian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karp, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheets, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labenski, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witowski, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lounsbury, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaturvedi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazdiyasni, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nacht, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freed, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petter, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubrovsky, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westlin, W. F.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Btk with CC-292 Provides Early Pharmacodynamic Assessment of Activity in Mice and Humans</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>346</i></span>,  <span class="NLM_fpage">219</span>– <span class="NLM_lpage">228</span>, <span class="refDoi"> DOI: 10.1124/jpet.113.203489</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1124%2Fjpet.113.203489" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=23709115" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFOjsbbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=346&publication_year=2013&pages=219-228&author=E.+K.+Evansauthor=R.+Testerauthor=S.+Aslanianauthor=R.+Karpauthor=M.+Sheetsauthor=M.+T.+Labenskiauthor=S.+R.+Witowskiauthor=H.+Lounsburyauthor=P.+Chaturvediauthor=H.+Mazdiyasniauthor=Z.+Zhuauthor=M.+Nachtauthor=M.+I.+Freedauthor=R.+C.+Petterauthor=A.+Dubrovskyauthor=J.+Singhauthor=W.+F.+Westlin&title=Inhibition+of+Btk+with+CC-292+Provides+Early+Pharmacodynamic+Assessment+of+Activity+in+Mice+and+Humans&doi=10.1124%2Fjpet.113.203489"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans</span></div><div class="casAuthors">Evans, Erica K.; Tester, Richland; Aslanian, Sharon; Karp, Russell; Sheets, Michael; Labenski, Matthew T.; Witowski, Steven R.; Lounsbury, Heather; Chaturvedi, Prasoon; Mazdiyasni, Hormoz; Zhu, Zhendong; Nacht, Mariana; Freed, Martin I.; Petter, Russell C.; Dubrovskiy, Alex; Singh, Juswinder; Westlin, William F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">346</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">219-228</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Targeted therapies that suppress B cell receptor (BCR) signaling have emerged as promising agents in autoimmune disease and B cell malignancies.  Bruton's tyrosine kinase (Btk) plays a crucial role in B cell development and activation through the BCR signaling pathway and represents a new target for diseases characterized by inappropriate B cell activity.  N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide (CC-292) is a highly selective, covalent Btk inhibitor and a sensitive and quant. assay that measures CC-292-Btk engagement has been developed.  This translational pharmacodynamic assay has accompanied CC-292 through each step of drug discovery and development.  These studies demonstrate the quantity of Btk bound by CC-292 correlates with the efficacy of CC-292 in vitro and in the collagen-induced arthritis model of autoimmune disease.  Recently, CC-292 has entered human clin. trials with a trial design that has provided rapid insight into safety, pharmacokinetics, and pharmacodynamics.  This first-in-human healthy volunteer trial has demonstrated that a single oral dose of 2 mg/kg CC-292 consistently engaged all circulating Btk protein and provides the basis for rational dose selection in future clin. trials.  This targeted covalent drug design approach has enabled the discovery and early clin. development of CC-292 and has provided support for Btk as a valuable drug target for B-cell mediated disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrN2l8ZCVqCFLVg90H21EOLACvtfcHk0ljo97oaen1kVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFOjsbbM&md5=95fac997a246e59d943dd554af358a65</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1124%2Fjpet.113.203489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.113.203489%26sid%3Dliteratum%253Aachs%26aulast%3DEvans%26aufirst%3DE.%2BK.%26aulast%3DTester%26aufirst%3DR.%26aulast%3DAslanian%26aufirst%3DS.%26aulast%3DKarp%26aufirst%3DR.%26aulast%3DSheets%26aufirst%3DM.%26aulast%3DLabenski%26aufirst%3DM.%2BT.%26aulast%3DWitowski%26aufirst%3DS.%2BR.%26aulast%3DLounsbury%26aufirst%3DH.%26aulast%3DChaturvedi%26aufirst%3DP.%26aulast%3DMazdiyasni%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DNacht%26aufirst%3DM.%26aulast%3DFreed%26aufirst%3DM.%2BI.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DDubrovsky%26aufirst%3DA.%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DWestlin%26aufirst%3DW.%2BF.%26atitle%3DInhibition%2520of%2520Btk%2520with%2520CC-292%2520Provides%2520Early%2520Pharmacodynamic%2520Assessment%2520of%2520Activity%2520in%2520Mice%2520and%2520Humans%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2013%26volume%3D346%26spage%3D219%26epage%3D228%26doi%3D10.1124%2Fjpet.113.203489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Postelnek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vu, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, D.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradshaw, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pashine, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivasan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Mahony, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narula, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeMartino, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fine, J. S.</span></span> <span> </span><span class="NLM_article-title">RN486, a Selective Bruton’s Tyrosine Kinase Inhibitor, Abrogates Immune Hypersensitivity Responses and Arthritis in Rodents</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>341</i></span>,  <span class="NLM_fpage">90</span>– <span class="NLM_lpage">103</span>, <span class="refDoi"> DOI: 10.1124/jpet.111.187740</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1124%2Fjpet.111.187740" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=22228807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BC38XltVagt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=341&publication_year=2012&pages=90-103&author=D.+Xuauthor=Y.+Kimauthor=J.+Postelnekauthor=M.+D.+Vuauthor=D.-Q.+Huauthor=C.+Liaoauthor=M.+Bradshawauthor=J.+Hsuauthor=J.+Zhangauthor=A.+Pashineauthor=D.+Srinivasanauthor=J.+Woodsauthor=A.+Levinauthor=A.+O%E2%80%99Mahonyauthor=T.+D.+Owensauthor=Y.+Louauthor=R.+J.+Hillauthor=S.+Narulaauthor=J.+DeMartinoauthor=J.+S.+Fine&title=RN486%2C+a+Selective+Bruton%E2%80%99s+Tyrosine+Kinase+Inhibitor%2C+Abrogates+Immune+Hypersensitivity+Responses+and+Arthritis+in+Rodents&doi=10.1124%2Fjpet.111.187740"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents</span></div><div class="casAuthors">Xu, Daigen; Kim, Yong; Postelnek, Jennifer; Vu, Minh Diem; Hu, Dong-Qing; Liao, Cheng; Bradshaw, Mike; Hsu, Jonathan; Zhang, Jun; Pashine, Achal; Srinivasan, Dinesh; Woods, John; Levin, Anita; O'Mahony, Alison; Owens, Timothy D.; Lou, Yan; Hill, Ronald J.; Narula, Satwant; DeMartino, Julie; Fine, Jay S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">341</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">90-103</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Genetic mutation and pharmacol. inhibition of Bruton's tyrosine kinase (Btk) both have been shown to prevent the development of collagen-induced arthritis (CIA) in mice, providing a rationale for the development of Btk inhibitors for treating rheumatoid arthritis (RA).  In the present study, we characterized a novel Btk inhibitor, 6-cyclopropyl-8-fluoro-2-(2-hydroxymethyl-3-{1-methyl-5-[5-(4-methyl-piperazin-1-yl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-pyridin-3-yl}-phenyl)-2H-isoquinolin-1-one (RN486), in vitro and in rodent models of immune hypersensitivity and arthritis.  We demonstrated that RN486 not only potently and selectively inhibited the Btk enzyme, but also displayed functional activities in human cell-based assays in multiple cell types, blocking Fcε receptor crosslinking-induced degranulation in mast cells (IC50 = 2.9 nM), Fcγ receptor engagement-mediated tumor necrosis factor α prodn. in monocytes (IC50 = 7.0 nM), and B cell antigen receptor-induced expression of an activation marker, CD69, in B cells in whole blood (IC50 = 21.0 nM).  RN486 displayed similar functional activities in rodent models, effectively preventing type I and type III hypersensitivity responses.  More importantly, RN486 produced robust anti-inflammatory and bone-protective effects in mouse CIA and rat adjuvant-induced arthritis (AIA) models.  In the AIA model, RN486 inhibited both joint and systemic inflammation either alone or in combination with methotrexate, reducing both paw swelling and inflammatory markers in the blood.  Together, our findings not only demonstrate that Btk plays an essential and conserved role in regulating immunoreceptor-mediated immune responses in both humans and rodents, but also provide evidence and mechanistic insights to support the development of selective Btk inhibitors as small-mol. disease-modifying drugs for RA and potentially other autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXBTQENfl5RbVg90H21EOLACvtfcHk0li_XqUz-yA7_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XltVagt7g%253D&md5=06be56a47afd2eb09e0871710c1d2b47</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1124%2Fjpet.111.187740&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.111.187740%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DD.%26aulast%3DKim%26aufirst%3DY.%26aulast%3DPostelnek%26aufirst%3DJ.%26aulast%3DVu%26aufirst%3DM.%2BD.%26aulast%3DHu%26aufirst%3DD.-Q.%26aulast%3DLiao%26aufirst%3DC.%26aulast%3DBradshaw%26aufirst%3DM.%26aulast%3DHsu%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DPashine%26aufirst%3DA.%26aulast%3DSrinivasan%26aufirst%3DD.%26aulast%3DWoods%26aufirst%3DJ.%26aulast%3DLevin%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Mahony%26aufirst%3DA.%26aulast%3DOwens%26aufirst%3DT.%2BD.%26aulast%3DLou%26aufirst%3DY.%26aulast%3DHill%26aufirst%3DR.%2BJ.%26aulast%3DNarula%26aufirst%3DS.%26aulast%3DDeMartino%26aufirst%3DJ.%26aulast%3DFine%26aufirst%3DJ.%2BS.%26atitle%3DRN486%252C%2520a%2520Selective%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520Inhibitor%252C%2520Abrogates%2520Immune%2520Hypersensitivity%2520Responses%2520and%2520Arthritis%2520in%2520Rodents%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2012%26volume%3D341%26spage%3D90%26epage%3D103%26doi%3D10.1124%2Fjpet.111.187740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mina-Osorio, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaStant, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keirstead, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittard, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayala, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefanova, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrido, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimaano, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilton, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giron, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Postelnek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Min, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramanujam, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeMartino, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narula, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, D.</span></span> <span> </span><span class="NLM_article-title">Suppression of Glomerulonephritis in Lupus-Prone NZB × NZW Mice by RN486, a Selective Inhibitor of Bruton’s Tyrosine Kinase</span>. <i>Arthritis Rheum.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">2380</span>– <span class="NLM_lpage">2391</span>, <span class="refDoi"> DOI: 10.1002/art.38047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1002%2Fart.38047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=23754328" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlGmtbnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2013&pages=2380-2391&author=P.+Mina-Osorioauthor=J.+LaStantauthor=N.+Keirsteadauthor=T.+Whittardauthor=J.+Ayalaauthor=S.+Stefanovaauthor=R.+Garridoauthor=N.+Dimaanoauthor=H.+Hiltonauthor=M.+Gironauthor=K.+Y.+Lauauthor=J.+Hangauthor=J.+Postelnekauthor=Y.+Kimauthor=S.+Minauthor=A.+Patelauthor=J.+Woodsauthor=M.+Ramanujamauthor=J.+DeMartinoauthor=S.+Narulaauthor=D.+Xu&title=Suppression+of+Glomerulonephritis+in+Lupus-Prone+NZB+%C3%97+NZW+Mice+by+RN486%2C+a+Selective+Inhibitor+of+Bruton%E2%80%99s+Tyrosine+Kinase&doi=10.1002%2Fart.38047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Suppression of Glomerulonephritis in Lupus-Prone NZB × NZW Mice by RN486, a Selective Inhibitor of Bruton's Tyrosine Kinase</span></div><div class="casAuthors">Mina-Osorio, Paola; LaStant, Jacob; Keirstead, Natalie; Whittard, Toni; Ayala, Julia; Stefanova, Stella; Garrido, Rosario; Dimaano, Nena; Hilton, Holly; Giron, Mario; Lau, Kai-Yeung; Hang, Julie; Postelnek, Jennifer; Kim, Yong; Min, Soo; Patel, Alka; Woods, John; Ramanujam, Meera; DeMartino, Julie; Narula, Satwant; Xu, Daigen</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2380-2391</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective : Bruton's tyrosine kinase (BTK) plays a crit. role in B cell development and function.  We recently described a selective BTK inhibitor, RN486, that blocks B cell receptor (BCR) and Fcγ receptor signaling and is efficacious in animal models of arthritis.  The aim of this study was to examine the potential efficacy of BTK in systemic lupus erythematosus (SLE), using an NZB × NZW mouse model of spontaneous SLE.  Methods : Mice received RN486 or its vehicle (administered in chow) at a final concn. of 30 mg/kg for 8 wk, starting at 32 wk of age.  Results : The administration of RN486 completely stopped disease progression, as detd. by histol. and functional analyses of glomerular nephritis.  The efficacy was assocd. with striking inhibition of B cell activation, as demonstrated by a significant redn. in CD69 expression in response to BCR crosslinking.  RN486 markedly reduced the secretion of IgG anti-double-stranded DNA (anti-dsDNA) secretion, as detd. by enzyme-linked immunosorbent and enzyme-linked immunospot assays.  Flow cytometric anal. demonstrated depletion of CD138highB220low plasma cells in the spleen.  RN486 inhibited secretion of IgG anti-dsDNA but not IgM anti-dsDNA, suggesting that pharmacol. blockade of BTK resembles the reported transgenic expression of low levels of endogenous BTK in B cells.  In addn., RN486 may also impact the effector function of autoantibodies, as evidenced by a significant redn. in immune complex-mediated activation of human monocytes in vitro and down-regulation of the expression of macrophage-related and interferon-inducible genes in both the kidneys and spleens of treated mice.  Conclusion : Collectively, our data suggest that BTK inhibitors may simultaneously target autoantibody-producing and effector cells in SLE, thus constituting a promising therapeutic alternative for this disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCcpbnXMOlybVg90H21EOLACvtfcHk0li_XqUz-yA7_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlGmtbnF&md5=14979f458a23da7916e7ee9df042ac81</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1002%2Fart.38047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.38047%26sid%3Dliteratum%253Aachs%26aulast%3DMina-Osorio%26aufirst%3DP.%26aulast%3DLaStant%26aufirst%3DJ.%26aulast%3DKeirstead%26aufirst%3DN.%26aulast%3DWhittard%26aufirst%3DT.%26aulast%3DAyala%26aufirst%3DJ.%26aulast%3DStefanova%26aufirst%3DS.%26aulast%3DGarrido%26aufirst%3DR.%26aulast%3DDimaano%26aufirst%3DN.%26aulast%3DHilton%26aufirst%3DH.%26aulast%3DGiron%26aufirst%3DM.%26aulast%3DLau%26aufirst%3DK.%2BY.%26aulast%3DHang%26aufirst%3DJ.%26aulast%3DPostelnek%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DY.%26aulast%3DMin%26aufirst%3DS.%26aulast%3DPatel%26aufirst%3DA.%26aulast%3DWoods%26aufirst%3DJ.%26aulast%3DRamanujam%26aufirst%3DM.%26aulast%3DDeMartino%26aufirst%3DJ.%26aulast%3DNarula%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DD.%26atitle%3DSuppression%2520of%2520Glomerulonephritis%2520in%2520Lupus-Prone%2520NZB%2520%25C3%2597%2520NZW%2520Mice%2520by%2520RN486%252C%2520a%2520Selective%2520Inhibitor%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%26jtitle%3DArthritis%2520Rheum.%26date%3D2013%26volume%3D65%26spage%3D2380%26epage%3D2391%26doi%3D10.1002%2Fart.38047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hutcheson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanarsa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bashmakov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grewal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sajitharan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buggy, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satterthwaite, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohan, C.</span></span> <span> </span><span class="NLM_article-title">Modulating Proximal Cell Signaling by Targeting Btk Ameliorates Humoral Autoimmunity and End-Organ Disease in Murine Lupus</span>. <i>Arthritis Res. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">R243</span>, <span class="refDoi"> DOI: 10.1186/ar4086</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1186%2Far4086" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=23136880" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BC3sXitlSgtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2012&pages=R243&author=J.+Hutchesonauthor=K.+Vanarsaauthor=A.+Bashmakovauthor=S.+Grewalauthor=D.+Sajitharanauthor=B.+Y.+Changauthor=J.+J.+Buggyauthor=X.+J.+Zhouauthor=Y.+Duauthor=A.+B.+Satterthwaiteauthor=C.+Mohan&title=Modulating+Proximal+Cell+Signaling+by+Targeting+Btk+Ameliorates+Humoral+Autoimmunity+and+End-Organ+Disease+in+Murine+Lupus&doi=10.1186%2Far4086"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Modulating proximal cell signaling by targeting Btk ameliorates humoral autoimmunity and end-organ disease in murine lupus</span></div><div class="casAuthors">Hutcheson, Jack; Vanarsa, Kamala; Bashmakov, Anna; Grewal, Simer; Sajitharan, Deena; Chang, Betty Y.; Buggy, Joseph J.; Zhou, Xin J.; Du, Yong; Satterthwaite, Anne B.; Mohan, Chandra</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis Research & Therapy</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">R243</span>CODEN:
                <span class="NLM_cas:coden">ARTRCV</span>;
        ISSN:<span class="NLM_cas:issn">1478-6362</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Introduction: Systemic lupus erythematosus is a chronic autoimmune disease characterized by an abundance of autoantibodies against nuclear antigens.  Bruton's tyrosine kinase (Btk) is a proximal transducer of the BCR signal that allows for B-cell activation and differentiation.  Recently, selective inhibition of Btk by PCI-32765 has shown promise in limiting activity of multiple cells types in various models of cancer and autoimmunity.  The aim of this study was to det. the effect of Btk inhibition by PCI-32765 on the development of lupus in lupus-prone B6.Sle1 and B6.Sle1.Sle3 mice.  Methods: B6.Sle1 or B6.Sle1.Sle3 mice received drinking water contg. either the Btk inhibitor PCI-32765 or vehicle for 56 days.  Following treatment, mice were examd. for clin. and pathol. characteristics of lupus.  The effect of PCI-32765 on specific cell types was also investigated.  Results: In this study, we report that Btk inhibition dampens humoral autoimmunity in B6.Sle1 monocongenic mice.  Moreover, in B6.Sle1.Sle3 bicongenic mice that are prone to severe lupus, Btk inhibition also dampens humoral and cellular autoimmunity, as well as lupus nephritis.  Conclusions: These findings suggest that partial crippling of cell signaling in B cells and antigen presenting cells (APCs) may be a viable alternative to total depletion of these cells as a therapeutic modality for lupus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpj4G1JxmkwlLVg90H21EOLACvtfcHk0lhqDk9U1ZKSLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXitlSgtLc%253D&md5=ea49e641ea03d8aff5577d4f3f6b36fc</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1186%2Far4086&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Far4086%26sid%3Dliteratum%253Aachs%26aulast%3DHutcheson%26aufirst%3DJ.%26aulast%3DVanarsa%26aufirst%3DK.%26aulast%3DBashmakov%26aufirst%3DA.%26aulast%3DGrewal%26aufirst%3DS.%26aulast%3DSajitharan%26aufirst%3DD.%26aulast%3DChang%26aufirst%3DB.%2BY.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26aulast%3DZhou%26aufirst%3DX.%2BJ.%26aulast%3DDu%26aufirst%3DY.%26aulast%3DSatterthwaite%26aufirst%3DA.%2BB.%26aulast%3DMohan%26aufirst%3DC.%26atitle%3DModulating%2520Proximal%2520Cell%2520Signaling%2520by%2520Targeting%2520Btk%2520Ameliorates%2520Humoral%2520Autoimmunity%2520and%2520End-Organ%2520Disease%2520in%2520Murine%2520Lupus%26jtitle%3DArthritis%2520Res.%2520Ther.%26date%3D2012%26volume%3D14%26spage%3DR243%26doi%3D10.1186%2Far4086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rankin, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seth, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keegan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreyeva, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edmonds, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathialagan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benson, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Syed, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benoit, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyashiro, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peeva, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramaiah, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Messing, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Homer, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunissi-Joannopoulos, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nickerson-Nutter, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnute, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douhan, J.,  III</span></span> <span> </span><span class="NLM_article-title">Selective Inhibition of Btk Prevents Murine Lupus and Antibody-Mediated Glomerulonephritis</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>191</i></span>,  <span class="NLM_fpage">4540</span>– <span class="NLM_lpage">4550</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1301553</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.4049%2Fjimmunol.1301553" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=24068666" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1eqs7zE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=2013&pages=4540-4550&author=A.+L.+Rankinauthor=N.+Sethauthor=S.+Keeganauthor=T.+Andreyevaauthor=T.+A.+Cookauthor=J.+Edmondsauthor=N.+Mathialaganauthor=M.+J.+Bensonauthor=J.+Syedauthor=Y.+Zhanauthor=S.+E.+Benoitauthor=J.+S.+Miyashiroauthor=N.+Woodauthor=S.+Mohanauthor=E.+Peevaauthor=S.+K.+Ramaiahauthor=D.+Messingauthor=B.+L.+Homerauthor=K.+Dunissi-Joannopoulosauthor=C.+L.+Nickerson-Nutterauthor=M.+E.+Schnuteauthor=J.+Douhan&title=Selective+Inhibition+of+Btk+Prevents+Murine+Lupus+and+Antibody-Mediated+Glomerulonephritis&doi=10.4049%2Fjimmunol.1301553"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Inhibition of BTK Prevents Murine Lupus and Antibody-Mediated Glomerulonephritis</span></div><div class="casAuthors">Rankin, Andrew L.; Seth, Nilufer; Keegan, Sean; Andreyeva, Tatyana; Cook, Tim A.; Edmonds, Jason; Mathialagan, Nagappan; Benson, Micah J.; Syed, Jameel; Zhan, Yutian; Benoit, Stephen E.; Miyashiro, Joy S.; Wood, Nancy; Mohan, Shashi; Peeva, Elena; Ramaiah, Shashi K.; Messing, Dean; Homer, Bruce L.; Dunussi-Joannopoulos, Kyri; Nickerson-Nutter, Cheryl L.; Schnute, Mark E.; Douhan, John, III</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">191</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4540-4550</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Autoantibody prodn. and immune complex deposition within the kidney promote renal disease in patients with lupus nephritis.  Thus, therapeutics that inhibit these pathways may be efficacious in the treatment of systemic lupus erythematosus.  Bruton's tyrosine kinase (BTK) is a crit. signaling component of both BCR and FcR signaling.  We sought to assess the efficacy of inhibiting BTK in the development of lupus-like disease, and in this article describe (R)-5-amino-1-(1-cyanopiperidin-3-yl)-3-(4-[2,4-difluorophenoxy]phenyl)-1H-pyrazole-4-carboxamide (PF-06250112), a novel highly selective and potent BTK inhibitor.  We demonstrate in vitro that PF-06250112 inhibits both BCR-mediated signaling and proliferation, as well as FcR-mediated activation.  To assess the therapeutic impact of BTK inhibition, we treated aged NZBxWF1 mice with PF-06250112 and demonstrate that PF-06250112 significantly limits the spontaneous accumulation of splenic germinal center B cells and plasma cells.  Correspondingly, anti-dsDNA and autoantibody levels were reduced in a dose-dependent manner.  Moreover, administration of PF-06250112 prevented the development of proteinuria and improved glomerular pathol. scores in all treatment groups.  Strikingly, this therapeutic effect could occur with only a modest redn. obsd. in anti-dsDNA titers, implying a crit. role for BTK signaling in disease pathogenesis beyond inhibition of autoantibody prodn.  We subsequently demonstrate that PF-06250112 prevents proteinuria in an FcR-dependent, Ab-mediated model of glomerulonephritis.  Importantly, these results highlight that BTK inhibition potently limits the development of glomerulonephritis by impacting both cell- and effector mol.-mediated pathways.  These data provide support for evaluating the efficacy of BTK inhibition in systemic lupus erythematosus patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBldekay4INLVg90H21EOLACvtfcHk0lhqDk9U1ZKSLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1eqs7zE&md5=7abfb074bf422aa3fb63aa0bc3d8cf58</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1301553&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1301553%26sid%3Dliteratum%253Aachs%26aulast%3DRankin%26aufirst%3DA.%2BL.%26aulast%3DSeth%26aufirst%3DN.%26aulast%3DKeegan%26aufirst%3DS.%26aulast%3DAndreyeva%26aufirst%3DT.%26aulast%3DCook%26aufirst%3DT.%2BA.%26aulast%3DEdmonds%26aufirst%3DJ.%26aulast%3DMathialagan%26aufirst%3DN.%26aulast%3DBenson%26aufirst%3DM.%2BJ.%26aulast%3DSyed%26aufirst%3DJ.%26aulast%3DZhan%26aufirst%3DY.%26aulast%3DBenoit%26aufirst%3DS.%2BE.%26aulast%3DMiyashiro%26aufirst%3DJ.%2BS.%26aulast%3DWood%26aufirst%3DN.%26aulast%3DMohan%26aufirst%3DS.%26aulast%3DPeeva%26aufirst%3DE.%26aulast%3DRamaiah%26aufirst%3DS.%2BK.%26aulast%3DMessing%26aufirst%3DD.%26aulast%3DHomer%26aufirst%3DB.%2BL.%26aulast%3DDunissi-Joannopoulos%26aufirst%3DK.%26aulast%3DNickerson-Nutter%26aufirst%3DC.%2BL.%26aulast%3DSchnute%26aufirst%3DM.%2BE.%26aulast%3DDouhan%26aufirst%3DJ.%26atitle%3DSelective%2520Inhibition%2520of%2520Btk%2520Prevents%2520Murine%2520Lupus%2520and%2520Antibody-Mediated%2520Glomerulonephritis%26jtitle%3DJ.%2520Immunol.%26date%3D2013%26volume%3D191%26spage%3D4540%26epage%3D4550%26doi%3D10.4049%2Fjimmunol.1301553" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bender, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pereira, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samy, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu-Bujalski, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldwell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morandi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Head, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koehler, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genest, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okitsu, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grenningloh, R.</span></span> <span> </span><span class="NLM_article-title">Btk Inhibition Treats TLR7/IFN Driven Murine Lupus</span>. <i>Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>164</i></span>,  <span class="NLM_fpage">65</span>– <span class="NLM_lpage">77</span>, <span class="refDoi"> DOI: 10.1016/j.clim.2016.01.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1016%2Fj.clim.2016.01.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=26821304" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BC28XivVCrsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=164&publication_year=2016&pages=65-77&author=A.+T.+Benderauthor=A.+Pereiraauthor=K.+Fuauthor=E.+Samyauthor=Y.+Wuauthor=L.+Liu-Bujalskiauthor=R.+Caldwellauthor=Y.+Y.+Chenauthor=H.+Tianauthor=F.+Morandiauthor=J.+Headauthor=U.+Koehlerauthor=M.+Genestauthor=S.+L.+Okitsuauthor=D.+Xuauthor=R.+Grenningloh&title=Btk+Inhibition+Treats+TLR7%2FIFN+Driven+Murine+Lupus&doi=10.1016%2Fj.clim.2016.01.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Btk inhibition treats TLR7/IFN driven murine lupus</span></div><div class="casAuthors">Bender, Andrew T.; Pereira, Albertina; Fu, Kai; Samy, Eileen; Wu, Yin; Liu-Bujalski, Lesley; Caldwell, Richard; Chen, Yi-Ying; Tian, Hui; Morandi, Federica; Head, Jared; Koehler, Ursula; Genest, Melinda; Okitsu, Shinji L.; Xu, Daigen; Grenningloh, Roland</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Immunology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">164</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">65-77</span>CODEN:
                <span class="NLM_cas:coden">CLIIFY</span>;
        ISSN:<span class="NLM_cas:issn">1521-6616</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (Btk) is expressed in a variety of immune cells and previous work has demonstrated that blocking Btk is a promising strategy for treating autoimmune diseases.  Herein, we utilized a tool Btk inhibitor, M7583, to det. the therapeutic efficacy of Btk inhibition in two mouse lupus models driven by TLR7 activation and type I interferon.  In BXSB-Yaa lupus mice, Btk inhibition reduced autoantibodies, nephritis, and mortality.  In the pristane-induced DBA/1 lupus model, Btk inhibition suppressed arthritis, but autoantibodies and the IFN gene signature were not significantly affected; suggesting efficacy was mediated through inhibition of Fc receptors.  In vitro studies using primary human macrophages revealed that Btk inhibition can block activation by immune complexes and TLR7 which contributes to tissue damage in SLE.  Overall, our results provide translational insight into how Btk inhibition may provide benefit to a variety of SLE patients by affecting both BCR and FcR signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA2d9Kk41QULVg90H21EOLACvtfcHk0lhqDk9U1ZKSLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XivVCrsb4%253D&md5=f926090bf3c6659e31995cc6c4b08be9</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.clim.2016.01.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clim.2016.01.012%26sid%3Dliteratum%253Aachs%26aulast%3DBender%26aufirst%3DA.%2BT.%26aulast%3DPereira%26aufirst%3DA.%26aulast%3DFu%26aufirst%3DK.%26aulast%3DSamy%26aufirst%3DE.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DLiu-Bujalski%26aufirst%3DL.%26aulast%3DCaldwell%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DY.%2BY.%26aulast%3DTian%26aufirst%3DH.%26aulast%3DMorandi%26aufirst%3DF.%26aulast%3DHead%26aufirst%3DJ.%26aulast%3DKoehler%26aufirst%3DU.%26aulast%3DGenest%26aufirst%3DM.%26aulast%3DOkitsu%26aufirst%3DS.%2BL.%26aulast%3DXu%26aufirst%3DD.%26aulast%3DGrenningloh%26aufirst%3DR.%26atitle%3DBtk%2520Inhibition%2520Treats%2520TLR7%252FIFN%2520Driven%2520Murine%2520Lupus%26jtitle%3DClin.%2520Immunol.%26date%3D2016%26volume%3D164%26spage%3D65%26epage%3D77%26doi%3D10.1016%2Fj.clim.2016.01.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chalmers, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doerner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosanac, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khalil, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harcken, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimock, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Der, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herlitz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seccareccia, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fine, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramanujam, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Putterman, C.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Blockade of Immune Complex-Mediated Glomerulonephritis by Highly Selective Inhibition of Bruton’s Tyrosine Kinase</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">26164</span>, <span class="refDoi"> DOI: 10.1038/srep26164</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1038%2Fsrep26164" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=27192942" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BC28Xot1Gqt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=26164&author=S.+A.+Chalmersauthor=J.+Doernerauthor=T.+Bosanacauthor=S.+Khalilauthor=D.+Smithauthor=C.+Harckenauthor=J.+Dimockauthor=E.+Derauthor=L.+Herlitzauthor=D.+Webbauthor=E.+Seccarecciaauthor=D.+Fengauthor=J.+S.+Fineauthor=M.+Ramanujamauthor=E.+Kleinauthor=C.+Putterman&title=Therapeutic+Blockade+of+Immune+Complex-Mediated+Glomerulonephritis+by+Highly+Selective+Inhibition+of+Bruton%E2%80%99s+Tyrosine+Kinase&doi=10.1038%2Fsrep26164"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic Blockade of Immune Complex-Mediated Glomerulonephritis by Highly Selective Inhibition of Bruton's Tyrosine Kinase</span></div><div class="casAuthors">Chalmers, Samantha A.; Doerner, Jessica; Bosanac, Todd; Khalil, Sara; Smith, Dustin; Harcken, Christian; Dimock, Janice; Der, Evan; Herlitz, Leal; Webb, Deborah; Seccareccia, Elise; Feng, Di; Fine, Jay S.; Ramanujam, Meera; Klein, Elliott; Putterman, Chaim</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">26164</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Lupus nephritis (LN) is a potentially dangerous end organ pathol. that affects upwards of 60% of lupus patients.  Bruton's tyrosine kinase (BTK) is important for B cell development, Fc receptor signaling, and macrophage polarization.  In this study, we investigated the effects of a novel, highly selective and potent BTK inhibitor, BI-BTK-1, in an inducible model of LN in which mice receive nephrotoxic serum (NTS) contg. anti-glomerular antibodies.  Mice were treated once daily with vehicle alone or BI-BTK-1, either prophylactically or therapeutically.  When compared with control treated mice, NTS-challenged mice treated prophylactically with BI-BTK-1 exhibited significantly attenuated kidney disease, which was dose dependent.  BI-BTK-1 treatment resulted in decreased infiltrating IBA-1+ cells, as well as C3 deposition within the kidney.  RT-PCR on whole kidney RNA and serum profiling indicated that BTK inhibition significantly decreased levels of LN-relevant inflammatory cytokines and chemokines.  Renal RNA expression profiling by RNA-seq revealed that BI-BTK-1 dramatically modulated pathways related to inflammation and glomerular injury.  Importantly, when administered therapeutically, BI-BTK-1 reversed established proteinuria and improved renal histopathol.  Our results highlight the important role for BTK in the pathogenesis of immune complex-mediated nephritis, and BTK inhibition as a promising therapeutic target for LN.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAplnw9VtL3rVg90H21EOLACvtfcHk0lhhXt0y5DHh4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xot1Gqt7o%253D&md5=ce83240c6f4ab86e25b9f17ef0dd32b7</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1038%2Fsrep26164&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep26164%26sid%3Dliteratum%253Aachs%26aulast%3DChalmers%26aufirst%3DS.%2BA.%26aulast%3DDoerner%26aufirst%3DJ.%26aulast%3DBosanac%26aufirst%3DT.%26aulast%3DKhalil%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DHarcken%26aufirst%3DC.%26aulast%3DDimock%26aufirst%3DJ.%26aulast%3DDer%26aufirst%3DE.%26aulast%3DHerlitz%26aufirst%3DL.%26aulast%3DWebb%26aufirst%3DD.%26aulast%3DSeccareccia%26aufirst%3DE.%26aulast%3DFeng%26aufirst%3DD.%26aulast%3DFine%26aufirst%3DJ.%2BS.%26aulast%3DRamanujam%26aufirst%3DM.%26aulast%3DKlein%26aufirst%3DE.%26aulast%3DPutterman%26aufirst%3DC.%26atitle%3DTherapeutic%2520Blockade%2520of%2520Immune%2520Complex-Mediated%2520Glomerulonephritis%2520by%2520Highly%2520Selective%2520Inhibition%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26spage%3D26164%26doi%3D10.1038%2Fsrep26164" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walter, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rule, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyer, M. J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cazin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quittet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchinson, C. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birkett, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamieson, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Courtenay-Luck, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshizawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharpe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohno, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cartron, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morschhauser, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fegan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salles, G.</span></span> <span> </span><span class="NLM_article-title">A Phase I Clinical Trial of the Selective Btk Inhibitor ONO/GS-4059 in Relapsed and Refractory Mature B-cell Malignancies,</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">411</span>– <span class="NLM_lpage">419</span>, <span class="refDoi"> DOI: 10.1182/blood-2015-08-664086</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1182%2Fblood-2015-08-664086" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2016&pages=411-419&author=H.+S.+Walterauthor=S.+A.+Ruleauthor=M.+J.+S.+Dyerauthor=L.+Karlinauthor=C.+Jonesauthor=B.+Cazinauthor=P.+Quittetauthor=N.+Shahauthor=C.+V.+Hutchinsonauthor=H.+Hondaauthor=K.+Duffyauthor=J.+Birkettauthor=V.+Jamiesonauthor=N.+Courtenay-Luckauthor=T.+Yoshizawaauthor=J.+Sharpeauthor=T.+Ohnoauthor=S.+Abeauthor=A.+Nishimuraauthor=G.+Cartronauthor=F.+Morschhauserauthor=C.+Feganauthor=G.+Salles&title=A+Phase+I+Clinical+Trial+of+the+Selective+Btk+Inhibitor+ONO%2FGS-4059+in+Relapsed+and+Refractory+Mature+B-cell+Malignancies%2C&doi=10.1182%2Fblood-2015-08-664086"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1182%2Fblood-2015-08-664086&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2015-08-664086%26sid%3Dliteratum%253Aachs%26aulast%3DWalter%26aufirst%3DH.%2BS.%26aulast%3DRule%26aufirst%3DS.%2BA.%26aulast%3DDyer%26aufirst%3DM.%2BJ.%2BS.%26aulast%3DKarlin%26aufirst%3DL.%26aulast%3DJones%26aufirst%3DC.%26aulast%3DCazin%26aufirst%3DB.%26aulast%3DQuittet%26aufirst%3DP.%26aulast%3DShah%26aufirst%3DN.%26aulast%3DHutchinson%26aufirst%3DC.%2BV.%26aulast%3DHonda%26aufirst%3DH.%26aulast%3DDuffy%26aufirst%3DK.%26aulast%3DBirkett%26aufirst%3DJ.%26aulast%3DJamieson%26aufirst%3DV.%26aulast%3DCourtenay-Luck%26aufirst%3DN.%26aulast%3DYoshizawa%26aufirst%3DT.%26aulast%3DSharpe%26aufirst%3DJ.%26aulast%3DOhno%26aufirst%3DT.%26aulast%3DAbe%26aufirst%3DS.%26aulast%3DNishimura%26aufirst%3DA.%26aulast%3DCartron%26aufirst%3DG.%26aulast%3DMorschhauser%26aufirst%3DF.%26aulast%3DFegan%26aufirst%3DC.%26aulast%3DSalles%26aufirst%3DG.%26atitle%3DA%2520Phase%2520I%2520Clinical%2520Trial%2520of%2520the%2520Selective%2520Btk%2520Inhibitor%2520ONO%252FGS-4059%2520in%2520Relapsed%2520and%2520Refractory%2520Mature%2520B-cell%2520Malignancies%252C%26jtitle%3DBlood%26date%3D2016%26volume%3D127%26spage%3D411%26epage%3D419%26doi%3D10.1182%2Fblood-2015-08-664086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Byrd, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrington, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devereux, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaves, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wierda, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awan, F. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillmen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghia, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrientos, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagel, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woyach, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaptein, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lannutti, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Covey, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fardis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGreivy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamdy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothbaum, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izumi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diacovo, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, R. R.</span></span> <span> </span><span class="NLM_article-title">Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>374</i></span>,  <span class="NLM_fpage">323</span>– <span class="NLM_lpage">332</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1509981</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1056%2FNEJMoa1509981" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=26641137" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlOlur%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=374&publication_year=2016&pages=323-332&author=J.+C.+Byrdauthor=B.+Harringtonauthor=S.+O%E2%80%99Brienauthor=J.+A.+Jonesauthor=A.+Schuhauthor=S.+Devereuxauthor=J.+Chavesauthor=W.+G.+Wierdaauthor=F.+T.+Awanauthor=J.+R.+Brownauthor=P.+Hillmenauthor=D.+M.+Stephensauthor=P.+Ghiaauthor=J.+C.+Barrientosauthor=J.+M.+Pagelauthor=J.+Woyachauthor=D.+Johnsonauthor=J.+Huangauthor=X.+Wangauthor=A.+Kapteinauthor=B.+J.+Lannuttiauthor=T.+Coveyauthor=M.+Fardisauthor=J.+McGreivyauthor=A.+Hamdyauthor=W.+Rothbaumauthor=R.+Izumiauthor=T.+G.+Diacovoauthor=A.+J.+Johnsonauthor=R.+R.+Furman&title=Acalabrutinib+%28ACP-196%29+in+Relapsed+Chronic+Lymphocytic+Leukemia&doi=10.1056%2FNEJMoa1509981"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia</span></div><div class="casAuthors">Byrd, John C.; Harrington, Bonnie; O'Brien, Susan; Jones, Jeffrey A.; Schuh, Anna; Devereux, Steve; Chaves, Jorge; Wierda, William G.; Awan, Farrukh T.; Brown, Jennifer R.; Hillmen, Peter; Stephens, Deborah M.; Ghia, Paolo; Barrientos, Jacqueline C.; Pagel, John M.; Woyach, Jennifer; Johnson, Dave; Huang, Jane; Wang, Xiaolin; Kaptein, Allard; Lannutti, Brian J.; Covey, Todd; Fardis, Maria; McGreivy, Jesse; Hamdy, Ahmed; Rothbaum, Wayne; Izumi, Raquel; Diacovo, Thomas G.; Johnson, Amy J.; Furman, Richard R.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">374</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">323-332</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Irreversible inhibition of Bruton's tyrosine kinase (BTK) by ibrutinib represents an important therapeutic advance for the treatment of chronic lymphocytic leukemia (CLL).  However, ibrutinib also irreversibly inhibits alternative kinase targets, which potentially compromises its therapeutic index.  Acalabrutinib (ACP-196) is a more selective, irreversible BTK inhibitor that is specifically designed to improve on the safety and efficacy of first-generation BTK inhibitors.  In this uncontrolled, phase 1-2, multicenter study, we administered oral acalabrutinib to 61 patients who had relapsed CLL to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of acalabrutinib.  Patients were treated with acalabrutinib at a dose of 100 to 400 mg once daily in the dose-escalation (phase 1) portion of the study and 100 mg twice daily in the expansion (phase 2) portion.  The median age of the patients was 62 years, and patients had received a median of three previous therapies for CLL; 31% had chromosome 17p13.1 deletion, and 75% had unmutated Ig heavy-chain variable genes.  No dose-limiting toxic effects occurred during the dose-escalation portion of the study.  The most common adverse events obsd. were headache (in 43% of the patients), diarrhea (in 39%), and in- creased wt. (in 26%).  Most adverse events were of grade 1 or 2.  At a median follow- up of 14.3 mo, the overall response rate was 95%, including 85% with a partial response and 10% with a partial response with lymphocytosis; the remaining 5% of patients had stable disease.  Among patients with chromosome 17p13.1 deletion, the overall response rate was 100%.  No cases of Richter's transformation (CLL that has evolved into large-cell lymphoma) and only one case of CLL progression have occurred.  In this study, the selective BTK inhibitor acalabrutinib had promising safety and efficacy profiles in patients with relapsed CLL, including those with chromosome 17p13.1 deletion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGHCPciF9hPrVg90H21EOLACvtfcHk0liCIURl37G-_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlOlur%252FI&md5=d20e0158f9ea308b9d06fa668154516e</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1509981&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1509981%26sid%3Dliteratum%253Aachs%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DHarrington%26aufirst%3DB.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%26aulast%3DJones%26aufirst%3DJ.%2BA.%26aulast%3DSchuh%26aufirst%3DA.%26aulast%3DDevereux%26aufirst%3DS.%26aulast%3DChaves%26aufirst%3DJ.%26aulast%3DWierda%26aufirst%3DW.%2BG.%26aulast%3DAwan%26aufirst%3DF.%2BT.%26aulast%3DBrown%26aufirst%3DJ.%2BR.%26aulast%3DHillmen%26aufirst%3DP.%26aulast%3DStephens%26aufirst%3DD.%2BM.%26aulast%3DGhia%26aufirst%3DP.%26aulast%3DBarrientos%26aufirst%3DJ.%2BC.%26aulast%3DPagel%26aufirst%3DJ.%2BM.%26aulast%3DWoyach%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DD.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DKaptein%26aufirst%3DA.%26aulast%3DLannutti%26aufirst%3DB.%2BJ.%26aulast%3DCovey%26aufirst%3DT.%26aulast%3DFardis%26aufirst%3DM.%26aulast%3DMcGreivy%26aufirst%3DJ.%26aulast%3DHamdy%26aufirst%3DA.%26aulast%3DRothbaum%26aufirst%3DW.%26aulast%3DIzumi%26aufirst%3DR.%26aulast%3DDiacovo%26aufirst%3DT.%2BG.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26aulast%3DFurman%26aufirst%3DR.%2BR.%26atitle%3DAcalabrutinib%2520%2528ACP-196%2529%2520in%2520Relapsed%2520Chronic%2520Lymphocytic%2520Leukemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2016%26volume%3D374%26spage%3D323%26epage%3D332%26doi%3D10.1056%2FNEJMoa1509981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabnis, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buhrlage, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Developing Irreversible Inhibitors of the Protein Kinase Cysteinome</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">146</span>– <span class="NLM_lpage">159</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2012.12.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1016%2Fj.chembiol.2012.12.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=23438744" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtFWitbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=146-159&author=Q.+Liuauthor=Y.+Sabnisauthor=Z.+Zhaoauthor=T.+Zhangauthor=S.+J.+Buhrlageauthor=L.+H.+Jonesauthor=N.+S.+Gray&title=Developing+Irreversible+Inhibitors+of+the+Protein+Kinase+Cysteinome&doi=10.1016%2Fj.chembiol.2012.12.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Developing Irreversible Inhibitors of the Protein Kinase Cysteinome</span></div><div class="casAuthors">Liu, Qingsong; Sabnis, Yogesh; Zhao, Zheng; Zhang, Tinghu; Buhrlage, Sara J.; Jones, Lyn H.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">146-159</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Protein kinases are a large family of approx. 530 highly conserved enzymes that transfer a γ-phosphate group from ATP to a variety of amino acid residues, such as tyrosine, serine, and threonine, that serves as a ubiquitous mechanism for cellular signal transduction.  The clin. success of a no. of kinase-directed drugs and the frequent observation of disease causing mutations in protein kinases suggest that a large no. of kinases may represent therapeutically relevant targets.  To date, the majority of clin. and preclin. kinase inhibitors are ATP competitive, noncovalent inhibitors that achieve selectivity through recognition of unique features of particular protein kinases.  Recently, there has been renewed interest in the development of irreversible inhibitors that form covalent bonds with cysteine or other nucleophilic residues in the ATP-binding pocket.  Irreversible kinase inhibitors have a no. of potential advantages including prolonged pharmacodynamics, suitability for rational design, high potency, and ability to validate pharmacol. specificity through mutation of the reactive cysteine residue.  Here, we review recent efforts to develop cysteine-targeted irreversible protein kinase inhibitors and discuss their modes of recognizing the ATP-binding pocket and their biol. activity profiles.  In addn., we provided an informatics assessment of the potential "kinase cysteinome" and discuss strategies for the efficient development of new covalent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVGD7TX3oIeLVg90H21EOLACvtfcHk0liCIURl37G-_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtFWitbs%253D&md5=cef80823123bae88362e816a0a638133</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2012.12.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2012.12.006%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DSabnis%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DBuhrlage%26aufirst%3DS.%2BJ.%26aulast%3DJones%26aufirst%3DL.%2BH.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDeveloping%2520Irreversible%2520Inhibitors%2520of%2520the%2520Protein%2520Kinase%2520Cysteinome%26jtitle%3DChem.%2520Biol.%26date%3D2013%26volume%3D20%26spage%3D146%26epage%3D159%26doi%3D10.1016%2Fj.chembiol.2012.12.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Erickson, R. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schutt, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarrant, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDowell, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewin-Koh, S.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedehus, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carano, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staflin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katewa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dambach, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misner, D. L.</span></span> <span> </span><span class="NLM_article-title">Bruton’s Tyrosine Kinase Small Molecule Inhibitors Induce a Distinct Pancreatic Toxicity in Rats</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>360</i></span>,  <span class="NLM_fpage">226</span>– <span class="NLM_lpage">238</span>, <span class="refDoi"> DOI: 10.1124/jpet.116.236224</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1124%2Fjpet.116.236224" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=27821712" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BC2sXptVOjtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=360&publication_year=2017&pages=226-238&author=R.+I.+Ericksonauthor=L.+K.+Schuttauthor=J.+M.+Tarrantauthor=M.+McDowellauthor=L.+Liuauthor=A.+R.+Johnsonauthor=S.-C.+Lewin-Kohauthor=M.+Hedehusauthor=J.+Rossauthor=R.+A.+Caranoauthor=K.+Staflinauthor=F.+Zhongauthor=J.+J.+Crawfordauthor=S.+Zhongauthor=K.+Reifauthor=A.+Katewaauthor=H.+Wongauthor=W.+B.+Youngauthor=D.+M.+Dambachauthor=D.+L.+Misner&title=Bruton%E2%80%99s+Tyrosine+Kinase+Small+Molecule+Inhibitors+Induce+a+Distinct+Pancreatic+Toxicity+in+Rats&doi=10.1124%2Fjpet.116.236224"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Bruton's tyrosine kinase small molecule inhibitors induce a distinct pancreatic toxicity in rats</span></div><div class="casAuthors">Erickson, Rebecca I.; Schutt, Leah K.; Tarrant, Jacqueline M.; McDowell, Michelle; Liu, Lichuan; Johnson, Adam R.; Lewin-Koh, Sock-Cheng; Hedehus, Maj; Ross, Jed; Carano, Richard A. D.; Staflin, Karin; Zhong, Fiona; Crawford, James J.; Zhong, Shelly; Reif, Karin; Katewa, Arna; Wong, Harvey; Young, Wendy B.; Dambach, Donna M.; Misner, Dinah L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">360</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">226-238</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK) is a member of the Tec family of cytoplasmic tyrosine kinases involved in B-cell and myeloid cell signaling.  Small mol. inhibitors of BTK are being investigated for treatment of several hematol. cancers and autoimmune diseases.  GDC-0853 ((S)-2-(3'-(hydroxymethyl)-1-methyl-5-((5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)-6-oxo-1,6-dihydro-[3,4'-bipyridin]-2'-yl)-7,7-dimethyl-3,4,7,8-tetrahydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1(6H)-one) is a selective and reversible oral small-mol. BTK inhibitor in development for the treatment of rheumatoid arthritis and systemic lupus erythematosus.  In Sprague-Dawley (SD) rats, administration of GDC-0853 and other structurally diverse BTK inhibitors for 7 days or longer caused pancreatic lesions consisting of multifocal islet-centered hemorrhage, inflammation, fibrosis, and pigment-laden macrophages with adjacent lobular exocrine acinar cell atrophy, degeneration, and inflammation.  Similar findings were not obsd. in mice or dogs at much higher exposures.  Hemorrhage in the peri-islet vasculature emerged between four and seven daily doses of GDC-0853 and was histol. similar to spontaneously occurring changes in aging SD rats.  This suggests that GDC-0853 could exacerbate a background finding in younger animals.  Glucose homeostasis was dysregulated following a glucose challenge; however, this occurred only after 28 days of administration and was not directly assocd. with onset or severity of pancreatic lesions.  There were no changes in other common serum biomarkers assessing endocrine and exocrine pancreatic function.  Addnl., these lesions were not readily detectable via Doppler ultrasound, computed tomog., or magnetic resonance imaging.  Our results indicate that pancreatic lesions in rats are likely a class effect of BTK inhibitors, which may exacerbate an islet-centered pathol. that is unlikely to be relevant to humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgiBmsDhUKIbVg90H21EOLACvtfcHk0liCIURl37G-_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXptVOjtLo%253D&md5=15b2ef2030ed978d81cec5be5e0a74c8</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1124%2Fjpet.116.236224&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.116.236224%26sid%3Dliteratum%253Aachs%26aulast%3DErickson%26aufirst%3DR.%2BI.%26aulast%3DSchutt%26aufirst%3DL.%2BK.%26aulast%3DTarrant%26aufirst%3DJ.%2BM.%26aulast%3DMcDowell%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DLewin-Koh%26aufirst%3DS.-C.%26aulast%3DHedehus%26aufirst%3DM.%26aulast%3DRoss%26aufirst%3DJ.%26aulast%3DCarano%26aufirst%3DR.%2BA.%26aulast%3DStaflin%26aufirst%3DK.%26aulast%3DZhong%26aufirst%3DF.%26aulast%3DCrawford%26aufirst%3DJ.%2BJ.%26aulast%3DZhong%26aufirst%3DS.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DKatewa%26aufirst%3DA.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DYoung%26aufirst%3DW.%2BB.%26aulast%3DDambach%26aufirst%3DD.%2BM.%26aulast%3DMisner%26aufirst%3DD.%2BL.%26atitle%3DBruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520Small%2520Molecule%2520Inhibitors%2520Induce%2520a%2520Distinct%2520Pancreatic%2520Toxicity%2520in%2520Rats%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2017%26volume%3D360%26spage%3D226%26epage%3D238%26doi%3D10.1124%2Fjpet.116.236224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pai, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">French, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hotzel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plise, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salphati, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Setchell, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ware, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lauriault, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schutt, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartley, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dambach, D.</span></span> <span> </span><span class="NLM_article-title">Antibody-Mediated Inhibition of Fibroblast Growth Factor 19 Results in Increased Bile Acids Synthesis and Ileal Malabsorption of Bile Acids in Cynomolgus Monkeys</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">446</span>– <span class="NLM_lpage">456</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kfs011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1093%2Ftoxsci%2Fkfs011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=22268002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BC38Xks1SitbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2012&pages=446-456&author=R.+Paiauthor=D.+Frenchauthor=N.+Maauthor=K.+Hotzelauthor=E.+Pliseauthor=L.+Salphatiauthor=K.+D.+Setchellauthor=J.+Wareauthor=V.+Lauriaultauthor=L.+Schuttauthor=D.+Hartleyauthor=D.+Dambach&title=Antibody-Mediated+Inhibition+of+Fibroblast+Growth+Factor+19+Results+in+Increased+Bile+Acids+Synthesis+and+Ileal+Malabsorption+of+Bile+Acids+in+Cynomolgus+Monkeys&doi=10.1093%2Ftoxsci%2Fkfs011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-Mediated Inhibition of Fibroblast Growth Factor 19 Results in Increased Bile Acids Synthesis and Ileal Malabsorption of Bile Acids in Cynomolgus Monkeys</span></div><div class="casAuthors">Pai, Rama; French, Dorothy; Ma, Ning; Hotzel, Kathy; Plise, Emile; Salphati, Laurent; Setchell, Kenneth D. R.; Ware, Joseph; Lauriault, Veronique; Schutt, Leah; Hartley, Dylan; Dambach, Donna</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">446-456</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-0929</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Fibroblast growth factor 19 (FGF19) represses cholesterol 7α-hydroxylase (Cyp7α1) and inhibits bile acid synthesis in vitro and in vivo.  Previous studies have shown that anti-FGF19 antibody treatment reduces growth of colon tumor xenografts and prevents hepatocellular carcinomas in FGF19 transgenic mice and thus may be a useful cancer target.  In a repeat dose safety study in cynomolgus monkeys, anti-FGF19 treatment (3-100 mg/kg) demonstrated dose-related liver toxicity accompanied by severe diarrhea and low food consumption.  The mechanism of anti-FGF19 toxicity was investigated using in vitro and in vivo approaches.  The authors' results show that anti-FGF19 antibody had no direct cytotoxic effect on monkey hepatocytes.  Anti-FGF19 increased Cyp7α1, as expected, but also increased bile acid efflux transporter gene (bile salt export pump, multidrug resistant protein 2 [MRP2], and MRP3) expression and reduced sodium taurocholate cotransporting polypeptide and org. anion transporter 2 expression in liver tissues from treated monkeys and in primary hepatocytes.  In addn., anti-FGF19 treatment increased solute transporter gene (ileal bile acid-binding protein, org. solute transporter α [OST-α], and OST-β) expression in ileal tissues from treated monkeys but not in Caco-2 cells.  However, deoxycholic acid (a secondary bile acid) increased expression of FGF19 and these solute transporter genes in Caco-2 cells.  Gas chromatog.-mass spectrometry anal. of monkey feces showed an increase in total bile acids and cholic acid derivs.  These findings suggest that high doses of anti-FGF19 increase Cyp7α1 expression and bile acid synthesis and alter the expression of bile transporters in the liver resulting in enhanced bile acid efflux and reduced uptake.  Increased bile acids alter expression of solute transporters in the ileum causing diarrhea and the enhanced enterohepatic recirculation of bile acids leading to liver toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqORkYjNAK2bLVg90H21EOLACvtfcHk0liS3eKPb2Mtlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xks1SitbY%253D&md5=b70cb6104a023ef79adda0cea34fc8a4</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfs011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfs011%26sid%3Dliteratum%253Aachs%26aulast%3DPai%26aufirst%3DR.%26aulast%3DFrench%26aufirst%3DD.%26aulast%3DMa%26aufirst%3DN.%26aulast%3DHotzel%26aufirst%3DK.%26aulast%3DPlise%26aufirst%3DE.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DSetchell%26aufirst%3DK.%2BD.%26aulast%3DWare%26aufirst%3DJ.%26aulast%3DLauriault%26aufirst%3DV.%26aulast%3DSchutt%26aufirst%3DL.%26aulast%3DHartley%26aufirst%3DD.%26aulast%3DDambach%26aufirst%3DD.%26atitle%3DAntibody-Mediated%2520Inhibition%2520of%2520Fibroblast%2520Growth%2520Factor%252019%2520Results%2520in%2520Increased%2520Bile%2520Acids%2520Synthesis%2520and%2520Ileal%2520Malabsorption%2520of%2520Bile%2520Acids%2520in%2520Cynomolgus%2520Monkeys%26jtitle%3DToxicol.%2520Sci.%26date%3D2012%26volume%3D126%26spage%3D446%26epage%3D456%26doi%3D10.1093%2Ftoxsci%2Fkfs011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pai, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortwine, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misner, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dambach, D.</span></span> <span> </span><span class="NLM_article-title">Application of an In Silico Approach to Predict Intrinsic In Vitro Cytotoxicity for Compounds in Primary Human Hepatocytes During Preclinical Development</span>. <i>Toxicologist</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>132</i></span>,  <span class="NLM_fpage">189</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2013&pages=189&author=R.+Paiauthor=B.+Weiauthor=P.+Changauthor=J.+J.+Crawfordauthor=W.+Youngauthor=D.+F.+Ortwineauthor=D.+L.+Misnerauthor=D.+Dambach&title=Application+of+an+In+Silico+Approach+to+Predict+Intrinsic+In+Vitro+Cytotoxicity+for+Compounds+in+Primary+Human+Hepatocytes+During+Preclinical+Development"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPai%26aufirst%3DR.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DChang%26aufirst%3DP.%26aulast%3DCrawford%26aufirst%3DJ.%2BJ.%26aulast%3DYoung%26aufirst%3DW.%26aulast%3DOrtwine%26aufirst%3DD.%2BF.%26aulast%3DMisner%26aufirst%3DD.%2BL.%26aulast%3DDambach%26aufirst%3DD.%26atitle%3DApplication%2520of%2520an%2520In%2520Silico%2520Approach%2520to%2520Predict%2520Intrinsic%2520In%2520Vitro%2520Cytotoxicity%2520for%2520Compounds%2520in%2520Primary%2520Human%2520Hepatocytes%2520During%2520Preclinical%2520Development%26jtitle%3DToxicologist%26date%3D2013%26volume%3D132%26spage%3D189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aliagas, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergeron, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaney, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradley, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koehler, M. F. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortwine, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsui, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gobbi, A.</span></span> <span> </span><span class="NLM_article-title">An Integrated Suite of Modeling Tools That Empower Scientists in Structure- and Property-Based Drug Design</span>. <i>J. Comput.-Aided Mol. Des.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">511</span>– <span class="NLM_lpage">523</span>, <span class="refDoi"> DOI: 10.1007/s10822-015-9845-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1007%2Fs10822-015-9845-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2015&pages=511-523&author=J.+A.+Fengauthor=I.+Aliagasauthor=P.+Bergeronauthor=J.+M.+Blaneyauthor=E.+K.+Bradleyauthor=M.+F.+T.+Koehlerauthor=M.+L.+Leeauthor=D.+F.+Ortwineauthor=V.+Tsuiauthor=J.+Wuauthor=A.+Gobbi&title=An+Integrated+Suite+of+Modeling+Tools+That+Empower+Scientists+in+Structure-+and+Property-Based+Drug+Design&doi=10.1007%2Fs10822-015-9845-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1007%2Fs10822-015-9845-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10822-015-9845-4%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DJ.%2BA.%26aulast%3DAliagas%26aufirst%3DI.%26aulast%3DBergeron%26aufirst%3DP.%26aulast%3DBlaney%26aufirst%3DJ.%2BM.%26aulast%3DBradley%26aufirst%3DE.%2BK.%26aulast%3DKoehler%26aufirst%3DM.%2BF.%2BT.%26aulast%3DLee%26aufirst%3DM.%2BL.%26aulast%3DOrtwine%26aufirst%3DD.%2BF.%26aulast%3DTsui%26aufirst%3DV.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DGobbi%26aufirst%3DA.%26atitle%3DAn%2520Integrated%2520Suite%2520of%2520Modeling%2520Tools%2520That%2520Empower%2520Scientists%2520in%2520Structure-%2520and%2520Property-Based%2520Drug%2520Design%26jtitle%3DJ.%2520Comput.-Aided%2520Mol.%2520Des.%26date%3D2015%26volume%3D29%26spage%3D511%26epage%3D523%26doi%3D10.1007%2Fs10822-015-9845-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuglstatter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondru, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, Z. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntosh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Litman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kocer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frauchiger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dewdney, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zecic, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taygerly, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarma, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabriel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, T. D.</span></span> <span> </span><span class="NLM_article-title">Structure-Based Drug Design of RN486, a Potent and Selective Bruton’s Tyrosine Kinase (BTK) Inhibitor, for the Treatment of Rheumatoid Arthritis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">512</span>– <span class="NLM_lpage">516</span>, <span class="refDoi"> DOI: 10.1021/jm500305p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500305p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlsl2qtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=512-516&author=Y.+Louauthor=X.+Hanauthor=A.+Kuglstatterauthor=R.+K.+Kondruauthor=Z.+K.+Sweeneyauthor=M.+Sothauthor=J.+McIntoshauthor=R.+Litmanauthor=J.+Suhauthor=B.+Kocerauthor=D.+Davisauthor=J.+Parkauthor=S.+Frauchigerauthor=N.+Dewdneyauthor=H.+Zecicauthor=J.+P.+Taygerlyauthor=K.+Sarmaauthor=J.+Hongauthor=R.+J.+Hillauthor=T.+Gabrielauthor=D.+M.+Goldsteinauthor=T.+D.+Owens&title=Structure-Based+Drug+Design+of+RN486%2C+a+Potent+and+Selective+Bruton%E2%80%99s+Tyrosine+Kinase+%28BTK%29+Inhibitor%2C+for+the+Treatment+of+Rheumatoid+Arthritis&doi=10.1021%2Fjm500305p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Drug Design of RN486, a Potent and Selective Bruton's Tyrosine Kinase (BTK) Inhibitor, for the Treatment of Rheumatoid Arthritis</span></div><div class="casAuthors">Lou, Yan; Han, Xiaochun; Kuglstatter, Andreas; Kondru, Rama K.; Sweeney, Zachary K.; Soth, Michael; McIntosh, Joel; Litman, Renee; Suh, Judy; Kocer, Buelent; Davis, Dana; Park, Jaehyeon; Frauchiger, Sandra; Dewdney, Nolan; Zecic, Hasim; Taygerly, Joshua P.; Sarma, Keshab; Hong, Junbae; Hill, Ronald J.; Gabriel, Tobias; Goldstein, David M.; Owens, Timothy D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">512-516</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Structure-based drug design was used to guide the optimization of a series of selective BTK inhibitors as potential treatments for Rheumatoid arthritis.  Highlights include the introduction of a benzyl alc. group and a fluorine substitution, each of which resulted in over 10-fold increase in activity.  Concurrent optimization of drug-like properties led to compd. I (RN486) (J. Pharmacol. Exp. Ther. 2012, 341, 90), which was selected for advanced preclin. characterization based on its favorable properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMdHX9-PE5I7Vg90H21EOLACvtfcHk0liS3eKPb2Mtlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlsl2qtb8%253D&md5=dc3c069b0e876f44846a30e3aa6a894a</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fjm500305p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500305p%26sid%3Dliteratum%253Aachs%26aulast%3DLou%26aufirst%3DY.%26aulast%3DHan%26aufirst%3DX.%26aulast%3DKuglstatter%26aufirst%3DA.%26aulast%3DKondru%26aufirst%3DR.%2BK.%26aulast%3DSweeney%26aufirst%3DZ.%2BK.%26aulast%3DSoth%26aufirst%3DM.%26aulast%3DMcIntosh%26aufirst%3DJ.%26aulast%3DLitman%26aufirst%3DR.%26aulast%3DSuh%26aufirst%3DJ.%26aulast%3DKocer%26aufirst%3DB.%26aulast%3DDavis%26aufirst%3DD.%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DFrauchiger%26aufirst%3DS.%26aulast%3DDewdney%26aufirst%3DN.%26aulast%3DZecic%26aufirst%3DH.%26aulast%3DTaygerly%26aufirst%3DJ.%2BP.%26aulast%3DSarma%26aufirst%3DK.%26aulast%3DHong%26aufirst%3DJ.%26aulast%3DHill%26aufirst%3DR.%2BJ.%26aulast%3DGabriel%26aufirst%3DT.%26aulast%3DGoldstein%26aufirst%3DD.%2BM.%26aulast%3DOwens%26aufirst%3DT.%2BD.%26atitle%3DStructure-Based%2520Drug%2520Design%2520of%2520RN486%252C%2520a%2520Potent%2520and%2520Selective%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520%2528BTK%2529%2520Inhibitor%252C%2520for%2520the%2520Treatment%2520of%2520Rheumatoid%2520Arthritis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D512%26epage%3D516%26doi%3D10.1021%2Fjm500305p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pease, J. H.</span></span> <span> </span><span class="NLM_article-title">A Novel Method for High Throughput Lipophilicity Determination by Microscale Shake Flask and Liquid Chromatography Tandem Mass Spectrometry</span>. <i>Comb. Chem. High Throughput Screening</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">817</span>– <span class="NLM_lpage">825</span>, <span class="refDoi"> DOI: 10.2174/1386207311301010007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.2174%2F1386207311301010007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=24168238" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFWktLbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2013&pages=817-825&author=B.+Linauthor=J.+H.+Pease&title=A+Novel+Method+for+High+Throughput+Lipophilicity+Determination+by+Microscale+Shake+Flask+and+Liquid+Chromatography+Tandem+Mass+Spectrometry&doi=10.2174%2F1386207311301010007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">A Novel Method for High Throughput Lipophilicity Determination by Microscale Shake Flask and Liquid Chromatography Tandem Mass Spectrometry</span></div><div class="casAuthors">Lin, Baiwei; Pease, Joseph H.</div><div class="citationInfo"><span class="NLM_cas:title">Combinatorial Chemistry & High Throughput Screening</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">817-825</span>CODEN:
                <span class="NLM_cas:coden">CCHSFU</span>;
        ISSN:<span class="NLM_cas:issn">1386-2073</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Modern small mol. drug design requires the optimization of not only the binding characteristics of the mol. but also its physicochem. properties for ADMET performance.  A key phys. property is lipophilicity and medicinal chemists need rapid access to high quality data in order to drive their decision making.  Traditionally lipophilicity (log D) measurements are performed with a shake flask method and UV detn.  This method suffers from low sensitivity and is not easily converted to a high throughput format.  Over the past decade, several groups have taken different approaches to improve this assay, including replacing the shake flask method with one that utilizes reverse phase HPLC.  Here we describe a new microscale shake flask method that utilizes UPLC-MS/MS to achieve increased throughput, sensitivity and accuracy.  Approaches for assessing data quality are also described.  This platform technol. only requires micrograms of compd. and is routinely used by most small mol. drug discovery project teams at Genentech.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoS0kv3IN4lnLVg90H21EOLACvtfcHk0ljzfK_p4exvvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFWktLbO&md5=1d863747144615780be712cc329ab344</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.2174%2F1386207311301010007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1386207311301010007%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DB.%26aulast%3DPease%26aufirst%3DJ.%2BH.%26atitle%3DA%2520Novel%2520Method%2520for%2520High%2520Throughput%2520Lipophilicity%2520Determination%2520by%2520Microscale%2520Shake%2520Flask%2520and%2520Liquid%2520Chromatography%2520Tandem%2520Mass%2520Spectrometry%26jtitle%3DComb.%2520Chem.%2520High%2520Throughput%2520Screening%26date%3D2013%26volume%3D16%26spage%3D817%26epage%3D825%26doi%3D10.2174%2F1386207311301010007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leach, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hann, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffen, E. J.</span></span> <span> </span><span class="NLM_article-title">Fragment Screening: An Introduction</span>. <i>Mol. BioSyst.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">429</span>– <span class="NLM_lpage">446</span>, <span class="refDoi"> DOI: 10.1039/b610069b</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1039%2Fb610069b" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVCks7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2006&pages=429-446&author=A.+R.+Leachauthor=M.+M.+Hannauthor=J.+N.+Burrowsauthor=E.+J.+Griffen&title=Fragment+Screening%3A+An+Introduction&doi=10.1039%2Fb610069b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Fragment screening: an introduction</span></div><div class="casAuthors">Leach, Andrew R.; Hann, Michael M.; Burrows, Jeremy N.; Griffen, Ed J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular BioSystems</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">429-446</span>CODEN:
                <span class="NLM_cas:coden">MBOIBW</span>;
        ISSN:<span class="NLM_cas:issn">1742-206X</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpttvt8xGGyL7Vg90H21EOLACvtfcHk0ljzfK_p4exvvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVCks7vE&md5=66d60d107405d7e87e90f5d2d29355ed</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1039%2Fb610069b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb610069b%26sid%3Dliteratum%253Aachs%26aulast%3DLeach%26aufirst%3DA.%2BR.%26aulast%3DHann%26aufirst%3DM.%2BM.%26aulast%3DBurrows%26aufirst%3DJ.%2BN.%26aulast%3DGriffen%26aufirst%3DE.%2BJ.%26atitle%3DFragment%2520Screening%253A%2520An%2520Introduction%26jtitle%3DMol.%2520BioSyst.%26date%3D2006%26volume%3D2%26spage%3D429%26epage%3D446%26doi%3D10.1039%2Fb610069b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leeson, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springthorpe, B.</span></span> <span> </span><span class="NLM_article-title">The Influence of Drug-Like Concepts on Decision-Making in Medicinal Chemistry,</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">881</span>– <span class="NLM_lpage">890</span>, <span class="refDoi"> DOI: 10.1038/nrd2445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1038%2Fnrd2445" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=881-890&author=P.+D.+Leesonauthor=B.+Springthorpe&title=The+Influence+of+Drug-Like+Concepts+on+Decision-Making+in+Medicinal+Chemistry%2C&doi=10.1038%2Fnrd2445"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1038%2Fnrd2445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2445%26sid%3Dliteratum%253Aachs%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DSpringthorpe%26aufirst%3DB.%26atitle%3DThe%2520Influence%2520of%2520Drug-Like%2520Concepts%2520on%2520Decision-Making%2520in%2520Medicinal%2520Chemistry%252C%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D881%26epage%3D890%26doi%3D10.1038%2Fnrd2445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, Z. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuglstatter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kocer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondru, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Litman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntosh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarma, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taygerly, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, T. D.</span></span> <span> </span><span class="NLM_article-title">Finding the Perfect Spot for Fluorine: Improving Potency Up To 40-Fold During a Rational Fluorine Scan of a Bruton’s Tyrosine Kinase (BTK) Inhibitor Scaffold</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">367</span>– <span class="NLM_lpage">371</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.11.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1016%2Fj.bmcl.2014.11.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=25466710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitValtrvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=367-371&author=Y.+Louauthor=Z.+K.+Sweeneyauthor=A.+Kuglstatterauthor=D.+Davisauthor=D.+M.+Goldsteinauthor=X.+Hanauthor=J.+Hongauthor=B.+Kocerauthor=R.+K.+Kondruauthor=R.+Litmanauthor=J.+McIntoshauthor=K.+Sarmaauthor=J.+Suhauthor=J.+Taygerlyauthor=T.+D.+Owens&title=Finding+the+Perfect+Spot+for+Fluorine%3A+Improving+Potency+Up+To+40-Fold+During+a+Rational+Fluorine+Scan+of+a+Bruton%E2%80%99s+Tyrosine+Kinase+%28BTK%29+Inhibitor+Scaffold&doi=10.1016%2Fj.bmcl.2014.11.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Finding the perfect spot for fluorine: Improving potency up to 40-fold during a rational fluorine scan of a Bruton's Tyrosine Kinase (BTK) inhibitor scaffold</span></div><div class="casAuthors">Lou, Yan; Sweeney, Zachary K.; Kuglstatter, Andreas; Davis, Dana; Goldstein, David M.; Han, Xiaochun; Hong, Junbae; Kocer, Buelent; Kondru, Rama K.; Litman, Renee; McIntosh, Joel; Sarma, Keshab; Suh, Judy; Taygerly, Joshua; Owens, Timothy D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">367-371</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A rational fluorine scan based on co-crystal structures was explored to increase the potency of a series of selective BTK inhibitors.  While fluorine substitution on a satd. bicyclic ring system yields no apparent benefit, the same operation on an unsatd. bicyclic ring can increase HWB activity by up to 40-fold.  Comparison of co-crystal structures of parent mols. and fluorinated counterparts revealed the importance of placing fluorine at the optimal position to achieve favorable interactions with protein side chains.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnBQYbDM1CNbVg90H21EOLACvtfcHk0ljzfK_p4exvvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitValtrvF&md5=e1f4815a0df9e91ce9150eacf196fc07</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.11.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.11.030%26sid%3Dliteratum%253Aachs%26aulast%3DLou%26aufirst%3DY.%26aulast%3DSweeney%26aufirst%3DZ.%2BK.%26aulast%3DKuglstatter%26aufirst%3DA.%26aulast%3DDavis%26aufirst%3DD.%26aulast%3DGoldstein%26aufirst%3DD.%2BM.%26aulast%3DHan%26aufirst%3DX.%26aulast%3DHong%26aufirst%3DJ.%26aulast%3DKocer%26aufirst%3DB.%26aulast%3DKondru%26aufirst%3DR.%2BK.%26aulast%3DLitman%26aufirst%3DR.%26aulast%3DMcIntosh%26aufirst%3DJ.%26aulast%3DSarma%26aufirst%3DK.%26aulast%3DSuh%26aufirst%3DJ.%26aulast%3DTaygerly%26aufirst%3DJ.%26aulast%3DOwens%26aufirst%3DT.%2BD.%26atitle%3DFinding%2520the%2520Perfect%2520Spot%2520for%2520Fluorine%253A%2520Improving%2520Potency%2520Up%2520To%252040-Fold%2520During%2520a%2520Rational%2520Fluorine%2520Scan%2520of%2520a%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520%2528BTK%2529%2520Inhibitor%2520Scaffold%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D367%26epage%3D371%26doi%3D10.1016%2Fj.bmcl.2014.11.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohli, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katewa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gogol, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belmont, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penuel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burton, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortwine, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franke, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estevez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mortara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergeron, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, W. B.</span></span> <span> </span><span class="NLM_article-title">Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">2897</span>– <span class="NLM_lpage">2907</span>, <span class="refDoi"> DOI: 10.1021/acschembio.6b00480</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.6b00480" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVWltr3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=2897-2907&author=A.+R.+Johnsonauthor=P.+B.+Kohliauthor=A.+Katewaauthor=E.+Gogolauthor=L.+Belmontauthor=R.+Choyauthor=E.+Penuelauthor=L.+Burtonauthor=C.+Eigenbrotauthor=C.+Yuauthor=D.+F.+Ortwineauthor=K.+Bowmanauthor=Y.+Frankeauthor=C.+Tamauthor=A.+Estevezauthor=K.+Mortaraauthor=J.+Wuauthor=H.+Liauthor=M.+Linauthor=P.+Bergeronauthor=J.+J.+Crawfordauthor=W.+B.+Young&title=Battling+Btk+Mutants+With+Noncovalent+Inhibitors+That+Overcome+Cys481+and+Thr474+Mutations&doi=10.1021%2Facschembio.6b00480"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations</span></div><div class="casAuthors">Johnson, Adam R.; Kohli, Pawan Bir; Katewa, Arna; Gogol, Emily; Belmont, Lisa D.; Choy, Regina; Penuel, Elicia; Burton, Luciana; Eigenbrot, Charles; Yu, Christine; Ortwine, Daniel F.; Bowman, Krista; Franke, Yvonne; Tam, Christine; Estevez, Alberto; Mortara, Kyle; Wu, Jiansheng; Li, Hong; Lin, May; Bergeron, Philippe; Crawford, James J.; Young, Wendy B.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2897-2907</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The Bruton's tyrosine kinase (Btk) inhibitor ibrutinib has shown impressive clin. efficacy in a range of B-cell malignancies, however acquired resistance has emerged and second generation therapies are now being sought.  Ibrutinib is a covalent, irreversible inhibitor that modifies Cys481 in the ATP binding site of Btk and renders the enzyme inactive, thereby blocking B-cell receptor signal transduction.  Not surprisingly, Cys481 is the most commonly mutated Btk residue in cases of acquired resistance to ibrutinib.  Mutations at other sites, including Thr474, a gatekeeper residue, have also been detected.  Herein the authors describe noncovalent Btk inhibitors that differ from covalent inhibitors like ibrutinib in that they do not interact with Cys481, they potently inhibit the ibrutinib-resistant Btk C481S mutant in vitro and in cells, and they are exquisitely selective for Btk.  Noncovalent inhibitors such as GNE-431 also show excellent potency against the C481R, T474I, and T474M mutants.  X-ray crystallog. anal. of Btk provides insight into the unique mode of binding of these inhibitors that explains their high selectivity for Btk and their retained activity against mutant forms of Btk.  This class of noncovalent Btk inhibitors may provide a treatment option to patients, esp. those who have acquired resistance to ibrutinib by mutation of Cys481 or Thr474.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkuzaMmxhJ67Vg90H21EOLACvtfcHk0lhpXBnWmo2JAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVWltr3E&md5=1e0458160f967ed01c259751cc2118e1</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Facschembio.6b00480&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.6b00480%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DKohli%26aufirst%3DP.%2BB.%26aulast%3DKatewa%26aufirst%3DA.%26aulast%3DGogol%26aufirst%3DE.%26aulast%3DBelmont%26aufirst%3DL.%26aulast%3DChoy%26aufirst%3DR.%26aulast%3DPenuel%26aufirst%3DE.%26aulast%3DBurton%26aufirst%3DL.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DOrtwine%26aufirst%3DD.%2BF.%26aulast%3DBowman%26aufirst%3DK.%26aulast%3DFranke%26aufirst%3DY.%26aulast%3DTam%26aufirst%3DC.%26aulast%3DEstevez%26aufirst%3DA.%26aulast%3DMortara%26aufirst%3DK.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DLin%26aufirst%3DM.%26aulast%3DBergeron%26aufirst%3DP.%26aulast%3DCrawford%26aufirst%3DJ.%2BJ.%26aulast%3DYoung%26aufirst%3DW.%2BB.%26atitle%3DBattling%2520Btk%2520Mutants%2520With%2520Noncovalent%2520Inhibitors%2520That%2520Overcome%2520Cys481%2520and%2520Thr474%2520Mutations%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2016%26volume%3D11%26spage%3D2897%26epage%3D2907%26doi%3D10.1021%2Facschembio.6b00480" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catlett, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adamczyk, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffies, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murthy, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowak, M.</span></span> <span> </span><span class="NLM_article-title">Safety, Pharmacokinetics, and Pharmacodynamics of BMS-986142, a Novel Reversible BTK Inhibitor, in Healthy Participants</span>. <i>Eur. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">689</span>– <span class="NLM_lpage">698</span>, <span class="refDoi"> DOI: 10.1007/s00228-017-2226-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1007%2Fs00228-017-2226-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=28265691" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjvVahs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2017&pages=689-698&author=S.+K.+Leeauthor=J.+Xingauthor=I.+M.+Catlettauthor=R.+Adamczykauthor=A.+Griffiesauthor=A.+Liuauthor=B.+Murthyauthor=M.+Nowak&title=Safety%2C+Pharmacokinetics%2C+and+Pharmacodynamics+of+BMS-986142%2C+a+Novel+Reversible+BTK+Inhibitor%2C+in+Healthy+Participants&doi=10.1007%2Fs00228-017-2226-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Safety, pharmacokinetics, and pharmacodynamics of BMS-986142, a novel reversible BTK inhibitor, in healthy participants</span></div><div class="casAuthors">Lee, Sun Ku; Xing, Jun; Catlett, Ian M.; Adamczyk, Robert; Griffies, Amber; Liu, Ang; Murthy, Bindu; Nowak, Miroslawa</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">689-698</span>CODEN:
                <span class="NLM_cas:coden">EJCPAS</span>;
        ISSN:<span class="NLM_cas:issn">0031-6970</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">BMS-986142 is an oral, small-mol. reversible inhibitor of Bruton's tyrosine kinase.  The main objectives of our phase I studies were to characterize the safety and tolerability, pharmacokinetics, and pharmacodynamics of BMS-986142 in healthy participants, and to investigate the potential for the effect of BMS-986142 on the PK of methotrexate (MTX) in combination.  In a combined single ascending dose and multiple ascending dose study, the safety, pharmacokinetics, and pharmacodynamics of BMS-986142 were assessed in healthy non-Japanese participants following administration of a single dose (5-900 mg) or multiple doses (25-350 mg, once daily for 14 days).  In a drug-drug interaction study, the effect of BMS-986142 (350 mg, once daily for 5 days) on the single-dose pharmacokinetics of MTX (7.5 mg) was assessed in healthy participants.  Results: BMS-986142 was generally well tolerated, alone and in combination with MTX.  BMS-986142 was rapidly absorbed with peak concns. occurring within 2 h, and was eliminated with a mean half-life ranging from 7 to 11 h.  Exposure of BMS-986142 appeared dose proportional within the dose ranges tested.  A dose- and concn.-dependent inhibition of CD69 expression was obsd. following administration of BMS-986142.  BMS-986142 did not affect the pharmacokinetics of MTX.  BMS-986142 was well tolerated at the doses tested, had pharmacokinetic and pharmacodynamic profiles which support once-daily dosing, and can be coadministered with MTX without the pharmacokinetic interaction of BMS-986142 on MTX.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkY5ZXpICJWrVg90H21EOLACvtfcHk0lhpXBnWmo2JAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjvVahs70%253D&md5=d1435ec2479d5a50d0a5b863cc98d803</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1007%2Fs00228-017-2226-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00228-017-2226-2%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DS.%2BK.%26aulast%3DXing%26aufirst%3DJ.%26aulast%3DCatlett%26aufirst%3DI.%2BM.%26aulast%3DAdamczyk%26aufirst%3DR.%26aulast%3DGriffies%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DA.%26aulast%3DMurthy%26aufirst%3DB.%26aulast%3DNowak%26aufirst%3DM.%26atitle%3DSafety%252C%2520Pharmacokinetics%252C%2520and%2520Pharmacodynamics%2520of%2520BMS-986142%252C%2520a%2520Novel%2520Reversible%2520BTK%2520Inhibitor%252C%2520in%2520Healthy%2520Participants%26jtitle%3DEur.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2017%26volume%3D73%26spage%3D689%26epage%3D698%26doi%3D10.1007%2Fs00228-017-2226-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goutopoulos, A.</span></span> <i>Abstracts of Papers, 254th ACS National Meeting & Exposition</i>, Washington, DC, August 20–24, 2017; <span class="NLM_publisher-name">American Chemical Society</span>: <span class="NLM_publisher-loc">Washington, DC</span>, <span class="NLM_year">2017</span>;  <span class="NLM_fpage">MEDI-268</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&pages=MEDI-268&author=A.+Goutopoulos&title=Abstracts+of+Papers%2C+254th+ACS+National+Meeting+%26+Exposition"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DGoutopoulos%26aufirst%3DA.%26jtitle%3DAbstracts%2520of%2520Papers%252C%2520254th%2520ACS%2520National%2520Meeting%2520%2526%2520Exposition%26pub%3DAmerican%2520Chemical%2520Society%26date%3D2017%26spage%3DMEDI-268" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Musumeci, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanna, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greco, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giacchello, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fallacara, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amato, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schenone, S.</span></span> <span> </span><span class="NLM_article-title">Pyrrolo[2,3-d]pyrimidines Active as Btk Inhibitors</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">1305</span>– <span class="NLM_lpage">1318</span>, <span class="refDoi"> DOI: 10.1080/13543776.2017.1355908</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1080%2F13543776.2017.1355908" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=28705083" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1Sgt7vK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=1305-1318&author=F.+Musumeciauthor=M.+Sannaauthor=C.+Grecoauthor=I.+Giacchelloauthor=A.+L.+Fallacaraauthor=R.+Amatoauthor=S.+Schenone&title=Pyrrolo%5B2%2C3-d%5Dpyrimidines+Active+as+Btk+Inhibitors&doi=10.1080%2F13543776.2017.1355908"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors</span></div><div class="casAuthors">Musumeci, Francesca; Sanna, Monica; Greco, Chiara; Giacchello, Ilaria; Fallacara, Anna Lucia; Amato, Rosario; Schenone, Silvia</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1305-1318</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Introduction: Btk is a tyrosine kinase dysregulated in several B-cell malignancies and autoimmune diseases, and this has given rise to a search for Btk inhibitors.  Nevertheless, only one Btk inhibitor, ibrutinib, has been approved to date, although other compds. are currently being evaluated in clin. trials or in preclinal stages.  Area covered: This review, after a brief introduction on Btk and its inhibitors already in clin. trials, focusses on pyrrolo[2,3-d]pyrimidine derivs. patented in the last five years as Btk inhibitors.  Indeed, the pyrrolo[2,3-d]pyrimidine scaffold, being a deaza-isostere of adenine, the nitrogenous base of ATP, is an actively pursued target for Btk inhibitors.  The patent literature since 2012 have been extensively investigated, pointing out the general features of the patented compds. and, when it is possible, their mechanism of action.  Expert opinion: The recently patented pyrrolo[2,3-d]pyrimidines, acting as reversible or irreversible inhibitors, showed a very interesting in vitro activity.  For this reason, the development of compds. endowed with this scaffold could afford a significant impact in the search for drug candidates for the treatment of immune diseases or B-cell malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPT0s7eVqXebVg90H21EOLACvtfcHk0lg3DfK3go5pBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1Sgt7vK&md5=294c9b8bcafe6f7831187cb963f2f072</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1080%2F13543776.2017.1355908&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2017.1355908%26sid%3Dliteratum%253Aachs%26aulast%3DMusumeci%26aufirst%3DF.%26aulast%3DSanna%26aufirst%3DM.%26aulast%3DGreco%26aufirst%3DC.%26aulast%3DGiacchello%26aufirst%3DI.%26aulast%3DFallacara%26aufirst%3DA.%2BL.%26aulast%3DAmato%26aufirst%3DR.%26aulast%3DSchenone%26aufirst%3DS.%26atitle%3DPyrrolo%255B2%252C3-d%255Dpyrimidines%2520Active%2520as%2520Btk%2520Inhibitors%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2017%26volume%3D27%26spage%3D1305%26epage%3D1318%26doi%3D10.1080%2F13543776.2017.1355908" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pompliano, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meek, T. D.</span></span> <span> </span><span class="NLM_article-title">Drug-Target Residence Time and its Implications for Lead Optimization</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">730</span>– <span class="NLM_lpage">739</span>, <span class="refDoi"> DOI: 10.1038/nrd2082</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1038%2Fnrd2082" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=16888652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BD28XptVCltro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=730-739&author=R.+A.+Copelandauthor=D.+L.+Pomplianoauthor=T.+D.+Meek&title=Drug-Target+Residence+Time+and+its+Implications+for+Lead+Optimization&doi=10.1038%2Fnrd2082"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-target residence time and its implications for lead optimization</span></div><div class="casAuthors">Copeland, Robert A.; Pompliano, David L.; Meek, Thomas D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">730-739</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Much of drug discovery today is predicated on the concept of selective targeting of particular bioactive macromols. by low-mol.-mass drugs.  The binding of drugs to their macromol. targets is therefore seen as paramount for pharmacol. activity.  In vitro assessment of drug-target interactions is classically quantified in terms of binding parameters such as IC50 or Kd.  This article presents an alternative perspective on drug optimization in terms of drug-target binary complex residence time, as quantified by the dissociative half-life of the drug-target binary complex.  We describe the potential advantages of long residence time in terms of duration of pharmacol. effect and target selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGry6SJrMlrrTbVg90H21EOLACvtfcHk0lg3DfK3go5pBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XptVCltro%253D&md5=60ede2301584b10ac4e8fa18e1e6d107</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1038%2Fnrd2082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2082%26sid%3Dliteratum%253Aachs%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26aulast%3DPompliano%26aufirst%3DD.%2BL.%26aulast%3DMeek%26aufirst%3DT.%2BD.%26atitle%3DDrug-Target%2520Residence%2520Time%2520and%2520its%2520Implications%2520for%2520Lead%2520Optimization%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D730%26epage%3D739%26doi%3D10.1038%2Fnrd2082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, R.
A.</span></span> <span> </span><span class="NLM_article-title">The Drug-Target Residence Time Model: a 10-year Retrospective,</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">87</span>– <span class="NLM_lpage">95</span>, <span class="refDoi"> DOI: 10.1038/nrd.2015.18</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1038%2Fnrd.2015.18" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=87-95&author=R.%0AA.+Copeland&title=The+Drug-Target+Residence+Time+Model%3A+a+10-year+Retrospective%2C&doi=10.1038%2Fnrd.2015.18"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2015.18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2015.18%26sid%3Dliteratum%253Aachs%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26atitle%3DThe%2520Drug-Target%2520Residence%2520Time%2520Model%253A%2520a%252010-year%2520Retrospective%252C%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2016%26volume%3D15%26spage%3D87%26epage%3D95%26doi%3D10.1038%2Fnrd.2015.18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, J. F.</span>; <span class="NLM_string-name">Walsh, C. T.</span></span> The Behavior and Significance of Slow-Binding Enzyme Inhibitors. In  <i>Advances in Enzymology and Related Areas of Molecular Biology</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meister, A.</span></span>, Ed.; <span class="NLM_publisher-name">Wiley</span>: <span class="NLM_publisher-loc">New York</span>, <span class="NLM_year">1988</span>; Vol.  <span class="NLM_volume">61</span>, pp  <span class="NLM_fpage">201</span>– <span class="NLM_lpage">301</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1002%2F9780470123072.ch5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1988&pages=201-301&author=J.+F.+Morrison&author=C.+T.+Walshauthor=A.+Meister&title=Advances+in+Enzymology+and+Related+Areas+of+Molecular+Biology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1002%2F9780470123072.ch5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9780470123072.ch5%26sid%3Dliteratum%253Aachs%26aulast%3DMorrison%26aufirst%3DJ.%2BF.%26btitle%3DAdvances%2520in%2520Enzymology%2520and%2520Related%2520Areas%2520of%2520Molecular%2520Biology%26aulast%3DMeister%26aufirst%3DA.%26pub%3DWiley%26date%3D1988%26volume%3D61%26spage%3D201%26epage%3D301" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schutt, L.</span>; <span class="NLM_string-name">Erickson, R.</span>; <span class="NLM_string-name">Tarrant, J.</span>; <span class="NLM_string-name">McDowell, M.</span>; <span class="NLM_string-name">Katewa, A.</span>; <span class="NLM_string-name">Wang, Y.</span>; <span class="NLM_string-name">Huang, T.</span>; <span class="NLM_string-name">Kennedy, W.</span>; <span class="NLM_string-name">Misner, D.</span>; <span class="NLM_string-name">Reif, K.</span></span> BTK Knockout Rat Model Demonstrates Rat-Specific BTK Inhibitor-Related Pancreatic Pathology is On-Target and Unlikely to be Relevant for Humans. Presented at  <i>35th Annual Symposium of the Society of Toxicologic Pathology</i>, San Diego, CA, June 26–29, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=L.+Schutt&author=R.+Erickson&author=J.+Tarrant&author=M.+McDowell&author=A.+Katewa&author=Y.+Wang&author=T.+Huang&author=W.+Kennedy&author=D.+Misner&author=K.+Reif&title=35th+Annual+Symposium+of+the+Society+of+Toxicologic+Pathology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DSchutt%26aufirst%3DL.%26jtitle%3D35th%2520Annual%2520Symposium%2520of%2520the%2520Society%2520of%2520Toxicologic%2520Pathology%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bender, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pereira, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grenningloh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Head, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morandi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haselmayer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu-Bujalski, L.</span></span> <span> </span><span class="NLM_article-title">Ability of Bruton’s Tyrosine Kinase Inhibitors to Sequester Y551 and Prevent Phosphorylation Determines Potency for Inhibition of Fc Receptor but not B-cell Receptor Signaling</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>91</i></span>,  <span class="NLM_fpage">208</span>– <span class="NLM_lpage">219</span>, <span class="refDoi"> DOI: 10.1124/mol.116.107037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1124%2Fmol.116.107037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=28062735" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpsFajtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2017&pages=208-219&author=A.+T.+Benderauthor=A.+Gardbergauthor=A.+Pereiraauthor=T.+Johnsonauthor=Y.+Wuauthor=R.+Grenninglohauthor=J.+Headauthor=F.+Morandiauthor=P.+Haselmayerauthor=L.+Liu-Bujalski&title=Ability+of+Bruton%E2%80%99s+Tyrosine+Kinase+Inhibitors+to+Sequester+Y551+and+Prevent+Phosphorylation+Determines+Potency+for+Inhibition+of+Fc+Receptor+but+not+B-cell+Receptor+Signaling&doi=10.1124%2Fmol.116.107037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Ability of Bruton's tyrosine kinase inhibitors to sequester Y551 and prevent phosphorylation determines potency for inhibition of Fc receptor but not B-cell receptor signaling</span></div><div class="casAuthors">Bender, Andrew T.; Gardberg, Anna; Pereira, Albertina; Johnson, Theresa; Wu, Yin; Grenningloh, Roland; Head, Jared; Morandi, Federica; Haselmayer, Philipp; Liu-Bujalski, Lesley</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">208-219</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (Btk) is expressed in a variety of hematopoietic cells.  Btk has been demonstrated to regulate signaling downstream of the B-cell receptor (BCR), Fc receptors (FcRs), and toll-like receptors.  It has become an attractive drug target because its inhibition may provide significant efficacy by simultaneously blocking multiple disease mechanisms.  Consequently, a large no. of Btk inhibitors have been developed.  These compds. have diverse binding modes, and both reversible and irreversible inhibitors have been developed.  Reported herein, we have tested nine Btk inhibitors and characterized on a mol. level how their interactions with Btk define their ability to block different signaling pathways.  By solving the crystal structures of Btk inhibitors bound to the enzyme, we discovered that the compds. can be classified by their ability to trigger sequestration of Btk residue Y551.  In cells, we found that sequestration of Y551 renders it inaccessible for phosphorylation.  The ability to sequester Y551 was an important determinant of potency against FcγR signaling as Y551 sequestering compds. were more potent for inhibiting basophils and mast cells.  This result was true for the inhibition of FcγR signaling as well.  In contrast, Y551 sequestration was less a factor in detg. potency against BCR signaling.  We also found that Btk activity is regulated differentially in basophils and B cells.  These results elucidate important determinants for Btk inhibitor potency against different signaling pathways and provide insight for designing new compds. with a broader inhibitory profile that will likely result in greater efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrN8F--ON3M7Vg90H21EOLACvtfcHk0lg3DfK3go5pBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpsFajtr8%253D&md5=f869d52d6bc1aabf352988787ff1cbcf</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1124%2Fmol.116.107037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.116.107037%26sid%3Dliteratum%253Aachs%26aulast%3DBender%26aufirst%3DA.%2BT.%26aulast%3DGardberg%26aufirst%3DA.%26aulast%3DPereira%26aufirst%3DA.%26aulast%3DJohnson%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DGrenningloh%26aufirst%3DR.%26aulast%3DHead%26aufirst%3DJ.%26aulast%3DMorandi%26aufirst%3DF.%26aulast%3DHaselmayer%26aufirst%3DP.%26aulast%3DLiu-Bujalski%26aufirst%3DL.%26atitle%3DAbility%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520Inhibitors%2520to%2520Sequester%2520Y551%2520and%2520Prevent%2520Phosphorylation%2520Determines%2520Potency%2520for%2520Inhibition%2520of%2520Fc%2520Receptor%2520but%2520not%2520B-cell%2520Receptor%2520Signaling%26jtitle%3DMol.%2520Pharmacol.%26date%3D2017%26volume%3D91%26spage%3D208%26epage%3D219%26doi%3D10.1124%2Fmol.116.107037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chang, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zapatka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrientos, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steggerda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckert, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francesco, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woyach, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Versele, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byrd, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stilgenbauer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buggy, J. J.</span></span> <span> </span><span class="NLM_article-title">Use of Tumor Genomic Profiling to Reveal Mechanisms of Resistance to the Btk Inhibitor Ibrutinib in Chronic Lymphocytic Leukemia (CLL)</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">7014</span>, <span class="refDoi"> DOI: 10.1200/jco.2013.31.15_suppl.7014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1200%2Fjco.2013.31.15_suppl.7014" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=7014&author=B.+Y.+Changauthor=R.+R.+Furmanauthor=M.+Zapatkaauthor=J.+C.+Barrientosauthor=D.+Liauthor=S.+Steggerdaauthor=K.+Eckertauthor=M.+Francescoauthor=J.+A.+Woyachauthor=A.+J.+Johnsonauthor=D.+F.+Jamesauthor=M.+Verseleauthor=J.+C.+Byrdauthor=S.+Stilgenbauerauthor=J.+J.+Buggy&title=Use+of+Tumor+Genomic+Profiling+to+Reveal+Mechanisms+of+Resistance+to+the+Btk+Inhibitor+Ibrutinib+in+Chronic+Lymphocytic+Leukemia+%28CLL%29&doi=10.1200%2Fjco.2013.31.15_suppl.7014"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1200%2Fjco.2013.31.15_suppl.7014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252Fjco.2013.31.15_suppl.7014%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DB.%2BY.%26aulast%3DFurman%26aufirst%3DR.%2BR.%26aulast%3DZapatka%26aufirst%3DM.%26aulast%3DBarrientos%26aufirst%3DJ.%2BC.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DSteggerda%26aufirst%3DS.%26aulast%3DEckert%26aufirst%3DK.%26aulast%3DFrancesco%26aufirst%3DM.%26aulast%3DWoyach%26aufirst%3DJ.%2BA.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26aulast%3DJames%26aufirst%3DD.%2BF.%26aulast%3DVersele%26aufirst%3DM.%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DStilgenbauer%26aufirst%3DS.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26atitle%3DUse%2520of%2520Tumor%2520Genomic%2520Profiling%2520to%2520Reveal%2520Mechanisms%2520of%2520Resistance%2520to%2520the%2520Btk%2520Inhibitor%2520Ibrutinib%2520in%2520Chronic%2520Lymphocytic%2520Leukemia%2520%2528CLL%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D31%26spage%3D7014%26doi%3D10.1200%2Fjco.2013.31.15_suppl.7014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, J. J.</span>; <span class="NLM_string-name">Ortwine, D. F.</span>; <span class="NLM_string-name">Wei, B.</span>; <span class="NLM_string-name">Young, W.
B.</span></span> <i>Heteroaryl Pyridone and Aza-pyridone Compounds as Inhibitors of Btk Activity</i>. PCT International Application <span class="NLM_patent">WO 2013/067274</span>, May 10, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=J.+J.+Crawford&author=D.+F.+Ortwine&author=B.+Wei&author=W.%0AB.+Young&title=Heteroaryl+Pyridone+and+Aza-pyridone+Compounds+as+Inhibitors+of+Btk+Activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCrawford%26aufirst%3DJ.%2BJ.%26jtitle%3DHeteroaryl%2520Pyridone%2520and%2520Aza-pyridone%2520Compounds%2520as%2520Inhibitors%2520of%2520Btk%2520Activity%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span> <i>RA: Safety and Efficacy Study of GDC-0853 Compared With Placebo and
Adalimumab in Participants With Rheumatoid Arthritis (RA)</i>; ClinicalTrials.gov Identifier: NCT02833350, <a href="https://clinicaltrials.gov/ct2/show/NCT02833350" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02833350</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+RA%3A+Safety+and+Efficacy+Study+of+GDC-0853+Compared+With+Placebo+and%0AAdalimumab+in+Participants+With+Rheumatoid+Arthritis+%28RA%29%3B+ClinicalTrials.gov+Identifier%3A+NCT02833350%2C+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02833350."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DRA%253A%2520Safety%2520and%2520Efficacy%2520Study%2520of%2520GDC-0853%2520Compared%2520With%2520Placebo%2520and%250AAdalimumab%2520in%2520Participants%2520With%2520Rheumatoid%2520Arthritis%2520%2528RA%2529" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span> <i>Lupus: A Study of the Safety and Efficacy of GDC-0853
in Participants
With Moderate to Severe Active Systemic Lupus Erythematosus</i>; ClinicalTrials.gov Identifier: NCT02908100, <a href="https://clinicaltrials.gov/ct2/show/NCT02908100" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02908100</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Lupus%3A+A+Study+of+the+Safety+and+Efficacy+of+GDC-0853%0Ain+Participants%0AWith+Moderate+to+Severe+Active+Systemic+Lupus+Erythematosus%3B+ClinicalTrials.gov+Identifier%3A+NCT02908100%2C+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02908100."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DLupus%253A%2520A%2520Study%2520of%2520the%2520Safety%2520and%2520Efficacy%2520of%2520GDC-0853%250Ain%2520Participants%250AWith%2520Moderate%2520to%2520Severe%2520Active%2520Systemic%2520Lupus%2520Erythematosus" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span> <i>CSU: Efficacy and Safety of GDC-0853 in Participants
With Refractory
Chronic Spontaneous Urticaria (CSU)</i>; ClinicalTrials.gov Identifier:
NCT03137069, <a href="https://clinicaltrials.gov/ct2/show/NCT03137069" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03137069</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+CSU%3A+Efficacy+and+Safety+of+GDC-0853+in+Participants%0AWith+Refractory%0AChronic+Spontaneous+Urticaria+%28CSU%29%3B+ClinicalTrials.gov+Identifier%3A%0ANCT03137069%2C+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03137069."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DCSU%253A%2520Efficacy%2520and%2520Safety%2520of%2520GDC-0853%2520in%2520Participants%250AWith%2520Refractory%250AChronic%2520Spontaneous%2520Urticaria%2520%2528CSU%2529" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 87 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Mark S. Tichenor, John J. M. Wiener, Navin L. Rao, Charlotte Pooley Deckhut, J. Kent Barbay, Kevin D. Kreutter, Genesis M. Bacani, Jianmei Wei, Leon Chang, Heather E. Murrey, Weixue Wang, Kay Ahn, Michael Huber, Elizabeth Rex, Kevin J. Coe, JieJun Wu, Mark Seierstad, Scott D. Bembenek, Kristi A. Leonard, Alec D. Lebsack, Jennifer D. Venable, <span class="NLM_string-name hlFld-ContribAuthor">James P. Edwards</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a Potent and Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase with Oral Anti-Inflammatory Activity. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>12 </em>
                                    (5)
                                     , 782-790. <a href="https://doi.org/10.1021/acsmedchemlett.1c00044" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.1c00044</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.1c00044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.1c00044%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Ba%252BPotent%252Band%252BSelective%252BCovalent%252BInhibitor%252Bof%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%252Bwith%252BOral%252BAnti-Inflammatory%252BActivity%26aulast%3DTichenor%26aufirst%3DMark%2BS.%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D27012021%26date%3D28032021%26date%3D05042021%26volume%3D12%26issue%3D5%26spage%3D782%26epage%3D790" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Richard A. Ward, Stephen Fawell, Nicolas Floc’h, Vikki Flemington, Darren McKerrecher, <span class="NLM_string-name hlFld-ContribAuthor">Paul D. Smith</span>. </span><span class="cited-content_cbyCitation_article-title">Challenges and Opportunities in Cancer Drug Resistance. </span><span class="cited-content_cbyCitation_journal-name">Chemical Reviews</span><span> <strong>2021,</strong> <em>121 </em>
                                    (6)
                                     , 3297-3351. <a href="https://doi.org/10.1021/acs.chemrev.0c00383" title="DOI URL">https://doi.org/10.1021/acs.chemrev.0c00383</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrev.0c00383&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrev.0c00383%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Reviews%26atitle%3DChallenges%252Band%252BOpportunities%252Bin%252BCancer%252BDrug%252BResistance%26aulast%3DWard%26aufirst%3DRichard%2BA.%26date%3D2021%26date%3D2020%26date%3D2020%26date%3D29042020%26date%3D21072020%26volume%3D121%26issue%3D6%26spage%3D3297%26epage%3D3351" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Zhouling Xie, Xiaoxiao Yang, Yajun Duan, Jihong Han, <span class="NLM_string-name hlFld-ContribAuthor">Chenzhong Liao</span>. </span><span class="cited-content_cbyCitation_article-title">Small-Molecule Kinase Inhibitors for the Treatment of Nononcologic Diseases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (3)
                                     , 1283-1345. <a href="https://doi.org/10.1021/acs.jmedchem.0c01511" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01511</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01511&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01511%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSmall-Molecule%252BKinase%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BNononcologic%252BDiseases%26aulast%3DXie%26aufirst%3DZhouling%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D29082020%26date%3D22012021%26volume%3D64%26issue%3D3%26spage%3D1283%26epage%3D1345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Bin Ma, Tonika Bohnert, Kevin L. Otipoby, Eric Tien, Million Arefayene, Judy Bai, Bekim Bajrami, Eris Bame, Timothy R. Chan, Michael Humora, J. Michael MacPhee, Douglas Marcotte, Devangi Mehta, Claire M. Metrick, George Moniz, Evelyne Polack, Urjana Poreci, Annick Prefontaine, Sarah Sheikh, Patricia Schroeder, Karen Smirnakis, Lei Zhang, Fengmei Zheng, <span class="NLM_string-name hlFld-ContribAuthor">Brian T. Hopkins</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of BIIB068: A Selective, Potent, Reversible Bruton’s Tyrosine Kinase Inhibitor as an Orally Efficacious Agent for Autoimmune Diseases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (21)
                                     , 12526-12541. <a href="https://doi.org/10.1021/acs.jmedchem.0c00702" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00702</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00702&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00702%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BBIIB068%25253A%252BA%252BSelective%25252C%252BPotent%25252C%252BReversible%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%252BInhibitor%252Bas%252Ban%252BOrally%252BEfficacious%252BAgent%252Bfor%252BAutoimmune%252BDiseases%26aulast%3DMa%26aufirst%3DBin%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D27042020%26date%3D06082020%26date%3D22072020%26volume%3D63%26issue%3D21%26spage%3D12526%26epage%3D12541" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Anurag S. Srivastava, Soo Ko, Scott H. Watterson, Mark A. Pattoli, Stacey Skala, Lihong Cheng, Mary T. Obermeier, Rodney Vickery, Lorell N. Discenza, Celia J. D’Arienzo, Kathleen M. Gillooly, Tracy L. Taylor, Claudine Pulicicchio, Kim W. McIntyre, Shiuhang Yip, Peng Li, Dawn Sun, Dauh-Rurng Wu, Jun Dai, Chunlei Wang, Yingru Zhang, Bei Wang, Joseph Pawluczyk, James Kempson, Rulin Zhao, Xiaoping Hou, Richard Rampulla, Arvind Mathur, Michael A. Galella, Luisa Salter-Cid, Joel C. Barrish, Percy H. Carter, Aberra Fura, James R. Burke, <span class="NLM_string-name hlFld-ContribAuthor">Joseph A. Tino</span>. </span><span class="cited-content_cbyCitation_article-title">Driving Potency with Rotationally Stable Atropisomers: Discovery of Pyridopyrimidinedione-Carbazole Inhibitors of BTK. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (11)
                                     , 2195-2203. <a href="https://doi.org/10.1021/acsmedchemlett.0c00335" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.0c00335</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.0c00335&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.0c00335%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDriving%252BPotency%252Bwith%252BRotationally%252BStable%252BAtropisomers%25253A%252BDiscovery%252Bof%252BPyridopyrimidinedione-Carbazole%252BInhibitors%252Bof%252BBTK%26aulast%3DSrivastava%26aufirst%3DAnurag%2BS.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D16062020%26date%3D16092020%26date%3D22092020%26date%3D16092020%26volume%3D11%26issue%3D11%26spage%3D2195%26epage%3D2203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xiaoyun Lu, Jeff B. Smaill, <span class="NLM_string-name hlFld-ContribAuthor">Ke Ding</span>. </span><span class="cited-content_cbyCitation_article-title">Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (19)
                                     , 10726-10741. <a href="https://doi.org/10.1021/acs.jmedchem.0c00507" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00507</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00507%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DMedicinal%252BChemistry%252BStrategies%252Bfor%252Bthe%252BDevelopment%252Bof%252BKinase%252BInhibitors%252BTargeting%252BPoint%252BMutations%26aulast%3DLu%26aufirst%3DXiaoyun%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D27032020%26date%3D02062020%26date%3D20052020%26volume%3D63%26issue%3D19%26spage%3D10726%26epage%3D10741" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xuejun Zhang, Xijun Sheng, Jie Shen, Shoubo Zhang, Wenjie Sun, Chunli Shen, Yi Li, Jun Wang, Huqiang Lv, Minghui Cui, Yuchuan Zhu, Lei Huang, Dongling Hao, Zhibo Qi, Guanglong Sun, Weifeng Mao, Yan Pan, Liang Shen, Xin Li, Guoping Hu, Zhen Gong, Shuhua Han, Jian Li, Shuhui Chen, Ronghua Tu, Xuehai Wang, <span class="NLM_string-name hlFld-ContribAuthor">Chengde Wu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and Evaluation of Pyrazolo[3,4-d]pyridazinone as a Potent and Orally Active Irreversible BTK Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (10)
                                     , 1863-1868. <a href="https://doi.org/10.1021/acsmedchemlett.9b00395" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.9b00395</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.9b00395&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.9b00395%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Band%252BEvaluation%252Bof%252BPyrazolo%25255B3%25252C4-d%25255Dpyridazinone%252Bas%252Ba%252BPotent%252Band%252BOrally%252BActive%252BIrreversible%252BBTK%252BInhibitor%26aulast%3DZhang%26aufirst%3DXuejun%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D23082019%26date%3D11122019%26date%3D16122019%26date%3D11122019%26volume%3D11%26issue%3D10%26spage%3D1863%26epage%3D1868" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">James J. Crawford, Wendy Lee, Adam R. Johnson, Kelly J. Delatorre, Jacob Chen, Charles Eigenbrot, Julia Heidmann, Satoko Kakiuchi-Kiyota, Arna Katewa, James R. Kiefer, Lichuan Liu, Joseph W. Lubach, Dinah Misner, Hans Purkey, Karin Reif, Jennifer Vogt, Harvey Wong, Christine Yu, <span class="NLM_string-name hlFld-ContribAuthor">Wendy B. Young</span>. </span><span class="cited-content_cbyCitation_article-title">Stereochemical Differences in Fluorocyclopropyl Amides Enable Tuning of Btk Inhibition and Off-Target Activity. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (8)
                                     , 1588-1597. <a href="https://doi.org/10.1021/acsmedchemlett.0c00249" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.0c00249</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.0c00249&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.0c00249%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DStereochemical%252BDifferences%252Bin%252BFluorocyclopropyl%252BAmides%252BEnable%252BTuning%252Bof%252BBtk%252BInhibition%252Band%252BOff-Target%252BActivity%26aulast%3DCrawford%26aufirst%3DJames%2BJ.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D13052020%26date%3D13072020%26date%3D20072020%26date%3D13072020%26volume%3D11%26issue%3D8%26spage%3D1588%26epage%3D1597" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Chenghong Zhang, James J. Crawford, Matthew L. Landry, Huifen Chen, Jane R. Kenny, S. Cyrus Khojasteh, Wendy Lee, Shuguang Ma, <span class="NLM_string-name hlFld-ContribAuthor">Wendy B. Young</span>. </span><span class="cited-content_cbyCitation_article-title">Strategies to Mitigate the Bioactivation of Aryl Amines. </span><span class="cited-content_cbyCitation_journal-name">Chemical Research in Toxicology</span><span> <strong>2020,</strong> <em>33 </em>
                                    (7)
                                     , 1950-1959. <a href="https://doi.org/10.1021/acs.chemrestox.0c00138" title="DOI URL">https://doi.org/10.1021/acs.chemrestox.0c00138</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrestox.0c00138&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrestox.0c00138%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Research%2520in%2520Toxicology%26atitle%3DStrategies%252Bto%252BMitigate%252Bthe%252BBioactivation%252Bof%252BAryl%252BAmines%26aulast%3DZhang%26aufirst%3DChenghong%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D09042020%26date%3D23062020%26date%3D08062020%26volume%3D33%26issue%3D7%26spage%3D1950%26epage%3D1959" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Daniela Angst, François Gessier, Philipp Janser, Anna Vulpetti, Rudolf Wälchli, Christian Beerli, Amanda Littlewood-Evans, Janet Dawson, Barbara Nuesslein-Hildesheim, Grazyna Wieczorek, Sascha Gutmann, Clemens Scheufler, Alexandra Hinniger, Alfred Zimmerlin, Enrico G. Funhoff, Robert Pulz, <span class="NLM_string-name hlFld-ContribAuthor">Bruno Cenni</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (10)
                                     , 5102-5118. <a href="https://doi.org/10.1021/acs.jmedchem.9b01916" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01916</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01916&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01916%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BLOU064%252B%252528Remibrutinib%252529%25252C%252Ba%252BPotent%252Band%252BHighly%252BSelective%252BCovalent%252BInhibitor%252Bof%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%26aulast%3DAngst%26aufirst%3DDaniela%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D19112019%26date%3D04032020%26date%3D21022020%26volume%3D63%26issue%3D10%26spage%3D5102%26epage%3D5118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor "> Bin    Ma    </span><span class="hlFld-ContribAuthor "> Chaomin    Li </span><span class="hlFld-ContribAuthor "> Brian T.    Hopkins </span><span class="hlFld-ContribAuthor "> Lloyd    Franklin </span><span class="hlFld-ContribAuthor "> Robbie    Chen    </span><span class="hlFld-ContribAuthor "> Tamera    Mack </span><span class="hlFld-ContribAuthor "> Daniel    Patience </span><span class="hlFld-ContribAuthor "> William F.    Kiesman </span><span class="hlFld-ContribAuthor "> Erin M.    O’Brien    </span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and Process Development of BIIB068: A Reversible Bruton’s Tyrosine Kinase (BTK) Inhibitor for the Treatment of Autoimmune Diseases. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 313-337. <a href="https://doi.org/10.1021/bk-2020-1369.ch010" title="DOI URL">https://doi.org/10.1021/bk-2020-1369.ch010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/bk-2020-1369.ch010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fbk-2020-1369.ch010%26sid%3Dliteratum%253Aachs%26atitle%3DDiscovery%252Band%252BProcess%252BDevelopment%252Bof%252BBIIB068%25253A%252BA%252BReversible%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%252B%252528BTK%252529%252BInhibitor%252Bfor%252Bthe%252BTreatment%252Bof%252BAutoimmune%252BDiseases%26aulast%3DMa%26aufirst%3DBin%26date%3D2020%26date%3D2020%26spage%3D313%26epage%3D337%26atitle%3DComplete%252BAccounts%252Bof%252BIntegrated%252BDrug%252BDiscovery%252Band%252BDevelopment%25253A%252BRecent%252BExamples%252Bfrom%252Bthe%252BPharmaceutical%252BIndustry%252BVolume%252B3%26aulast%3DPesti%26aufirst%3DJaan%2BA.%26date%3D2020%26date%3D2020%26volume%3D1369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Francesca Toselli, Marlene Fredenwall, Peder Svensson, Xue-Qing Li, Anders Johansson, Lars Weidolf, <span class="NLM_string-name hlFld-ContribAuthor">Martin A. Hayes</span>. </span><span class="cited-content_cbyCitation_article-title">Hip To Be Square: Oxetanes as Design Elements To Alter Metabolic Pathways. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (16)
                                     , 7383-7399. <a href="https://doi.org/10.1021/acs.jmedchem.9b00030" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00030</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00030%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DHip%252BTo%252BBe%252BSquare%25253A%252BOxetanes%252Bas%252BDesign%252BElements%252BTo%252BAlter%252BMetabolic%252BPathways%26aulast%3DToselli%26aufirst%3DFrancesca%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D06012019%26date%3D02082019%26date%3D16072019%26volume%3D62%26issue%3D16%26spage%3D7383%26epage%3D7399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Andrew
C. Flick, Carolyn A. Leverett, Hong X. Ding, Emma McInturff, Sarah J. Fink, Christopher J. Helal, <span class="NLM_string-name hlFld-ContribAuthor">Christopher J. O’Donnell</span>. </span><span class="cited-content_cbyCitation_article-title">Synthetic Approaches to the New Drugs Approved During 2017. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (16)
                                     , 7340-7382. <a href="https://doi.org/10.1021/acs.jmedchem.9b00196" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00196</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00196&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00196%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthetic%252BApproaches%252Bto%252Bthe%252BNew%252BDrugs%252BApproved%252BDuring%252B2017%26aulast%3DFlick%26aufirst%3DAndrew%2BC.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D30012019%26date%3D15042019%26date%3D02042019%26volume%3D62%26issue%3D16%26spage%3D7340%26epage%3D7382" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Sébastien L. Degorce, Michael S. Bodnarchuk, <span class="NLM_string-name hlFld-ContribAuthor">James S. Scott</span>. </span><span class="cited-content_cbyCitation_article-title">Lowering Lipophilicity by Adding Carbon: AzaSpiroHeptanes, a logD Lowering Twist. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>10 </em>
                                    (8)
                                     , 1198-1204. <a href="https://doi.org/10.1021/acsmedchemlett.9b00248" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.9b00248</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.9b00248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.9b00248%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DLowering%252BLipophilicity%252Bby%252BAdding%252BCarbon%25253A%252BAzaSpiroHeptanes%25252C%252Ba%252BlogD%252BLowering%252BTwist%26aulast%3DDegorce%26aufirst%3DS%25C3%25A9bastien%2BL.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D06062019%26date%3D18072019%26date%3D25072019%26date%3D18072019%26volume%3D10%26issue%3D8%26spage%3D1198%26epage%3D1204" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xia Yao, Xiuyun Sun, Shuyu Jin, Ling Yang, Hongjiang Xu, <span class="NLM_string-name hlFld-ContribAuthor">Yu Rao</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 4-Aminoquinoline-3-carboxamide Derivatives as Potent Reversible Bruton’s Tyrosine Kinase Inhibitors for the Treatment of Rheumatoid Arthritis. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (14)
                                     , 6561-6574. <a href="https://doi.org/10.1021/acs.jmedchem.9b00329" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00329</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00329&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00329%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B4-Aminoquinoline-3-carboxamide%252BDerivatives%252Bas%252BPotent%252BReversible%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BRheumatoid%252BArthritis%26aulast%3DYao%26aufirst%3DXia%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D21022019%26date%3D12072019%26date%3D01072019%26volume%3D62%26issue%3D14%26spage%3D6561%26epage%3D6574" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Hua Xu, Michael I. Jesson, Uthpala I. Seneviratne, Tsung H. Lin, M. Nusrat Sharif, Liang Xue, Chuong Nguyen, Robert A. Everley, John I. Trujillo, Douglas S. Johnson, Gary R. Point, Atli Thorarensen, Iain Kilty, <span class="NLM_string-name hlFld-ContribAuthor">Jean-Baptiste Telliez</span>. </span><span class="cited-content_cbyCitation_article-title">PF-06651600, a Dual JAK3/TEC Family Kinase Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Biology</span><span> <strong>2019,</strong> <em>14 </em>
                                    (6)
                                     , 1235-1242. <a href="https://doi.org/10.1021/acschembio.9b00188" title="DOI URL">https://doi.org/10.1021/acschembio.9b00188</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschembio.9b00188&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschembio.9b00188%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Biology%26atitle%3DPF-06651600%25252C%252Ba%252BDual%252BJAK3%25252FTEC%252BFamily%252BKinase%252BInhibitor%26aulast%3DXu%26aufirst%3DHua%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D08032019%26date%3D13052019%26date%3D22052019%26date%3D13052019%26volume%3D14%26issue%3D6%26spage%3D1235%26epage%3D1242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Scott H. Watterson, Qingjie Liu, Myra Beaudoin Bertrand, Douglas G. Batt, Ling Li, Mark A. Pattoli, Stacey Skala, Lihong Cheng, Mary T. Obermeier, Robin Moore, Zheng Yang, Rodney Vickery, Paul A. Elzinga, Lorell Discenza, Celia D’Arienzo, Kathleen M. Gillooly, Tracy L. Taylor, Claudine Pulicicchio, Yifan Zhang, Elizabeth Heimrich, Kim W. McIntyre, Qian Ruan, Richard A. Westhouse, Ian M. Catlett, Naiyu Zheng, Charu Chaudhry, Jun Dai, Michael A. Galella, Andrew J. Tebben, Matt Pokross, Jianqing Li, Rulin Zhao, Daniel Smith, Richard Rampulla, Alban Allentoff, Michael A. Wallace, Arvind Mathur, Luisa Salter-Cid, John E. Macor, Percy H. Carter, Aberra Fura, James R. Burke, <span class="NLM_string-name hlFld-ContribAuthor">Joseph A. Tino</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton’s Tyrosine Kinase (BTK). </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (7)
                                     , 3228-3250. <a href="https://doi.org/10.1021/acs.jmedchem.9b00167" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00167</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00167%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BBranebrutinib%252B%252528BMS-986195%252529%25253A%252BA%252BStrategy%252Bfor%252BIdentifying%252Ba%252BHighly%252BPotent%252Band%252BSelective%252BCovalent%252BInhibitor%252BProviding%252BRapid%252Bin%252BVivo%252BInactivation%252Bof%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%252B%252528BTK%252529%26aulast%3DWatterson%26aufirst%3DScott%2BH.%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D27012019%26date%3D29032019%26date%3D20032019%26volume%3D62%26issue%3D7%26spage%3D3228%26epage%3D3250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Mark E. Schnute, Stephen E. Benoit, Ingrid P. Buchler, Nicole Caspers, Margaret L. Grapperhaus, Seungil Han, Rajeev Hotchandani, Nelson Huang, Robert O. Hughes, Brian M. Juba, Kyung-Hee Kim, Erica Liu, Erin McCarthy, Dean Messing, Joy S. Miyashiro, Shashi Mohan, Thomas N. O’Connell, Jeffrey F. Ohren, Mihir D. Parikh, Michelle Schmidt, Shaun R. Selness, John R. Springer, Venkataraman Thanabal, John I. Trujillo, Daniel P. Walker, Zhao-Kui Wan, Jane M. Withka, Arthur J. Wittwer, Nancy L. Wood, Li Xing, Christoph W. Zapf, <span class="NLM_string-name hlFld-ContribAuthor">John Douhan, III</span>. </span><span class="cited-content_cbyCitation_article-title">Aminopyrazole Carboxamide Bruton’s Tyrosine Kinase Inhibitors. Irreversible to Reversible Covalent Reactive Group Tuning. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>10 </em>
                                    (1)
                                     , 80-85. <a href="https://doi.org/10.1021/acsmedchemlett.8b00461" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.8b00461</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.8b00461&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.8b00461%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DAminopyrazole%252BCarboxamide%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%252BInhibitors.%252BIrreversible%252Bto%252BReversible%252BCovalent%252BReactive%252BGroup%252BTuning%26aulast%3DSchnute%26aufirst%3DMark%2BE.%26date%3D2019%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D03102018%26date%3D03122018%26date%3D05122018%26date%3D03122018%26volume%3D10%26issue%3D1%26spage%3D80%26epage%3D85" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor "> James J.    Crawford    </span><span class="hlFld-ContribAuthor "> Haiming    Zhang </span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and Development of Non-Covalent, Reversible Bruton’s Tyrosine Kinase Inhibitor Fenebrutinib (GDC-0853). </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 239-266. <a href="https://doi.org/10.1021/bk-2019-1332.ch009" title="DOI URL">https://doi.org/10.1021/bk-2019-1332.ch009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/bk-2019-1332.ch009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fbk-2019-1332.ch009%26sid%3Dliteratum%253Aachs%26atitle%3DDiscovery%252Band%252BDevelopment%252Bof%252BNon-Covalent%25252C%252BReversible%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%252BInhibitor%252BFenebrutinib%252B%252528GDC-0853%252529%26aulast%3DCrawford%26aufirst%3DJames%2BJ.%26date%3D2019%26date%3D2019%26spage%3D239%26epage%3D266%26atitle%3DComplete%252BAccounts%252Bof%252BIntegrated%252BDrug%252BDiscovery%252Band%252BDevelopment%25253A%252BRecent%252BExamples%252Bfrom%252Bthe%252BPharmaceutical%252BIndustry%252BVolume%252B2%26aulast%3DPesti%26aufirst%3DJaan%2BA.%26date%3D2019%26date%3D2019%26volume%3D1332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Marian C. Bryan, <span class="NLM_string-name hlFld-ContribAuthor">Naomi S. Rajapaksa</span>. </span><span class="cited-content_cbyCitation_article-title">Kinase Inhibitors for the Treatment of Immunological Disorders: Recent Advances. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (20)
                                     , 9030-9058. <a href="https://doi.org/10.1021/acs.jmedchem.8b00667" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00667</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00667&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00667%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DKinase%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BImmunological%252BDisorders%25253A%252BRecent%252BAdvances%26aulast%3DBryan%26aufirst%3DMarian%2BC.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D26042018%26date%3D15062018%26date%3D05062018%26volume%3D61%26issue%3D20%26spage%3D9030%26epage%3D9058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Haiming Zhang, Theresa Cravillion, Ngiap-Kie Lim, Qingping Tian, Danial Beaudry, Jessica L. Defreese, Alec Fettes, Philippe James, David Linder, Sushant Malhotra, Chong Han, Remy Angelaud, <span class="NLM_string-name hlFld-ContribAuthor">Francis Gosselin</span>. </span><span class="cited-content_cbyCitation_article-title">Development of an Efficient Manufacturing Process for Reversible Bruton’s Tyrosine Kinase Inhibitor GDC-0853. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2018,</strong> <em>22 </em>
                                    (8)
                                     , 978-990. <a href="https://doi.org/10.1021/acs.oprd.8b00134" title="DOI URL">https://doi.org/10.1021/acs.oprd.8b00134</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.oprd.8b00134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.oprd.8b00134%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DDevelopment%252Bof%252Ban%252BEfficient%252BManufacturing%252BProcess%252Bfor%252BReversible%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%252BInhibitor%252BGDC-0853%26aulast%3DZhang%26aufirst%3DHaiming%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D25042018%26date%3D22072018%26date%3D02072018%26volume%3D22%26issue%3D8%26spage%3D978%26epage%3D990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Alexandru
D. Buhimschi, Haley A. Armstrong, Momar Toure, Saul Jaime-Figueroa, Timothy L. Chen, Amy M. Lehman, Jennifer A. Woyach, Amy J. Johnson, John C. Byrd, <span class="NLM_string-name hlFld-ContribAuthor">Craig M. Crews</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting the C481S Ibrutinib-Resistance Mutation in Bruton’s Tyrosine Kinase Using PROTAC-Mediated Degradation. </span><span class="cited-content_cbyCitation_journal-name">Biochemistry</span><span> <strong>2018,</strong> <em>57 </em>
                                    (26)
                                     , 3564-3575. <a href="https://doi.org/10.1021/acs.biochem.8b00391" title="DOI URL">https://doi.org/10.1021/acs.biochem.8b00391</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.biochem.8b00391&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.biochem.8b00391%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemistry%26atitle%3DTargeting%252Bthe%252BC481S%252BIbrutinib-Resistance%252BMutation%252Bin%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%252BUsing%252BPROTAC-Mediated%252BDegradation%26aulast%3DBuhimschi%26aufirst%3DAlexandru%2BD.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D04042018%26date%3D31052018%26date%3D14062018%26date%3D31052018%26volume%3D57%26issue%3D26%26spage%3D3564%26epage%3D3575" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yu Xue, Peiran Song, Zilan Song, Aoli Wang, Linjiang Tong, Meiyu Geng, Jian Ding, Qingsong Liu, Liping Sun, Hua Xie, <span class="NLM_string-name hlFld-ContribAuthor">Ao Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 4,7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrimido[5,4-b]pyrrolizines as Novel Bruton’s Tyrosine Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (10)
                                     , 4608-4627. <a href="https://doi.org/10.1021/acs.jmedchem.8b00441" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00441</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00441&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00441%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B4%25252C7-Diamino-5-%2525284-phenoxyphenyl%252529-6-methylene-pyrimido%25255B5%25252C4-b%25255Dpyrrolizines%252Bas%252BNovel%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%252BInhibitors%26aulast%3DXue%26aufirst%3DYu%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D19032018%26date%3D09052018%26date%3D01052018%26volume%3D61%26issue%3D10%26spage%3D4608%26epage%3D4627" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Danling  Gu</span>, <span class="hlFld-ContribAuthor ">Hanning  Tang</span>, <span class="hlFld-ContribAuthor ">Jiazhu  Wu</span>, <span class="hlFld-ContribAuthor ">Jianyong  Li</span>, <span class="hlFld-ContribAuthor ">Yi  Miao</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies. </span><span class="cited-content_cbyCitation_journal-name">Journal of Hematology & Oncology</span><span> <strong>2021,</strong> <em>14 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s13045-021-01049-7" title="DOI URL">https://doi.org/10.1186/s13045-021-01049-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s13045-021-01049-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs13045-021-01049-7%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Hematology%2520%2526%2520Oncology%26atitle%3DTargeting%252BBruton%252Btyrosine%252Bkinase%252Busing%252Bnon-covalent%252Binhibitors%252Bin%252BB%252Bcell%252Bmalignancies%26aulast%3DGu%26aufirst%3DDanling%26date%3D2021%26date%3D2021%26volume%3D14%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bei  Zhang</span>, <span class="hlFld-ContribAuthor ">Yue  Huang</span>, <span class="hlFld-ContribAuthor ">Si-Rui  Zhang</span>, <span class="hlFld-ContribAuthor ">Meng-Xing  Huang</span>, <span class="hlFld-ContribAuthor ">Chen  Zhang</span>, <span class="hlFld-ContribAuthor ">Hai-Bin  Luo</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of novel pyrazolopyrimidone derivatives as potent PDE1 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>114 </em>, 105104. <a href="https://doi.org/10.1016/j.bioorg.2021.105104" title="DOI URL">https://doi.org/10.1016/j.bioorg.2021.105104</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2021.105104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2021.105104%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252Bpyrazolopyrimidone%252Bderivatives%252Bas%252Bpotent%252BPDE1%252Binhibitors%26aulast%3DZhang%26aufirst%3DBei%26date%3D2021%26volume%3D114%26spage%3D105104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Brian T.  Hopkins</span>, <span class="hlFld-ContribAuthor ">Eris  Bame</span>, <span class="hlFld-ContribAuthor ">Noah  Bell</span>, <span class="hlFld-ContribAuthor ">Tonika  Bohnert</span>, <span class="hlFld-ContribAuthor ">Jon K.  Bowden-Verhoek</span>, <span class="hlFld-ContribAuthor ">Minna  Bui</span>, <span class="hlFld-ContribAuthor ">Mark T.  Cancilla</span>, <span class="hlFld-ContribAuthor ">Patrick  Conlon</span>, <span class="hlFld-ContribAuthor ">Patrick  Cullen</span>, <span class="hlFld-ContribAuthor ">Daniel A.  Erlanson</span>, <span class="hlFld-ContribAuthor ">Junfa  Fan</span>, <span class="hlFld-ContribAuthor ">Tarra  Fuchs-Knotts</span>, <span class="hlFld-ContribAuthor ">Stig  Hansen</span>, <span class="hlFld-ContribAuthor ">Stacey  Heumann</span>, <span class="hlFld-ContribAuthor ">Tracy J.  Jenkins</span>, <span class="hlFld-ContribAuthor ">Chuck  Gua</span>, <span class="hlFld-ContribAuthor ">Ying  Liu</span>, <span class="hlFld-ContribAuthor ">YuTing  Liu</span>, <span class="hlFld-ContribAuthor ">Mukush  Lulla</span>, <span class="hlFld-ContribAuthor ">Douglas  Marcotte</span>, <span class="hlFld-ContribAuthor ">Isaac  Marx</span>, <span class="hlFld-ContribAuthor ">Bob  McDowell</span>, <span class="hlFld-ContribAuthor ">Elisabeth  Mertsching</span>, <span class="hlFld-ContribAuthor ">Ella  Negrou</span>, <span class="hlFld-ContribAuthor ">Michael J.  Romanowski</span>, <span class="hlFld-ContribAuthor ">Daniel  Scott</span>, <span class="hlFld-ContribAuthor ">Laura  Silvian</span>, <span class="hlFld-ContribAuthor ">Wenjin  Yang</span>, <span class="hlFld-ContribAuthor ">Min  Zhong</span>. </span><span class="cited-content_cbyCitation_article-title">Utilizing structure based drug design and metabolic soft spot identification to optimize the in vitro potency and in vivo pharmacokinetic properties leading to the discovery of novel reversible Bruton’s tyrosine kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2021,</strong> <em>44 </em>, 116275. <a href="https://doi.org/10.1016/j.bmc.2021.116275" title="DOI URL">https://doi.org/10.1016/j.bmc.2021.116275</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2021.116275&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2021.116275%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DUtilizing%252Bstructure%252Bbased%252Bdrug%252Bdesign%252Band%252Bmetabolic%252Bsoft%252Bspot%252Bidentification%252Bto%252Boptimize%252Bthe%252Bin%252Bvitro%252Bpotency%252Band%252Bin%252Bvivo%252Bpharmacokinetic%252Bproperties%252Bleading%252Bto%252Bthe%252Bdiscovery%252Bof%252Bnovel%252Breversible%252BBruton%2525E2%252580%252599s%252Btyrosine%252Bkinase%252Binhibitors%26aulast%3DHopkins%26aufirst%3DBrian%2BT.%26date%3D2021%26volume%3D44%26spage%3D116275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rula  Zain</span>, <span class="hlFld-ContribAuthor ">Mauno  Vihinen</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-Function Relationships of Covalent and Non-Covalent BTK Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Immunology</span><span> <strong>2021,</strong> <em>12 </em><a href="https://doi.org/10.3389/fimmu.2021.694853" title="DOI URL">https://doi.org/10.3389/fimmu.2021.694853</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fimmu.2021.694853&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffimmu.2021.694853%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Immunology%26atitle%3DStructure-Function%252BRelationships%252Bof%252BCovalent%252Band%252BNon-Covalent%252BBTK%252BInhibitors%26aulast%3DZain%26aufirst%3DRula%26date%3D2021%26date%3D2021%26volume%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Roy  Fleischmann</span>. </span><span class="cited-content_cbyCitation_article-title">The Results of Well-conducted Negative Clinical Trials Should Be Reported in a Peer-reviewed Journal. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Rheumatology</span><span> <strong>2021,</strong> <em>48 </em>
                                    (7)
                                     , 957-959. <a href="https://doi.org/10.3899/jrheum.201622" title="DOI URL">https://doi.org/10.3899/jrheum.201622</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3899/jrheum.201622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3899%2Fjrheum.201622%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Rheumatology%26atitle%3DThe%252BResults%252Bof%252BWell-conducted%252BNegative%252BClinical%252BTrials%252BShould%252BBe%252BReported%252Bin%252Ba%252BPeer-reviewed%252BJournal%26aulast%3DFleischmann%26aufirst%3DRoy%26date%3D2021%26date%3D2021%26volume%3D48%26issue%3D7%26spage%3D957%26epage%3D959" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Robert A.  Copeland</span>. </span><span class="cited-content_cbyCitation_article-title">Evolution of the drug-target residence time model. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Drug Discovery</span><span> <strong>2021,</strong> <em>39 </em>, 1-11. <a href="https://doi.org/10.1080/17460441.2021.1948997" title="DOI URL">https://doi.org/10.1080/17460441.2021.1948997</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/17460441.2021.1948997&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F17460441.2021.1948997%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Drug%2520Discovery%26atitle%3DEvolution%252Bof%252Bthe%252Bdrug-target%252Bresidence%252Btime%252Bmodel%26aulast%3DCopeland%26aufirst%3DRobert%2BA.%26date%3D2021%26date%3D2021%26volume%3D39%26spage%3D1%26epage%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lauren E.  Kueffer</span>, <span class="hlFld-ContribAuthor ">Raji E.  Joseph</span>, <span class="hlFld-ContribAuthor ">Amy H.  Andreotti</span>. </span><span class="cited-content_cbyCitation_article-title">Reining in BTK: Interdomain Interactions and Their Importance in the Regulatory Control of BTK. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Cell and Developmental Biology</span><span> <strong>2021,</strong> <em>9 </em><a href="https://doi.org/10.3389/fcell.2021.655489" title="DOI URL">https://doi.org/10.3389/fcell.2021.655489</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fcell.2021.655489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffcell.2021.655489%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Cell%2520and%2520Developmental%2520Biology%26atitle%3DReining%252Bin%252BBTK%25253A%252BInterdomain%252BInteractions%252Band%252BTheir%252BImportance%252Bin%252Bthe%252BRegulatory%252BControl%252Bof%252BBTK%26aulast%3DKueffer%26aufirst%3DLauren%2BE.%26date%3D2021%26date%3D2021%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Inhye E.  Ahn</span>, <span class="hlFld-ContribAuthor ">Jennifer R.  Brown</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting Bruton’s Tyrosine Kinase in CLL. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Immunology</span><span> <strong>2021,</strong> <em>12 </em><a href="https://doi.org/10.3389/fimmu.2021.687458" title="DOI URL">https://doi.org/10.3389/fimmu.2021.687458</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fimmu.2021.687458&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffimmu.2021.687458%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Immunology%26atitle%3DTargeting%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%252Bin%252BCLL%26aulast%3DAhn%26aufirst%3DInhye%2BE.%26date%3D2021%26date%3D2021%26volume%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hui  Qiu</span>, <span class="hlFld-ContribAuthor ">Zahid  Ali</span>, <span class="hlFld-ContribAuthor ">Andrew  Bender</span>, <span class="hlFld-ContribAuthor ">Richard  Caldwell</span>, <span class="hlFld-ContribAuthor ">Yi-Ying  Chen</span>, <span class="hlFld-ContribAuthor ">Zhizhou  Fang</span>, <span class="hlFld-ContribAuthor ">Anna  Gardberg</span>, <span class="hlFld-ContribAuthor ">Nina  Glaser</span>, <span class="hlFld-ContribAuthor ">Anja  Goettsche</span>, <span class="hlFld-ContribAuthor ">Andreas  Goutopoulos</span>, <span class="hlFld-ContribAuthor ">Roland  Grenningloh</span>, <span class="hlFld-ContribAuthor ">Bettina  Hanschke</span>, <span class="hlFld-ContribAuthor ">Jared  Head</span>, <span class="hlFld-ContribAuthor ">Theresa  Johnson</span>, <span class="hlFld-ContribAuthor ">Christopher  Jones</span>, <span class="hlFld-ContribAuthor ">Reinaldo  Jones</span>, <span class="hlFld-ContribAuthor ">Shashank  Kulkarni</span>, <span class="hlFld-ContribAuthor ">Christine  Maurer</span>, <span class="hlFld-ContribAuthor ">Federica  Morandi</span>, <span class="hlFld-ContribAuthor ">Constantin  Neagu</span>, <span class="hlFld-ContribAuthor ">Sven  Poetzsch</span>, <span class="hlFld-ContribAuthor ">Justin  Potnick</span>, <span class="hlFld-ContribAuthor ">Ralf  Schmidt</span>, <span class="hlFld-ContribAuthor ">Katherine  Roe</span>, <span class="hlFld-ContribAuthor ">Ariele  Viacava Follis</span>, <span class="hlFld-ContribAuthor ">Carolyn  Wing</span>, <span class="hlFld-ContribAuthor ">Xiaohua  Zhu</span>, <span class="hlFld-ContribAuthor ">Brian  Sherer</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of potent and selective reversible Bruton’s tyrosine kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2021,</strong> <em>40 </em>, 116163. <a href="https://doi.org/10.1016/j.bmc.2021.116163" title="DOI URL">https://doi.org/10.1016/j.bmc.2021.116163</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2021.116163&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2021.116163%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bpotent%252Band%252Bselective%252Breversible%252BBruton%2525E2%252580%252599s%252Btyrosine%252Bkinase%252Binhibitors%26aulast%3DQiu%26aufirst%3DHui%26date%3D2021%26volume%3D40%26spage%3D116163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nitin  Sood</span>, <span class="hlFld-ContribAuthor ">Abraham  Varghese</span>, <span class="hlFld-ContribAuthor ">Joydeep  Chakrabarty</span>, <span class="hlFld-ContribAuthor ">Subhash  Chezhian</span>, <span class="hlFld-ContribAuthor ">Pranav  Sopory</span>. </span><span class="cited-content_cbyCitation_article-title">Acalabrutinib in management of chronic lymphocytic leukemia: An Indian perspective. </span><span class="cited-content_cbyCitation_journal-name">eJHaem</span><span> <strong>2021,</strong> <em>3 </em><a href="https://doi.org/10.1002/jha2.227" title="DOI URL">https://doi.org/10.1002/jha2.227</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jha2.227&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjha2.227%26sid%3Dliteratum%253Aachs%26jtitle%3DeJHaem%26atitle%3DAcalabrutinib%252Bin%252Bmanagement%252Bof%252Bchronic%252Blymphocytic%252Bleukemia%25253A%252BAn%252BIndian%252Bperspective%26aulast%3DSood%26aufirst%3DNitin%26date%3D2021%26date%3D2021%26volume%3D3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">H. Yesid  Estupiñán</span>, <span class="hlFld-ContribAuthor ">Qing  Wang</span>, <span class="hlFld-ContribAuthor ">Anna  Berglöf</span>, <span class="hlFld-ContribAuthor ">Gerard C. P.  Schaafsma</span>, <span class="hlFld-ContribAuthor ">Yuye  Shi</span>, <span class="hlFld-ContribAuthor ">Litao  Zhou</span>, <span class="hlFld-ContribAuthor ">Dara K.  Mohammad</span>, <span class="hlFld-ContribAuthor ">Liang  Yu</span>, <span class="hlFld-ContribAuthor ">Mauno  Vihinen</span>, <span class="hlFld-ContribAuthor ">Rula  Zain</span>, <span class="hlFld-ContribAuthor ">C. I. Edvard  Smith</span>. </span><span class="cited-content_cbyCitation_article-title">BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib. </span><span class="cited-content_cbyCitation_journal-name">Leukemia</span><span> <strong>2021,</strong> <em>35 </em>
                                    (5)
                                     , 1317-1329. <a href="https://doi.org/10.1038/s41375-021-01123-6" title="DOI URL">https://doi.org/10.1038/s41375-021-01123-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41375-021-01123-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41375-021-01123-6%26sid%3Dliteratum%253Aachs%26jtitle%3DLeukemia%26atitle%3DBTK%252Bgatekeeper%252Bresidue%252Bvariation%252Bcombined%252Bwith%252Bcysteine%252B481%252Bsubstitution%252Bcauses%252Bsuper-resistance%252Bto%252Birreversible%252Binhibitors%252Bacalabrutinib%25252C%252Bibrutinib%252Band%252Bzanubrutinib%26aulast%3DEstupin%25CC%2583%25C3%25A1n%26aufirst%3DH.%2BYesid%26date%3D2021%26date%3D2021%26volume%3D35%26issue%3D5%26spage%3D1317%26epage%3D1329" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Matthias R.  Bauer</span>, <span class="hlFld-ContribAuthor ">Paolo  Di Fruscia</span>, <span class="hlFld-ContribAuthor ">Simon C. C.  Lucas</span>, <span class="hlFld-ContribAuthor ">Iacovos N.  Michaelides</span>, <span class="hlFld-ContribAuthor ">Jennifer E.  Nelson</span>, <span class="hlFld-ContribAuthor ">R. Ian  Storer</span>, <span class="hlFld-ContribAuthor ">Benjamin C.  Whitehurst</span>. </span><span class="cited-content_cbyCitation_article-title">Put a ring on it: application of small aliphatic rings in medicinal chemistry. </span><span class="cited-content_cbyCitation_journal-name">RSC Medicinal Chemistry</span><span> <strong>2021,</strong> <em>12 </em>
                                    (4)
                                     , 448-471. <a href="https://doi.org/10.1039/D0MD00370K" title="DOI URL">https://doi.org/10.1039/D0MD00370K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0MD00370K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0MD00370K%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Medicinal%2520Chemistry%26atitle%3DPut%252Ba%252Bring%252Bon%252Bit%25253A%252Bapplication%252Bof%252Bsmall%252Baliphatic%252Brings%252Bin%252Bmedicinal%252Bchemistry%26aulast%3DBauer%26aufirst%3DMatthias%2BR.%26date%3D2021%26date%3D2021%26volume%3D12%26issue%3D4%26spage%3D448%26epage%3D471" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Melanie C.  Dispenza</span>. </span><span class="cited-content_cbyCitation_article-title">The Use of Bruton’s Tyrosine Kinase Inhibitors to Treat Allergic Disorders. </span><span class="cited-content_cbyCitation_journal-name">Current Treatment Options in Allergy</span><span> <strong>2021,</strong> <em>25 </em><a href="https://doi.org/10.1007/s40521-021-00286-y" title="DOI URL">https://doi.org/10.1007/s40521-021-00286-y</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s40521-021-00286-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs40521-021-00286-y%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Treatment%2520Options%2520in%2520Allergy%26atitle%3DThe%252BUse%252Bof%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%252BInhibitors%252Bto%252BTreat%252BAllergic%252BDisorders%26aulast%3DDispenza%26aufirst%3DMelanie%2BC.%26date%3D2021%26date%3D2021%26volume%3D25" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Martin  Kaul</span>, <span class="hlFld-ContribAuthor ">Peter  End</span>, <span class="hlFld-ContribAuthor ">Maciej  Cabanski</span>, <span class="hlFld-ContribAuthor ">Carole  Schuhler</span>, <span class="hlFld-ContribAuthor ">Annamaria  Jakab</span>, <span class="hlFld-ContribAuthor ">Magdalena  Kistowska</span>, <span class="hlFld-ContribAuthor ">Arvind  Kinhikar</span>, <span class="hlFld-ContribAuthor ">Alessio  Maiolica</span>, <span class="hlFld-ContribAuthor ">Angela  Sinn</span>, <span class="hlFld-ContribAuthor ">Rainard  Fuhr</span>, <span class="hlFld-ContribAuthor ">Bruno  Cenni</span>. </span><span class="cited-content_cbyCitation_article-title">Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial. </span><span class="cited-content_cbyCitation_journal-name">Clinical and Translational Science</span><span> <strong>2021,</strong> <em>151 </em><a href="https://doi.org/10.1111/cts.13005" title="DOI URL">https://doi.org/10.1111/cts.13005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cts.13005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcts.13005%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520and%2520Translational%2520Science%26atitle%3DRemibrutinib%252B%252528LOU064%252529%25253A%252BA%252Bselective%252Bpotent%252Boral%252BBTK%252Binhibitor%252Bwith%252Bpromising%252Bclinical%252Bsafety%252Band%252Bpharmacodynamics%252Bin%252Ba%252Brandomized%252Bphase%252BI%252Btrial%26aulast%3DKaul%26aufirst%3DMartin%26date%3D2021%26date%3D2021%26volume%3D151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yun  Zhang</span>, <span class="hlFld-ContribAuthor ">Andrew  Pike</span>. </span><span class="cited-content_cbyCitation_article-title">Pyridones in drug discovery: Recent advances. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>38 </em>, 127849. <a href="https://doi.org/10.1016/j.bmcl.2021.127849" title="DOI URL">https://doi.org/10.1016/j.bmcl.2021.127849</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2021.127849&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2021.127849%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DPyridones%252Bin%252Bdrug%252Bdiscovery%25253A%252BRecent%252Badvances%26aulast%3DZhang%26aufirst%3DYun%26date%3D2021%26volume%3D38%26spage%3D127849" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiamin  Zheng</span>, <span class="hlFld-ContribAuthor ">Jun  Wu</span>, <span class="hlFld-ContribAuthor ">Xiao  Ding</span>, <span class="hlFld-ContribAuthor ">Hong C.  Shen</span>, <span class="hlFld-ContribAuthor ">Ge  Zou</span>. </span><span class="cited-content_cbyCitation_article-title">Small molecule approaches to treat autoimmune and inflammatory diseases (Part I): Kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>38 </em>, 127862. <a href="https://doi.org/10.1016/j.bmcl.2021.127862" title="DOI URL">https://doi.org/10.1016/j.bmcl.2021.127862</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2021.127862&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2021.127862%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSmall%252Bmolecule%252Bapproaches%252Bto%252Btreat%252Bautoimmune%252Band%252Binflammatory%252Bdiseases%252B%252528Part%252BI%252529%25253A%252BKinase%252Binhibitors%26aulast%3DZheng%26aufirst%3DJiamin%26date%3D2021%26volume%3D38%26spage%3D127862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tobias  Litzenburger</span>, <span class="hlFld-ContribAuthor ">Jürgen  Steffgen</span>, <span class="hlFld-ContribAuthor ">Ewald  Benediktus</span>, <span class="hlFld-ContribAuthor ">Fabian  Müller</span>, <span class="hlFld-ContribAuthor ">Armin  Schultz</span>, <span class="hlFld-ContribAuthor ">Elliott  Klein</span>, <span class="hlFld-ContribAuthor ">Meera  Ramanujam</span>, <span class="hlFld-ContribAuthor ">Christian  Harcken</span>, <span class="hlFld-ContribAuthor ">Alpana  Gupta</span>, <span class="hlFld-ContribAuthor ">Jing  Wu</span>, <span class="hlFld-ContribAuthor ">Sabrina  Wiebe</span>, <span class="hlFld-ContribAuthor ">Xiujiang  Li</span>, <span class="hlFld-ContribAuthor ">Mary  Flack</span>, <span class="hlFld-ContribAuthor ">Steven J.  Padula</span>, <span class="hlFld-ContribAuthor ">Sudha  Visvanathan</span>, <span class="hlFld-ContribAuthor ">Andreas  Hünnemeyer</span>, <span class="hlFld-ContribAuthor ">Jianan  Hui</span>. </span><span class="cited-content_cbyCitation_article-title">Safety, pharmacokinetics and pharmacodynamics of BI 705564, a highly selective, covalent inhibitor of Bruton's tyrosine kinase, in Phase I clinical trials in healthy volunteers. </span><span class="cited-content_cbyCitation_journal-name">British Journal of Clinical Pharmacology</span><span> <strong>2021,</strong> <em>87 </em>
                                    (4)
                                     , 1824-1838. <a href="https://doi.org/10.1111/bcp.14571" title="DOI URL">https://doi.org/10.1111/bcp.14571</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/bcp.14571&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fbcp.14571%26sid%3Dliteratum%253Aachs%26jtitle%3DBritish%2520Journal%2520of%2520Clinical%2520Pharmacology%26atitle%3DSafety%25252C%252Bpharmacokinetics%252Band%252Bpharmacodynamics%252Bof%252BBI%252B705564%25252C%252Ba%252Bhighly%252Bselective%25252C%252Bcovalent%252Binhibitor%252Bof%252BBruton%252527s%252Btyrosine%252Bkinase%25252C%252Bin%252BPhase%252BI%252Bclinical%252Btrials%252Bin%252Bhealthy%252Bvolunteers%26aulast%3DLitzenburger%26aufirst%3DTobias%26date%3D2021%26date%3D2020%26volume%3D87%26issue%3D4%26spage%3D1824%26epage%3D1838" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">H. Yesid  Estupiñán</span>, <span class="hlFld-ContribAuthor ">Anna  Berglöf</span>, <span class="hlFld-ContribAuthor ">Rula  Zain</span>, <span class="hlFld-ContribAuthor ">C. I. Edvard  Smith</span>. </span><span class="cited-content_cbyCitation_article-title">Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Cell and Developmental Biology</span><span> <strong>2021,</strong> <em>9 </em><a href="https://doi.org/10.3389/fcell.2021.630942" title="DOI URL">https://doi.org/10.3389/fcell.2021.630942</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fcell.2021.630942&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffcell.2021.630942%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Cell%2520and%2520Developmental%2520Biology%26atitle%3DComparative%252BAnalysis%252Bof%252BBTK%252BInhibitors%252Band%252BMechanisms%252BUnderlying%252BAdverse%252BEffects%26aulast%3DEstupi%25C3%25B1%25C3%25A1n%26aufirst%3DH.%2BYesid%26date%3D2021%26date%3D2021%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Philipp  von Hundelshausen</span>, <span class="hlFld-ContribAuthor ">Wolfgang  Siess</span>. </span><span class="cited-content_cbyCitation_article-title">Bleeding by Bruton Tyrosine Kinase-Inhibitors: Dependency on Drug Type and Disease. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2021,</strong> <em>13 </em>
                                    (5)
                                     , 1103. <a href="https://doi.org/10.3390/cancers13051103" title="DOI URL">https://doi.org/10.3390/cancers13051103</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers13051103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers13051103%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DBleeding%252Bby%252BBruton%252BTyrosine%252BKinase-Inhibitors%25253A%252BDependency%252Bon%252BDrug%252BType%252Band%252BDisease%26aulast%3Dvon%2BHundelshausen%26aufirst%3DPhilipp%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D5%26spage%3D1103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Soňa  Krajčovičová</span>, <span class="hlFld-ContribAuthor ">Radek  Jorda</span>, <span class="hlFld-ContribAuthor ">David  Vanda</span>, <span class="hlFld-ContribAuthor ">Miroslav  Soural</span>, <span class="hlFld-ContribAuthor ">Vladimír  Kryštof</span>. </span><span class="cited-content_cbyCitation_article-title">1,4,6-Trisubstituted imidazo[4,5-c]pyridines as inhibitors of Bruton’s tyrosine kinase. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>211 </em>, 113094. <a href="https://doi.org/10.1016/j.ejmech.2020.113094" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.113094</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.113094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.113094%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3D1%25252C4%25252C6-Trisubstituted%252Bimidazo%25255B4%25252C5-c%25255Dpyridines%252Bas%252Binhibitors%252Bof%252BBruton%2525E2%252580%252599s%252Btyrosine%252Bkinase%26aulast%3DKraj%25C4%258Dovi%25C4%258Dov%25C3%25A1%26aufirst%3DSo%25C5%2588a%26date%3D2021%26volume%3D211%26spage%3D113094" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Leonard  Sung</span>. </span><span class="cited-content_cbyCitation_article-title">Covalent drugs in development for immune-mediated diseases. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 33-74. <a href="https://doi.org/10.1016/bs.armc.2021.03.001" title="DOI URL">https://doi.org/10.1016/bs.armc.2021.03.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.armc.2021.03.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.armc.2021.03.001%26sid%3Dliteratum%253Aachs%26atitle%3DCovalent%252Bdrugs%252Bin%252Bdevelopment%252Bfor%252Bimmune-mediated%252Bdiseases%26aulast%3DSung%26aufirst%3DLeonard%26date%3D2021%26spage%3D33%26epage%3D74%26pub%3DElsevier%26atitle%3DThe%252BDesign%252Bof%252BCovalent-Based%252BInhibitors%26date%3D2021%26volume%3D56" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Austin  Negron</span>, <span class="hlFld-ContribAuthor ">Olaf  Stüve</span>, <span class="hlFld-ContribAuthor ">Thomas G.  Forsthuber</span>. </span><span class="cited-content_cbyCitation_article-title">Ectopic Lymphoid Follicles in Multiple Sclerosis: Centers for Disease Control?. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Neurology</span><span> <strong>2020,</strong> <em>11 </em><a href="https://doi.org/10.3389/fneur.2020.607766" title="DOI URL">https://doi.org/10.3389/fneur.2020.607766</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fneur.2020.607766&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffneur.2020.607766%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Neurology%26atitle%3DEctopic%252BLymphoid%252BFollicles%252Bin%252BMultiple%252BSclerosis%25253A%252BCenters%252Bfor%252BDisease%252BControl%25253F%26aulast%3DNegron%26aufirst%3DAustin%26date%3D2020%26date%3D2020%26volume%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrew  Lipsky</span>, <span class="hlFld-ContribAuthor ">Nicole  Lamanna</span>. </span><span class="cited-content_cbyCitation_article-title">Managing toxicities of Bruton tyrosine kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Hematology</span><span> <strong>2020,</strong> <em>2020 </em>
                                    (1)
                                     , 336-345. <a href="https://doi.org/10.1182/hematology.2020000118" title="DOI URL">https://doi.org/10.1182/hematology.2020000118</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1182/hematology.2020000118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1182%2Fhematology.2020000118%26sid%3Dliteratum%253Aachs%26jtitle%3DHematology%26atitle%3DManaging%252Btoxicities%252Bof%252BBruton%252Btyrosine%252Bkinase%252Binhibitors%26aulast%3DLipsky%26aufirst%3DAndrew%26date%3D2020%26volume%3D2020%26issue%3D1%26spage%3D336%26epage%3D345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Matthew R.  Durk</span>, <span class="hlFld-ContribAuthor ">Nicholas S.  Jones</span>, <span class="hlFld-ContribAuthor ">Jia  Liu</span>, <span class="hlFld-ContribAuthor ">Karthik  Nagapudi</span>, <span class="hlFld-ContribAuthor ">Chen  Mao</span>, <span class="hlFld-ContribAuthor ">Emile G.  Plise</span>, <span class="hlFld-ContribAuthor ">Susan  Wong</span>, <span class="hlFld-ContribAuthor ">Jacob Z.  Chen</span>, <span class="hlFld-ContribAuthor ">Yuan  Chen</span>, <span class="hlFld-ContribAuthor ">Leslie W.  Chinn</span>, <span class="hlFld-ContribAuthor ">Po‐Chang  Chiang</span>. </span><span class="cited-content_cbyCitation_article-title">Understanding the Effect of Hydroxypropyl‐β‐Cyclodextrin on Fenebrutinib Absorption in an Itraconazole–Fenebrutinib Drug–Drug Interaction Study. </span><span class="cited-content_cbyCitation_journal-name">Clinical Pharmacology & Therapeutics</span><span> <strong>2020,</strong> <em>108 </em>
                                    (6)
                                     , 1224-1232. <a href="https://doi.org/10.1002/cpt.1943" title="DOI URL">https://doi.org/10.1002/cpt.1943</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cpt.1943&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcpt.1943%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Pharmacology%2520%2526%2520Therapeutics%26atitle%3DUnderstanding%252Bthe%252BEffect%252Bof%252BHydroxypropyl%2525E2%252580%252590%2525CE%2525B2%2525E2%252580%252590Cyclodextrin%252Bon%252BFenebrutinib%252BAbsorption%252Bin%252Ban%252BItraconazole%2525E2%252580%252593Fenebrutinib%252BDrug%2525E2%252580%252593Drug%252BInteraction%252BStudy%26aulast%3DDurk%26aufirst%3DMatthew%2BR.%26date%3D2020%26date%3D2020%26volume%3D108%26issue%3D6%26spage%3D1224%26epage%3D1232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Raji E  Joseph</span>, <span class="hlFld-ContribAuthor ">Neha  Amatya</span>, <span class="hlFld-ContribAuthor ">D Bruce  Fulton</span>, <span class="hlFld-ContribAuthor ">John R  Engen</span>, <span class="hlFld-ContribAuthor ">Thomas E  Wales</span>, <span class="hlFld-ContribAuthor ">Amy  Andreotti</span>. </span><span class="cited-content_cbyCitation_article-title">Differential impact of BTK active site inhibitors on the conformational state of full-length BTK. </span><span class="cited-content_cbyCitation_journal-name">eLife</span><span> <strong>2020,</strong> <em>9 </em><a href="https://doi.org/10.7554/eLife.60470" title="DOI URL">https://doi.org/10.7554/eLife.60470</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.7554/eLife.60470&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.7554%2FeLife.60470%26sid%3Dliteratum%253Aachs%26jtitle%3DeLife%26atitle%3DDifferential%252Bimpact%252Bof%252BBTK%252Bactive%252Bsite%252Binhibitors%252Bon%252Bthe%252Bconformational%252Bstate%252Bof%252Bfull-length%252BBTK%26aulast%3DJoseph%26aufirst%3DRaji%2BE%26date%3D2020%26date%3D2020%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wolfgang  Siess</span>, <span class="hlFld-ContribAuthor ">Philipp Von  Hundelshausen</span>, <span class="hlFld-ContribAuthor ">Reinhard  Lorenz</span>. </span><span class="cited-content_cbyCitation_article-title">Selective inhibition of thromboinflammation in COVID-19 by Btk inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Platelets</span><span> <strong>2020,</strong> <em>31 </em>
                                    (8)
                                     , 989-992. <a href="https://doi.org/10.1080/09537104.2020.1809647" title="DOI URL">https://doi.org/10.1080/09537104.2020.1809647</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/09537104.2020.1809647&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F09537104.2020.1809647%26sid%3Dliteratum%253Aachs%26jtitle%3DPlatelets%26atitle%3DSelective%252Binhibition%252Bof%252Bthromboinflammation%252Bin%252BCOVID-19%252Bby%252BBtk%252Binhibitors%26aulast%3DSiess%26aufirst%3DWolfgang%26date%3D2020%26date%3D2020%26volume%3D31%26issue%3D8%26spage%3D989%26epage%3D992" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kanwaljit K.  Brar</span>, <span class="hlFld-ContribAuthor ">Bruce J.  Lanser</span>, <span class="hlFld-ContribAuthor ">Amanda  Schneider</span>, <span class="hlFld-ContribAuthor ">Anna  Nowak-Wegrzyn</span>. </span><span class="cited-content_cbyCitation_article-title">Biologics for the Treatment of Food Allergies. </span><span class="cited-content_cbyCitation_journal-name">Immunology and Allergy Clinics of North America</span><span> <strong>2020,</strong> <em>40 </em>
                                    (4)
                                     , 575-591. <a href="https://doi.org/10.1016/j.iac.2020.06.002" title="DOI URL">https://doi.org/10.1016/j.iac.2020.06.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.iac.2020.06.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.iac.2020.06.002%26sid%3Dliteratum%253Aachs%26jtitle%3DImmunology%2520and%2520Allergy%2520Clinics%2520of%2520North%2520America%26atitle%3DBiologics%252Bfor%252Bthe%252BTreatment%252Bof%252BFood%252BAllergies%26aulast%3DBrar%26aufirst%3DKanwaljit%2BK.%26date%3D2020%26volume%3D40%26issue%3D4%26spage%3D575%26epage%3D591" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kirti J.  Johal</span>, <span class="hlFld-ContribAuthor ">Sarbjit S.  Saini</span>. </span><span class="cited-content_cbyCitation_article-title">Current and emerging treatments for chronic spontaneous urticaria. </span><span class="cited-content_cbyCitation_journal-name">Annals of Allergy, Asthma & Immunology</span><span> <strong>2020,</strong> <em>125 </em>
                                    (4)
                                     , 380-387. <a href="https://doi.org/10.1016/j.anai.2019.08.465" title="DOI URL">https://doi.org/10.1016/j.anai.2019.08.465</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.anai.2019.08.465&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.anai.2019.08.465%26sid%3Dliteratum%253Aachs%26jtitle%3DAnnals%2520of%2520Allergy%252C%2520Asthma%2520%2526%2520Immunology%26atitle%3DCurrent%252Band%252Bemerging%252Btreatments%252Bfor%252Bchronic%252Bspontaneous%252Burticaria%26aulast%3DJohal%26aufirst%3DKirti%2BJ.%26date%3D2020%26volume%3D125%26issue%3D4%26spage%3D380%26epage%3D387" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ngiap-Kie  Lim</span>, <span class="hlFld-ContribAuthor ">Haiming  Zhang</span>, <span class="hlFld-ContribAuthor ">C. Gregory  Sowell</span>, <span class="hlFld-ContribAuthor ">Francis  Gosselin</span>. </span><span class="cited-content_cbyCitation_article-title">A fit for purpose synthesis of Bruton’s tyrosine kinase inhibitor GDC-0852. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron Letters</span><span> <strong>2020,</strong> <em>61 </em>
                                    (44)
                                     , 152447. <a href="https://doi.org/10.1016/j.tetlet.2020.152447" title="DOI URL">https://doi.org/10.1016/j.tetlet.2020.152447</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tetlet.2020.152447&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tetlet.2020.152447%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%2520Letters%26atitle%3DA%252Bfit%252Bfor%252Bpurpose%252Bsynthesis%252Bof%252BBruton%2525E2%252580%252599s%252Btyrosine%252Bkinase%252Binhibitor%252BGDC-0852%26aulast%3DLim%26aufirst%3DNgiap-Kie%26date%3D2020%26volume%3D61%26issue%3D44%26spage%3D152447" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stanley  Cohen</span>, <span class="hlFld-ContribAuthor ">Katie  Tuckwell</span>, <span class="hlFld-ContribAuthor ">Tamiko R.  Katsumoto</span>, <span class="hlFld-ContribAuthor ">Rui  Zhao</span>, <span class="hlFld-ContribAuthor ">Joshua  Galanter</span>, <span class="hlFld-ContribAuthor ">Chin  Lee</span>, <span class="hlFld-ContribAuthor ">Julie  Rae</span>, <span class="hlFld-ContribAuthor ">Balazs  Toth</span>, <span class="hlFld-ContribAuthor ">Nandhini  Ramamoorthi</span>, <span class="hlFld-ContribAuthor ">Jason A.  Hackney</span>, <span class="hlFld-ContribAuthor ">Alberto  Berman</span>, <span class="hlFld-ContribAuthor ">Nemanja  Damjanov</span>, <span class="hlFld-ContribAuthor ">Dmytro  Fedkov</span>, <span class="hlFld-ContribAuthor ">Slawomir  Jeka</span>, <span class="hlFld-ContribAuthor ">Leslie W.  Chinn</span>, <span class="hlFld-ContribAuthor ">Michael J.  Townsend</span>, <span class="hlFld-ContribAuthor ">Alyssa M.  Morimoto</span>, <span class="hlFld-ContribAuthor ">Mark C.  Genovese</span>, <span class="hlFld-ContribAuthor ">Alberto  Berman</span>, <span class="hlFld-ContribAuthor ">Alejandro  Porto</span>, <span class="hlFld-ContribAuthor ">Amelia  Granel</span>, <span class="hlFld-ContribAuthor ">Cecilia  Asnal</span>, <span class="hlFld-ContribAuthor ">Eduardo Fabian  Mysler</span>, <span class="hlFld-ContribAuthor ">Gladys Alicia  Testa</span>, <span class="hlFld-ContribAuthor ">Jose Luis Velasco  Zamora</span>, <span class="hlFld-ContribAuthor ">Jose Luis Cristian  Moreno</span>, <span class="hlFld-ContribAuthor ">Juan Pablo  Gulin</span>, <span class="hlFld-ContribAuthor ">Julio  Hofman</span>, <span class="hlFld-ContribAuthor ">Maria Rosa  Ulla</span>, <span class="hlFld-ContribAuthor ">Mirtha  Sabelli</span>, <span class="hlFld-ContribAuthor ">Pablo Alejandro  Mannucci</span>, <span class="hlFld-ContribAuthor ">Pablo Jorge  Maid</span>, <span class="hlFld-ContribAuthor ">Ana Cláudia Cauceglia  Melazzi</span>, <span class="hlFld-ContribAuthor ">Antônio Scafuto  Scotton</span>, <span class="hlFld-ContribAuthor ">Antônio Carlos  Ximenes</span>, <span class="hlFld-ContribAuthor ">Elisete  Funes</span>, <span class="hlFld-ContribAuthor ">Emerson Alves  Gimenez</span>, <span class="hlFld-ContribAuthor ">Flora Maria D’Andrea  Marcolino</span>, <span class="hlFld-ContribAuthor ">João Francisco Marques  Neto</span>, <span class="hlFld-ContribAuthor ">Mauro Waldemar  Keiserman</span>, <span class="hlFld-ContribAuthor ">Sebastião Cézar  Radominski</span>, <span class="hlFld-ContribAuthor ">Sônia Maria Alvarenga Anti Loduca  Lima</span>, <span class="hlFld-ContribAuthor ">Thaís Rohde  Pavan</span>, <span class="hlFld-ContribAuthor ">Valderílio Feijó  Azevedo</span>, <span class="hlFld-ContribAuthor ">Aneliya  Koleva</span>, <span class="hlFld-ContribAuthor ">Antoaneta  Toncheva</span>, <span class="hlFld-ContribAuthor ">Daniela  Bichovska</span>, <span class="hlFld-ContribAuthor ">Delina  Ivanova</span>, <span class="hlFld-ContribAuthor ">Dimitar  Penev</span>, <span class="hlFld-ContribAuthor ">Emil  Dimitrov</span>, <span class="hlFld-ContribAuthor ">Mariyana  Mihaylova</span>, <span class="hlFld-ContribAuthor ">Nadezhda  Kapandjieva</span>, <span class="hlFld-ContribAuthor ">Natalia  Marinova</span>, <span class="hlFld-ContribAuthor ">Tanya  Aleksieva</span>, <span class="hlFld-ContribAuthor ">Tanya  Tsvetanova</span>, <span class="hlFld-ContribAuthor ">Tsvetanka  Petranova</span>, <span class="hlFld-ContribAuthor ">Valentina  Popova</span>, <span class="hlFld-ContribAuthor ">Yuliy  Spasov</span>, <span class="hlFld-ContribAuthor ">Carlos Enrique  Toro</span>, <span class="hlFld-ContribAuthor ">Carlos Ernesto  Arteaga Unigarro</span>, <span class="hlFld-ContribAuthor ">Edwin  Jauregui</span>, <span class="hlFld-ContribAuthor ">Javier Dario Marquez  Hernandez</span>, <span class="hlFld-ContribAuthor ">Juan Jose Jaller  Raad</span>, <span class="hlFld-ContribAuthor ">Patricia Julieta Velez  Sanchez</span>, <span class="hlFld-ContribAuthor ">Chang Keun  Lee</span>, <span class="hlFld-ContribAuthor ">Chang‐Hee  Suh</span>, <span class="hlFld-ContribAuthor ">Eun Young  Lee</span>, <span class="hlFld-ContribAuthor ">Sang‐Heon  Lee</span>, <span class="hlFld-ContribAuthor ">Seong Wook  Kang</span>, <span class="hlFld-ContribAuthor ">Shin‐Seok  Lee</span>, <span class="hlFld-ContribAuthor ">Yun Jong  Lee</span>, <span class="hlFld-ContribAuthor ">Beatriz Elena Zazueta  Montiel</span>, <span class="hlFld-ContribAuthor ">Blanca Irma  Pinzon de la O</span>, <span class="hlFld-ContribAuthor ">Daniel Xibille  Friedmann</span>, <span class="hlFld-ContribAuthor ">Francisco Rosas  Lopez</span>, <span class="hlFld-ContribAuthor ">Isaura Rodriguez  Torres</span>, <span class="hlFld-ContribAuthor ">Luis Jara  Quezada</span>, <span class="hlFld-ContribAuthor ">Marco Maradiaga  Ceceña</span>, <span class="hlFld-ContribAuthor ">Miguel Cortes  Hernandez</span>, <span class="hlFld-ContribAuthor ">Miguel Saavedra  Salinas</span>, <span class="hlFld-ContribAuthor ">Agnieszka  Rapa</span>, <span class="hlFld-ContribAuthor ">Agnieszka  Pawtel</span>, <span class="hlFld-ContribAuthor ">Agnieszka  Zielinska</span>, <span class="hlFld-ContribAuthor ">Anna  Dudek</span>, <span class="hlFld-ContribAuthor ">Anna  Rychlewska‐Hanczewska</span>, <span class="hlFld-ContribAuthor ">Anna  Strzelecka</span>, <span class="hlFld-ContribAuthor ">Artur  Racewicz</span>, <span class="hlFld-ContribAuthor ">Barbara  Stasiuk</span>, <span class="hlFld-ContribAuthor ">Katarzyna  Gruszecka</span>, <span class="hlFld-ContribAuthor ">Krystyna  Dworak</span>, <span class="hlFld-ContribAuthor ">Slawomir  Jeka</span>, <span class="hlFld-ContribAuthor ">Tomasz  Lowenhoff</span>, <span class="hlFld-ContribAuthor ">Alexey  Maslyanskiy</span>, <span class="hlFld-ContribAuthor ">Andrey  Rebrov</span>, <span class="hlFld-ContribAuthor ">Diana  Krechikova</span>, <span class="hlFld-ContribAuthor ">Elena  Zhugrova</span>, <span class="hlFld-ContribAuthor ">Evgeniya  Shmidt</span>, <span class="hlFld-ContribAuthor ">Galina  Matsievskaya</span>, <span class="hlFld-ContribAuthor ">Irina  Vinogradova</span>, <span class="hlFld-ContribAuthor ">Irina  Ler</span>, <span class="hlFld-ContribAuthor ">Larisa  Eliseeva</span>, <span class="hlFld-ContribAuthor ">Ludmila  Savina</span>, <span class="hlFld-ContribAuthor ">Marina  Stanislav</span>, <span class="hlFld-ContribAuthor ">Mikhail  Sandin</span>, <span class="hlFld-ContribAuthor ">Natalia  Zyablova</span>, <span class="hlFld-ContribAuthor ">Nikolay  Korshunov</span>, <span class="hlFld-ContribAuthor ">Nino  Mosesova</span>, <span class="hlFld-ContribAuthor ">Oksana  Polovnikova</span>, <span class="hlFld-ContribAuthor ">Olga  Nesmeyanova</span>, <span class="hlFld-ContribAuthor ">Ruzana  Samigullina</span>, <span class="hlFld-ContribAuthor ">Sergey  Moiseev</span>, <span class="hlFld-ContribAuthor ">Sergey  Noskov</span>, <span class="hlFld-ContribAuthor ">Tatiana  Raskina</span>, <span class="hlFld-ContribAuthor ">Tatiana  Popova</span>, <span class="hlFld-ContribAuthor ">Valeriy  Marchenko</span>, <span class="hlFld-ContribAuthor ">Aleksandar  Jovanovski</span>, <span class="hlFld-ContribAuthor ">Bojana  Stamenkovic</span>, <span class="hlFld-ContribAuthor ">Gorica  Ristic</span>, <span class="hlFld-ContribAuthor ">Milijanka  Lazarevic</span>, <span class="hlFld-ContribAuthor ">Mirjana  Veselinovic</span>, <span class="hlFld-ContribAuthor ">Nada  Vujasinovic‐Stupar</span>, <span class="hlFld-ContribAuthor ">Nemanja  Damjanov</span>, <span class="hlFld-ContribAuthor ">Predrag  Ostojic</span>, <span class="hlFld-ContribAuthor ">Andriy  Yagensky</span>, <span class="hlFld-ContribAuthor ">Andriy  Gnylorybov</span>, <span class="hlFld-ContribAuthor ">Dmytro  Rekalov</span>, <span class="hlFld-ContribAuthor ">Dmytroo  Reshotko</span>, <span class="hlFld-ContribAuthor ">Dmytro  Fedkov</span>, <span class="hlFld-ContribAuthor ">Georgiy  Dzyak</span>, <span class="hlFld-ContribAuthor ">Iurii  Gasanov</span>, <span class="hlFld-ContribAuthor ">Ludmila  Khimion</span>, <span class="hlFld-ContribAuthor ">Mykola  Stanislavchuk</span>, <span class="hlFld-ContribAuthor ">Natalya  Prykhodko</span>, <span class="hlFld-ContribAuthor ">Oleg  Nadashkevych</span>, <span class="hlFld-ContribAuthor ">Oleg  Bortkevych</span>, <span class="hlFld-ContribAuthor ">Orest  Abrahamovych</span>, <span class="hlFld-ContribAuthor ">Roman  Yatsyshyn</span>, <span class="hlFld-ContribAuthor ">Samvel  Turyanytsya</span>, <span class="hlFld-ContribAuthor ">Svitlana  Smiyan</span>, <span class="hlFld-ContribAuthor ">Vadym  Vizir</span>, <span class="hlFld-ContribAuthor ">Victoria  Kachur</span>, <span class="hlFld-ContribAuthor ">Vira  Tseluyko</span>, <span class="hlFld-ContribAuthor ">Vladyslav  Povoroznyuk</span>, <span class="hlFld-ContribAuthor ">Volodymyr  Koshlia</span>, <span class="hlFld-ContribAuthor ">Vyacheslav  Zhdan</span>, <span class="hlFld-ContribAuthor ">Yurii  Lymar</span>, <span class="hlFld-ContribAuthor ">Yuriy  Mostovoy</span>, <span class="hlFld-ContribAuthor ">Angela  Hawkes</span>, <span class="hlFld-ContribAuthor ">Arthur  Mabaquiao</span>, <span class="hlFld-ContribAuthor ">Cong‐Qiu  Chu</span>, <span class="hlFld-ContribAuthor ">Craig  Scoville</span>, <span class="hlFld-ContribAuthor ">David  Wyatt</span>, <span class="hlFld-ContribAuthor ">Debra  Weinstein</span>, <span class="hlFld-ContribAuthor ">Harris  McIlwain</span>, <span class="hlFld-ContribAuthor ">Jacqueline  Vo</span>, <span class="hlFld-ContribAuthor ">Jeffrey  Poiley</span>, <span class="hlFld-ContribAuthor ">Joseph  Forstot</span>, <span class="hlFld-ContribAuthor ">Kathryn  Dao</span>, <span class="hlFld-ContribAuthor ">Mark  Turner</span>, <span class="hlFld-ContribAuthor ">Mark  Genovese</span>, <span class="hlFld-ContribAuthor ">Michael  Borofsky</span>, <span class="hlFld-ContribAuthor ">Paul  Caldron</span>, <span class="hlFld-ContribAuthor ">Philip  Waller</span>, <span class="hlFld-ContribAuthor ">Robert  Levin</span>, <span class="hlFld-ContribAuthor ">Samy  Metyas</span>, <span class="hlFld-ContribAuthor ">Scott  Stein</span>, <span class="hlFld-ContribAuthor ">Sharukh  Shroff</span>, <span class="hlFld-ContribAuthor ">Shirley  Pang</span>, <span class="hlFld-ContribAuthor ">Stanley  Cohen</span>, <span class="hlFld-ContribAuthor ">Tauseef  Syed</span>, <span class="hlFld-ContribAuthor ">Vishala  Chindalore</span>. </span><span class="cited-content_cbyCitation_article-title">Fenebrutinib Versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Double‐Blind, Phase
              II
              Trial. </span><span class="cited-content_cbyCitation_journal-name">Arthritis & Rheumatology</span><span> <strong>2020,</strong> <em>72 </em>
                                    (9)
                                     , 1435-1446. <a href="https://doi.org/10.1002/art.41275" title="DOI URL">https://doi.org/10.1002/art.41275</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/art.41275&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fart.41275%26sid%3Dliteratum%253Aachs%26jtitle%3DArthritis%2520%2526%2520Rheumatology%26atitle%3DFenebrutinib%252BVersus%252BPlacebo%252Bor%252BAdalimumab%252Bin%252BRheumatoid%252BArthritis%25253A%252BA%252BRandomized%25252C%252BDouble%2525E2%252580%252590Blind%25252C%252BPhase%252BII%252BTrial%26aulast%3DCohen%26aufirst%3DStanley%26date%3D2020%26date%3D2020%26volume%3D72%26issue%3D9%26spage%3D1435%26epage%3D1446" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Neelam  Pery</span>, <span class="hlFld-ContribAuthor ">Nayab Batool  Rizvi</span>, <span class="hlFld-ContribAuthor ">Muhammad Imtiaz  Shafiq</span>. </span><span class="cited-content_cbyCitation_article-title">Development of piperidinyl dipyrrrolopyridine-based dual inhibitors of Janus kinase and Bruton’s tyrosine kinase: a potential therapeutic probability to deal with rheumatoid arthritis. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Modeling</span><span> <strong>2020,</strong> <em>26 </em>
                                    (9)
                                     <a href="https://doi.org/10.1007/s00894-020-04512-3" title="DOI URL">https://doi.org/10.1007/s00894-020-04512-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00894-020-04512-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00894-020-04512-3%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Modeling%26atitle%3DDevelopment%252Bof%252Bpiperidinyl%252Bdipyrrrolopyridine-based%252Bdual%252Binhibitors%252Bof%252BJanus%252Bkinase%252Band%252BBruton%2525E2%252580%252599s%252Btyrosine%252Bkinase%25253A%252Ba%252Bpotential%252Btherapeutic%252Bprobability%252Bto%252Bdeal%252Bwith%252Brheumatoid%252Barthritis%26aulast%3DPery%26aufirst%3DNeelam%26date%3D2020%26date%3D2020%26volume%3D26%26issue%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jian  Liu</span>, <span class="hlFld-ContribAuthor ">Deodial  Guiadeen</span>, <span class="hlFld-ContribAuthor ">Arto  Krikorian</span>, <span class="hlFld-ContribAuthor ">Xiaolei  Gao</span>, <span class="hlFld-ContribAuthor ">James  Wang</span>, <span class="hlFld-ContribAuthor ">Sobhana  Babu Boga</span>, <span class="hlFld-ContribAuthor ">Abdul-Basit  Alhassan</span>, <span class="hlFld-ContribAuthor ">Wensheng  Yu</span>, <span class="hlFld-ContribAuthor ">Oleg  Selyutin</span>, <span class="hlFld-ContribAuthor ">Younong  Yu</span>, <span class="hlFld-ContribAuthor ">Rajan  Anand</span>, <span class="hlFld-ContribAuthor ">Jiayi  Xu</span>, <span class="hlFld-ContribAuthor ">Joseph  Kelly</span>, <span class="hlFld-ContribAuthor ">Joseph L.  Duffy</span>, <span class="hlFld-ContribAuthor ">Shilan  Liu</span>, <span class="hlFld-ContribAuthor ">Chundao  Yang</span>, <span class="hlFld-ContribAuthor ">Hao  Wu</span>, <span class="hlFld-ContribAuthor ">Jiaqiang  Cai</span>, <span class="hlFld-ContribAuthor ">Chad  Bennett</span>, <span class="hlFld-ContribAuthor ">Kevin M.  Maloney</span>, <span class="hlFld-ContribAuthor ">Sriram  Tyagarajan</span>, <span class="hlFld-ContribAuthor ">Ying-Duo  Gao</span>, <span class="hlFld-ContribAuthor ">Thierry O.  Fischmann</span>, <span class="hlFld-ContribAuthor ">Jeremy  Presland</span>, <span class="hlFld-ContribAuthor ">My  Mansueto</span>, <span class="hlFld-ContribAuthor ">Zangwei  Xu</span>, <span class="hlFld-ContribAuthor ">Erica  Leccese</span>, <span class="hlFld-ContribAuthor ">Jie  Zhang-Hoover</span>, <span class="hlFld-ContribAuthor ">Ian  Knemeyer</span>, <span class="hlFld-ContribAuthor ">Charles G.  Garlisi</span>, <span class="hlFld-ContribAuthor ">Peter  Stivers</span>, <span class="hlFld-ContribAuthor ">Philip E.  Brandish</span>, <span class="hlFld-ContribAuthor ">Alexandra  Hicks</span>, <span class="hlFld-ContribAuthor ">Ronald  Kim</span>, <span class="hlFld-ContribAuthor ">Joseph A.  Kozlowski</span>. </span><span class="cited-content_cbyCitation_article-title">Potent, non-covalent reversible BTK inhibitors with 8-amino-imidazo[1,5-a]pyrazine core featuring 3-position bicyclic ring substitutes. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>30 </em>
                                    (17)
                                     , 127390. <a href="https://doi.org/10.1016/j.bmcl.2020.127390" title="DOI URL">https://doi.org/10.1016/j.bmcl.2020.127390</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2020.127390&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2020.127390%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DPotent%25252C%252Bnon-covalent%252Breversible%252BBTK%252Binhibitors%252Bwith%252B8-amino-imidazo%25255B1%25252C5-a%25255Dpyrazine%252Bcore%252Bfeaturing%252B3-position%252Bbicyclic%252Bring%252Bsubstitutes%26aulast%3DLiu%26aufirst%3DJian%26date%3D2020%26volume%3D30%26issue%3D17%26spage%3D127390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Elizabeth C.  Goodale</span>, <span class="hlFld-ContribAuthor ">Katarina E.  Varjonen</span>, <span class="hlFld-ContribAuthor ">Catherine A.  Outerbridge</span>, <span class="hlFld-ContribAuthor ">Petra  Bizikova</span>, <span class="hlFld-ContribAuthor ">Dori  Borjesson</span>, <span class="hlFld-ContribAuthor ">Dedee F.  Murrell</span>, <span class="hlFld-ContribAuthor ">Angelina  Bisconte</span>, <span class="hlFld-ContribAuthor ">Michelle  Francesco</span>, <span class="hlFld-ContribAuthor ">Ronald J.  Hill</span>, <span class="hlFld-ContribAuthor ">Mohammad  Masjedizadeh</span>, <span class="hlFld-ContribAuthor ">Philip  Nunn</span>, <span class="hlFld-ContribAuthor ">Steven G.  Gourlay</span>, <span class="hlFld-ContribAuthor ">Stephen D.  White</span>. </span><span class="cited-content_cbyCitation_article-title">Efficacy of a Bruton's Tyrosine Kinase Inhibitor (PRN‐473) in the treatment of canine pemphigus foliaceus. </span><span class="cited-content_cbyCitation_journal-name">Veterinary Dermatology</span><span> <strong>2020,</strong> <em>31 </em>
                                    (4)
                                     , 291. <a href="https://doi.org/10.1111/vde.12841" title="DOI URL">https://doi.org/10.1111/vde.12841</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/vde.12841&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fvde.12841%26sid%3Dliteratum%253Aachs%26jtitle%3DVeterinary%2520Dermatology%26atitle%3DEfficacy%252Bof%252Ba%252BBruton%252527s%252BTyrosine%252BKinase%252BInhibitor%252B%252528PRN%2525E2%252580%252590473%252529%252Bin%252Bthe%252Btreatment%252Bof%252Bcanine%252Bpemphigus%252Bfoliaceus%26aulast%3DGoodale%26aufirst%3DElizabeth%2BC.%26date%3D2020%26date%3D2020%26volume%3D31%26issue%3D4%26spage%3D291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Elżbieta  Iskierka-Jażdżewska</span>, <span class="hlFld-ContribAuthor ">Tadeusz  Robak</span>. </span><span class="cited-content_cbyCitation_article-title">Investigational treatments for chronic lymphocytic leukemia: a focus on phase 1 and 2 clinical trials. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Investigational Drugs</span><span> <strong>2020,</strong> <em>29 </em>
                                    (7)
                                     , 709-722. <a href="https://doi.org/10.1080/13543784.2020.1770225" title="DOI URL">https://doi.org/10.1080/13543784.2020.1770225</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543784.2020.1770225&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543784.2020.1770225%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Investigational%2520Drugs%26atitle%3DInvestigational%252Btreatments%252Bfor%252Bchronic%252Blymphocytic%252Bleukemia%25253A%252Ba%252Bfocus%252Bon%252Bphase%252B1%252Band%252B2%252Bclinical%252Btrials%26aulast%3DIskierka-Ja%25C5%25BCd%25C5%25BCewska%26aufirst%3DEl%25C5%25BCbieta%26date%3D2020%26date%3D2020%26volume%3D29%26issue%3D7%26spage%3D709%26epage%3D722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lenka  Sedlarikova</span>, <span class="hlFld-ContribAuthor ">Anna  Petrackova</span>, <span class="hlFld-ContribAuthor ">Tomas  Papajik</span>, <span class="hlFld-ContribAuthor ">Peter  Turcsanyi</span>, <span class="hlFld-ContribAuthor ">Eva  Kriegova</span>. </span><span class="cited-content_cbyCitation_article-title">Resistance-Associated Mutations in Chronic Lymphocytic Leukemia Patients Treated With Novel Agents. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Oncology</span><span> <strong>2020,</strong> <em>10 </em><a href="https://doi.org/10.3389/fonc.2020.00894" title="DOI URL">https://doi.org/10.3389/fonc.2020.00894</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fonc.2020.00894&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffonc.2020.00894%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Oncology%26atitle%3DResistance-Associated%252BMutations%252Bin%252BChronic%252BLymphocytic%252BLeukemia%252BPatients%252BTreated%252BWith%252BNovel%252BAgents%26aulast%3DSedlarikova%26aufirst%3DLenka%26date%3D2020%26date%3D2020%26volume%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cesar A.  Corzo</span>, <span class="hlFld-ContribAuthor ">Eugene  Varfolomeev</span>, <span class="hlFld-ContribAuthor ">A. Francesca  Setiadi</span>, <span class="hlFld-ContribAuthor ">Ross  Francis</span>, <span class="hlFld-ContribAuthor ">Sha  Klabunde</span>, <span class="hlFld-ContribAuthor ">Kate  Senger</span>, <span class="hlFld-ContribAuthor ">Swathi  Sujatha-Bhaskar</span>, <span class="hlFld-ContribAuthor ">Joy  Drobnick</span>, <span class="hlFld-ContribAuthor ">Steven  Do</span>, <span class="hlFld-ContribAuthor ">Eric  Suto</span>, <span class="hlFld-ContribAuthor ">Zhiyu  Huang</span>, <span class="hlFld-ContribAuthor ">Jeffrey  Eastham-Anderson</span>, <span class="hlFld-ContribAuthor ">Arna  Katewa</span>, <span class="hlFld-ContribAuthor ">Jodie  Pang</span>, <span class="hlFld-ContribAuthor ">Melanie  Domeyer</span>, <span class="hlFld-ContribAuthor ">Christopher  Dela Cruz</span>, <span class="hlFld-ContribAuthor ">Andres  Paler-Martinez</span>, <span class="hlFld-ContribAuthor ">Vivian W. C.  Lau</span>, <span class="hlFld-ContribAuthor ">Azadeh  Hadadianpour</span>, <span class="hlFld-ContribAuthor ">Vladimir  Ramirez-Carrozi</span>, <span class="hlFld-ContribAuthor ">Yonglian  Sun</span>, <span class="hlFld-ContribAuthor ">Katherine  Bao</span>, <span class="hlFld-ContribAuthor ">Daqi  Xu</span>, <span class="hlFld-ContribAuthor ">Emily  Hunley</span>, <span class="hlFld-ContribAuthor ">Hans D.  Brightbill</span>, <span class="hlFld-ContribAuthor ">Soren  Warming</span>, <span class="hlFld-ContribAuthor ">Merone  Roose-Girma</span>, <span class="hlFld-ContribAuthor ">Alfred  Wong</span>, <span class="hlFld-ContribAuthor ">Lucinda  Tam</span>, <span class="hlFld-ContribAuthor ">Claire L.  Emson</span>, <span class="hlFld-ContribAuthor ">James J.  Crawford</span>, <span class="hlFld-ContribAuthor ">Wendy B.  Young</span>, <span class="hlFld-ContribAuthor ">Rajita  Pappu</span>, <span class="hlFld-ContribAuthor ">Brent S.  McKenzie</span>, <span class="hlFld-ContribAuthor ">Vida  Asghari</span>, <span class="hlFld-ContribAuthor ">Domagoj  Vucic</span>, <span class="hlFld-ContribAuthor ">Jason A.  Hackney</span>, <span class="hlFld-ContribAuthor ">Cary D.  Austin</span>, <span class="hlFld-ContribAuthor ">Wyne P.  Lee</span>, <span class="hlFld-ContribAuthor ">Annemarie  Lekkerkerker</span>, <span class="hlFld-ContribAuthor ">Nico  Ghilardi</span>, <span class="hlFld-ContribAuthor ">Marian C.  Bryan</span>, <span class="hlFld-ContribAuthor ">James R.  Kiefer</span>, <span class="hlFld-ContribAuthor ">Michael J.  Townsend</span>, <span class="hlFld-ContribAuthor ">Ali A.  Zarrin</span>. </span><span class="cited-content_cbyCitation_article-title">The kinase IRAK4 promotes endosomal TLR and immune complex signaling in B cells and plasmacytoid dendritic cells. </span><span class="cited-content_cbyCitation_journal-name">Science Signaling</span><span> <strong>2020,</strong> <em>13 </em>
                                    (634)
                                     , eaaz1053. <a href="https://doi.org/10.1126/scisignal.aaz1053" title="DOI URL">https://doi.org/10.1126/scisignal.aaz1053</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1126/scisignal.aaz1053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1126%2Fscisignal.aaz1053%26sid%3Dliteratum%253Aachs%26jtitle%3DScience%2520Signaling%26atitle%3DThe%252Bkinase%252BIRAK4%252Bpromotes%252Bendosomal%252BTLR%252Band%252Bimmune%252Bcomplex%252Bsignaling%252Bin%252BB%252Bcells%252Band%252Bplasmacytoid%252Bdendritic%252Bcells%26aulast%3DCorzo%26aufirst%3DCesar%2BA.%26date%3D2020%26date%3D2020%26volume%3D13%26issue%3D634%26spage%3Deaaz1053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuan  Chen</span>, <span class="hlFld-ContribAuthor ">Fang  Ma</span>, <span class="hlFld-ContribAuthor ">Nicholas S.  Jones</span>, <span class="hlFld-ContribAuthor ">Kenta  Yoshida</span>, <span class="hlFld-ContribAuthor ">Po‐Chang  Chiang</span>, <span class="hlFld-ContribAuthor ">Matthew R.  Durk</span>, <span class="hlFld-ContribAuthor ">Matthew R.  Wright</span>, <span class="hlFld-ContribAuthor ">Jin Yan  Jin</span>, <span class="hlFld-ContribAuthor ">Leslie W.  Chinn</span>. </span><span class="cited-content_cbyCitation_article-title">Physiologically‐Based Pharmacokinetic Model‐Informed Drug Development for Fenebrutinib: Understanding Complex Drug‐Drug Interactions. </span><span class="cited-content_cbyCitation_journal-name">CPT: Pharmacometrics & Systems Pharmacology</span><span> <strong>2020,</strong> <em>9 </em>
                                    (6)
                                     , 332-341. <a href="https://doi.org/10.1002/psp4.12515" title="DOI URL">https://doi.org/10.1002/psp4.12515</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/psp4.12515&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fpsp4.12515%26sid%3Dliteratum%253Aachs%26jtitle%3DCPT%253A%2520Pharmacometrics%2520%2526%2520Systems%2520Pharmacology%26atitle%3DPhysiologically%2525E2%252580%252590Based%252BPharmacokinetic%252BModel%2525E2%252580%252590Informed%252BDrug%252BDevelopment%252Bfor%252BFenebrutinib%25253A%252BUnderstanding%252BComplex%252BDrug%2525E2%252580%252590Drug%252BInteractions%26aulast%3DChen%26aufirst%3DYuan%26date%3D2020%26date%3D2020%26volume%3D9%26issue%3D6%26spage%3D332%26epage%3D341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Colin D.  Godwin</span>, <span class="hlFld-ContribAuthor ">Olivia M.  Bates</span>, <span class="hlFld-ContribAuthor ">Eliotte E.  Garling</span>, <span class="hlFld-ContribAuthor ">Mary E.  Beddoe</span>, <span class="hlFld-ContribAuthor ">George S.  Laszlo</span>, <span class="hlFld-ContribAuthor ">Roland B.  Walter</span>. </span><span class="cited-content_cbyCitation_article-title">The Bruton’s tyrosine kinase inhibitor ibrutinib abrogates bispecific antibody‐mediated T‐cell cytotoxicity. </span><span class="cited-content_cbyCitation_journal-name">British Journal of Haematology</span><span> <strong>2020,</strong> <em>189 </em>
                                    (1)
                                     <a href="https://doi.org/10.1111/bjh.16406" title="DOI URL">https://doi.org/10.1111/bjh.16406</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/bjh.16406&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fbjh.16406%26sid%3Dliteratum%253Aachs%26jtitle%3DBritish%2520Journal%2520of%2520Haematology%26atitle%3DThe%252BBruton%2525E2%252580%252599s%252Btyrosine%2525C2%2525A0kinase%2525C2%2525A0inhibitor%252Bibrutinib%252Babrogates%252Bbispecific%252Bantibody%2525E2%252580%252590mediated%252BT%2525E2%252580%252590cell%252Bcytotoxicity%26aulast%3DGodwin%26aufirst%3DColin%2BD.%26date%3D2020%26date%3D2020%26volume%3D189%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Phyllis  Chan</span>, <span class="hlFld-ContribAuthor ">Jiajie  Yu</span>, <span class="hlFld-ContribAuthor ">Leslie  Chinn</span>, <span class="hlFld-ContribAuthor ">Marita  Prohn</span>, <span class="hlFld-ContribAuthor ">Jan  Huisman</span>, <span class="hlFld-ContribAuthor ">Brett  Matzuka</span>, <span class="hlFld-ContribAuthor ">William  Hanley</span>, <span class="hlFld-ContribAuthor ">Katie  Tuckwell</span>, <span class="hlFld-ContribAuthor ">Angelica  Quartino</span>. </span><span class="cited-content_cbyCitation_article-title">Population Pharmacokinetics, Efficacy Exposure-response Analysis, and Model-based Meta-analysis of Fenebrutinib in Subjects with Rheumatoid Arthritis. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceutical Research</span><span> <strong>2020,</strong> <em>37 </em>
                                    (2)
                                     <a href="https://doi.org/10.1007/s11095-019-2752-y" title="DOI URL">https://doi.org/10.1007/s11095-019-2752-y</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11095-019-2752-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11095-019-2752-y%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceutical%2520Research%26atitle%3DPopulation%252BPharmacokinetics%25252C%252BEfficacy%252BExposure-response%252BAnalysis%25252C%252Band%252BModel-based%252BMeta-analysis%252Bof%252BFenebrutinib%252Bin%252BSubjects%252Bwith%252BRheumatoid%252BArthritis%26aulast%3DChan%26aufirst%3DPhyllis%26date%3D2020%26date%3D2020%26volume%3D37%26issue%3D2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">E. F.  Sagitova</span>, <span class="hlFld-ContribAuthor ">L. N.  Sobenina</span>, <span class="hlFld-ContribAuthor ">B. A.  Trofimov</span>. </span><span class="cited-content_cbyCitation_article-title">From Acylethynylpyrroles to Pyrrolo[1,2-a]pyrazines in One Step. </span><span class="cited-content_cbyCitation_journal-name">Russian Journal of Organic Chemistry</span><span> <strong>2020,</strong> <em>56 </em>
                                    (2)
                                     , 225-233. <a href="https://doi.org/10.1134/S1070428020020082" title="DOI URL">https://doi.org/10.1134/S1070428020020082</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1134/S1070428020020082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1134%2FS1070428020020082%26sid%3Dliteratum%253Aachs%26jtitle%3DRussian%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DFrom%252BAcylethynylpyrroles%252Bto%252BPyrrolo%25255B1%25252C2-a%25255Dpyrazines%252Bin%252BOne%252BStep%26aulast%3DSagitova%26aufirst%3DE.%2BF.%26date%3D2020%26date%3D2020%26volume%3D56%26issue%3D2%26spage%3D225%26epage%3D233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nicholas S.  Jones</span>, <span class="hlFld-ContribAuthor ">Kenta  Yoshida</span>, <span class="hlFld-ContribAuthor ">Laurent  Salphati</span>, <span class="hlFld-ContribAuthor ">Jane R.  Kenny</span>, <span class="hlFld-ContribAuthor ">Matthew R.  Durk</span>, <span class="hlFld-ContribAuthor ">Leslie W.  Chinn</span>. </span><span class="cited-content_cbyCitation_article-title">Complex DDI by Fenebrutinib and the Use of Transporter Endogenous Biomarkers to Elucidate the Mechanism of
              DDI. </span><span class="cited-content_cbyCitation_journal-name">Clinical Pharmacology & Therapeutics</span><span> <strong>2020,</strong> <em>107 </em>
                                    (1)
                                     , 269-277. <a href="https://doi.org/10.1002/cpt.1599" title="DOI URL">https://doi.org/10.1002/cpt.1599</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cpt.1599&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcpt.1599%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Pharmacology%2520%2526%2520Therapeutics%26atitle%3DComplex%252BDDI%252Bby%252BFenebrutinib%252Band%252Bthe%252BUse%252Bof%252BTransporter%252BEndogenous%252BBiomarkers%252Bto%252BElucidate%252Bthe%252BMechanism%252Bof%252BDDI%26aulast%3DJones%26aufirst%3DNicholas%2BS.%26date%3D2020%26date%3D2019%26volume%3D107%26issue%3D1%26spage%3D269%26epage%3D277" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">David  Nardo</span>, <span class="hlFld-ContribAuthor ">David  Henson</span>, <span class="hlFld-ContribAuthor ">Joe E.  Springer</span>, <span class="hlFld-ContribAuthor ">Vincent J.  Venditto</span>. </span><span class="cited-content_cbyCitation_article-title">Modulating the immune response with liposomal delivery. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 159-211. <a href="https://doi.org/10.1016/B978-0-12-816705-2.00006-0" title="DOI URL">https://doi.org/10.1016/B978-0-12-816705-2.00006-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-816705-2.00006-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-816705-2.00006-0%26sid%3Dliteratum%253Aachs%26atitle%3DModulating%252Bthe%252Bimmune%252Bresponse%252Bwith%252Bliposomal%252Bdelivery%26aulast%3DNardo%26aufirst%3DDavid%26date%3D2020%26spage%3D159%26epage%3D211%26pub%3DElsevier%26atitle%3DNanomaterials%252Bfor%252BClinical%252BApplications%26date%3D2020%26volume%3D379" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pavel  Kolkhir</span>, <span class="hlFld-ContribAuthor ">Sabine  Altrichter</span>, <span class="hlFld-ContribAuthor ">Melba  Munoz</span>, <span class="hlFld-ContribAuthor ">Tomasz  Hawro</span>, <span class="hlFld-ContribAuthor ">Marcus  Maurer</span>. </span><span class="cited-content_cbyCitation_article-title">New treatments for chronic urticaria. </span><span class="cited-content_cbyCitation_journal-name">Annals of Allergy, Asthma & Immunology</span><span> <strong>2020,</strong> <em>124 </em>
                                    (1)
                                     , 2-12. <a href="https://doi.org/10.1016/j.anai.2019.08.014" title="DOI URL">https://doi.org/10.1016/j.anai.2019.08.014</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.anai.2019.08.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.anai.2019.08.014%26sid%3Dliteratum%253Aachs%26jtitle%3DAnnals%2520of%2520Allergy%252C%2520Asthma%2520%2526%2520Immunology%26atitle%3DNew%252Btreatments%252Bfor%252Bchronic%252Burticaria%26aulast%3DKolkhir%26aufirst%3DPavel%26date%3D2020%26volume%3D124%26issue%3D1%26spage%3D2%26epage%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Luise  Goldmann</span>, <span class="hlFld-ContribAuthor ">Rundan  Duan</span>, <span class="hlFld-ContribAuthor ">Thorsten  Kragh</span>, <span class="hlFld-ContribAuthor ">Georg  Wittmann</span>, <span class="hlFld-ContribAuthor ">Christian  Weber</span>, <span class="hlFld-ContribAuthor ">Reinhard  Lorenz</span>, <span class="hlFld-ContribAuthor ">Philipp  von Hundelshausen</span>, <span class="hlFld-ContribAuthor ">Michael  Spannagl</span>, <span class="hlFld-ContribAuthor ">Wolfgang  Siess</span>. </span><span class="cited-content_cbyCitation_article-title">Oral Bruton tyrosine kinase inhibitors block activation of the platelet Fc receptor CD32a (FcγRIIA): a new option in HIT?. </span><span class="cited-content_cbyCitation_journal-name">Blood Advances</span><span> <strong>2019,</strong> <em>3 </em>
                                    (23)
                                     , 4021-4033. <a href="https://doi.org/10.1182/bloodadvances.2019000617" title="DOI URL">https://doi.org/10.1182/bloodadvances.2019000617</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1182/bloodadvances.2019000617&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1182%2Fbloodadvances.2019000617%26sid%3Dliteratum%253Aachs%26jtitle%3DBlood%2520Advances%26atitle%3DOral%252BBruton%252Btyrosine%252Bkinase%252Binhibitors%252Bblock%252Bactivation%252Bof%252Bthe%252Bplatelet%252BFc%252Breceptor%252BCD32a%252B%252528Fc%2525CE%2525B3RIIA%252529%25253A%252Ba%252Bnew%252Boption%252Bin%252BHIT%25253F%26aulast%3DGoldmann%26aufirst%3DLuise%26date%3D2019%26date%3D2019%26volume%3D3%26issue%3D23%26spage%3D4021%26epage%3D4033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bartosz  Puła</span>, <span class="hlFld-ContribAuthor ">Aleksandra  Gołos</span>, <span class="hlFld-ContribAuthor ">Patryk  Górniak</span>, <span class="hlFld-ContribAuthor ">Krzysztof  Jamroziak</span>. </span><span class="cited-content_cbyCitation_article-title">Overcoming Ibrutinib Resistance in Chronic Lymphocytic Leukemia. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2019,</strong> <em>11 </em>
                                    (12)
                                     , 1834. <a href="https://doi.org/10.3390/cancers11121834" title="DOI URL">https://doi.org/10.3390/cancers11121834</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers11121834&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers11121834%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DOvercoming%252BIbrutinib%252BResistance%252Bin%252BChronic%252BLymphocytic%252BLeukemia%26aulast%3DPu%25C5%2582a%26aufirst%3DBartosz%26date%3D2019%26date%3D2019%26volume%3D11%26issue%3D12%26spage%3D1834" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Adam S.  Kittai</span>, <span class="hlFld-ContribAuthor ">Jennifer A.  Woyach</span>. </span><span class="cited-content_cbyCitation_article-title">Resistance Mechanisms to Targeted Agents in Chronic Lymphocytic Leukemia. </span><span class="cited-content_cbyCitation_journal-name">The Cancer Journal</span><span> <strong>2019,</strong> <em>25 </em>
                                    (6)
                                     , 428-435. <a href="https://doi.org/10.1097/PPO.0000000000000406" title="DOI URL">https://doi.org/10.1097/PPO.0000000000000406</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1097/PPO.0000000000000406&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1097%2FPPO.0000000000000406%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Cancer%2520Journal%26atitle%3DResistance%252BMechanisms%252Bto%252BTargeted%252BAgents%252Bin%252BChronic%252BLymphocytic%252BLeukemia%26aulast%3DKittai%26aufirst%3DAdam%2BS.%26date%3D2019%26volume%3D25%26issue%3D6%26spage%3D428%26epage%3D435" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nicholas Steven  Jones</span>, <span class="hlFld-ContribAuthor ">Helen  Winter</span>, <span class="hlFld-ContribAuthor ">Tamiko R.  Katsumoto</span>, <span class="hlFld-ContribAuthor ">Marilyn  Florero</span>, <span class="hlFld-ContribAuthor ">Elaine  Murray</span>, <span class="hlFld-ContribAuthor ">Helen  Walker</span>, <span class="hlFld-ContribAuthor ">Nand  Singh</span>, <span class="hlFld-ContribAuthor ">Leslie W.  Chinn</span>. </span><span class="cited-content_cbyCitation_article-title">Absence of Pharmacokinetic Interactions between the Bruton’s Tyrosine Kinase Inhibitor Fenebrutinib and Methotrexate. </span><span class="cited-content_cbyCitation_journal-name">Journal of Pharmacology and Experimental Therapeutics</span><span> <strong>2019,</strong> <em>371 </em>
                                    (1)
                                     , 202-207. <a href="https://doi.org/10.1124/jpet.119.257089" title="DOI URL">https://doi.org/10.1124/jpet.119.257089</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1124/jpet.119.257089&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1124%2Fjpet.119.257089%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Pharmacology%2520and%2520Experimental%2520Therapeutics%26atitle%3DAbsence%252Bof%252BPharmacokinetic%252BInteractions%252Bbetween%252Bthe%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%252BInhibitor%252BFenebrutinib%252Band%252BMethotrexate%26aulast%3DJones%26aufirst%3DNicholas%2BSteven%26date%3D2019%26date%3D2019%26volume%3D371%26issue%3D1%26spage%3D202%26epage%3D207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">James  Keaney</span>, <span class="hlFld-ContribAuthor ">Julien  Gasser</span>, <span class="hlFld-ContribAuthor ">Gaëlle  Gillet</span>, <span class="hlFld-ContribAuthor ">Diana  Scholz</span>, <span class="hlFld-ContribAuthor ">Irena  Kadiu</span>. </span><span class="cited-content_cbyCitation_article-title">Inhibition of Bruton’s Tyrosine Kinase Modulates Microglial Phagocytosis: Therapeutic Implications for Alzheimer’s Disease. </span><span class="cited-content_cbyCitation_journal-name">Journal of Neuroimmune Pharmacology</span><span> <strong>2019,</strong> <em>14 </em>
                                    (3)
                                     , 448-461. <a href="https://doi.org/10.1007/s11481-019-09839-0" title="DOI URL">https://doi.org/10.1007/s11481-019-09839-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11481-019-09839-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11481-019-09839-0%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Neuroimmune%2520Pharmacology%26atitle%3DInhibition%252Bof%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%252BModulates%252BMicroglial%252BPhagocytosis%25253A%252BTherapeutic%252BImplications%252Bfor%252BAlzheimer%2525E2%252580%252599s%252BDisease%26aulast%3DKeaney%26aufirst%3DJames%26date%3D2019%26date%3D2019%26volume%3D14%26issue%3D3%26spage%3D448%26epage%3D461" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zheng  Zhai</span>, <span class="hlFld-ContribAuthor ">Ridong  Li</span>, <span class="hlFld-ContribAuthor ">Xinyu  Bai</span>, <span class="hlFld-ContribAuthor ">Xianling  Ning</span>, <span class="hlFld-ContribAuthor ">Zhiqiang  Lin</span>, <span class="hlFld-ContribAuthor ">Xuyang  Zhao</span>, <span class="hlFld-ContribAuthor ">Yan  Jin</span>, <span class="hlFld-ContribAuthor ">Yuxin  Yin</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of novel dithiocarbamate-substituted diphenylaminopyrimidine derivatives as BTK inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2019,</strong> <em>27 </em>
                                    (18)
                                     , 4124-4142. <a href="https://doi.org/10.1016/j.bmc.2019.07.043" title="DOI URL">https://doi.org/10.1016/j.bmc.2019.07.043</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2019.07.043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2019.07.043%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252Bdithiocarbamate-substituted%252Bdiphenylaminopyrimidine%252Bderivatives%252Bas%252BBTK%252Binhibitors%26aulast%3DZhai%26aufirst%3DZheng%26date%3D2019%26volume%3D27%26issue%3D18%26spage%3D4124%26epage%3D4142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Keriann M.  Backus</span>, <span class="hlFld-ContribAuthor ">Jian  Cao</span>, <span class="hlFld-ContribAuthor ">Sean M.  Maddox</span>. </span><span class="cited-content_cbyCitation_article-title">Opportunities and challenges for the development of covalent chemical immunomodulators. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2019,</strong> <em>27 </em>
                                    (15)
                                     , 3421-3439. <a href="https://doi.org/10.1016/j.bmc.2019.05.050" title="DOI URL">https://doi.org/10.1016/j.bmc.2019.05.050</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2019.05.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2019.05.050%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DOpportunities%252Band%252Bchallenges%252Bfor%252Bthe%252Bdevelopment%252Bof%252Bcovalent%252Bchemical%252Bimmunomodulators%26aulast%3DBackus%26aufirst%3DKeriann%2BM.%26date%3D2019%26volume%3D27%26issue%3D15%26spage%3D3421%26epage%3D3439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Han-Qing  Wu</span>, <span class="hlFld-ContribAuthor ">Kai  Yang</span>, <span class="hlFld-ContribAuthor ">Xiao-Yun  Chen</span>, <span class="hlFld-ContribAuthor ">Mani  Arulkumar</span>, <span class="hlFld-ContribAuthor ">Neng  Wang</span>, <span class="hlFld-ContribAuthor ">Si-Hong  Chen</span>, <span class="hlFld-ContribAuthor ">Zhao-Yang  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">A 3,4-dihalo-2(5
              H
              )-furanone initiated ring-opening reaction of DABCO in the absence of a metal catalyst and additive and its application in a one-pot two-step reaction. </span><span class="cited-content_cbyCitation_journal-name">Green Chemistry</span><span> <strong>2019,</strong> <em>21 </em>
                                    (14)
                                     , 3782-3788. <a href="https://doi.org/10.1039/C9GC01740B" title="DOI URL">https://doi.org/10.1039/C9GC01740B</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9GC01740B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9GC01740B%26sid%3Dliteratum%253Aachs%26jtitle%3DGreen%2520Chemistry%26atitle%3DA%252B3%25252C4-dihalo-2%2525285%252BH%252B%252529-furanone%252Binitiated%252Bring-opening%252Breaction%252Bof%252BDABCO%252Bin%252Bthe%252Babsence%252Bof%252Ba%252Bmetal%252Bcatalyst%252Band%252Badditive%252Band%252Bits%252Bapplication%252Bin%252Ba%252Bone-pot%252Btwo-step%252Breaction%26aulast%3DWu%26aufirst%3DHan-Qing%26date%3D2019%26date%3D2019%26volume%3D21%26issue%3D14%26spage%3D3782%26epage%3D3788" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Brian T.  Hopkins</span>, <span class="hlFld-ContribAuthor ">Eris  Bame</span>, <span class="hlFld-ContribAuthor ">Noah  Bell</span>, <span class="hlFld-ContribAuthor ">Tonika  Bohnert</span>, <span class="hlFld-ContribAuthor ">Jon K.  Bowden-Verhoek</span>, <span class="hlFld-ContribAuthor ">Minna  Bui</span>, <span class="hlFld-ContribAuthor ">Mark T.  Cancilla</span>, <span class="hlFld-ContribAuthor ">Patrick  Conlon</span>, <span class="hlFld-ContribAuthor ">Patrick  Cullen</span>, <span class="hlFld-ContribAuthor ">Daniel A.  Erlanson</span>, <span class="hlFld-ContribAuthor ">Junfa  Fan</span>, <span class="hlFld-ContribAuthor ">Tarra  Fuchs-Knotts</span>, <span class="hlFld-ContribAuthor ">Stig  Hansen</span>, <span class="hlFld-ContribAuthor ">Stacey  Heumann</span>, <span class="hlFld-ContribAuthor ">Tracy J.  Jenkins</span>, <span class="hlFld-ContribAuthor ">Douglas  Marcotte</span>, <span class="hlFld-ContribAuthor ">Bob  McDowell</span>, <span class="hlFld-ContribAuthor ">Elisabeth  Mertsching</span>, <span class="hlFld-ContribAuthor ">Ella  Negrou</span>, <span class="hlFld-ContribAuthor ">Kevin L.  Otipoby</span>, <span class="hlFld-ContribAuthor ">Urjana  Poreci</span>, <span class="hlFld-ContribAuthor ">Michael J.  Romanowski</span>, <span class="hlFld-ContribAuthor ">Daniel  Scott</span>, <span class="hlFld-ContribAuthor ">Laura  Silvian</span>, <span class="hlFld-ContribAuthor ">Wenjin  Yang</span>, <span class="hlFld-ContribAuthor ">Min  Zhong</span>. </span><span class="cited-content_cbyCitation_article-title">Optimization of novel reversible Bruton’s tyrosine kinase inhibitors identified using Tethering-fragment-based screens. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2019,</strong> <em>27 </em>
                                    (13)
                                     , 2905-2913. <a href="https://doi.org/10.1016/j.bmc.2019.05.021" title="DOI URL">https://doi.org/10.1016/j.bmc.2019.05.021</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2019.05.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2019.05.021%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DOptimization%252Bof%252Bnovel%252Breversible%252BBruton%2525E2%252580%252599s%252Btyrosine%252Bkinase%252Binhibitors%252Bidentified%252Busing%252BTethering-fragment-based%252Bscreens%26aulast%3DHopkins%26aufirst%3DBrian%2BT.%26date%3D2019%26volume%3D27%26issue%3D13%26spage%3D2905%26epage%3D2913" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xavier  Montalban</span>, <span class="hlFld-ContribAuthor ">Douglas L.  Arnold</span>, <span class="hlFld-ContribAuthor ">Martin S.  Weber</span>, <span class="hlFld-ContribAuthor ">Ivan  Staikov</span>, <span class="hlFld-ContribAuthor ">Karolina  Piasecka-Stryczynska</span>, <span class="hlFld-ContribAuthor ">Jonathan  Willmer</span>, <span class="hlFld-ContribAuthor ">Emily C.  Martin</span>, <span class="hlFld-ContribAuthor ">Fernando  Dangond</span>, <span class="hlFld-ContribAuthor ">Sana  Syed</span>, <span class="hlFld-ContribAuthor ">Jerry S.  Wolinsky</span>. </span><span class="cited-content_cbyCitation_article-title">Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis. </span><span class="cited-content_cbyCitation_journal-name">New England Journal of Medicine</span><span> <strong>2019,</strong> <em>380 </em>
                                    (25)
                                     , 2406-2417. <a href="https://doi.org/10.1056/NEJMoa1901981" title="DOI URL">https://doi.org/10.1056/NEJMoa1901981</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1056/NEJMoa1901981&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1056%2FNEJMoa1901981%26sid%3Dliteratum%253Aachs%26jtitle%3DNew%2520England%2520Journal%2520of%2520Medicine%26atitle%3DPlacebo-Controlled%252BTrial%252Bof%252Ban%252BOral%252BBTK%252BInhibitor%252Bin%252BMultiple%252BSclerosis%26aulast%3DMontalban%26aufirst%3DXavier%26date%3D2019%26volume%3D380%26issue%3D25%26spage%3D2406%26epage%3D2417" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shenqiu  Wang</span>, <span class="hlFld-ContribAuthor ">Sayan  Mondal</span>, <span class="hlFld-ContribAuthor ">Chunying  Zhao</span>, <span class="hlFld-ContribAuthor ">Marjan  Berishaj</span>, <span class="hlFld-ContribAuthor ">Phani  Ghanakota</span>, <span class="hlFld-ContribAuthor ">Connie Lee  Batlevi</span>, <span class="hlFld-ContribAuthor ">Ahmet  Dogan</span>, <span class="hlFld-ContribAuthor ">Venkatraman E.  Seshan</span>, <span class="hlFld-ContribAuthor ">Robert  Abel</span>, <span class="hlFld-ContribAuthor ">Michael R.  Green</span>, <span class="hlFld-ContribAuthor ">Anas  Younes</span>, <span class="hlFld-ContribAuthor ">Hans-Guido  Wendel</span>. </span><span class="cited-content_cbyCitation_article-title">Noncovalent inhibitors reveal BTK gatekeeper and auto-inhibitory residues that control its transforming activity. </span><span class="cited-content_cbyCitation_journal-name">JCI Insight</span><span> <strong>2019,</strong> <em>4 </em>
                                    (12)
                                     <a href="https://doi.org/10.1172/jci.insight.127566" title="DOI URL">https://doi.org/10.1172/jci.insight.127566</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1172/jci.insight.127566&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1172%2Fjci.insight.127566%26sid%3Dliteratum%253Aachs%26jtitle%3DJCI%2520Insight%26atitle%3DNoncovalent%252Binhibitors%252Breveal%252BBTK%252Bgatekeeper%252Band%252Bauto-inhibitory%252Bresidues%252Bthat%252Bcontrol%252Bits%252Btransforming%252Bactivity%26aulast%3DWang%26aufirst%3DShenqiu%26date%3D2019%26date%3D2019%26volume%3D4%26issue%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">David A.  Bond</span>, <span class="hlFld-ContribAuthor ">Jennifer A.  Woyach</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting BTK in CLL: Beyond Ibrutinib. </span><span class="cited-content_cbyCitation_journal-name">Current Hematologic Malignancy Reports</span><span> <strong>2019,</strong> <em>14 </em>
                                    (3)
                                     , 197-205. <a href="https://doi.org/10.1007/s11899-019-00512-0" title="DOI URL">https://doi.org/10.1007/s11899-019-00512-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11899-019-00512-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11899-019-00512-0%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Hematologic%2520Malignancy%2520Reports%26atitle%3DTargeting%252BBTK%252Bin%252BCLL%25253A%252BBeyond%252BIbrutinib%26aulast%3DBond%26aufirst%3DDavid%2BA.%26date%3D2019%26date%3D2019%26volume%3D14%26issue%3D3%26spage%3D197%26epage%3D205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Philipp  Haselmayer</span>, <span class="hlFld-ContribAuthor ">Montserrat  Camps</span>, <span class="hlFld-ContribAuthor ">Lesley  Liu-Bujalski</span>, <span class="hlFld-ContribAuthor ">Ngan  Nguyen</span>, <span class="hlFld-ContribAuthor ">Federica  Morandi</span>, <span class="hlFld-ContribAuthor ">Jared  Head</span>, <span class="hlFld-ContribAuthor ">Alison  O’Mahony</span>, <span class="hlFld-ContribAuthor ">Simone C.  Zimmerli</span>, <span class="hlFld-ContribAuthor ">Lisa  Bruns</span>, <span class="hlFld-ContribAuthor ">Andrew T.  Bender</span>, <span class="hlFld-ContribAuthor ">Patricia  Schroeder</span>, <span class="hlFld-ContribAuthor ">Roland  Grenningloh</span>. </span><span class="cited-content_cbyCitation_article-title">Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Immunology</span><span> <strong>2019,</strong> <em>202 </em>
                                    (10)
                                     , 2888-2906. <a href="https://doi.org/10.4049/jimmunol.1800583" title="DOI URL">https://doi.org/10.4049/jimmunol.1800583</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4049/jimmunol.1800583&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4049%2Fjimmunol.1800583%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Immunology%26atitle%3DEfficacy%252Band%252BPharmacodynamic%252BModeling%252Bof%252Bthe%252BBTK%252BInhibitor%252BEvobrutinib%252Bin%252BAutoimmune%252BDisease%252BModels%26aulast%3DHaselmayer%26aufirst%3DPhilipp%26date%3D2019%26date%3D2019%26volume%3D202%26issue%3D10%26spage%3D2888%26epage%3D2906" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chufeng  Zhang</span>, <span class="hlFld-ContribAuthor ">Heying  Pei</span>, <span class="hlFld-ContribAuthor ">Jun  He</span>, <span class="hlFld-ContribAuthor ">Jiali  Zhu</span>, <span class="hlFld-ContribAuthor ">Weimin  Li</span>, <span class="hlFld-ContribAuthor ">Ting  Niu</span>, <span class="hlFld-ContribAuthor ">Mingli  Xiang</span>, <span class="hlFld-ContribAuthor ">Lijuan  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and evaluation of novel 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as potent, selective and reversible Bruton's tyrosine kinase (BTK) inhibitors for the treatment of rheumatoid arthritis. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>169 </em>, 121-143. <a href="https://doi.org/10.1016/j.ejmech.2019.02.077" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.02.077</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.02.077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.02.077%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bevaluation%252Bof%252Bnovel%252B7H-pyrrolo%25255B2%25252C3-d%25255Dpyrimidin-4-amine%252Bderivatives%252Bas%252Bpotent%25252C%252Bselective%252Band%252Breversible%252BBruton%252527s%252Btyrosine%252Bkinase%252B%252528BTK%252529%252Binhibitors%252Bfor%252Bthe%252Btreatment%252Bof%252Brheumatoid%252Barthritis%26aulast%3DZhang%26aufirst%3DChufeng%26date%3D2019%26volume%3D169%26spage%3D121%26epage%3D143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Samuel J. S.  Rubin</span>, <span class="hlFld-ContribAuthor ">Michelle S.  Bloom</span>, <span class="hlFld-ContribAuthor ">William H.  Robinson</span>. </span><span class="cited-content_cbyCitation_article-title">B cell checkpoints in autoimmune rheumatic diseases. </span><span class="cited-content_cbyCitation_journal-name">Nature Reviews Rheumatology</span><span> <strong>2019,</strong> <em>15 </em>
                                    (5)
                                     , 303-315. <a href="https://doi.org/10.1038/s41584-019-0211-0" title="DOI URL">https://doi.org/10.1038/s41584-019-0211-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41584-019-0211-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41584-019-0211-0%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Reviews%2520Rheumatology%26atitle%3DB%252Bcell%252Bcheckpoints%252Bin%252Bautoimmune%252Brheumatic%252Bdiseases%26aulast%3DRubin%26aufirst%3DSamuel%2BJ.%2BS.%26date%3D2019%26date%3D2019%26volume%3D15%26issue%3D5%26spage%3D303%26epage%3D315" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Deyan Y.  Yosifov</span>, <span class="hlFld-ContribAuthor ">Christine  Wolf</span>, <span class="hlFld-ContribAuthor ">Stephan  Stilgenbauer</span>, <span class="hlFld-ContribAuthor ">Daniel  Mertens</span>. </span><span class="cited-content_cbyCitation_article-title">From Biology to Therapy: The CLL Success Story. </span><span class="cited-content_cbyCitation_journal-name">HemaSphere</span><span> <strong>2019,</strong> <em>3 </em>
                                    (2)
                                     , e175. <a href="https://doi.org/10.1097/HS9.0000000000000175" title="DOI URL">https://doi.org/10.1097/HS9.0000000000000175</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1097/HS9.0000000000000175&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1097%2FHS9.0000000000000175%26sid%3Dliteratum%253Aachs%26jtitle%3DHemaSphere%26atitle%3DFrom%252BBiology%252Bto%252BTherapy%25253A%252BThe%252BCLL%252BSuccess%252BStory%26aulast%3DYosifov%26aufirst%3DDeyan%2BY.%26date%3D2019%26volume%3D3%26issue%3D2%26spage%3De175" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eva  Nittinger</span>, <span class="hlFld-ContribAuthor ">Paul  Gibbons</span>, <span class="hlFld-ContribAuthor ">Charles  Eigenbrot</span>, <span class="hlFld-ContribAuthor ">Doug R.  Davies</span>, <span class="hlFld-ContribAuthor ">Brigitte  Maurer</span>, <span class="hlFld-ContribAuthor ">Christine L.  Yu</span>, <span class="hlFld-ContribAuthor ">James R.  Kiefer</span>, <span class="hlFld-ContribAuthor ">Andreas  Kuglstatter</span>, <span class="hlFld-ContribAuthor ">Jeremy  Murray</span>, <span class="hlFld-ContribAuthor ">Daniel F.  Ortwine</span>, <span class="hlFld-ContribAuthor ">Yong  Tang</span>, <span class="hlFld-ContribAuthor ">Vickie  Tsui</span>. </span><span class="cited-content_cbyCitation_article-title">Water molecules in protein–ligand interfaces. Evaluation of software tools and SAR comparison. </span><span class="cited-content_cbyCitation_journal-name">Journal of Computer-Aided Molecular Design</span><span> <strong>2019,</strong> <em>33 </em>
                                    (3)
                                     , 307-330. <a href="https://doi.org/10.1007/s10822-019-00187-y" title="DOI URL">https://doi.org/10.1007/s10822-019-00187-y</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10822-019-00187-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10822-019-00187-y%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Computer-Aided%2520Molecular%2520Design%26atitle%3DWater%252Bmolecules%252Bin%252Bprotein%2525E2%252580%252593ligand%252Binterfaces.%252BEvaluation%252Bof%252Bsoftware%252Btools%252Band%252BSAR%252Bcomparison%26aulast%3DNittinger%26aufirst%3DEva%26date%3D2019%26date%3D2019%26volume%3D33%26issue%3D3%26spage%3D307%26epage%3D330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrew D.  Harper</span>, <span class="hlFld-ContribAuthor ">R. Alan  Aitken</span>. </span><span class="cited-content_cbyCitation_article-title">The Chemistry of Thieno[c]pyrrolones, Dihydrothieno[c]pyrrolones, and Their Fused Derivatives. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 227-314. <a href="https://doi.org/10.1016/bs.aihch.2018.09.001" title="DOI URL">https://doi.org/10.1016/bs.aihch.2018.09.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.aihch.2018.09.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.aihch.2018.09.001%26sid%3Dliteratum%253Aachs%26atitle%3DThe%252BChemistry%252Bof%252BThieno%25255Bc%25255Dpyrrolones%25252C%252BDihydrothieno%25255Bc%25255Dpyrrolones%25252C%252Band%252BTheir%252BFused%252BDerivatives%26aulast%3DHarper%26aufirst%3DAndrew%2BD.%26date%3D2019%26spage%3D227%26epage%3D314%26pub%3DElsevier%26date%3D2019%26volume%3D127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nan  Zheng</span>, <span class="hlFld-ContribAuthor ">Qun  Hao</span>, <span class="hlFld-ContribAuthor ">Kuaile  Lin</span>, <span class="hlFld-ContribAuthor ">Jing  Pan</span>, <span class="hlFld-ContribAuthor ">Yingxia  Li</span>, <span class="hlFld-ContribAuthor ">Weicheng  Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological evaluation of novel 1-substituted 3-(3-phenoxyprop-1-yn-1-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amines as potent Bruton's tyrosine kinase (BTK) inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>29 </em>
                                    (2)
                                     , 225-229. <a href="https://doi.org/10.1016/j.bmcl.2018.11.051" title="DOI URL">https://doi.org/10.1016/j.bmcl.2018.11.051</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2018.11.051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2018.11.051%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252B1-substituted%252B3-%2525283-phenoxyprop-1-yn-1-yl%252529-1H-pyrazolo%25255B3%25252C4-d%25255Dpyrimidin-4-amines%252Bas%252Bpotent%252BBruton%252527s%252Btyrosine%252Bkinase%252B%252528BTK%252529%252Binhibitors%26aulast%3DZheng%26aufirst%3DNan%26date%3D2019%26volume%3D29%26issue%3D2%26spage%3D225%26epage%3D229" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sean D.  Reiff</span>, <span class="hlFld-ContribAuthor ">Elizabeth M.  Muhowski</span>, <span class="hlFld-ContribAuthor ">Daphne  Guinn</span>, <span class="hlFld-ContribAuthor ">Amy  Lehman</span>, <span class="hlFld-ContribAuthor ">Catherine A.  Fabian</span>, <span class="hlFld-ContribAuthor ">Carolyn  Cheney</span>, <span class="hlFld-ContribAuthor ">Rose  Mantel</span>, <span class="hlFld-ContribAuthor ">Lisa  Smith</span>, <span class="hlFld-ContribAuthor ">Amy J.  Johnson</span>, <span class="hlFld-ContribAuthor ">Wendy B.  Young</span>, <span class="hlFld-ContribAuthor ">Adam R.  Johnson</span>, <span class="hlFld-ContribAuthor ">Lichuan  Liu</span>, <span class="hlFld-ContribAuthor ">John C.  Byrd</span>, <span class="hlFld-ContribAuthor ">Jennifer A.  Woyach</span>. </span><span class="cited-content_cbyCitation_article-title">Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL. </span><span class="cited-content_cbyCitation_journal-name">Blood</span><span> <strong>2018,</strong> <em>132 </em>
                                    (10)
                                     , 1039-1049. <a href="https://doi.org/10.1182/blood-2017-10-809020" title="DOI URL">https://doi.org/10.1182/blood-2017-10-809020</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1182/blood-2017-10-809020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1182%2Fblood-2017-10-809020%26sid%3Dliteratum%253Aachs%26jtitle%3DBlood%26atitle%3DNoncovalent%252Binhibition%252Bof%252BC481S%252BBruton%252Btyrosine%252Bkinase%252Bby%252BGDC-0853%25253A%252Ba%252Bnew%252Btreatment%252Bstrategy%252Bfor%252Bibrutinib-resistant%252BCLL%26aulast%3DReiff%26aufirst%3DSean%2BD.%26date%3D2018%26volume%3D132%26issue%3D10%26spage%3D1039%26epage%3D1049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ann E.  Herman</span>, <span class="hlFld-ContribAuthor ">Leslie W.  Chinn</span>, <span class="hlFld-ContribAuthor ">Shweta G.  Kotwal</span>, <span class="hlFld-ContribAuthor ">Elaine R.  Murray</span>, <span class="hlFld-ContribAuthor ">Rui  Zhao</span>, <span class="hlFld-ContribAuthor ">Marilyn  Florero</span>, <span class="hlFld-ContribAuthor ">Alyse  Lin</span>, <span class="hlFld-ContribAuthor ">Anita  Moein</span>, <span class="hlFld-ContribAuthor ">Rena  Wang</span>, <span class="hlFld-ContribAuthor ">Meire  Bremer</span>, <span class="hlFld-ContribAuthor ">Serika  Kokubu</span>, <span class="hlFld-ContribAuthor ">Adrian P.  Serone</span>, <span class="hlFld-ContribAuthor ">Eva L.  Hanze</span>, <span class="hlFld-ContribAuthor ">Anders  Viberg</span>, <span class="hlFld-ContribAuthor ">Alyssa M.  Morimoto</span>, <span class="hlFld-ContribAuthor ">Helen R.  Winter</span>, <span class="hlFld-ContribAuthor ">Tamiko R.  Katsumoto</span>. </span><span class="cited-content_cbyCitation_article-title">Safety, Pharmacokinetics, and Pharmacodynamics in Healthy Volunteers Treated With GDC‐0853, a Selective Reversible Bruton's Tyrosine Kinase Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Clinical Pharmacology & Therapeutics</span><span> <strong>2018,</strong> <em>103 </em>
                                    (6)
                                     , 1020-1028. <a href="https://doi.org/10.1002/cpt.1056" title="DOI URL">https://doi.org/10.1002/cpt.1056</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cpt.1056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcpt.1056%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Pharmacology%2520%2526%2520Therapeutics%26atitle%3DSafety%25252C%252BPharmacokinetics%25252C%252Band%252BPharmacodynamics%252Bin%252BHealthy%252BVolunteers%252BTreated%252BWith%252BGDC%2525E2%252580%2525900853%25252C%252Ba%252BSelective%252BReversible%252BBruton%252527s%252BTyrosine%252BKinase%252BInhibitor%26aulast%3DHerman%26aufirst%3DAnn%2BE.%26date%3D2018%26date%3D2018%26volume%3D103%26issue%3D6%26spage%3D1020%26epage%3D1028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/medium/jm-2017-017125_0024.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/large/jm-2017-017125_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01712&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/medium/jm-2017-017125_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/large/jm-2017-017125_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Selected examples of clinical stage Btk inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/large/jm-2017-017125_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01712&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/medium/jm-2017-017125_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/large/jm-2017-017125_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Progression of Genentech’s published Btk inhibitors from GDC-0834 to G-278.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/large/jm-2017-017125_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01712&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/medium/jm-2017-017125_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/large/jm-2017-017125_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Matched pair plots for Btk inhibitors containing an Ar–F (l) or pyridyl (r) linker. Lines join matched pairs: (a) HLM stability (mL/min/kg) and (b) LLE = p<i>K</i><sub>i</sub> – clogD.<a onclick="showRef(event, 'ref47 ref48'); return false;" href="javascript:void(0);" class="ref ref47 ref48">(47,48)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/large/jm-2017-017125_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01712&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/medium/jm-2017-017125_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/large/jm-2017-017125_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Solvent exposed surface of Btk around the oxetanylpiperazine motifs: (A) model of oxetanylpiperazine.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> and (B) from the X-ray cocrystal structure of <b>29</b> bound to Btk (see <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/large/jm-2017-017125_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01712&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/medium/jm-2017-017125_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/large/jm-2017-017125_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. X-ray cocrystal structure of the <b>29</b>/Btk kinase domain complex (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5VFI">5VFI</a>) with key residues labeled. The molecular surface of <b>29</b> is in blue and protein–ligand H-bonds are shown as dashed lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/large/jm-2017-017125_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01712&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/medium/jm-2017-017125_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/large/jm-2017-017125_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. (a) Kinase selectivity of Btk inhibitors ibrutinib <b>1</b>, spebrutinib <b>2</b>, tirabrutinib <b>3</b>, acalabrutinib <b>4</b>, evobrutinib, BMS-986142, and GDC-0853 <b>29</b>. <i>In vitro</i> kinase selectivity for Btk inhibitors was determined in the SelectScreen panel (ThermoFisher, Madison, WI) comprised of activity assays and ATP site competitive binding assays. Percent (%) inhibition was assessed at a 1-μM test concentration: red, ≥80% inhibition; yellow, 50–80% inhibition; green, ≤50% inhibition or not tested. Compound <b>29</b> was tested in 287 total kinase assays, whereas the other 6 inhibitors were tested against a subset of approximately 220 of these kinases, and only those kinases that were tested against all 7 inhibitors are represented (see the <a href="/doi/suppl/10.1021/acs.jmedchem.7b01712/suppl_file/jm7b01712_si_002.pdf" class="ext-link">Supporting Information</a> for all of the % inhibition data against all kinases). (b) Potency of Btk inhibitors against off-target kinases. IC<sub>50</sub> values were determined as described in the methods against kinases that were inhibited by >50% at 1 μM. The IC<sub>50</sub> values for <b>29</b> and six other clinical stage Btk inhibitors are provided in the <a href="/doi/suppl/10.1021/acs.jmedchem.7b01712/suppl_file/jm7b01712_si_002.pdf" class="ext-link">Supporting Information</a>. Because of its low potency toward inhibition of Btk (IC<sub>50</sub> = 37.9 nM), no off-target IC<sub>50</sub> values were collected for evobrutinib. (c) Inhibition of kinases that have a cysteine that is analogous to Btk Cys-481. Inhibitors were tested at 1 μM as described above for <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>a and the % inhibition is shown.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/large/jm-2017-017125_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01712&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/medium/jm-2017-017125_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/large/jm-2017-017125_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. An <i>in vitro</i> biochemical jump dilution experiment illustrates the long Btk residence time of <b>29</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/large/jm-2017-017125_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01712&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/medium/jm-2017-017125_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/large/jm-2017-017125_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Efficacy of GDC-0853 (<b>29</b>) in rat type II collagen-induced arthritis (CIA). Female Lewis rats with developing CIA (<i>n</i> = 10 per group) were dosed orally either once (A) or twice (B) daily for 16 days (study days 0–15) with vehicle [HPMCT (pH 3): 1% HPMC E4M, 100 mM citrate buffer (pH 3), and 0.2% Tween 80], the indicated doses of <b>29</b> or the reference compound dexamethasone (0.05 mg/kg QD). Daily ankle diameter measurements are shown as mean ± SEM and were significantly (by ANOVA) reduced toward normal for all drug-treated rats as compared with the respective disease control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/large/jm-2017-017125_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01712&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/medium/jm-2017-017125_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/large/jm-2017-017125_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Plasma concentration of <b>29</b> vs time plots for female Lewis rats with developing CIA. Graphical representation of the pharmacokinetic profile of <b>29</b> after 6 days of once daily (A) or twice daily (B) oral dosing (i.e., study day 14 in <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). Each concentration represents a mean concentration from three rats from a satellite group designated for pharmacokinetic collections. For BID dosing (B), doses were given 12 h apart and concentrations were collected only for a 12-h period. Dotted lines denote the mean IC<sub>50</sub> = 9 nM, IC<sub>70</sub> = 27 nM, and IC<sub>90</sub> = 135 nM levels, as determined by inhibition of Btk Y223 autophosphorylation in rat whole blood.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/large/jm-2017-017125_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01712&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/medium/jm-2017-017125_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/large/jm-2017-017125_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Superposition of the X-ray structures of <b>29 (</b>GDC-0853) (cyan) and <b>1</b> (ibrutinib)<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> (purple) bound in the kinase domain of Btk. The orthogonal binding modes of these inhibitors are apparent: <b>1</b> (ibrutinib) occupies the kinase back pocket behind the gatekeeper T474 and also interacts with C481; <b>29</b> does neither.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/large/jm-2017-017125_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01712&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/medium/jm-2017-017125_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/large/jm-2017-017125_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. <b>29</b> (GDC-0853) blocked cellular autophosphorylation of WT Btk and the C481S mutant: (a) Btk protein levels and Btk Y223 autophosphorylation was assessed by western blotting, with anti-total or anti-pY223 Btk antibodies, respectively, of HEK293T cells transiently transfected with plasmids encoding WT (lane 2) or C481S Btk (lane 3) or nontransfected cells (lane 1). (b) <b>1</b> and <b>29</b> both blocked cellular autophosphorylation of Y223 in WT Btk. However, only <b>29</b> was able to inhibit cellular autophosphorylation of Y223 of the C481S Btk mutant protein. Ibrutinib (<b>1</b>) was unable to block cellular Y223 autophosphorylation of Btk C481S. The effect of <b>29</b> or <b>1</b> (ibrutinib) on WT Btk and Btk-C481S mutant phosphorylation on Y223 was assessed and quantified as previously described.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/large/jm-2017-017125_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01712&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/medium/jm-2017-017125_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/large/jm-2017-017125_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of <b>29</b> Part 1: Synthesis of Intermediate <b>42</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/large/jm-2017-017125_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01712&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Ethoxycarbonylmethylene triphenylphosphoran, benzene, 14 h, 37%; (b) NaN<sub>3</sub>, DMSO, 75 °C, 8 h, 37%; (c) NaH, DMF, bromoacetonitrile, 14 h, 95%; (d) 10% Pd/C, 12% HCl in EtOH/EtOAc, H<sub>2</sub> (50 psi), 6 h; (e) NaOEt, EtOH, 55 °C, overnight, 61%, 2 steps; (f) 2-bromo-4-chloronicotinaldehyde (<b>42</b>), Pd<sub>2</sub>(dba)<sub>3</sub>, Xantphos, Cs<sub>2</sub>CO<sub>3</sub>, dioxane, 100 °C, 5 h, 63%.</p></p></figure><figure data-id="sch2" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/medium/jm-2017-017125_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/large/jm-2017-017125_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of <b>29</b> Part 2<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-6/acs.jmedchem.7b01712/20180315/images/large/jm-2017-017125_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b01712&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Pd<sub>2</sub>(dba)<sub>3</sub>, BINAP, Cs<sub>2</sub>CO<sub>3</sub>, dioxane, 100 °C, 15 h, 63%; (b) H<sub>2</sub>, Pd/C, MeOH, 16 h, 93%; (c) 3,5-dibromo-1-methylpyridin-2(1<i>H</i>)-one, Pd<sub>2</sub>(dba)<sub>3</sub>, Xantphos, Cs<sub>2</sub>CO<sub>3</sub>, dioxane, 100 °C, 16 h, 61%; (d) HCl in dioxane, DCM, 4 h, 95%; (e) oxetan-3-one, NaBH<sub>3</sub>CN, ZnCl<sub>2</sub>, MeOH, 50 °C, 4 h, 73%; (f) bis(pinacolato)diboron, Pd<sub>2</sub>(dba)3, Xphos, KOAc, dioxane, 70 °C, 2 h, 90%; (g) Pd(dppf)Cl<sub>2</sub>, K<sub>3</sub>PO<sub>4</sub>, THF, H<sub>2</sub>O, reflux, 3 h, 31%; (h) NaBH<sub>4</sub>, MeOH, 1 h, 44%.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i39">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_36426" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_36426" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 63 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Satterthwaite, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witte, O. N.</span></span> <span> </span><span class="NLM_article-title">Btk Function In B Cell Development and Response</span>. <i>Semin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">309</span>– <span class="NLM_lpage">316</span>, <span class="refDoi"> DOI: 10.1006/smim.1998.0123</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1006%2Fsmim.1998.0123" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=9695187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADyaK1cXltlCiuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1998&pages=309-316&author=A.+B.+Satterthwaiteauthor=Z.+Liauthor=O.+N.+Witte&title=Btk+Function+In+B+Cell+Development+and+Response&doi=10.1006%2Fsmim.1998.0123"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Btk function in B cell development and response</span></div><div class="casAuthors">Satterthwaite, Anne B.; Li, Zuomei; Witte, Owen N.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Immunology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">309-316</span>CODEN:
                <span class="NLM_cas:coden">SEIME2</span>;
        ISSN:<span class="NLM_cas:issn">1044-5323</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">A review with 85 refs.  Mutations in Bruton's tyrosine kinase (Btk) result in the B cell immunodeficiencies XLA (X-linked agammaglobulinemia) in humans and Xid (X-linked immunodeficiency) in mice.  Both the maintenance of peripheral B cell nos. and their response to B cell antigen receptor (BCR) crosslinking depend on Btk.  Btk integrates signals from multiple cell surface receptors, including BCR and G-protein coupled receptors.  These Btk dependent signals control B cell proliferation and survival by mediating Ca2+ flux, activating JNK and p38 and inducing cell cycle regulatory genes.  (c) 1998 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVrVOyUeT25bVg90H21EOLACvtfcHk0ljN3Sutxo8ccQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXltlCiuro%253D&md5=f03605bc9f39d663d28794c7b7e40138</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1006%2Fsmim.1998.0123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fsmim.1998.0123%26sid%3Dliteratum%253Aachs%26aulast%3DSatterthwaite%26aufirst%3DA.%2BB.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DWitte%26aufirst%3DO.%2BN.%26atitle%3DBtk%2520Function%2520In%2520B%2520Cell%2520Development%2520and%2520Response%26jtitle%3DSemin.%2520Immunol.%26date%3D1998%26volume%3D10%26spage%3D309%26epage%3D316%26doi%3D10.1006%2Fsmim.1998.0123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khan, W. N.</span></span> <span> </span><span class="NLM_article-title">Regulation of B Lymphocyte Development and Activation by Bruton’s Tyrosine Kinase</span>. <i>Immunol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">147</span>– <span class="NLM_lpage">156</span>, <span class="refDoi"> DOI: 10.1385/IR:23:2-3:147</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1385%2FIR%3A23%3A2-3%3A147" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=11444380" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BD3MXltFWqsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2001&pages=147-156&author=W.+N.+Khan&title=Regulation+of+B+Lymphocyte+Development+and+Activation+by+Bruton%E2%80%99s+Tyrosine+Kinase&doi=10.1385%2FIR%3A23%3A2-3%3A147"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of B lymphocyte development and activation by Bruton's tyrosine kinase</span></div><div class="casAuthors">Khan, Wasif N.</div><div class="citationInfo"><span class="NLM_cas:title">Immunologic Research</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">2 & 3</span>),
    <span class="NLM_cas:pages">147-156</span>CODEN:
                <span class="NLM_cas:coden">IMRSEB</span>;
        ISSN:<span class="NLM_cas:issn">0257-277X</span>.
    
            (<span class="NLM_cas:orgname">Humana Press Inc.</span>)
        </div><div class="casAbstract">A review discussed the role of Bruton's tyrosine kinase in B lymphocyte development and activation.  The generation and maintenance of B lymphocytes is controlled by biochem. signals transmitted by the B cell antigen receptor (BCR) complex.  These signals are transduced by multiple cytoplasmic protein tyrosine kinases (PTKs) including Lyn, Syk, and Bruton's tyrosine kinase (BTK).  Upon BCR engagement, these PTKs activate downstream effectors, including transcription factors that modulate gene expression.  In turn, activation of downstream effectors is crit. for B cell survival, cell cycle progression, and antibody prodn.  Our studies focus on the role of BTK in these biol. responses.  We have discovered that BTK is required for activation of the BCR-responsive transcription factor, NF-κB.  Furthermore, BTK-dependent activation of NF-κB is essential for reprogramming the expression of genes that control B cell survival and proliferation.  The biochem. mechanisms by which BTK regulates signaling components that activate NF-κB, and the identification of BTK-responsive genes are under investigation.  Elucidation of these regulatory mechanisms is expected to reveal new therapeutic targets for B cell pathologies involving defects in BTK, including X-linked agammaglobulinemia (XLA).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrx0btKIFSX9LVg90H21EOLACvtfcHk0lhVe1n3BSk_DQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXltFWqsb0%253D&md5=564d950f06ab14daff2b45f5a3d863f4</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1385%2FIR%3A23%3A2-3%3A147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1385%252FIR%253A23%253A2-3%253A147%26sid%3Dliteratum%253Aachs%26aulast%3DKhan%26aufirst%3DW.%2BN.%26atitle%3DRegulation%2520of%2520B%2520Lymphocyte%2520Development%2520and%2520Activation%2520by%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%26jtitle%3DImmunol.%2520Res.%26date%3D2001%26volume%3D23%26spage%3D147%26epage%3D156%26doi%3D10.1385%2FIR%3A23%3A2-3%3A147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boucheron, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unger, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellmeier, W.</span></span> <span> </span><span class="NLM_article-title">The Role of Tec Family Kinases in Myeloid Cells</span>. <i>Int. Arch. Allergy Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>134</i></span>,  <span class="NLM_fpage">65</span>– <span class="NLM_lpage">78</span>, <span class="refDoi"> DOI: 10.1159/000078339</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1159%2F000078339" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=15133303" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BD2cXktFKlsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2004&pages=65-78&author=U.+Schmidtauthor=N.+Boucheronauthor=B.+Ungerauthor=W.+Ellmeier&title=The+Role+of+Tec+Family+Kinases+in+Myeloid+Cells&doi=10.1159%2F000078339"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The Role of Tec Family Kinases in Myeloid Cells</span></div><div class="casAuthors">Schmidt, Uwe; Boucheron, Nicole; Unger, Bernd; Ellmeier, Wilfried</div><div class="citationInfo"><span class="NLM_cas:title">International Archives of Allergy and Immunology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">134</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">65-78</span>CODEN:
                <span class="NLM_cas:coden">IAAIEG</span>;
        ISSN:<span class="NLM_cas:issn">1018-2438</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">A review.  Members of the Tec kinase family (Bmx, Btk, Itk, Rlk and Tec) are primarily expressed in the hematopoietic system and form, after the Src kinase family, the second largest class of non-receptor protein tyrosine kinases.  During lymphocyte development and activation Tec kinases have important functions in signaling pathways downstream of the antigen receptors.  Tec family kinases are also expressed in cells of the myeloid lineage.  However, with the exception of mast cells and platelets, their biol. role in the myeloid system is only poorly understood.  This review summarizes the current knowledge about the function of Tec family kinases in hematopoietic cells of the myeloid lineage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpewxKP7kBxe7Vg90H21EOLACvtfcHk0lhVe1n3BSk_DQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXktFKlsr8%253D&md5=e6e88b9b59049d9e55e95b6621a27453</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1159%2F000078339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000078339%26sid%3Dliteratum%253Aachs%26aulast%3DSchmidt%26aufirst%3DU.%26aulast%3DBoucheron%26aufirst%3DN.%26aulast%3DUnger%26aufirst%3DB.%26aulast%3DEllmeier%26aufirst%3DW.%26atitle%3DThe%2520Role%2520of%2520Tec%2520Family%2520Kinases%2520in%2520Myeloid%2520Cells%26jtitle%3DInt.%2520Arch.%2520Allergy%2520Immunol.%26date%3D2004%26volume%3D134%26spage%3D65%26epage%3D78%26doi%3D10.1159%2F000078339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brunner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirth, T.</span></span> <span> </span><span class="NLM_article-title">Bruton’s Tyrosine Kinase is Involved in Innate and Adaptive Immunity</span>. <i>Histol. Histopathol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">945</span>– <span class="NLM_lpage">955</span>, <span class="refDoi"> DOI: 10.14670/HH-20.945</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.14670%2FHH-20.945" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=15944945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpsFKjtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2005&pages=945-955&author=C.+Brunnerauthor=B.+M%C3%BCllerauthor=T.+Wirth&title=Bruton%E2%80%99s+Tyrosine+Kinase+is+Involved+in+Innate+and+Adaptive+Immunity&doi=10.14670%2FHH-20.945"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Bruton's Tyrosine Kinase is involved in innate and adaptive immunity</span></div><div class="casAuthors">Brunner, C.; Mueller, B.; Wirth, T.</div><div class="citationInfo"><span class="NLM_cas:title">Histology and Histopathology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">945-955</span>CODEN:
                <span class="NLM_cas:coden">HIHIES</span>;
        ISSN:<span class="NLM_cas:issn">0213-3911</span>.
    
            (<span class="NLM_cas:orgname">Jimenez Godoy, S.A.</span>)
        </div><div class="casAbstract">A review.  Btk is a cytoplasmic tyrosine kinase, which is mainly involved in B cell receptor signaling.  Gene targeting expts. revealed that Btk is important for B cell development and function.  However, Btk is not only expressed in B cells, but also in most other hematopoietic lineages except for T cells and plasma cells.  Recently we found that Btk is involved in Toll-like receptor signaling.  Toll-like receptors play an important role in innate immunity.  They are highly expressed on mast cells, macrophages and dendritic cells, which are essential for the recognition and consequently for the elimination of microbial pathogens.  Therefore Btk might play an important role for the function of immunocompetent cells of innate as well as adaptive immunity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQA-9NFdeNr7Vg90H21EOLACvtfcHk0lhVe1n3BSk_DQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpsFKjtL4%253D&md5=97cbcc5df2704d4b58933085ab8ff929</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.14670%2FHH-20.945&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.14670%252FHH-20.945%26sid%3Dliteratum%253Aachs%26aulast%3DBrunner%26aufirst%3DC.%26aulast%3DM%25C3%25BCller%26aufirst%3DB.%26aulast%3DWirth%26aufirst%3DT.%26atitle%3DBruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520is%2520Involved%2520in%2520Innate%2520and%2520Adaptive%2520Immunity%26jtitle%3DHistol.%2520Histopathol.%26date%3D2005%26volume%3D20%26spage%3D945%26epage%3D955%26doi%3D10.14670%2FHH-20.945" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di
Paolo, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balazs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbosa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barck, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bravo, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carano, R. A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darrow, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeForge, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diehl, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrando, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallion, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giannetti, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gribling, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hymowitz, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kropf, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maciejewski, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staker, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitney, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currie, K. S.</span></span> <span> </span><span class="NLM_article-title">Specific Btk Inhibition Suppresses B Cell- And Myeloid Cell-Mediated Arthritis</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">50</span>, <span class="refDoi"> DOI: 10.1038/nchembio.481</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1038%2Fnchembio.481" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=21113169" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVOrsLjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=41-50&author=J.+A.+Di%0APaoloauthor=T.+Huangauthor=M.+Balazsauthor=J.+Barbosaauthor=K.+H.+Barckauthor=B.+J.+Bravoauthor=R.+A.+D.+Caranoauthor=J.+Darrowauthor=D.+R.+Daviesauthor=L.+E.+DeForgeauthor=L.+Diehlauthor=R.+Ferrandoauthor=S.+L.+Gallionauthor=A.+M.+Giannettiauthor=P.+Griblingauthor=V.+Hurezauthor=S.+G.+Hymowitzauthor=R.+Jonesauthor=J.+E.+Kropfauthor=W.+P.+Leeauthor=P.+M.+Maciejewskiauthor=S.+A.+Mitchellauthor=H.+Rongauthor=B.+L.+Stakerauthor=J.+A.+Whitneyauthor=S.+Yehauthor=W.+B.+Youngauthor=C.+Yuauthor=J.+Zhangauthor=K.+Reifauthor=K.+S.+Currie&title=Specific+Btk+Inhibition+Suppresses+B+Cell-+And+Myeloid+Cell-Mediated+Arthritis&doi=10.1038%2Fnchembio.481"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis</span></div><div class="casAuthors">Di Paolo, Julie A.; Huang, Tao; Balazs, Mercedesz; Barbosa, James; Barck, Kai H.; Bravo, Brandon J.; Carano, Richard A. D.; Darrow, James; Davies, Douglas R.; DeForge, Laura E.; Diehl, Lauri; Ferrando, Ronald; Gallion, Steven L.; Giannetti, Anthony M.; Gribling, Peter; Hurez, Vincent; Hymowitz, Sarah G.; Jones, Randall; Kropf, Jeffrey E.; Lee, Wyne P.; Maciejewski, Patricia M.; Mitchell, Scott A.; Rong, Hong; Staker, Bart L.; Whitney, J. Andrew; Yeh, Sherry; Young, Wendy B.; Yu, Christine; Zhang, Juan; Reif, Karin; Currie, Kevin S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-50</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (Btk) is a therapeutic target for rheumatoid arthritis, but the cellular and mol. mechanisms by which Btk mediates inflammation are poorly understood.  Here we describe the discovery of CGI1746, a small-mol. Btk inhibitor chemotype with a new binding mode that stabilizes an inactive nonphosphorylated enzyme conformation.  CGI1746 has exquisite selectivity for Btk and inhibits both auto- and transphosphorylation steps necessary for enzyme activation.  Using CGI1746, we demonstrate that Btk regulates inflammatory arthritis by two distinct mechanisms.  CGI1746 blocks B cell receptor-dependent B cell proliferation and in prophylactic regimens reduces autoantibody levels in collagen-induced arthritis.  In macrophages, Btk inhibition abolishes FcγRIII-induced TNFα, IL-1β and IL-6 prodn.  Accordingly, in myeloid- and FcγR-dependent autoantibody-induced arthritis, CGI1746 decreases cytokine levels within joints and ameliorates disease.  These results provide new understanding of the function of Btk in both B cell- or myeloid cell-driven disease processes and provide a compelling rationale for targeting Btk in rheumatoid arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoegiZYoitP57Vg90H21EOLACvtfcHk0lhowhP2CLbJGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVOrsLjP&md5=99d925c71bc1b201191ebde0f1c0b50f</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.481&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.481%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BPaolo%26aufirst%3DJ.%2BA.%26aulast%3DHuang%26aufirst%3DT.%26aulast%3DBalazs%26aufirst%3DM.%26aulast%3DBarbosa%26aufirst%3DJ.%26aulast%3DBarck%26aufirst%3DK.%2BH.%26aulast%3DBravo%26aufirst%3DB.%2BJ.%26aulast%3DCarano%26aufirst%3DR.%2BA.%2BD.%26aulast%3DDarrow%26aufirst%3DJ.%26aulast%3DDavies%26aufirst%3DD.%2BR.%26aulast%3DDeForge%26aufirst%3DL.%2BE.%26aulast%3DDiehl%26aufirst%3DL.%26aulast%3DFerrando%26aufirst%3DR.%26aulast%3DGallion%26aufirst%3DS.%2BL.%26aulast%3DGiannetti%26aufirst%3DA.%2BM.%26aulast%3DGribling%26aufirst%3DP.%26aulast%3DHurez%26aufirst%3DV.%26aulast%3DHymowitz%26aufirst%3DS.%2BG.%26aulast%3DJones%26aufirst%3DR.%26aulast%3DKropf%26aufirst%3DJ.%2BE.%26aulast%3DLee%26aufirst%3DW.%2BP.%26aulast%3DMaciejewski%26aufirst%3DP.%2BM.%26aulast%3DMitchell%26aufirst%3DS.%2BA.%26aulast%3DRong%26aufirst%3DH.%26aulast%3DStaker%26aufirst%3DB.%2BL.%26aulast%3DWhitney%26aufirst%3DJ.%2BA.%26aulast%3DYeh%26aufirst%3DS.%26aulast%3DYoung%26aufirst%3DW.%2BB.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26atitle%3DSpecific%2520Btk%2520Inhibition%2520Suppresses%2520B%2520Cell-%2520And%2520Myeloid%2520Cell-Mediated%2520Arthritis%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2011%26volume%3D7%26spage%3D41%26epage%3D50%26doi%3D10.1038%2Fnchembio.481" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rawlings, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saffran, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukada, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Largaespada, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimaldi, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohr, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bazan, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witte, O. N.</span></span> <span> </span><span class="NLM_article-title">Mutation of Unique Region of Bruton’s Tyrosine Kinase in Immunodeficient XID Mice</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>261</i></span>,  <span class="NLM_fpage">358</span>– <span class="NLM_lpage">361</span>, <span class="refDoi"> DOI: 10.1126/science.8332901</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1126%2Fscience.8332901" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=261&publication_year=1993&pages=358-361&author=D.+J.+Rawlingsauthor=D.+C.+Saffranauthor=S.+Tsukadaauthor=D.+A.+Largaespadaauthor=J.+C.+Grimaldiauthor=L.+Cohenauthor=R.+N.+Mohrauthor=J.+F.+Bazanauthor=M.+Howardauthor=N.+G.+Copelandauthor=N.+A.+Jenkinsauthor=O.+N.+Witte&title=Mutation+of+Unique+Region+of+Bruton%E2%80%99s+Tyrosine+Kinase+in+Immunodeficient+XID+Mice&doi=10.1126%2Fscience.8332901"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1126%2Fscience.8332901&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.8332901%26sid%3Dliteratum%253Aachs%26aulast%3DRawlings%26aufirst%3DD.%2BJ.%26aulast%3DSaffran%26aufirst%3DD.%2BC.%26aulast%3DTsukada%26aufirst%3DS.%26aulast%3DLargaespada%26aufirst%3DD.%2BA.%26aulast%3DGrimaldi%26aufirst%3DJ.%2BC.%26aulast%3DCohen%26aufirst%3DL.%26aulast%3DMohr%26aufirst%3DR.%2BN.%26aulast%3DBazan%26aufirst%3DJ.%2BF.%26aulast%3DHoward%26aufirst%3DM.%26aulast%3DCopeland%26aufirst%3DN.%2BG.%26aulast%3DJenkins%26aufirst%3DN.%2BA.%26aulast%3DWitte%26aufirst%3DO.%2BN.%26atitle%3DMutation%2520of%2520Unique%2520Region%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520in%2520Immunodeficient%2520XID%2520Mice%26jtitle%3DScience%26date%3D1993%26volume%3D261%26spage%3D358%26epage%3D361%26doi%3D10.1126%2Fscience.8332901" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Satterthwaite, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witte, O. N.</span></span> <span> </span><span class="NLM_article-title">The Role of Bruton’s Tyrosine Kinase in B-cell Development and Function: a Genetic Perspective,</span>. <i>Immunol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>175</i></span>,  <span class="NLM_fpage">120</span>– <span class="NLM_lpage">127</span>, <span class="refDoi"> DOI: 10.1111/j.1600-065X.2000.imr017504.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1111%2Fj.1600-065X.2000.imr017504.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10933597" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BD3cXls12gs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=2000&pages=120-127&author=A.+B.+Satterthwaiteauthor=O.+N.+Witte&title=The+Role+of+Bruton%E2%80%99s+Tyrosine+Kinase+in+B-cell+Development+and+Function%3A+a+Genetic+Perspective%2C&doi=10.1111%2Fj.1600-065X.2000.imr017504.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The role of Bruton's tyrosine kinase in B-cell development and function: A genetic perspective</span></div><div class="casAuthors">Satterthwaite, Anne B.; Witte, Owen N.</div><div class="citationInfo"><span class="NLM_cas:title">Immunological Reviews</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">175</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">120-127</span>CODEN:
                <span class="NLM_cas:coden">IMRED2</span>;
        ISSN:<span class="NLM_cas:issn">0105-2896</span>.
    
            (<span class="NLM_cas:orgname">Munksgaard International Publishers Ltd.</span>)
        </div><div class="casAbstract">A review with 95 refs.  Mutations in Bruton's tyrosine kinase (Btk) result in the B-cell immunodeficiencies X-linked agammaglobulinemia in humans and X-linked immunodeficiency in mice.  These diseases are characterized by blocks in B-cell development at multiple stages and impaired function of residual mature B cells.  The authors focus here on a series of in vivo genetic studies that have begun to define the mechanism by which Btk regulates B-cell development and function.  The functional interactions between Btk and other signaling mols. defined by this approach are more complex than initially appreciated from in vitro biochem. and cell culture studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpysAcsASekh7Vg90H21EOLACvtfcHk0lhowhP2CLbJGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXls12gs7g%253D&md5=8fb36554501b75b645cc2a807c29d6ac</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-065X.2000.imr017504.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-065X.2000.imr017504.x%26sid%3Dliteratum%253Aachs%26aulast%3DSatterthwaite%26aufirst%3DA.%2BB.%26aulast%3DWitte%26aufirst%3DO.%2BN.%26atitle%3DThe%2520Role%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520in%2520B-cell%2520Development%2520and%2520Function%253A%2520a%2520Genetic%2520Perspective%252C%26jtitle%3DImmunol.%2520Rev.%26date%3D2000%26volume%3D175%26spage%3D120%26epage%3D127%26doi%3D10.1111%2Fj.1600-065X.2000.imr017504.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Genevier, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinshelwood, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaspar, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rigley, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saeland, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rousset, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levinsky, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callard, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinnon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovering, R. C.</span></span> <span> </span><span class="NLM_article-title">Expression of Bruton’s Tyrosine Kinase Protein Within the B Cell Lineage</span>. <i>Eur. J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">3100</span>– <span class="NLM_lpage">3105</span>, <span class="refDoi"> DOI: 10.1002/eji.1830241228</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1002%2Feji.1830241228" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=1994&pages=3100-3105&author=H.+C.+Genevierauthor=S.+Hinshelwoodauthor=H.+B.+Gasparauthor=K.+P.+Rigleyauthor=D.+Brownauthor=S.+Saelandauthor=F.+Roussetauthor=R.+J.+Levinskyauthor=R.+E.+Callardauthor=C.+Kinnonauthor=R.+C.+Lovering&title=Expression+of+Bruton%E2%80%99s+Tyrosine+Kinase+Protein+Within+the+B+Cell+Lineage&doi=10.1002%2Feji.1830241228"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1002%2Feji.1830241228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Feji.1830241228%26sid%3Dliteratum%253Aachs%26aulast%3DGenevier%26aufirst%3DH.%2BC.%26aulast%3DHinshelwood%26aufirst%3DS.%26aulast%3DGaspar%26aufirst%3DH.%2BB.%26aulast%3DRigley%26aufirst%3DK.%2BP.%26aulast%3DBrown%26aufirst%3DD.%26aulast%3DSaeland%26aufirst%3DS.%26aulast%3DRousset%26aufirst%3DF.%26aulast%3DLevinsky%26aufirst%3DR.%2BJ.%26aulast%3DCallard%26aufirst%3DR.%2BE.%26aulast%3DKinnon%26aufirst%3DC.%26aulast%3DLovering%26aufirst%3DR.%2BC.%26atitle%3DExpression%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520Protein%2520Within%2520the%2520B%2520Cell%2520Lineage%26jtitle%3DEur.%2520J.%2520Immunol.%26date%3D1994%26volume%3D24%26spage%3D3100%26epage%3D3105%26doi%3D10.1002%2Feji.1830241228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bruton, O. C.</span></span> <span> </span><span class="NLM_article-title">Agammaglobulinemia</span>. <i>Pediatrics</i> <span class="NLM_year" style="font-weight: bold;">1952</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">722</span>– <span class="NLM_lpage">729</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=14929630" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A280%3ADyaG38%252FlvFOnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1952&pages=722-729&author=O.+C.+Bruton&title=Agammaglobulinemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Agammaglobulinemia</span></div><div class="casAuthors">BRUTON O C</div><div class="citationInfo"><span class="NLM_cas:title">Pediatrics</span>
        (<span class="NLM_cas:date">1952</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">722-8</span>
        ISSN:<span class="NLM_cas:issn">0031-4005</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ99IDXIc3tbqqcneEtCi92fW6udTcc2ea78ZnSbcqHALntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaG38%252FlvFOnsg%253D%253D&md5=737a40c8a7c8f591efca619f2ba894aa</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBruton%26aufirst%3DO.%2BC.%26atitle%3DAgammaglobulinemia%26jtitle%3DPediatrics%26date%3D1952%26volume%3D9%26spage%3D722%26epage%3D729" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaveri, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maddur, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hegde, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacroix-Desmazes, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bayry, J.</span></span> <span> </span><span class="NLM_article-title">Intravenous Immunoglobulins in Immunodeficiencies: More Than Mere Replacement Therapy</span>. <i>Clin. Exp. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>164</i></span> (<span class="NLM_issue">Suppl 2</span>),  <span class="NLM_fpage">2</span>– <span class="NLM_lpage">5</span>, <span class="refDoi"> DOI: 10.1111/j.1365-2249.2011.04387.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1111%2Fj.1365-2249.2011.04387.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=21466545" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnvVehtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=164&publication_year=2011&pages=2-5&issue=Suppl+2&author=S.+V.+Kaveriauthor=M.+S.+Maddurauthor=P.+Hegdeauthor=S.+Lacroix-Desmazesauthor=J.+Bayry&title=Intravenous+Immunoglobulins+in+Immunodeficiencies%3A+More+Than+Mere+Replacement+Therapy&doi=10.1111%2Fj.1365-2249.2011.04387.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Intravenous immunoglobulins in immunodeficiencies: more than mere replacement therapy</span></div><div class="casAuthors">Kaveri, S. V.; Maddur, M. S.; Hegde, P.; Lacroix-Desmazes, S.; Bayry, J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and Experimental Immunology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">164</span>
        (<span class="NLM_cas:issue">Suppl. 2</span>),
    <span class="NLM_cas:pages">2-5</span>CODEN:
                <span class="NLM_cas:coden">CEXIAL</span>;
        ISSN:<span class="NLM_cas:issn">0009-9104</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  I.v. Ig (IVIG) is a therapeutic compd. prepd. from pools of plasma obtained from several thousand healthy blood donors.  For more than 20 years, IVIG has been used in the treatment of a wide range of primary and secondary immunodeficiencies.  IVIG now represents a std. therapeutic option for most antibody deficiencies.  Routinely, IVIG is used in patients with X-linked agammaglobulinemia (XLA), common variable immunodeficiency (CVID), X-linked hyper-IgM, severe combined immunodeficiency, Wiskott-Aldrich syndrome, and selective IgG class deficiency.  In addn., IVIG is used extensively in the treatment of a wide variety of autoimmune disorders.  IVIG is administered at distinct doses in the two clin. settings: whereas immunodeficient patients are treated with replacement levels of IVIG, patients with autoimmune and inflammatory diseases are administered with very high doses of IVIG.  Several lines of exptl. evidence gathered in the recent years suggest that the therapeutic beneficial effect of IVIG in immunodeficiencies reflects an active role for IVIG, rather than a mere passive transfer of antibodies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCxnh_OFe14bVg90H21EOLACvtfcHk0li3l8znPVkkAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnvVehtLs%253D&md5=483fc8a4b947e21a248a66c148d9075f</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2249.2011.04387.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2249.2011.04387.x%26sid%3Dliteratum%253Aachs%26aulast%3DKaveri%26aufirst%3DS.%2BV.%26aulast%3DMaddur%26aufirst%3DM.%2BS.%26aulast%3DHegde%26aufirst%3DP.%26aulast%3DLacroix-Desmazes%26aufirst%3DS.%26aulast%3DBayry%26aufirst%3DJ.%26atitle%3DIntravenous%2520Immunoglobulins%2520in%2520Immunodeficiencies%253A%2520More%2520Than%2520Mere%2520Replacement%2520Therapy%26jtitle%3DClin.%2520Exp.%2520Immunol.%26date%3D2011%26volume%3D164%26issue%3DSuppl%25202%26spage%3D2%26epage%3D5%26doi%3D10.1111%2Fj.1365-2249.2011.04387.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ochs, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. I.</span></span> <span> </span><span class="NLM_article-title">X-linked Agammaglobulinemia. A Clinical and Molecular Analysis</span>. <i>Medicine</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">287</span>– <span class="NLM_lpage">299</span>, <span class="refDoi"> DOI: 10.1097/00005792-199611000-00001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1097%2F00005792-199611000-00001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=8982147" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A280%3ADyaK2s7js1Oksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=1996&pages=287-299&author=H.+D.+Ochsauthor=C.+I.+Smith&title=X-linked+Agammaglobulinemia.+A+Clinical+and+Molecular+Analysis&doi=10.1097%2F00005792-199611000-00001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">X-linked agammaglobulinemia. A clinical and molecular analysis</span></div><div class="casAuthors">Ochs H D; Smith C I</div><div class="citationInfo"><span class="NLM_cas:title">Medicine</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">287-99</span>
        ISSN:<span class="NLM_cas:issn">0025-7974</span>.
    </div><div class="casAbstract">X-linked agammaglobulinemia (XLA), characterized by a profound deficiency of B lymphocytes due to an arrest in B lymphocyte development, is caused by mutations in the gene encoding Btk (Bruton tyrosine kinase).  The BTK gene has been cloned and the genomic organization determined.  BTK codes for 19 exons and is expressed in all hematopoietic cell lineages but is selectively down-regulated in T lymphocytes and plasma cells.  The different Btk domains include PH, TH, SH3, SH2, and the kinase (SH1) domains.  Btk, a cytoplasmic protein tyrosine kinase, is involved in cell signaling, although the precise pathway remains elusive.  Mutation analysis has been performed in 236 families representing 282 patients.  Mutations are scattered throughout the gene and consist of missense, nonsense, and splice site mutations as well as deletions and insertions.  The major consequence of nonfunctional Btk appears to be a delay or block of the development of pro-B cells to pre-B cells and then to mature lymphocytes.  Because IgG is actively transported across the placenta, affected newborns have normal levels of serum IgG at birth followed by gradually decreasing IgG levels and development of hypogammaglobulinemia and increased susceptibility to infections.  Bacterial infections are the most common clinical manifestation.  Resistance to viral infection is intact, except for an unusual susceptibility to infections with enteroviruses that may result in vaccine-related paralytic poliomyelitis or a dermatomyositis-meningoencephalitis syndrome.  The diagnosis of XLA is based on the presence of lymphoid hypoplasia, markedly reduced serum levels of all 3 major classes of immunoglobulins, failure to make antibody to antigenic stimulation, and almost complete absence of B lymphocytes in the peripheral blood.  Carrier detection and prenatal diagnosis are possible.  The prophylactic infusion of high-dose intravenous immunoglobulin (IVIG) and the use of antibiotics have markedly improved the long-term prognosis of patients with XLA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTcFX6ocpNz4tts4TFFB11gfW6udTcc2ea78ZnSbcqHALntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2s7js1Oksg%253D%253D&md5=a8f9be39459087b1de4975aa6067eee5</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1097%2F00005792-199611000-00001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00005792-199611000-00001%26sid%3Dliteratum%253Aachs%26aulast%3DOchs%26aufirst%3DH.%2BD.%26aulast%3DSmith%26aufirst%3DC.%2BI.%26atitle%3DX-linked%2520Agammaglobulinemia.%2520A%2520Clinical%2520and%2520Molecular%2520Analysis%26jtitle%3DMedicine%26date%3D1996%26volume%3D75%26spage%3D287%26epage%3D299%26doi%3D10.1097%2F00005792-199611000-00001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">So, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fruman, D. A.</span></span> <span> </span><span class="NLM_article-title">PI3K Signalling In B- and T-Lymphocytes: New Developments and Therapeutic Advances</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>442</i></span>,  <span class="NLM_fpage">465</span>– <span class="NLM_lpage">481</span>, <span class="refDoi"> DOI: 10.1042/BJ20112092</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1042%2FBJ20112092" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=442&publication_year=2012&pages=465-481&author=L.+Soauthor=D.+A.+Fruman&title=PI3K+Signalling+In+B-+and+T-Lymphocytes%3A+New+Developments+and+Therapeutic+Advances&doi=10.1042%2FBJ20112092"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1042%2FBJ20112092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20112092%26sid%3Dliteratum%253Aachs%26aulast%3DSo%26aufirst%3DL.%26aulast%3DFruman%26aufirst%3DD.%2BA.%26atitle%3DPI3K%2520Signalling%2520In%2520B-%2520and%2520T-Lymphocytes%253A%2520New%2520Developments%2520and%2520Therapeutic%2520Advances%26jtitle%3DBiochem.%2520J.%26date%3D2012%26volume%3D442%26spage%3D465%26epage%3D481%26doi%3D10.1042%2FBJ20112092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Puri, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Paolo, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gold, M. R.</span></span> <span> </span><span class="NLM_article-title">B-cell Receptor Signaling Inhibitors for Treatment of Autoimmune Inflammatory Diseases and B-cell Malignancies</span>. <i>Int. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">397</span>– <span class="NLM_lpage">427</span>, <span class="refDoi"> DOI: 10.3109/08830185.2013.818140</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.3109%2F08830185.2013.818140" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=23886342" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFygsrrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2013&pages=397-427&author=K.+D.+Puriauthor=J.+A.+Di+Paoloauthor=M.+R.+Gold&title=B-cell+Receptor+Signaling+Inhibitors+for+Treatment+of+Autoimmune+Inflammatory+Diseases+and+B-cell+Malignancies&doi=10.3109%2F08830185.2013.818140"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">B-Cell Receptor Signaling Inhibitors for Treatment of Autoimmune Inflammatory Diseases and B-Cell Malignancies</span></div><div class="casAuthors">Puri, Kamal D.; Di Paolo, Julie A.; Gold, Michael R.</div><div class="citationInfo"><span class="NLM_cas:title">International Reviews of Immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">397-427</span>CODEN:
                <span class="NLM_cas:coden">IRIMEH</span>;
        ISSN:<span class="NLM_cas:issn">0883-0185</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  B-cell receptor (BCR) signaling is essential for normal B-cell development, selection, survival, proliferation, and differentiation into antibody-secreting cells.  Similarly, this pathway plays a key role in the pathogenesis of multiple B-cell malignancies.  Genetic and pharmacol. approaches have established an important role for the Spleen tyrosine kinase (Syk), Bruton's tyrosine kinase (Btk), and phosphatidylinositol 3-kinase isoform p110delta (PI3Kδ) in coupling the BCR and other BCRs to B-cell survival, migration, and activation.  In the past few years, several small-mol. inhibitory drugs that target PI3Kδ, Btk, and Syk have been developed and shown to have efficacy in clin. trials for the treatment of several types of B-cell malignancies.  Emerging preclin. data have also shown a crit. role of BCR signaling in the activation and function of self-reactive B cells that contribute to autoimmune diseases.  Because BCR signaling plays a major role in both B-cell-mediated autoimmune inflammation and B-cell malignancies, inhibition of this pathway may represent a promising new strategy for treating these diseases.  This review summarizes recent achievements in the mechanism of action, pharmacol. properties, and clin. activity and toxicity of these BCR signaling inhibitors, with a focus on their emerging role in treating lymphoid malignancies and autoimmune disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpLDUjmfDEurVg90H21EOLACvtfcHk0ljoME-Md_Mcng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFygsrrO&md5=85ace1d58bb75405311bfe4a613ae2a7</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.3109%2F08830185.2013.818140&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F08830185.2013.818140%26sid%3Dliteratum%253Aachs%26aulast%3DPuri%26aufirst%3DK.%2BD.%26aulast%3DDi%2BPaolo%26aufirst%3DJ.%2BA.%26aulast%3DGold%26aufirst%3DM.%2BR.%26atitle%3DB-cell%2520Receptor%2520Signaling%2520Inhibitors%2520for%2520Treatment%2520of%2520Autoimmune%2520Inflammatory%2520Diseases%2520and%2520B-cell%2520Malignancies%26jtitle%3DInt.%2520Rev.%2520Immunol.%26date%3D2013%26volume%3D32%26spage%3D397%26epage%3D427%26doi%3D10.3109%2F08830185.2013.818140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katewa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hackney, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suto, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramamoorthi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bremer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currie, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blomgren, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeVoss, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiPaolo, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesch, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeForge, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liimatta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubach, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McVay, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modrusan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Townsend, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, K.</span></span> <span> </span><span class="NLM_article-title">Btk-Specific Inhibition Blocks Pathogenic Plasma Cell Signatures and Myeloid Cell-Associated Damage in IFN-α Driven Lupus Nephritis</span>. <i>JCI Insight</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">e90111</span>, <span class="refDoi"> DOI: 10.1172/jci.insight.90111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1172%2Fjci.insight.90111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=28405610" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2017&pages=e90111&author=A.+Katewaauthor=Y.+Wangauthor=J.+A.+Hackneyauthor=T.+Huangauthor=E.+Sutoauthor=N.+Ramamoorthiauthor=C.+D.+Austinauthor=M.+Bremerauthor=J.+Z.+Chenauthor=J.+J.+Crawfordauthor=K.+S.+Currieauthor=P.+Blomgrenauthor=J.+DeVossauthor=J.+A.+DiPaoloauthor=J.+Hauauthor=A.+Johnsonauthor=J.+Leschauthor=L.+E.+DeForgeauthor=Z.+Linauthor=M.+Liimattaauthor=J.+W.+Lubachauthor=S.+McVayauthor=Z.+Modrusanauthor=A.+Nguyenauthor=C.+Poonauthor=J.+Wangauthor=L.+Liuauthor=W.+P.+Leeauthor=H.+Wongauthor=W.+B.+Youngauthor=M.+J.+Townsendauthor=K.+Reif&title=Btk-Specific+Inhibition+Blocks+Pathogenic+Plasma+Cell+Signatures+and+Myeloid+Cell-Associated+Damage+in+IFN-%CE%B1+Driven+Lupus+Nephritis&doi=10.1172%2Fjci.insight.90111"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1172%2Fjci.insight.90111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252Fjci.insight.90111%26sid%3Dliteratum%253Aachs%26aulast%3DKatewa%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DHackney%26aufirst%3DJ.%2BA.%26aulast%3DHuang%26aufirst%3DT.%26aulast%3DSuto%26aufirst%3DE.%26aulast%3DRamamoorthi%26aufirst%3DN.%26aulast%3DAustin%26aufirst%3DC.%2BD.%26aulast%3DBremer%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DJ.%2BZ.%26aulast%3DCrawford%26aufirst%3DJ.%2BJ.%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26aulast%3DBlomgren%26aufirst%3DP.%26aulast%3DDeVoss%26aufirst%3DJ.%26aulast%3DDiPaolo%26aufirst%3DJ.%2BA.%26aulast%3DHau%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DA.%26aulast%3DLesch%26aufirst%3DJ.%26aulast%3DDeForge%26aufirst%3DL.%2BE.%26aulast%3DLin%26aufirst%3DZ.%26aulast%3DLiimatta%26aufirst%3DM.%26aulast%3DLubach%26aufirst%3DJ.%2BW.%26aulast%3DMcVay%26aufirst%3DS.%26aulast%3DModrusan%26aufirst%3DZ.%26aulast%3DNguyen%26aufirst%3DA.%26aulast%3DPoon%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DLee%26aufirst%3DW.%2BP.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DYoung%26aufirst%3DW.%2BB.%26aulast%3DTownsend%26aufirst%3DM.%2BJ.%26aulast%3DReif%26aufirst%3DK.%26atitle%3DBtk-Specific%2520Inhibition%2520Blocks%2520Pathogenic%2520Plasma%2520Cell%2520Signatures%2520and%2520Myeloid%2520Cell-Associated%2520Damage%2520in%2520IFN-%25CE%25B1%2520Driven%2520Lupus%2520Nephritis%26jtitle%3DJCI%2520Insight%26date%3D2017%26volume%3D2%26spage%3De90111%26doi%3D10.1172%2Fjci.insight.90111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheerens, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultz, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sprengeler, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrill, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mendonca, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, K. C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grothaus, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeffery, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spoerke, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honigberg, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dalrymple, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, J. T.</span></span> <span> </span><span class="NLM_article-title">Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">58</span>– <span class="NLM_lpage">61</span>, <span class="refDoi"> DOI: 10.1002/cmdc.200600221</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1002%2Fcmdc.200600221" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=17154430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsVWjsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=58-61&author=Z.+Panauthor=H.+Scheerensauthor=S.-J.+Liauthor=B.+E.+Schultzauthor=P.+A.+Sprengelerauthor=L.+C.+Burrillauthor=R.+V.+Mendoncaauthor=M.+D.+Sweeneyauthor=K.+C.+K.+Scottauthor=P.+G.+Grothausauthor=D.+A.+Jefferyauthor=J.+M.+Spoerkeauthor=L.+A.+Honigbergauthor=P.+R.+Youngauthor=S.+A.+Dalrympleauthor=J.+T.+Palmer&title=Discovery+of+Selective+Irreversible+Inhibitors+for+Bruton%E2%80%99s+Tyrosine+Kinase&doi=10.1002%2Fcmdc.200600221"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of selective irreversible inhibitors for bruton's tyrosine kinase</span></div><div class="casAuthors">Pan, Zhengying; Scheerens, Heleen; Li, Shyr-Jiann; Schultz, Brian E.; Sprengeler, Paul A.; Burrill, L. Chuck; Mendonca, Rohan V.; Sweeney, Michael D.; Scott, Keana C. K.; Grothaus, Paul G.; Jeffery, Douglas A.; Spoerke, Jill M.; Honigberg, Lee A.; Young, Peter R.; Dalrymple, Stacie A.; Palmer, James T.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">58-61</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Synthesis and pharmacol. evaluation of a series of peptidomimetic quinoline derivs. was undertaken to evaluate their efficacy in acting as selective irreversible inhibitors of Bruton's tyrosine kinase (Btk).  With the relative scarcity of knowledge on the inhibition of Btk it is crucial to discover a potent and selective tool compd. for this kinase.  Herein is described the discovery of selective irreversible Btk inhibitors and their efficacy in a mouse RA model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovT3kBCYECdbVg90H21EOLACvtfcHk0ljoME-Md_Mcng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsVWjsbg%253D&md5=023ba8bca9942ad0127d7cf32293e9d2</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200600221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200600221%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DZ.%26aulast%3DScheerens%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DS.-J.%26aulast%3DSchultz%26aufirst%3DB.%2BE.%26aulast%3DSprengeler%26aufirst%3DP.%2BA.%26aulast%3DBurrill%26aufirst%3DL.%2BC.%26aulast%3DMendonca%26aufirst%3DR.%2BV.%26aulast%3DSweeney%26aufirst%3DM.%2BD.%26aulast%3DScott%26aufirst%3DK.%2BC.%2BK.%26aulast%3DGrothaus%26aufirst%3DP.%2BG.%26aulast%3DJeffery%26aufirst%3DD.%2BA.%26aulast%3DSpoerke%26aufirst%3DJ.%2BM.%26aulast%3DHonigberg%26aufirst%3DL.%2BA.%26aulast%3DYoung%26aufirst%3DP.%2BR.%26aulast%3DDalrymple%26aufirst%3DS.%2BA.%26aulast%3DPalmer%26aufirst%3DJ.%2BT.%26atitle%3DDiscovery%2520of%2520Selective%2520Irreversible%2520Inhibitors%2520for%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%26jtitle%3DChemMedChem%26date%3D2007%26volume%3D2%26spage%3D58%26epage%3D61%26doi%3D10.1002%2Fcmdc.200600221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robak, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robak, E.</span></span> <span> </span><span class="NLM_article-title">Tyrosine Kinase Inhibitors as Potential Drugs for B-cell Lymphoid Malignancies and Autoimmune Disorders</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">921</span>– <span class="NLM_lpage">947</span>, <span class="refDoi"> DOI: 10.1517/13543784.2012.685650</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1517%2F13543784.2012.685650" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2012&pages=921-947&author=T.+Robakauthor=E.+Robak&title=Tyrosine+Kinase+Inhibitors+as+Potential+Drugs+for+B-cell+Lymphoid+Malignancies+and+Autoimmune+Disorders&doi=10.1517%2F13543784.2012.685650"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1517%2F13543784.2012.685650&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.2012.685650%26sid%3Dliteratum%253Aachs%26aulast%3DRobak%26aufirst%3DT.%26aulast%3DRobak%26aufirst%3DE.%26atitle%3DTyrosine%2520Kinase%2520Inhibitors%2520as%2520Potential%2520Drugs%2520for%2520B-cell%2520Lymphoid%2520Malignancies%2520and%2520Autoimmune%2520Disorders%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2012%26volume%3D21%26spage%3D921%26epage%3D947%26doi%3D10.1517%2F13543784.2012.685650" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuglstatter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondru, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, D. M.</span></span> <span> </span><span class="NLM_article-title">Bruton’s Tyrosine Kinase Inhibitors: Approaches to Potent and Selective Inhibition, Pre-clinical and Clinical Evaluation for Inflammatory Diseases and B Cell Malignancies</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">4539</span>– <span class="NLM_lpage">4550</span>, <span class="refDoi"> DOI: 10.1021/jm300035p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300035p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=4539-4550&author=Y.+Louauthor=T.+D.+Owensauthor=A.+Kuglstatterauthor=R.+K.+Kondruauthor=D.+M.+Goldstein&title=Bruton%E2%80%99s+Tyrosine+Kinase+Inhibitors%3A+Approaches+to+Potent+and+Selective+Inhibition%2C+Pre-clinical+and+Clinical+Evaluation+for+Inflammatory+Diseases+and+B+Cell+Malignancies&doi=10.1021%2Fjm300035p"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm300035p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300035p%26sid%3Dliteratum%253Aachs%26aulast%3DLou%26aufirst%3DY.%26aulast%3DOwens%26aufirst%3DT.%2BD.%26aulast%3DKuglstatter%26aufirst%3DA.%26aulast%3DKondru%26aufirst%3DR.%2BK.%26aulast%3DGoldstein%26aufirst%3DD.%2BM.%26atitle%3DBruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520Inhibitors%253A%2520Approaches%2520to%2520Potent%2520and%2520Selective%2520Inhibition%252C%2520Pre-clinical%2520and%2520Clinical%2520Evaluation%2520for%2520Inflammatory%2520Diseases%2520and%2520B%2520Cell%2520Malignancies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D4539%26epage%3D4550%26doi%3D10.1021%2Fjm300035p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Currie, K. S.</span></span> Targeting the B-cell Receptor Pathway in Hematological Maligancies. In  <i>2015 Medicinal Chemistry Reviews</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, M. C.</span></span>, Ed.; <span class="NLM_publisher-name">American Chemical Society Division of Medicinal Chemistry</span>: <span class="NLM_publisher-loc">Washington, DC</span>, <span class="NLM_year">2016</span>; pp  <span class="NLM_fpage">225</span>– <span class="NLM_lpage">234</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&pages=225-234&author=K.+S.+Currieauthor=M.+C.+Desai&title=2015+Medicinal+Chemistry+Reviews"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26btitle%3D2015%2520Medicinal%2520Chemistry%2520Reviews%26aulast%3DDesai%26aufirst%3DM.%2BC.%26pub%3DAmerican%2520Chemical%2520Society%2520Division%2520of%2520Medicinal%2520Chemistry%26date%3D2016%26spage%3D225%26epage%3D234" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dougan, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komandla, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanouni, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knight, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawson, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabat, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyrick, C.</span></span> <span> </span><span class="NLM_article-title">Fragment-Based Discovery of a Small Molecule Inhibitor of Bruton’s Tyrosine Kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">5437</span>– <span class="NLM_lpage">5444</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00734</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00734" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVans7rF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=5437-5444&author=C.+R.+Smithauthor=D.+R.+Douganauthor=M.+Komandlaauthor=T.+Kanouniauthor=B.+Knightauthor=J.+D.+Lawsonauthor=M.+Sabatauthor=E.+R.+Taylorauthor=P.+Vuauthor=C.+Wyrick&title=Fragment-Based+Discovery+of+a+Small+Molecule+Inhibitor+of+Bruton%E2%80%99s+Tyrosine+Kinase&doi=10.1021%2Facs.jmedchem.5b00734"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Fragment-Based Discovery of a Small Molecule Inhibitor of Bruton's Tyrosine Kinase</span></div><div class="casAuthors">Smith, Christopher R.; Dougan, Douglas R.; Komandla, Mallareddy; Kanouni, Toufike; Knight, Beverly; Lawson, J. David; Sabat, Mark; Taylor, Ewan R.; Vu, Phong; Wyrick, Corey</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5437-5444</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery and optimization of a series of 4-aminocinnoline-3-carboxamide inhibitors of Bruton's tyrosine kinase are reported.  A fragment-based screening approach incorporating x-ray cocrystallog. was used to identify a cinnoline fragment and characterize its binding mode in the ATP binding site of Btk.  Optimization of the fragment hit resulted in the identification of a lead compd. I which reduced paw swelling in a dose- and exposure-dependent fashion in a rat model of collagen-induced arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozENTW7pHlFrVg90H21EOLACvtfcHk0lgRxHu2-lC75g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVans7rF&md5=d6626fabcc3e2aa6a9180dc702a5030c</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00734&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00734%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DC.%2BR.%26aulast%3DDougan%26aufirst%3DD.%2BR.%26aulast%3DKomandla%26aufirst%3DM.%26aulast%3DKanouni%26aufirst%3DT.%26aulast%3DKnight%26aufirst%3DB.%26aulast%3DLawson%26aufirst%3DJ.%2BD.%26aulast%3DSabat%26aufirst%3DM.%26aulast%3DTaylor%26aufirst%3DE.%2BR.%26aulast%3DVu%26aufirst%3DP.%26aulast%3DWyrick%26aufirst%3DC.%26atitle%3DFragment-Based%2520Discovery%2520of%2520a%2520Small%2520Molecule%2520Inhibitor%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D5437%26epage%3D5444%26doi%3D10.1021%2Facs.jmedchem.5b00734" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Young, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbosa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blomgren, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bremer, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dambach, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallion, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hymowitz, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kropf, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubach, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macaluso, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maciejewski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortwine, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Paolo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheerens, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sowell, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currie, K. S.</span></span> <span> </span><span class="NLM_article-title">Potent and Selective Bruton’s Tyrosine Kinase Inhibitors: Discovery of GDC-0834</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1333</span>– <span class="NLM_lpage">1337</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.01.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1016%2Fj.bmcl.2015.01.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=25701252" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BC2MXisVSit7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=1333-1337&author=W.+B.+Youngauthor=J.+Barbosaauthor=P.+Blomgrenauthor=M.+C.+Bremerauthor=J.+J.+Crawfordauthor=D.+Dambachauthor=S.+Gallionauthor=S.+G.+Hymowitzauthor=J.+E.+Kropfauthor=S.+H.+Leeauthor=L.+Liuauthor=J.+W.+Lubachauthor=J.+Macalusoauthor=P.+Maciejewskiauthor=B.+Maurerauthor=S.+A.+Mitchellauthor=D.+F.+Ortwineauthor=J.+Di+Paoloauthor=K.+Reifauthor=H.+Scheerensauthor=A.+Schmittauthor=C.+G.+Sowellauthor=X.+Wangauthor=H.+Wongauthor=J.-M.+Xiongauthor=J.+Xuauthor=Z.+Zhaoauthor=K.+S.+Currie&title=Potent+and+Selective+Bruton%E2%80%99s+Tyrosine+Kinase+Inhibitors%3A+Discovery+of+GDC-0834&doi=10.1016%2Fj.bmcl.2015.01.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Potent and selective Bruton's tyrosine kinase inhibitors: Discovery of GDC-0834</span></div><div class="casAuthors">Young, Wendy B.; Barbosa, James; Blomgren, Peter; Bremer, Meire C.; Crawford, James J.; Dambach, Donna; Gallion, Steve; Hymowitz, Sarah G.; Kropf, Jeffrey E.; Lee, Seung H.; Liu, Lichuan; Lubach, Joseph W.; Macaluso, Jen; Maciejewski, Pat; Maurer, Brigitte; Mitchell, Scott A.; Ortwine, Daniel F.; Di Paolo, Julie; Reif, Karin; Scheerens, Heleen; Schmitt, Aaron; Sowell, C. Gregory; Wang, Xiaojing; Wong, Harvey; Xiong, Jin-Ming; Xu, Jianjun; Zhao, Zhongdong; Currie, Kevin S.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1333-1337</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">SAR studies focused on improving the pharmacokinetic (PK) properties of the previously reported potent and selective Btk inhibitor CGI-1746 resulted in the clin. candidate GDC-0834, which retained the potency and selectivity of CGI-1746, but with much improved PK in preclin. animal models.  Structure based design efforts drove this work as modifications to CGI-1746 were investigated at both the solvent exposed region as well as 'H3 binding pocket'.  However, in vitro metabolic evaluation of GDC-0834 revealed a non CYP-mediated metabolic process that was more prevalent in human than preclin. species (mouse, rat, dog, cyno), leading to a high-level of uncertainly in predicting human pharmacokinetics.  Due to its promising potency, selectivity, and preclin. efficacy, a single dose IND was filed and GDC-0834 was taken in to a single dose phase I trial in healthy volunteers to quickly evaluate the human pharmacokinetics.  In human, GDC-0834 was found to be highly labile at the exo-cyclic amide bond that links the tetrahydrobenzothiophene moiety to the central aniline ring, resulting in insufficient parent drug exposure.  This information informed the back-up program and discovery of improved inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhL04eYDiT3bVg90H21EOLACvtfcHk0lgMe6rLGWMgjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXisVSit7w%253D&md5=fdebc0199c8222e093cfb9583244bce3</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.01.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.01.032%26sid%3Dliteratum%253Aachs%26aulast%3DYoung%26aufirst%3DW.%2BB.%26aulast%3DBarbosa%26aufirst%3DJ.%26aulast%3DBlomgren%26aufirst%3DP.%26aulast%3DBremer%26aufirst%3DM.%2BC.%26aulast%3DCrawford%26aufirst%3DJ.%2BJ.%26aulast%3DDambach%26aufirst%3DD.%26aulast%3DGallion%26aufirst%3DS.%26aulast%3DHymowitz%26aufirst%3DS.%2BG.%26aulast%3DKropf%26aufirst%3DJ.%2BE.%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DLubach%26aufirst%3DJ.%2BW.%26aulast%3DMacaluso%26aufirst%3DJ.%26aulast%3DMaciejewski%26aufirst%3DP.%26aulast%3DMaurer%26aufirst%3DB.%26aulast%3DMitchell%26aufirst%3DS.%2BA.%26aulast%3DOrtwine%26aufirst%3DD.%2BF.%26aulast%3DDi%2BPaolo%26aufirst%3DJ.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DScheerens%26aufirst%3DH.%26aulast%3DSchmitt%26aufirst%3DA.%26aulast%3DSowell%26aufirst%3DC.%2BG.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DXiong%26aufirst%3DJ.-M.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26atitle%3DPotent%2520and%2520Selective%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520Inhibitors%253A%2520Discovery%2520of%2520GDC-0834%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D1333%26epage%3D1337%26doi%3D10.1016%2Fj.bmcl.2015.01.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Young, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbosa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blomgren, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bremer, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dambach, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallion, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kropf, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubach, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macaluso, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maciejewski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortwine, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Paolo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheerens, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currie, K. S.</span></span> <span> </span><span class="NLM_article-title">Discovery of Highly Potent and Selective Bruton’s Tyrosine Kinase Inhibitors: Pyridazinone Analogs With Improved Metabolic Stability</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">575</span>– <span class="NLM_lpage">579</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2015.11.076</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1016%2Fj.bmcl.2015.11.076" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=26675441" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvF2ms77M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=575-579&author=W.+B.+Youngauthor=J.+Barbosaauthor=P.+Blomgrenauthor=M.+C.+Bremerauthor=J.+J.+Crawfordauthor=D.+Dambachauthor=C.+Eigenbrotauthor=S.+Gallionauthor=A.+R.+Johnsonauthor=J.+E.+Kropfauthor=S.+H.+Leeauthor=L.+Liuauthor=J.+W.+Lubachauthor=J.+Macalusoauthor=P.+Maciejewskiauthor=S.+A.+Mitchellauthor=D.+F.+Ortwineauthor=J.+Di+Paoloauthor=K.+Reifauthor=H.+Scheerensauthor=A.+Schmittauthor=X.+Wangauthor=H.+Wongauthor=J.-M.+Xiongauthor=J.+Xuauthor=C.+Yuauthor=Z.+Zhaoauthor=K.+S.+Currie&title=Discovery+of+Highly+Potent+and+Selective+Bruton%E2%80%99s+Tyrosine+Kinase+Inhibitors%3A+Pyridazinone+Analogs+With+Improved+Metabolic+Stability&doi=10.1016%2Fj.bmcl.2015.11.076"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of highly potent and selective Bruton's tyrosine kinase inhibitors: Pyridazinone analogs with improved metabolic stability</span></div><div class="casAuthors">Young, Wendy B.; Barbosa, James; Blomgren, Peter; Bremer, Meire C.; Crawford, James J.; Dambach, Donna; Eigenbrot, Charles; Gallion, Steve; Johnson, Adam R.; Kropf, Jeffrey E.; Lee, Seung H.; Liu, Lichuan; Lubach, Joseph W.; Macaluso, Jen; Maciejewski, Pat; Mitchell, Scott A.; Ortwine, Daniel F.; Di Paolo, Julie; Reif, Karin; Scheerens, Heleen; Schmitt, Aaron; Wang, Xiaojing; Wong, Harvey; Xiong, Jin-Ming; Xu, Jianjun; Yu, Christine; Zhao, Zhongdong; Currie, Kevin S.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">575-579</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">BTK inhibitor GDC-0834 was found to be rapidly metabolized in human studies, resulting in a suspension of clin. trials.  The primary route of metab. was through cleavage of the acyclic amide bond connecting the terminal tetrahydrobenzothiophene with the central linker aryl ring.  SAR studies were focused on reducing metabolic cleavage of this amide, and resulted in the identification of several central aryl linker substituents that conferred improved stability.  The most promising substituted aryl linkers were then incorporated into an optimized pyridazinone scaffold, resulting in the identification of lead analog I, possessing improved potency, metabolic stability and preclin. properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWhbh3H4N2ErVg90H21EOLACvtfcHk0lgMe6rLGWMgjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvF2ms77M&md5=ff074fc16518d072ccb9b7b5d8520a03</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.11.076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.11.076%26sid%3Dliteratum%253Aachs%26aulast%3DYoung%26aufirst%3DW.%2BB.%26aulast%3DBarbosa%26aufirst%3DJ.%26aulast%3DBlomgren%26aufirst%3DP.%26aulast%3DBremer%26aufirst%3DM.%2BC.%26aulast%3DCrawford%26aufirst%3DJ.%2BJ.%26aulast%3DDambach%26aufirst%3DD.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DGallion%26aufirst%3DS.%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DKropf%26aufirst%3DJ.%2BE.%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DLubach%26aufirst%3DJ.%2BW.%26aulast%3DMacaluso%26aufirst%3DJ.%26aulast%3DMaciejewski%26aufirst%3DP.%26aulast%3DMitchell%26aufirst%3DS.%2BA.%26aulast%3DOrtwine%26aufirst%3DD.%2BF.%26aulast%3DDi%2BPaolo%26aufirst%3DJ.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DScheerens%26aufirst%3DH.%26aulast%3DSchmitt%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DXiong%26aufirst%3DJ.-M.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26atitle%3DDiscovery%2520of%2520Highly%2520Potent%2520and%2520Selective%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520Inhibitors%253A%2520Pyridazinone%2520Analogs%2520With%2520Improved%2520Metabolic%2520Stability%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D575%26epage%3D579%26doi%3D10.1016%2Fj.bmcl.2015.11.076" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbosa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blomgren, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bremer, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallion, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katewa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kropf, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubach, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macaluso, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maciejewski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortwine, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiPaolo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheerens, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currie, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, W. B.</span></span> <span> </span><span class="NLM_article-title">Discovery of Potent and Selective Tricyclic Inhibitors of Bruton’s Tyrosine Kinase with Improved Druglike Properties</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">608</span>– <span class="NLM_lpage">613</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00103</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00103" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BC2sXntVGgs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=608-613&author=X.+Wangauthor=J.+Barbosaauthor=P.+Blomgrenauthor=M.+C.+Bremerauthor=J.+Chenauthor=J.+J.+Crawfordauthor=W.+Dengauthor=L.+Dongauthor=C.+Eigenbrotauthor=S.+Gallionauthor=J.+Hauauthor=H.+Huauthor=A.+R.+Johnsonauthor=A.+Katewaauthor=J.+E.+Kropfauthor=S.+H.+Leeauthor=L.+Liuauthor=J.+W.+Lubachauthor=J.+Macalusoauthor=P.+Maciejewskiauthor=S.+A.+Mitchellauthor=D.+F.+Ortwineauthor=J.+DiPaoloauthor=K.+Reifauthor=H.+Scheerensauthor=A.+Schmittauthor=H.+Wongauthor=J.+M.+Xiongauthor=J.+Xuauthor=Z.+Zhaoauthor=F.+Zhouauthor=K.+S.+Currieauthor=W.+B.+Young&title=Discovery+of+Potent+and+Selective+Tricyclic+Inhibitors+of+Bruton%E2%80%99s+Tyrosine+Kinase+with+Improved+Druglike+Properties&doi=10.1021%2Facsmedchemlett.7b00103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Potent and Selective Tricyclic Inhibitors of Bruton's Tyrosine Kinase with Improved Druglike Properties</span></div><div class="casAuthors">Wang, Xiaojing; Barbosa, James; Blomgren, Peter; Bremer, Meire C.; Chen, Jacob; Crawford, James J.; Deng, Wei; Dong, Liming; Eigenbrot, Charles; Gallion, Steve; Hau, Jonathon; Hu, Huiyong; Johnson, Adam R.; Katewa, Arna; Kropf, Jeffrey E.; Lee, Seung H.; Liu, Lichuan; Lubach, Joseph W.; Macaluso, Jen; Maciejewski, Pat; Mitchell, Scott A.; Ortwine, Daniel F.; DiPaolo, Julie; Reif, Karin; Scheerens, Heleen; Schmitt, Aaron; Wong, Harvey; Xiong, Jin-Ming; Xu, Jianjun; Zhao, Zhongdong; Zhou, Fusheng; Currie, Kevin S.; Young, Wendy B.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">608-613</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In our continued effort to discover and develop best-in-class Bruton's tyrosine kinase (Btk) inhibitors for the treatment of B-cell lymphomas, rheumatoid arthritis, and systemic lupus erythematosus, we devised a series of novel tricyclic compds. that improved upon the druglike properties of our previous chem. matter.  Compds. exemplified by G-744 are highly potent, selective for Btk, metabolically stable, well tolerated, and efficacious in an animal model of arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooogQZhchmHrVg90H21EOLACvtfcHk0lgMe6rLGWMgjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXntVGgs7o%253D&md5=81e9b9c5cc497fc88e033a9de88090be</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00103%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DBarbosa%26aufirst%3DJ.%26aulast%3DBlomgren%26aufirst%3DP.%26aulast%3DBremer%26aufirst%3DM.%2BC.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DCrawford%26aufirst%3DJ.%2BJ.%26aulast%3DDeng%26aufirst%3DW.%26aulast%3DDong%26aufirst%3DL.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DGallion%26aufirst%3DS.%26aulast%3DHau%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DH.%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DKatewa%26aufirst%3DA.%26aulast%3DKropf%26aufirst%3DJ.%2BE.%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DLubach%26aufirst%3DJ.%2BW.%26aulast%3DMacaluso%26aufirst%3DJ.%26aulast%3DMaciejewski%26aufirst%3DP.%26aulast%3DMitchell%26aufirst%3DS.%2BA.%26aulast%3DOrtwine%26aufirst%3DD.%2BF.%26aulast%3DDiPaolo%26aufirst%3DJ.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DScheerens%26aufirst%3DH.%26aulast%3DSchmitt%26aufirst%3DA.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DXiong%26aufirst%3DJ.%2BM.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DF.%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26aulast%3DYoung%26aufirst%3DW.%2BB.%26atitle%3DDiscovery%2520of%2520Potent%2520and%2520Selective%2520Tricyclic%2520Inhibitors%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520with%2520Improved%2520Druglike%2520Properties%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D608%26epage%3D613%26doi%3D10.1021%2Facsmedchemlett.7b00103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Lucca, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langevine, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batt, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertrand, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yip, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traeger, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattoli, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obermeier, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vickery, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Discenza, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arienzo, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimrich, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillooly, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulicicchio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galella, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tebben, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muckelbauer, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rampulla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter-Cid, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrish, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tino, J. A.</span></span> <span> </span><span class="NLM_article-title">Discovery of 6-Fluoro-5-(R)-(3-(S)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-2-methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (BMS-986142): A Reversible Inhibitor of Bruton’s Tyrosine Kinase (BTK) Conformationally Constrained by Two Locked Atropisomers</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">9173</span>– <span class="NLM_lpage">9200</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01088</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01088" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVKjsrfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=9173-9200&author=S.+H.+Wattersonauthor=G.+V.+De+Luccaauthor=Q.+Shiauthor=C.+M.+Langevineauthor=Q.+Liuauthor=D.+G.+Battauthor=M.+B.+Bertrandauthor=H.+Gongauthor=J.+Daiauthor=S.+Yipauthor=P.+Liauthor=D.+Sunauthor=D.-R.+Wuauthor=C.+Wangauthor=Y.+Zhangauthor=S.+C.+Traegerauthor=M.+A.+Pattoliauthor=S.+Skalaauthor=L.+Chengauthor=M.+T.+Obermeierauthor=R.+Vickeryauthor=L.+N.+Discenzaauthor=C.+J.+D%E2%80%99Arienzoauthor=Y.+Zhangauthor=E.+Heimrichauthor=K.+M.+Gilloolyauthor=T.+L.+Taylorauthor=C.+Pulicicchioauthor=K.+W.+McIntyreauthor=M.+A.+Galellaauthor=A.+J.+Tebbenauthor=J.+K.+Muckelbauerauthor=C.+Changauthor=R.+Rampullaauthor=A.+Mathurauthor=L.+Salter-Cidauthor=J.+C.+Barrishauthor=P.+H.+Carterauthor=A.+Furaauthor=J.+R.+Burkeauthor=J.+A.+Tino&title=Discovery+of+6-Fluoro-5-%28R%29-%283-%28S%29-%288-fluoro-1-methyl-2%2C4-dioxo-1%2C2-dihydroquinazolin-3%284H%29-yl%29-2-methylphenyl%29-2-%28S%29-%282-hydroxypropan-2-yl%29-2%2C3%2C4%2C9-tetrahydro-1H-carbazole-8-carboxamide+%28BMS-986142%29%3A+A+Reversible+Inhibitor+of+Bruton%E2%80%99s+Tyrosine+Kinase+%28BTK%29+Conformationally+Constrained+by+Two+Locked+Atropisomers&doi=10.1021%2Facs.jmedchem.6b01088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 6-Fluoro-5-(R)-(3-(S)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-2-methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (BMS-986142): A Reversible Inhibitor of Bruton's Tyrosine Kinase (BTK) Conformationally Constrained by Two Locked Atropisomers</span></div><div class="casAuthors">Watterson, Scott H.; De Lucca, George V.; Shi, Qing; Langevine, Charles M.; Liu, Qingjie; Batt, Douglas G.; Beaudoin Bertrand, Myra; Gong, Hua; Dai, Jun; Yip, Shiuhang; Li, Peng; Sun, Dawn; Wu, Dauh-Rurng; Wang, Chunlei; Zhang, Yingru; Traeger, Sarah C.; Pattoli, Mark A.; Skala, Stacey; Cheng, Lihong; Obermeier, Mary T.; Vickery, Rodney; Discenza, Lorell N.; D'Arienzo, Celia J.; Zhang, Yifan; Heimrich, Elizabeth; Gillooly, Kathleen M.; Taylor, Tracy L.; Pulicicchio, Claudine; McIntyre, Kim W.; Galella, Michael A.; Tebben, Andy J.; Muckelbauer, Jodi K.; Chang, ChiehYing; Rampulla, Richard; Mathur, Arvind; Salter-Cid, Luisa; Barrish, Joel C.; Carter, Percy H.; Fura, Aberra; Burke, James R.; Tino, Joseph A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">9173-9200</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK), a nonreceptor tyrosine kinase, is a member of the Tec family of kinases.  BTK plays an essential role in B cell receptor (BCR)-mediated signaling as well as Fcγ receptor signaling in monocytes and Fcε receptor signaling in mast cells and basophils, all of which have been implicated in the pathophysiol. of autoimmune disease.  As a result, inhibition of BTK is anticipated to provide an effective strategy for the clin. treatment of autoimmune diseases such as lupus and rheumatoid arthritis.  This article details the structure-activity relationships (SAR) leading to a novel series of highly potent and selective carbazole and tetrahydrocarbazole based, reversible inhibitors of BTK.  Of particular interest is that two atropisomeric centers were rotationally locked to provide a single, stable atropisomer, resulting in enhanced potency and selectivity as well as a redn. in safety liabilities.  With significantly enhanced potency and selectivity, excellent in vivo properties and efficacy, and a very desirable tolerability and safety profile, 14f (BMS-986142) was advanced into clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmpBAygRAsYrVg90H21EOLACvtfcHk0lgsmGucABeVUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVKjsrfF&md5=91098abc802521b9ad91563d20ac5893</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01088%26sid%3Dliteratum%253Aachs%26aulast%3DWatterson%26aufirst%3DS.%2BH.%26aulast%3DDe%2BLucca%26aufirst%3DG.%2BV.%26aulast%3DShi%26aufirst%3DQ.%26aulast%3DLangevine%26aufirst%3DC.%2BM.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DBatt%26aufirst%3DD.%2BG.%26aulast%3DBertrand%26aufirst%3DM.%2BB.%26aulast%3DGong%26aufirst%3DH.%26aulast%3DDai%26aufirst%3DJ.%26aulast%3DYip%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DWu%26aufirst%3DD.-R.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DTraeger%26aufirst%3DS.%2BC.%26aulast%3DPattoli%26aufirst%3DM.%2BA.%26aulast%3DSkala%26aufirst%3DS.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DObermeier%26aufirst%3DM.%2BT.%26aulast%3DVickery%26aufirst%3DR.%26aulast%3DDiscenza%26aufirst%3DL.%2BN.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%2BJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHeimrich%26aufirst%3DE.%26aulast%3DGillooly%26aufirst%3DK.%2BM.%26aulast%3DTaylor%26aufirst%3DT.%2BL.%26aulast%3DPulicicchio%26aufirst%3DC.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DGalella%26aufirst%3DM.%2BA.%26aulast%3DTebben%26aufirst%3DA.%2BJ.%26aulast%3DMuckelbauer%26aufirst%3DJ.%2BK.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DRampulla%26aufirst%3DR.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DSalter-Cid%26aufirst%3DL.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DFura%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DTino%26aufirst%3DJ.%2BA.%26atitle%3DDiscovery%2520of%25206-Fluoro-5-%2528R%2529-%25283-%2528S%2529-%25288-fluoro-1-methyl-2%252C4-dioxo-1%252C2-dihydroquinazolin-3%25284H%2529-yl%2529-2-methylphenyl%2529-2-%2528S%2529-%25282-hydroxypropan-2-yl%2529-2%252C3%252C4%252C9-tetrahydro-1H-carbazole-8-carboxamide%2520%2528BMS-986142%2529%253A%2520A%2520Reversible%2520Inhibitor%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520%2528BTK%2529%2520Conformationally%2520Constrained%2520by%2520Two%2520Locked%2520Atropisomers%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D9173%26epage%3D9200%26doi%3D10.1021%2Facs.jmedchem.6b01088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Honigberg, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sirisawad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loury, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thamm, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buggy, J. J.</span></span> <span> </span><span class="NLM_article-title">The Bruton Tyrosine Kinase Inhibitor PCI-32765 Blocks B Cell Activation and is Efficacious in Models of Autoimmune Disease and B-cell Malignancy</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">13075</span>– <span class="NLM_lpage">13080</span>, <span class="refDoi"> DOI: 10.1073/pnas.1004594107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1073%2Fpnas.1004594107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=20615965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsVCrsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=13075-13080&author=L.+A.+Honigbergauthor=A.+M.+Smithauthor=M.+Sirisawadauthor=E.+Vernerauthor=D.+Louryauthor=B.+Changauthor=S.+Liauthor=Z.+Panauthor=D.+H.+Thammauthor=R.+A.+Millerauthor=J.+J.+Buggy&title=The+Bruton+Tyrosine+Kinase+Inhibitor+PCI-32765+Blocks+B+Cell+Activation+and+is+Efficacious+in+Models+of+Autoimmune+Disease+and+B-cell+Malignancy&doi=10.1073%2Fpnas.1004594107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy</span></div><div class="casAuthors">Honigberg, Lee A.; Smith, Ashley M.; Sirisawad, Mint; Verner, Erik; Loury, David; Chang, Betty; Li, Shyr; Pan, Zhengying; Thamm, Douglas H.; Miller, Richard A.; Buggy, Joseph J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">13075-13080, S13075/1-S13075/3</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Activation of the B-cell antigen receptor (BCR) signaling pathway contributes to the initiation and maintenance of B-cell malignancies and autoimmune diseases.  The Bruton tyrosine kinase (Btk) is specifically required for BCR signaling as demonstrated by human and mouse mutations that disrupt Btk function and prevent B-cell maturation at steps that require a functional BCR pathway.  Herein we describe a selective and irreversible Btk inhibitor, PCI-32765, that is currently under clin. development in patients with B-cell non-Hodgkin lymphoma.  We have used this inhibitor to investigate the biol. effects of Btk inhibition on mature B-cell function and the progression of B cell-assocd. diseases in vivo.  PCI-32765 blocked BCR signaling in human peripheral B cells at concns. that did not affect T cell receptor signaling.  In mice with collagen-induced arthritis, orally administered PCI-32765 reduced the level of circulating autoantibodies and completely suppressed disease.  PCI-32765 also inhibited autoantibody prodn. and the development of kidney disease in the MRL-Fas(lpr) lupus model.  Occupancy of the Btk active site by PCI-32765 was monitored in vitro and in vivo using a fluorescent affinity probe for Btk.  Active site occupancy of Btk was tightly correlated with the blockade of BCR signaling and in vivo efficacy.  Finally, PCI-32765 induced objective clin. responses in dogs with spontaneous B-cell non-Hodgkin lymphoma.  These findings support Btk inhibition as a therapeutic approach for the treatment of human diseases assocd. with activation of the BCR pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoT4OQHme7oHLVg90H21EOLACvtfcHk0lgSQ8PlWlO3gA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsVCrsbk%253D&md5=196ce4a05bb9c622c49cb7e908682e63</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1004594107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1004594107%26sid%3Dliteratum%253Aachs%26aulast%3DHonigberg%26aufirst%3DL.%2BA.%26aulast%3DSmith%26aufirst%3DA.%2BM.%26aulast%3DSirisawad%26aufirst%3DM.%26aulast%3DVerner%26aufirst%3DE.%26aulast%3DLoury%26aufirst%3DD.%26aulast%3DChang%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DPan%26aufirst%3DZ.%26aulast%3DThamm%26aufirst%3DD.%2BH.%26aulast%3DMiller%26aufirst%3DR.%2BA.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26atitle%3DThe%2520Bruton%2520Tyrosine%2520Kinase%2520Inhibitor%2520PCI-32765%2520Blocks%2520B%2520Cell%2520Activation%2520and%2520is%2520Efficacious%2520in%2520Models%2520of%2520Autoimmune%2520Disease%2520and%2520B-cell%2520Malignancy%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2010%26volume%3D107%26spage%3D13075%26epage%3D13080%26doi%3D10.1073%2Fpnas.1004594107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Advani, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buggy, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharman, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyd, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolibaba, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sukbuntherng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izumi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamdy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedrick, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fowler, N. H.</span></span> <span> </span><span class="NLM_article-title">Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) has Significant Activity in Patients with Relapsed/Refractory B-cell Malignancies</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">88</span>– <span class="NLM_lpage">94</span>, <span class="refDoi"> DOI: 10.1200/JCO.2012.42.7906</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1200%2FJCO.2012.42.7906" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=23045577" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BC3sXitFaltLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=88-94&author=R.+H.+Advaniauthor=J.+J.+Buggyauthor=J.+P.+Sharmanauthor=S.+M.+Smithauthor=T.+E.+Boydauthor=B.+Grantauthor=K.+S.+Kolibabaauthor=R.+R.+Furmanauthor=S.+Rodriguezauthor=B.+Y.+Changauthor=J.+Sukbuntherngauthor=R.+Izumiauthor=A.+Hamdyauthor=E.+Hedrickauthor=N.+H.+Fowler&title=Bruton+Tyrosine+Kinase+Inhibitor+Ibrutinib+%28PCI-32765%29+has+Significant+Activity+in+Patients+with+Relapsed%2FRefractory+B-cell+Malignancies&doi=10.1200%2FJCO.2012.42.7906"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies</span></div><div class="casAuthors">Advani, Ranjana H.; Buggy, Joseph J.; Sharman, Jeff P.; Smith, Sonali M.; Boyd, Thomas E.; Grant, Barbara; Kolibaba, Kathryn S.; Furman, Richard R.; Rodriguez, Sara; Chang, Betty Y.; Sukbuntherng, Juthamas; Izumi, Raquel; Hamdy, Ahmed; Hedrick, Eric; Fowler, Nathan H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">88-94</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose Survival and progression of mature B-cell malignancies depend on signals from the B-cell antigen receptor, and Bruton tyrosine kinase (BTK) is a crit. signaling kinase in this pathway.  We evaluated ibrutinib (PCI-32765), a small-mol. irreversible inhibitor of BTK, in patients with B-cell malignancies.  Patients and Methods Patients with relapsed or refractory B-cell lymphoma and chronic lymphocytic leukemia received escalating oral doses of ibrutinib.  Two schedules were evaluated: one, 28 days on, 7 days off; and two, once-daily continuous dosing.  Occupancy of BTK by ibrutinib in peripheral blood was monitored using a fluorescent affinity probe.  Dose escalation proceeded until either the max.-tolerated dose (MTD) was achieved or, in the absence of MTD, until three dose levels above full BTK occupancy by ibrutinib.  Response was evaluated every two cycles.  Results Fifty-six patients with a variety of B-cell malignancies were treated over seven cohorts.  Most adverse events were grade 1 and 2 in severity and self-limited.  Dose-limiting events were not obsd., even with prolonged dosing.  Full occupancy of the BTK active site occurred at 2.5 mg/kg per day, and dose escalation continued to 12.5 mg/kg per day without reaching MTD.  Pharmacokinetic data indicated rapid absorption and elimination, yet BTK occupancy was maintained for at least 24 h, consistent with the irreversible mechanism.  Objective response rate in 50 evaluable patients was 60%, including complete response of 16%.  Median progression-free survival in all patients was 13.6 mo.  Conclusion Ibrutinib, a novel BTK-targeting inhibitor, is well tolerated, with substantial activity across B-cell histologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqj_UZPM0nBrVg90H21EOLACvtfcHk0lgSQ8PlWlO3gA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXitFaltLg%253D&md5=e955490a02af9a321823033b9e258cb6</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1200%2FJCO.2012.42.7906&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2012.42.7906%26sid%3Dliteratum%253Aachs%26aulast%3DAdvani%26aufirst%3DR.%2BH.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26aulast%3DSharman%26aufirst%3DJ.%2BP.%26aulast%3DSmith%26aufirst%3DS.%2BM.%26aulast%3DBoyd%26aufirst%3DT.%2BE.%26aulast%3DGrant%26aufirst%3DB.%26aulast%3DKolibaba%26aufirst%3DK.%2BS.%26aulast%3DFurman%26aufirst%3DR.%2BR.%26aulast%3DRodriguez%26aufirst%3DS.%26aulast%3DChang%26aufirst%3DB.%2BY.%26aulast%3DSukbuntherng%26aufirst%3DJ.%26aulast%3DIzumi%26aufirst%3DR.%26aulast%3DHamdy%26aufirst%3DA.%26aulast%3DHedrick%26aufirst%3DE.%26aulast%3DFowler%26aufirst%3DN.%2BH.%26atitle%3DBruton%2520Tyrosine%2520Kinase%2520Inhibitor%2520Ibrutinib%2520%2528PCI-32765%2529%2520has%2520Significant%2520Activity%2520in%2520Patients%2520with%2520Relapsed%252FRefractory%2520B-cell%2520Malignancies%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D31%26spage%3D88%26epage%3D94%26doi%3D10.1200%2FJCO.2012.42.7906" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Byrd, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coutre, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flinn, I. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burger, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharman, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wierda, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heerema, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sukbuntherng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clow, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedrick, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buggy, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S.</span></span> <span> </span><span class="NLM_article-title">Targeting Btk with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>369</i></span>,  <span class="NLM_fpage">32</span>– <span class="NLM_lpage">42</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1215637</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1056%2FNEJMoa1215637" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=23782158" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFygu7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=369&publication_year=2013&pages=32-42&author=J.+C.+Byrdauthor=R.+R.+Furmanauthor=S.+E.+Coutreauthor=I.+W.+Flinnauthor=J.+A.+Burgerauthor=K.+A.+Blumauthor=B.+Grantauthor=J.+P.+Sharmanauthor=M.+Colemanauthor=W.+G.+Wierdaauthor=J.+A.+Jonesauthor=W.+Zhaoauthor=N.+A.+Heeremaauthor=A.+J.+Johnsonauthor=J.+Sukbuntherngauthor=B.+Y.+Changauthor=F.+Clowauthor=E.+Hedrickauthor=J.+J.+Buggyauthor=D.+F.+Jamesauthor=S.+O%E2%80%99Brien&title=Targeting+Btk+with+Ibrutinib+in+Relapsed+Chronic+Lymphocytic+Leukemia&doi=10.1056%2FNEJMoa1215637"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia</span></div><div class="casAuthors">Byrd, John C.; Furman, Richard R.; Coutre, Steven E.; Flinn, Ian W.; Burger, Jan A.; Blum, Kristie A.; Grant, Barbara; Sharman, Jeff P.; Coleman, Morton; Wierda, William G.; Jones, Jeffrey A.; Zhao, Weiqiang; Heerema, Nyla A.; Johnson, Amy J.; Sukbuntherng, Juthamas; Chang, Betty Y.; Clow, Fong; Hedrick, Eric; Buggy, Joseph J.; James, Danelle F.; O'Brien, Susan</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">369</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">32-42</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background The treatment of relapsed chronic lymphocytic leukemia (CLL) has resulted in few durable remissions.  Bruton's tyrosine kinase (BTK), an essential component of B-cell-receptor signaling, mediates interactions with the tumor microenvironment and promotes the survival and proliferation of CLL cells.  Methods We conducted a phase 1b-2 multicenter study to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of ibrutinib (PCI-32765), a first-in-class, oral covalent inhibitor of BTK designed for treatment of B-cell cancers, in patients with relapsed or refractory CLL or small lymphocytic lymphoma.  A total of 85 patients, the majority of whom were considered to have high-risk disease, received ibrutinib orally once daily; 51 received 420 mg, and 34 received 840 mg.  Results Toxic effects were predominantly grade 1 or 2 and included transient diarrhea, fatigue, and upper respiratory tract infection; thus, patients could receive extended treatment with minimal hematol. toxic effects.  The overall response rate was the same in the group that received 420 mg and the group that received 840 mg (71%), and an addnl. 20% and 15% of patients in the resp. groups had a partial response with lymphocytosis.  The response was independent of clin. and genomic risk factors present before treatment, including advanced-stage disease, the no. of previous therapies, and the 17p13.1 deletion.  At 26 mo, the estd. progression-free survival rate was 75% and the rate of overall survival was 83%.  Conclusions Ibrutinib was assocd. with a high frequency of durable remissions in patients with relapsed or refractory CLL and small lymphocytic lymphoma, including patients with high-risk genetic lesions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1EhPQxMRz7rVg90H21EOLACvtfcHk0ljgkeaxQsQ-yg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFygu7zN&md5=32a5eb6ab06beeecf64d9ada84139925</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1215637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1215637%26sid%3Dliteratum%253Aachs%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DFurman%26aufirst%3DR.%2BR.%26aulast%3DCoutre%26aufirst%3DS.%2BE.%26aulast%3DFlinn%26aufirst%3DI.%2BW.%26aulast%3DBurger%26aufirst%3DJ.%2BA.%26aulast%3DBlum%26aufirst%3DK.%2BA.%26aulast%3DGrant%26aufirst%3DB.%26aulast%3DSharman%26aufirst%3DJ.%2BP.%26aulast%3DColeman%26aufirst%3DM.%26aulast%3DWierda%26aufirst%3DW.%2BG.%26aulast%3DJones%26aufirst%3DJ.%2BA.%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DHeerema%26aufirst%3DN.%2BA.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26aulast%3DSukbuntherng%26aufirst%3DJ.%26aulast%3DChang%26aufirst%3DB.%2BY.%26aulast%3DClow%26aufirst%3DF.%26aulast%3DHedrick%26aufirst%3DE.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26aulast%3DJames%26aufirst%3DD.%2BF.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%26atitle%3DTargeting%2520Btk%2520with%2520Ibrutinib%2520in%2520Relapsed%2520Chronic%2520Lymphocytic%2520Leukemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D369%26spage%3D32%26epage%3D42%26doi%3D10.1056%2FNEJMoa1215637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rule, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Auer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahl, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jurczak, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Advani, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romaguera, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrientos, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chmielowska, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radford, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stilgenbauer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dreyling, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jedzejczak, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spurgeon, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newberry, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGreivy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clow, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buggy, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaupre, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunkel, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, K. A.</span></span> <span> </span><span class="NLM_article-title">Targeting Btk with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>369</i></span>,  <span class="NLM_fpage">507</span>– <span class="NLM_lpage">516</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1306220</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1056%2FNEJMoa1306220" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=23782157" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1OgtL%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=369&publication_year=2013&pages=507-516&author=M.+L.+Wangauthor=S.+Ruleauthor=P.+Martinauthor=A.+Goyauthor=R.+Auerauthor=B.+S.+Kahlauthor=W.+Jurczakauthor=R.+H.+Advaniauthor=J.+E.+Romagueraauthor=M.+E.+Williamsauthor=J.+C.+Barrientosauthor=E.+Chmielowskaauthor=J.+Radfordauthor=S.+Stilgenbauerauthor=M.+Dreylingauthor=W.+W.+Jedzejczakauthor=P.+Johnsonauthor=S.+E.+Spurgeonauthor=L.+Liauthor=L.+Zhangauthor=K.+Newberryauthor=Z.+Ouauthor=N.+Chengauthor=B.+Fangauthor=J.+McGreivyauthor=F.+Clowauthor=J.+J.+Buggyauthor=B.+Y.+Changauthor=D.+M.+Beaupreauthor=L.+A.+Kunkelauthor=K.+A.+Blum&title=Targeting+Btk+with+Ibrutinib+in+Relapsed+or+Refractory+Mantle-Cell+Lymphoma&doi=10.1056%2FNEJMoa1306220"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma</span></div><div class="casAuthors">Wang, Michael L.; Rule, Simon; Martin, Peter; Goy, Andre; Auer, Rebecca; Kahl, Brad S.; Jurczak, Wojciech; Advani, Ranjana H.; Romaguera, Jorge E.; Williams, Michael E.; Barrientos, Jacqueline C.; Chmielowska, Ewa; Radford, John; Stilgenbauer, Stephan; Dreyling, Martin; Jedrzejczak, Wieslaw Wiktor; Johnson, Peter; Spurgeon, Stephen E.; Li, Lei; Zhang, Liang; Newberry, Kate; Ou, Zhishuo; Cheng, Nancy; Fang, Bingliang; McGreivy, Jesse; Clow, Fong; Buggy, Joseph J.; Chang, Betty Y.; Beaupre, Darrin M.; Kunkel, Lori A.; Blum, Kristie A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">369</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">507-516</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Bruton's tyrosine kinase (BTK) is a mediator of the B-cell-receptor signaling pathway implicated in the pathogenesis of B-cell cancers.  In a phase 1 study, ibrutinib, a BTK inhibitor, showed antitumor activity in several types of non-Hodgkin's lymphoma, including mantle-cell lymphoma.  METHODS: In this phase 2 study, we investigated oral ibrutinib, at a daily dose of 560 mg, in 111 patients with relapsed or refractory mantle-cell lymphoma.  Patients were enrolled into two groups: those who had previously received at least 2 cycles of bortezomib therapy and those who had received less than 2 complete cycles of bortezomib or had received no prior bortezomib therapy.  The primary end point was the overall response rate.  Secondary end points were duration of response, progression-free survival, overall survival, and safety.  RESULTS: The median age was 68 years, and 86% of patients had intermediate-risk or high-risk mantle-cell lymphoma according to clin. prognostic factors.  Patients had received a median of three prior therapies.  The most common treatment-related adverse events were mild or moderate diarrhea, fatigue, and nausea.  Grade 3 or higher hematol. events were infrequent and included neutropenia (in 16% of patients), thrombocytopenia (in 11%), and anemia (in 10%).  A response rate of 68% (75 patients) was obsd., with a complete response rate of 21% and a partial response rate of 47%; prior treatment with bortezomib had no effect on the response rate.  With an estd. median follow-up of 15.3 mo, the estd. median response duration was 17.5 mo (95% confidence interval [CI], 15.8 to not reached), the estd. median progression-free survival was 13.9 mo (95% CI, 7.0 to not reached), and the median overall survival was not reached.  The estd. rate of overall survival was 58% at 18 mo.  CONCLUSIONS: Ibrutinib shows durable single-agent efficacy in relapsed or refractory mantle-cell lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovUuOKvHS0NrVg90H21EOLACvtfcHk0lh1zoKBSfjiKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1OgtL%252FF&md5=7a92bbd5acf86e614cea96f44503e12b</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1306220&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1306220%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DM.%2BL.%26aulast%3DRule%26aufirst%3DS.%26aulast%3DMartin%26aufirst%3DP.%26aulast%3DGoy%26aufirst%3DA.%26aulast%3DAuer%26aufirst%3DR.%26aulast%3DKahl%26aufirst%3DB.%2BS.%26aulast%3DJurczak%26aufirst%3DW.%26aulast%3DAdvani%26aufirst%3DR.%2BH.%26aulast%3DRomaguera%26aufirst%3DJ.%2BE.%26aulast%3DWilliams%26aufirst%3DM.%2BE.%26aulast%3DBarrientos%26aufirst%3DJ.%2BC.%26aulast%3DChmielowska%26aufirst%3DE.%26aulast%3DRadford%26aufirst%3DJ.%26aulast%3DStilgenbauer%26aufirst%3DS.%26aulast%3DDreyling%26aufirst%3DM.%26aulast%3DJedzejczak%26aufirst%3DW.%2BW.%26aulast%3DJohnson%26aufirst%3DP.%26aulast%3DSpurgeon%26aufirst%3DS.%2BE.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DNewberry%26aufirst%3DK.%26aulast%3DOu%26aufirst%3DZ.%26aulast%3DCheng%26aufirst%3DN.%26aulast%3DFang%26aufirst%3DB.%26aulast%3DMcGreivy%26aufirst%3DJ.%26aulast%3DClow%26aufirst%3DF.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26aulast%3DChang%26aufirst%3DB.%2BY.%26aulast%3DBeaupre%26aufirst%3DD.%2BM.%26aulast%3DKunkel%26aufirst%3DL.%2BA.%26aulast%3DBlum%26aufirst%3DK.%2BA.%26atitle%3DTargeting%2520Btk%2520with%2520Ibrutinib%2520in%2520Relapsed%2520or%2520Refractory%2520Mantle-Cell%2520Lymphoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D369%26spage%3D507%26epage%3D516%26doi%3D10.1056%2FNEJMoa1306220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Noy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vos, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thieblemont, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flowers, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morschhauser, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peles, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrientos, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munneke, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimery, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaupre, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, R.</span></span> <span> </span><span class="NLM_article-title">Targeting BTK with Ibrutinib in Relapsed/Refractory Marginal Zone Lymphoma</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>129</i></span>,  <span class="NLM_fpage">2224</span>– <span class="NLM_lpage">2232</span>, <span class="refDoi"> DOI: 10.1182/blood-2016-10-747345</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1182%2Fblood-2016-10-747345" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=129&publication_year=2017&pages=2224-2232&author=A.+Noyauthor=S.+de+Vosauthor=C.+Thieblemontauthor=P.+Martinauthor=C.+R.+Flowersauthor=F.+Morschhauserauthor=G.+P.+Collinsauthor=S.+Maauthor=M.+Colemanauthor=S.+Pelesauthor=S.+Smithauthor=J.+C.+Barrientosauthor=A.+Smithauthor=B.+Munnekeauthor=I.+Dimeryauthor=D.+M.+Beaupreauthor=R.+Chen&title=Targeting+BTK+with+Ibrutinib+in+Relapsed%2FRefractory+Marginal+Zone+Lymphoma&doi=10.1182%2Fblood-2016-10-747345"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1182%2Fblood-2016-10-747345&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2016-10-747345%26sid%3Dliteratum%253Aachs%26aulast%3DNoy%26aufirst%3DA.%26aulast%3Dde%2BVos%26aufirst%3DS.%26aulast%3DThieblemont%26aufirst%3DC.%26aulast%3DMartin%26aufirst%3DP.%26aulast%3DFlowers%26aufirst%3DC.%2BR.%26aulast%3DMorschhauser%26aufirst%3DF.%26aulast%3DCollins%26aufirst%3DG.%2BP.%26aulast%3DMa%26aufirst%3DS.%26aulast%3DColeman%26aufirst%3DM.%26aulast%3DPeles%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DS.%26aulast%3DBarrientos%26aufirst%3DJ.%2BC.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DMunneke%26aufirst%3DB.%26aulast%3DDimery%26aufirst%3DI.%26aulast%3DBeaupre%26aufirst%3DD.%2BM.%26aulast%3DChen%26aufirst%3DR.%26atitle%3DTargeting%2520BTK%2520with%2520Ibrutinib%2520in%2520Relapsed%252FRefractory%2520Marginal%2520Zone%2520Lymphoma%26jtitle%3DBlood%26date%3D2017%26volume%3D129%26spage%3D2224%26epage%3D2232%26doi%3D10.1182%2Fblood-2016-10-747345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Treon, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tripsas, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meid, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warren, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varma, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Argyropolous, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodig, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zehnder, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aster, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghobrial, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castillo, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laubach, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunter, Z. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salman, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clow, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graef, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palomba, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Advani, R. H.</span></span> <span> </span><span class="NLM_article-title">Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>372</i></span>,  <span class="NLM_fpage">1430</span>– <span class="NLM_lpage">1440</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1501548</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1056%2FNEJMoa1501548" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=25853747" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BC2MXns1Wrt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=372&publication_year=2015&pages=1430-1440&author=S.+P.+Treonauthor=C.+K.+Tripsasauthor=K.+Meidauthor=D.+Warrenauthor=G.+Varmaauthor=R.+Greenauthor=K.+V.+Argyropolousauthor=G.+Yangauthor=Y.+Caoauthor=L.+Xuauthor=C.+J.+Pattersonauthor=S.+Rodigauthor=J.+L.+Zehnderauthor=J.+C.+Asterauthor=N.+L.+Harrisauthor=S.+Kananauthor=I.+Ghobrialauthor=J.+J.+Castilloauthor=J.+P.+Laubachauthor=Z.+R.+Hunterauthor=Z.+Salmanauthor=J.+Liauthor=M.+Chengauthor=F.+Clowauthor=T.+Graefauthor=M.+L.+Palombaauthor=R.+H.+Advani&title=Ibrutinib+in+Previously+Treated+Waldenstr%C3%B6m%E2%80%99s+Macroglobulinemia&doi=10.1056%2FNEJMoa1501548"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Ibrutinib in previously treated waldenstrom's macroglobulinemia</span></div><div class="casAuthors">Treon, Steven P.; Tripsas, Christina K.; Meid, Kirsten; Warren, Diane; Varma, Gaurav; Green, Rebecca; Argyropoulos, Kimon V.; Yang, Guang; Cao, Yang; Xu, Lian; Patterson, Christopher J.; Rodig, Scott; Zehnder, James L.; Aster, Jon C.; Harris, Nancy Lee; Kanan, Sandra; Ghobrial, Irene; Castillo, Jorge J.; Laubach, Jacob P.; Hunter, Zachary R.; Salman, Zeena; Li, Jianling; Cheng, Mei; Clow, Fong; Graef, Thorsten; Palomba, M. Lia; Advani, Ranjana H.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">372</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1430-1440</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">MYD88L265P and CXCR4WHIM mutations are highly prevalent in Waldenstrom's macroglobulinemia.  MYD88L265P triggers tumor-cell growth through Bruton's tyrosine kinase, a target of ibrutinib.  CXCR4WHIM mutations confer in vitro resistance to ibrutinib.  We performed a prospective study of ibrutinib in 63 symptomatic patients with Waldenstrom's macroglobulinemia who had received at least one previous treatment, and we investigated the effect of MYD88 and CXCR4 mutations on outcomes.  Ibrutinib at a daily dose of 420 mg was administered orally until disease progression or the development of unacceptable toxic effects.  After the patients received ibrutinib, median serum IgM levels decreased from 3520 mg per dL to 880 mg per dL, median Hb levels increased from 10.5 g per dL to 13.8 g per dL, and bone marrow involvement decreased from 60% to 25% (P<0.01 for all comparisons).  The median time to at least a minor response was 4 wk.  The overall response rate was 90.5%, and the major response rate was 73.0%; these rates were highest among patients with MYD88L265PCXCR4WT (with WT indicating wild-type) (100% overall response rate and 91.2% major response rate), followed by patients with MYD88L265PCXCR4WHIM (85.7% and 61.9%, resp.) and patients with MYD88WTCXCR4WT (71.4% and 28.6%).  The estd. 2-yr progression-free and overall survival rates among all patients were 69.1% and 95.2%, resp.  Treatment-related toxic effects of grade 2 or higher included neutropenia (in 22% of the patients) and thrombocytopenia (in 14%), which were more common in heavily pretreated patients; postprocedural bleeding (in 3%); epistaxis assocd. with the use of fish-oil supplements (in 3%); and atrial fibrillation assocd. with a history of arrhythmia (5%).  Ibrutinib was highly active, assocd. with durable responses, and safe in pretreated patients with Waldenstrom's macroglobulinemia.  MYD88 and CXCR4 mutation status affected responses to this drug. (Funded by Pharmacyclics and others; ClinicalTrials.gov no., NCT01614821.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoifbEcGkxnFrVg90H21EOLACvtfcHk0ljQulQI27JRog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXns1Wrt7w%253D&md5=00d1d3dd9be87801725d8c161afa899c</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1501548&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1501548%26sid%3Dliteratum%253Aachs%26aulast%3DTreon%26aufirst%3DS.%2BP.%26aulast%3DTripsas%26aufirst%3DC.%2BK.%26aulast%3DMeid%26aufirst%3DK.%26aulast%3DWarren%26aufirst%3DD.%26aulast%3DVarma%26aufirst%3DG.%26aulast%3DGreen%26aufirst%3DR.%26aulast%3DArgyropolous%26aufirst%3DK.%2BV.%26aulast%3DYang%26aufirst%3DG.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DPatterson%26aufirst%3DC.%2BJ.%26aulast%3DRodig%26aufirst%3DS.%26aulast%3DZehnder%26aufirst%3DJ.%2BL.%26aulast%3DAster%26aufirst%3DJ.%2BC.%26aulast%3DHarris%26aufirst%3DN.%2BL.%26aulast%3DKanan%26aufirst%3DS.%26aulast%3DGhobrial%26aufirst%3DI.%26aulast%3DCastillo%26aufirst%3DJ.%2BJ.%26aulast%3DLaubach%26aufirst%3DJ.%2BP.%26aulast%3DHunter%26aufirst%3DZ.%2BR.%26aulast%3DSalman%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DClow%26aufirst%3DF.%26aulast%3DGraef%26aufirst%3DT.%26aulast%3DPalomba%26aufirst%3DM.%2BL.%26aulast%3DAdvani%26aufirst%3DR.%2BH.%26atitle%3DIbrutinib%2520in%2520Previously%2520Treated%2520Waldenstr%25C3%25B6m%25E2%2580%2599s%2520Macroglobulinemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D372%26spage%3D1430%26epage%3D1440%26doi%3D10.1056%2FNEJMoa1501548" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Paolo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbosa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, H.</span></span> <span> </span><span class="NLM_article-title">Antiarthritis Effect of a Novel Bruton’s Tyrosine Kinase (BTK) Inhibitor in Rat Collagen-Induced Arthritis and Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling: Relationships Between Inhibition of BTK Phosphorylation and Efficacy</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>338</i></span>,  <span class="NLM_fpage">154</span>– <span class="NLM_lpage">163</span>, <span class="refDoi"> DOI: 10.1124/jpet.111.181545</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1124%2Fjpet.111.181545" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=21521773" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosFCiu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=338&publication_year=2011&pages=154-163&author=L.+Liuauthor=J.+Di+Paoloauthor=J.+Barbosaauthor=H.+Rongauthor=K.+Reifauthor=H.+Wong&title=Antiarthritis+Effect+of+a+Novel+Bruton%E2%80%99s+Tyrosine+Kinase+%28BTK%29+Inhibitor+in+Rat+Collagen-Induced+Arthritis+and+Mechanism-Based+Pharmacokinetic%2FPharmacodynamic+Modeling%3A+Relationships+Between+Inhibition+of+BTK+Phosphorylation+and+Efficacy&doi=10.1124%2Fjpet.111.181545"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Antiarthritis effect of a novel Bruton's tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy</span></div><div class="casAuthors">Liu, Lichuan; Di Paolo, Julie; Barbosa, Jim; Rong, Hong; Reif, Karin; Wong, Harvey</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">338</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">154-163</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK) plays a crit. role in the development, differentiation, and proliferation of B-lineage cells, making it an attractive target for the treatment of rheumatoid arthritis.  The objective of this study was to evaluate the antiarthritis effect of GDC-0834 [R-N-(3-(6-(4-(1,4-dimethyl-3-oxopiperazin-2-yl)phenylamino)-4-methyl-5-oxo-4,5-dihydropyrazin-2-yl)-2-methylphenyl)-4,5,6,7-tetrahydrobenzo[b]thiophene-2-carboxamide], a potent and selective BTK inhibitor, and characterize the relationship between inhibition of BTK phosphorylation (pBTK) and efficacy.  GDC-0834 inhibited BTK with an in vitro IC50 of 5.9 and 6.4 nM in biochem. and cellular assays, resp., and in vivo IC50 of 1.1 and 5.6 μM in mouse and rat, resp.  Administration of GDC-0834 (30-100 mg/kg) in a rat collagen-induced arthritis (CIA) model resulted in a dose-dependent decrease of ankle swelling and redn. of morphol. pathol.  An integrated disease progression pharmacokinetic/pharmacodynamic model where efficacy is driven by pBTK inhibition was fit to ankle-diam. time-course data.  This model incorporated a transit model to characterize nondrug-related decreases in ankle swelling occurring at later stages of disease progression in CIA rats.  The time course of ankle swelling in vehicle animals was described well by the base model.  Simultaneous fitting of data from vehicle- and GDC-0834-treated groups showed that overall 73% inhibition of pBTK was needed to decrease the rate const. describing the ankle swelling increase (kin) by half.  These findings suggest a high degree of pBTK inhibition is required for maximal activity of the pathway on inflammatory arthritis in rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUtceutx0oDrVg90H21EOLACvtfcHk0ljQulQI27JRog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosFCiu7w%253D&md5=52ec6f33d9fc743036baea87a2d6bce1</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1124%2Fjpet.111.181545&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.111.181545%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DDi%2BPaolo%26aufirst%3DJ.%26aulast%3DBarbosa%26aufirst%3DJ.%26aulast%3DRong%26aufirst%3DH.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DWong%26aufirst%3DH.%26atitle%3DAntiarthritis%2520Effect%2520of%2520a%2520Novel%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520%2528BTK%2529%2520Inhibitor%2520in%2520Rat%2520Collagen-Induced%2520Arthritis%2520and%2520Mechanism-Based%2520Pharmacokinetic%252FPharmacodynamic%2520Modeling%253A%2520Relationships%2520Between%2520Inhibition%2520of%2520BTK%2520Phosphorylation%2520and%2520Efficacy%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2011%26volume%3D338%26spage%3D154%26epage%3D163%26doi%3D10.1124%2Fjpet.111.181545" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Evans, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tester, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aslanian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karp, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheets, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labenski, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witowski, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lounsbury, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaturvedi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazdiyasni, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nacht, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freed, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petter, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubrovsky, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westlin, W. F.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Btk with CC-292 Provides Early Pharmacodynamic Assessment of Activity in Mice and Humans</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>346</i></span>,  <span class="NLM_fpage">219</span>– <span class="NLM_lpage">228</span>, <span class="refDoi"> DOI: 10.1124/jpet.113.203489</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1124%2Fjpet.113.203489" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=23709115" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFOjsbbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=346&publication_year=2013&pages=219-228&author=E.+K.+Evansauthor=R.+Testerauthor=S.+Aslanianauthor=R.+Karpauthor=M.+Sheetsauthor=M.+T.+Labenskiauthor=S.+R.+Witowskiauthor=H.+Lounsburyauthor=P.+Chaturvediauthor=H.+Mazdiyasniauthor=Z.+Zhuauthor=M.+Nachtauthor=M.+I.+Freedauthor=R.+C.+Petterauthor=A.+Dubrovskyauthor=J.+Singhauthor=W.+F.+Westlin&title=Inhibition+of+Btk+with+CC-292+Provides+Early+Pharmacodynamic+Assessment+of+Activity+in+Mice+and+Humans&doi=10.1124%2Fjpet.113.203489"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans</span></div><div class="casAuthors">Evans, Erica K.; Tester, Richland; Aslanian, Sharon; Karp, Russell; Sheets, Michael; Labenski, Matthew T.; Witowski, Steven R.; Lounsbury, Heather; Chaturvedi, Prasoon; Mazdiyasni, Hormoz; Zhu, Zhendong; Nacht, Mariana; Freed, Martin I.; Petter, Russell C.; Dubrovskiy, Alex; Singh, Juswinder; Westlin, William F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">346</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">219-228</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Targeted therapies that suppress B cell receptor (BCR) signaling have emerged as promising agents in autoimmune disease and B cell malignancies.  Bruton's tyrosine kinase (Btk) plays a crucial role in B cell development and activation through the BCR signaling pathway and represents a new target for diseases characterized by inappropriate B cell activity.  N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide (CC-292) is a highly selective, covalent Btk inhibitor and a sensitive and quant. assay that measures CC-292-Btk engagement has been developed.  This translational pharmacodynamic assay has accompanied CC-292 through each step of drug discovery and development.  These studies demonstrate the quantity of Btk bound by CC-292 correlates with the efficacy of CC-292 in vitro and in the collagen-induced arthritis model of autoimmune disease.  Recently, CC-292 has entered human clin. trials with a trial design that has provided rapid insight into safety, pharmacokinetics, and pharmacodynamics.  This first-in-human healthy volunteer trial has demonstrated that a single oral dose of 2 mg/kg CC-292 consistently engaged all circulating Btk protein and provides the basis for rational dose selection in future clin. trials.  This targeted covalent drug design approach has enabled the discovery and early clin. development of CC-292 and has provided support for Btk as a valuable drug target for B-cell mediated disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrN2l8ZCVqCFLVg90H21EOLACvtfcHk0lg3kWU-Yopk5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFOjsbbM&md5=95fac997a246e59d943dd554af358a65</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1124%2Fjpet.113.203489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.113.203489%26sid%3Dliteratum%253Aachs%26aulast%3DEvans%26aufirst%3DE.%2BK.%26aulast%3DTester%26aufirst%3DR.%26aulast%3DAslanian%26aufirst%3DS.%26aulast%3DKarp%26aufirst%3DR.%26aulast%3DSheets%26aufirst%3DM.%26aulast%3DLabenski%26aufirst%3DM.%2BT.%26aulast%3DWitowski%26aufirst%3DS.%2BR.%26aulast%3DLounsbury%26aufirst%3DH.%26aulast%3DChaturvedi%26aufirst%3DP.%26aulast%3DMazdiyasni%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DNacht%26aufirst%3DM.%26aulast%3DFreed%26aufirst%3DM.%2BI.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DDubrovsky%26aufirst%3DA.%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DWestlin%26aufirst%3DW.%2BF.%26atitle%3DInhibition%2520of%2520Btk%2520with%2520CC-292%2520Provides%2520Early%2520Pharmacodynamic%2520Assessment%2520of%2520Activity%2520in%2520Mice%2520and%2520Humans%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2013%26volume%3D346%26spage%3D219%26epage%3D228%26doi%3D10.1124%2Fjpet.113.203489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Postelnek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vu, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, D.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradshaw, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pashine, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivasan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Mahony, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narula, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeMartino, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fine, J. S.</span></span> <span> </span><span class="NLM_article-title">RN486, a Selective Bruton’s Tyrosine Kinase Inhibitor, Abrogates Immune Hypersensitivity Responses and Arthritis in Rodents</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>341</i></span>,  <span class="NLM_fpage">90</span>– <span class="NLM_lpage">103</span>, <span class="refDoi"> DOI: 10.1124/jpet.111.187740</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1124%2Fjpet.111.187740" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=22228807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BC38XltVagt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=341&publication_year=2012&pages=90-103&author=D.+Xuauthor=Y.+Kimauthor=J.+Postelnekauthor=M.+D.+Vuauthor=D.-Q.+Huauthor=C.+Liaoauthor=M.+Bradshawauthor=J.+Hsuauthor=J.+Zhangauthor=A.+Pashineauthor=D.+Srinivasanauthor=J.+Woodsauthor=A.+Levinauthor=A.+O%E2%80%99Mahonyauthor=T.+D.+Owensauthor=Y.+Louauthor=R.+J.+Hillauthor=S.+Narulaauthor=J.+DeMartinoauthor=J.+S.+Fine&title=RN486%2C+a+Selective+Bruton%E2%80%99s+Tyrosine+Kinase+Inhibitor%2C+Abrogates+Immune+Hypersensitivity+Responses+and+Arthritis+in+Rodents&doi=10.1124%2Fjpet.111.187740"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents</span></div><div class="casAuthors">Xu, Daigen; Kim, Yong; Postelnek, Jennifer; Vu, Minh Diem; Hu, Dong-Qing; Liao, Cheng; Bradshaw, Mike; Hsu, Jonathan; Zhang, Jun; Pashine, Achal; Srinivasan, Dinesh; Woods, John; Levin, Anita; O'Mahony, Alison; Owens, Timothy D.; Lou, Yan; Hill, Ronald J.; Narula, Satwant; DeMartino, Julie; Fine, Jay S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">341</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">90-103</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Genetic mutation and pharmacol. inhibition of Bruton's tyrosine kinase (Btk) both have been shown to prevent the development of collagen-induced arthritis (CIA) in mice, providing a rationale for the development of Btk inhibitors for treating rheumatoid arthritis (RA).  In the present study, we characterized a novel Btk inhibitor, 6-cyclopropyl-8-fluoro-2-(2-hydroxymethyl-3-{1-methyl-5-[5-(4-methyl-piperazin-1-yl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-pyridin-3-yl}-phenyl)-2H-isoquinolin-1-one (RN486), in vitro and in rodent models of immune hypersensitivity and arthritis.  We demonstrated that RN486 not only potently and selectively inhibited the Btk enzyme, but also displayed functional activities in human cell-based assays in multiple cell types, blocking Fcε receptor crosslinking-induced degranulation in mast cells (IC50 = 2.9 nM), Fcγ receptor engagement-mediated tumor necrosis factor α prodn. in monocytes (IC50 = 7.0 nM), and B cell antigen receptor-induced expression of an activation marker, CD69, in B cells in whole blood (IC50 = 21.0 nM).  RN486 displayed similar functional activities in rodent models, effectively preventing type I and type III hypersensitivity responses.  More importantly, RN486 produced robust anti-inflammatory and bone-protective effects in mouse CIA and rat adjuvant-induced arthritis (AIA) models.  In the AIA model, RN486 inhibited both joint and systemic inflammation either alone or in combination with methotrexate, reducing both paw swelling and inflammatory markers in the blood.  Together, our findings not only demonstrate that Btk plays an essential and conserved role in regulating immunoreceptor-mediated immune responses in both humans and rodents, but also provide evidence and mechanistic insights to support the development of selective Btk inhibitors as small-mol. disease-modifying drugs for RA and potentially other autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXBTQENfl5RbVg90H21EOLACvtfcHk0lg3kWU-Yopk5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XltVagt7g%253D&md5=06be56a47afd2eb09e0871710c1d2b47</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1124%2Fjpet.111.187740&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.111.187740%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DD.%26aulast%3DKim%26aufirst%3DY.%26aulast%3DPostelnek%26aufirst%3DJ.%26aulast%3DVu%26aufirst%3DM.%2BD.%26aulast%3DHu%26aufirst%3DD.-Q.%26aulast%3DLiao%26aufirst%3DC.%26aulast%3DBradshaw%26aufirst%3DM.%26aulast%3DHsu%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DPashine%26aufirst%3DA.%26aulast%3DSrinivasan%26aufirst%3DD.%26aulast%3DWoods%26aufirst%3DJ.%26aulast%3DLevin%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Mahony%26aufirst%3DA.%26aulast%3DOwens%26aufirst%3DT.%2BD.%26aulast%3DLou%26aufirst%3DY.%26aulast%3DHill%26aufirst%3DR.%2BJ.%26aulast%3DNarula%26aufirst%3DS.%26aulast%3DDeMartino%26aufirst%3DJ.%26aulast%3DFine%26aufirst%3DJ.%2BS.%26atitle%3DRN486%252C%2520a%2520Selective%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520Inhibitor%252C%2520Abrogates%2520Immune%2520Hypersensitivity%2520Responses%2520and%2520Arthritis%2520in%2520Rodents%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2012%26volume%3D341%26spage%3D90%26epage%3D103%26doi%3D10.1124%2Fjpet.111.187740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mina-Osorio, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaStant, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keirstead, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittard, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayala, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefanova, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrido, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimaano, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilton, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giron, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Postelnek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Min, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramanujam, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeMartino, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narula, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, D.</span></span> <span> </span><span class="NLM_article-title">Suppression of Glomerulonephritis in Lupus-Prone NZB × NZW Mice by RN486, a Selective Inhibitor of Bruton’s Tyrosine Kinase</span>. <i>Arthritis Rheum.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">2380</span>– <span class="NLM_lpage">2391</span>, <span class="refDoi"> DOI: 10.1002/art.38047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1002%2Fart.38047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=23754328" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlGmtbnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2013&pages=2380-2391&author=P.+Mina-Osorioauthor=J.+LaStantauthor=N.+Keirsteadauthor=T.+Whittardauthor=J.+Ayalaauthor=S.+Stefanovaauthor=R.+Garridoauthor=N.+Dimaanoauthor=H.+Hiltonauthor=M.+Gironauthor=K.+Y.+Lauauthor=J.+Hangauthor=J.+Postelnekauthor=Y.+Kimauthor=S.+Minauthor=A.+Patelauthor=J.+Woodsauthor=M.+Ramanujamauthor=J.+DeMartinoauthor=S.+Narulaauthor=D.+Xu&title=Suppression+of+Glomerulonephritis+in+Lupus-Prone+NZB+%C3%97+NZW+Mice+by+RN486%2C+a+Selective+Inhibitor+of+Bruton%E2%80%99s+Tyrosine+Kinase&doi=10.1002%2Fart.38047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Suppression of Glomerulonephritis in Lupus-Prone NZB × NZW Mice by RN486, a Selective Inhibitor of Bruton's Tyrosine Kinase</span></div><div class="casAuthors">Mina-Osorio, Paola; LaStant, Jacob; Keirstead, Natalie; Whittard, Toni; Ayala, Julia; Stefanova, Stella; Garrido, Rosario; Dimaano, Nena; Hilton, Holly; Giron, Mario; Lau, Kai-Yeung; Hang, Julie; Postelnek, Jennifer; Kim, Yong; Min, Soo; Patel, Alka; Woods, John; Ramanujam, Meera; DeMartino, Julie; Narula, Satwant; Xu, Daigen</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2380-2391</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective : Bruton's tyrosine kinase (BTK) plays a crit. role in B cell development and function.  We recently described a selective BTK inhibitor, RN486, that blocks B cell receptor (BCR) and Fcγ receptor signaling and is efficacious in animal models of arthritis.  The aim of this study was to examine the potential efficacy of BTK in systemic lupus erythematosus (SLE), using an NZB × NZW mouse model of spontaneous SLE.  Methods : Mice received RN486 or its vehicle (administered in chow) at a final concn. of 30 mg/kg for 8 wk, starting at 32 wk of age.  Results : The administration of RN486 completely stopped disease progression, as detd. by histol. and functional analyses of glomerular nephritis.  The efficacy was assocd. with striking inhibition of B cell activation, as demonstrated by a significant redn. in CD69 expression in response to BCR crosslinking.  RN486 markedly reduced the secretion of IgG anti-double-stranded DNA (anti-dsDNA) secretion, as detd. by enzyme-linked immunosorbent and enzyme-linked immunospot assays.  Flow cytometric anal. demonstrated depletion of CD138highB220low plasma cells in the spleen.  RN486 inhibited secretion of IgG anti-dsDNA but not IgM anti-dsDNA, suggesting that pharmacol. blockade of BTK resembles the reported transgenic expression of low levels of endogenous BTK in B cells.  In addn., RN486 may also impact the effector function of autoantibodies, as evidenced by a significant redn. in immune complex-mediated activation of human monocytes in vitro and down-regulation of the expression of macrophage-related and interferon-inducible genes in both the kidneys and spleens of treated mice.  Conclusion : Collectively, our data suggest that BTK inhibitors may simultaneously target autoantibody-producing and effector cells in SLE, thus constituting a promising therapeutic alternative for this disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCcpbnXMOlybVg90H21EOLACvtfcHk0lg9jDJ-sDNo0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlGmtbnF&md5=14979f458a23da7916e7ee9df042ac81</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1002%2Fart.38047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.38047%26sid%3Dliteratum%253Aachs%26aulast%3DMina-Osorio%26aufirst%3DP.%26aulast%3DLaStant%26aufirst%3DJ.%26aulast%3DKeirstead%26aufirst%3DN.%26aulast%3DWhittard%26aufirst%3DT.%26aulast%3DAyala%26aufirst%3DJ.%26aulast%3DStefanova%26aufirst%3DS.%26aulast%3DGarrido%26aufirst%3DR.%26aulast%3DDimaano%26aufirst%3DN.%26aulast%3DHilton%26aufirst%3DH.%26aulast%3DGiron%26aufirst%3DM.%26aulast%3DLau%26aufirst%3DK.%2BY.%26aulast%3DHang%26aufirst%3DJ.%26aulast%3DPostelnek%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DY.%26aulast%3DMin%26aufirst%3DS.%26aulast%3DPatel%26aufirst%3DA.%26aulast%3DWoods%26aufirst%3DJ.%26aulast%3DRamanujam%26aufirst%3DM.%26aulast%3DDeMartino%26aufirst%3DJ.%26aulast%3DNarula%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DD.%26atitle%3DSuppression%2520of%2520Glomerulonephritis%2520in%2520Lupus-Prone%2520NZB%2520%25C3%2597%2520NZW%2520Mice%2520by%2520RN486%252C%2520a%2520Selective%2520Inhibitor%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%26jtitle%3DArthritis%2520Rheum.%26date%3D2013%26volume%3D65%26spage%3D2380%26epage%3D2391%26doi%3D10.1002%2Fart.38047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hutcheson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanarsa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bashmakov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grewal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sajitharan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buggy, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satterthwaite, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohan, C.</span></span> <span> </span><span class="NLM_article-title">Modulating Proximal Cell Signaling by Targeting Btk Ameliorates Humoral Autoimmunity and End-Organ Disease in Murine Lupus</span>. <i>Arthritis Res. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">R243</span>, <span class="refDoi"> DOI: 10.1186/ar4086</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1186%2Far4086" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=23136880" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BC3sXitlSgtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2012&pages=R243&author=J.+Hutchesonauthor=K.+Vanarsaauthor=A.+Bashmakovauthor=S.+Grewalauthor=D.+Sajitharanauthor=B.+Y.+Changauthor=J.+J.+Buggyauthor=X.+J.+Zhouauthor=Y.+Duauthor=A.+B.+Satterthwaiteauthor=C.+Mohan&title=Modulating+Proximal+Cell+Signaling+by+Targeting+Btk+Ameliorates+Humoral+Autoimmunity+and+End-Organ+Disease+in+Murine+Lupus&doi=10.1186%2Far4086"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Modulating proximal cell signaling by targeting Btk ameliorates humoral autoimmunity and end-organ disease in murine lupus</span></div><div class="casAuthors">Hutcheson, Jack; Vanarsa, Kamala; Bashmakov, Anna; Grewal, Simer; Sajitharan, Deena; Chang, Betty Y.; Buggy, Joseph J.; Zhou, Xin J.; Du, Yong; Satterthwaite, Anne B.; Mohan, Chandra</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis Research & Therapy</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">R243</span>CODEN:
                <span class="NLM_cas:coden">ARTRCV</span>;
        ISSN:<span class="NLM_cas:issn">1478-6362</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Introduction: Systemic lupus erythematosus is a chronic autoimmune disease characterized by an abundance of autoantibodies against nuclear antigens.  Bruton's tyrosine kinase (Btk) is a proximal transducer of the BCR signal that allows for B-cell activation and differentiation.  Recently, selective inhibition of Btk by PCI-32765 has shown promise in limiting activity of multiple cells types in various models of cancer and autoimmunity.  The aim of this study was to det. the effect of Btk inhibition by PCI-32765 on the development of lupus in lupus-prone B6.Sle1 and B6.Sle1.Sle3 mice.  Methods: B6.Sle1 or B6.Sle1.Sle3 mice received drinking water contg. either the Btk inhibitor PCI-32765 or vehicle for 56 days.  Following treatment, mice were examd. for clin. and pathol. characteristics of lupus.  The effect of PCI-32765 on specific cell types was also investigated.  Results: In this study, we report that Btk inhibition dampens humoral autoimmunity in B6.Sle1 monocongenic mice.  Moreover, in B6.Sle1.Sle3 bicongenic mice that are prone to severe lupus, Btk inhibition also dampens humoral and cellular autoimmunity, as well as lupus nephritis.  Conclusions: These findings suggest that partial crippling of cell signaling in B cells and antigen presenting cells (APCs) may be a viable alternative to total depletion of these cells as a therapeutic modality for lupus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpj4G1JxmkwlLVg90H21EOLACvtfcHk0lg9jDJ-sDNo0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXitlSgtLc%253D&md5=ea49e641ea03d8aff5577d4f3f6b36fc</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1186%2Far4086&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Far4086%26sid%3Dliteratum%253Aachs%26aulast%3DHutcheson%26aufirst%3DJ.%26aulast%3DVanarsa%26aufirst%3DK.%26aulast%3DBashmakov%26aufirst%3DA.%26aulast%3DGrewal%26aufirst%3DS.%26aulast%3DSajitharan%26aufirst%3DD.%26aulast%3DChang%26aufirst%3DB.%2BY.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26aulast%3DZhou%26aufirst%3DX.%2BJ.%26aulast%3DDu%26aufirst%3DY.%26aulast%3DSatterthwaite%26aufirst%3DA.%2BB.%26aulast%3DMohan%26aufirst%3DC.%26atitle%3DModulating%2520Proximal%2520Cell%2520Signaling%2520by%2520Targeting%2520Btk%2520Ameliorates%2520Humoral%2520Autoimmunity%2520and%2520End-Organ%2520Disease%2520in%2520Murine%2520Lupus%26jtitle%3DArthritis%2520Res.%2520Ther.%26date%3D2012%26volume%3D14%26spage%3DR243%26doi%3D10.1186%2Far4086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rankin, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seth, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keegan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andreyeva, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edmonds, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathialagan, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benson, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Syed, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benoit, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyashiro, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peeva, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramaiah, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Messing, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Homer, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunissi-Joannopoulos, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nickerson-Nutter, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnute, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douhan, J.,  III</span></span> <span> </span><span class="NLM_article-title">Selective Inhibition of Btk Prevents Murine Lupus and Antibody-Mediated Glomerulonephritis</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>191</i></span>,  <span class="NLM_fpage">4540</span>– <span class="NLM_lpage">4550</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1301553</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.4049%2Fjimmunol.1301553" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=24068666" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1eqs7zE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=2013&pages=4540-4550&author=A.+L.+Rankinauthor=N.+Sethauthor=S.+Keeganauthor=T.+Andreyevaauthor=T.+A.+Cookauthor=J.+Edmondsauthor=N.+Mathialaganauthor=M.+J.+Bensonauthor=J.+Syedauthor=Y.+Zhanauthor=S.+E.+Benoitauthor=J.+S.+Miyashiroauthor=N.+Woodauthor=S.+Mohanauthor=E.+Peevaauthor=S.+K.+Ramaiahauthor=D.+Messingauthor=B.+L.+Homerauthor=K.+Dunissi-Joannopoulosauthor=C.+L.+Nickerson-Nutterauthor=M.+E.+Schnuteauthor=J.+Douhan&title=Selective+Inhibition+of+Btk+Prevents+Murine+Lupus+and+Antibody-Mediated+Glomerulonephritis&doi=10.4049%2Fjimmunol.1301553"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Inhibition of BTK Prevents Murine Lupus and Antibody-Mediated Glomerulonephritis</span></div><div class="casAuthors">Rankin, Andrew L.; Seth, Nilufer; Keegan, Sean; Andreyeva, Tatyana; Cook, Tim A.; Edmonds, Jason; Mathialagan, Nagappan; Benson, Micah J.; Syed, Jameel; Zhan, Yutian; Benoit, Stephen E.; Miyashiro, Joy S.; Wood, Nancy; Mohan, Shashi; Peeva, Elena; Ramaiah, Shashi K.; Messing, Dean; Homer, Bruce L.; Dunussi-Joannopoulos, Kyri; Nickerson-Nutter, Cheryl L.; Schnute, Mark E.; Douhan, John, III</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">191</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4540-4550</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Autoantibody prodn. and immune complex deposition within the kidney promote renal disease in patients with lupus nephritis.  Thus, therapeutics that inhibit these pathways may be efficacious in the treatment of systemic lupus erythematosus.  Bruton's tyrosine kinase (BTK) is a crit. signaling component of both BCR and FcR signaling.  We sought to assess the efficacy of inhibiting BTK in the development of lupus-like disease, and in this article describe (R)-5-amino-1-(1-cyanopiperidin-3-yl)-3-(4-[2,4-difluorophenoxy]phenyl)-1H-pyrazole-4-carboxamide (PF-06250112), a novel highly selective and potent BTK inhibitor.  We demonstrate in vitro that PF-06250112 inhibits both BCR-mediated signaling and proliferation, as well as FcR-mediated activation.  To assess the therapeutic impact of BTK inhibition, we treated aged NZBxWF1 mice with PF-06250112 and demonstrate that PF-06250112 significantly limits the spontaneous accumulation of splenic germinal center B cells and plasma cells.  Correspondingly, anti-dsDNA and autoantibody levels were reduced in a dose-dependent manner.  Moreover, administration of PF-06250112 prevented the development of proteinuria and improved glomerular pathol. scores in all treatment groups.  Strikingly, this therapeutic effect could occur with only a modest redn. obsd. in anti-dsDNA titers, implying a crit. role for BTK signaling in disease pathogenesis beyond inhibition of autoantibody prodn.  We subsequently demonstrate that PF-06250112 prevents proteinuria in an FcR-dependent, Ab-mediated model of glomerulonephritis.  Importantly, these results highlight that BTK inhibition potently limits the development of glomerulonephritis by impacting both cell- and effector mol.-mediated pathways.  These data provide support for evaluating the efficacy of BTK inhibition in systemic lupus erythematosus patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBldekay4INLVg90H21EOLACvtfcHk0lhMhXXrG3uE8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1eqs7zE&md5=7abfb074bf422aa3fb63aa0bc3d8cf58</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1301553&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1301553%26sid%3Dliteratum%253Aachs%26aulast%3DRankin%26aufirst%3DA.%2BL.%26aulast%3DSeth%26aufirst%3DN.%26aulast%3DKeegan%26aufirst%3DS.%26aulast%3DAndreyeva%26aufirst%3DT.%26aulast%3DCook%26aufirst%3DT.%2BA.%26aulast%3DEdmonds%26aufirst%3DJ.%26aulast%3DMathialagan%26aufirst%3DN.%26aulast%3DBenson%26aufirst%3DM.%2BJ.%26aulast%3DSyed%26aufirst%3DJ.%26aulast%3DZhan%26aufirst%3DY.%26aulast%3DBenoit%26aufirst%3DS.%2BE.%26aulast%3DMiyashiro%26aufirst%3DJ.%2BS.%26aulast%3DWood%26aufirst%3DN.%26aulast%3DMohan%26aufirst%3DS.%26aulast%3DPeeva%26aufirst%3DE.%26aulast%3DRamaiah%26aufirst%3DS.%2BK.%26aulast%3DMessing%26aufirst%3DD.%26aulast%3DHomer%26aufirst%3DB.%2BL.%26aulast%3DDunissi-Joannopoulos%26aufirst%3DK.%26aulast%3DNickerson-Nutter%26aufirst%3DC.%2BL.%26aulast%3DSchnute%26aufirst%3DM.%2BE.%26aulast%3DDouhan%26aufirst%3DJ.%26atitle%3DSelective%2520Inhibition%2520of%2520Btk%2520Prevents%2520Murine%2520Lupus%2520and%2520Antibody-Mediated%2520Glomerulonephritis%26jtitle%3DJ.%2520Immunol.%26date%3D2013%26volume%3D191%26spage%3D4540%26epage%3D4550%26doi%3D10.4049%2Fjimmunol.1301553" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bender, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pereira, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samy, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu-Bujalski, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldwell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morandi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Head, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koehler, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genest, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okitsu, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grenningloh, R.</span></span> <span> </span><span class="NLM_article-title">Btk Inhibition Treats TLR7/IFN Driven Murine Lupus</span>. <i>Clin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>164</i></span>,  <span class="NLM_fpage">65</span>– <span class="NLM_lpage">77</span>, <span class="refDoi"> DOI: 10.1016/j.clim.2016.01.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1016%2Fj.clim.2016.01.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=26821304" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BC28XivVCrsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=164&publication_year=2016&pages=65-77&author=A.+T.+Benderauthor=A.+Pereiraauthor=K.+Fuauthor=E.+Samyauthor=Y.+Wuauthor=L.+Liu-Bujalskiauthor=R.+Caldwellauthor=Y.+Y.+Chenauthor=H.+Tianauthor=F.+Morandiauthor=J.+Headauthor=U.+Koehlerauthor=M.+Genestauthor=S.+L.+Okitsuauthor=D.+Xuauthor=R.+Grenningloh&title=Btk+Inhibition+Treats+TLR7%2FIFN+Driven+Murine+Lupus&doi=10.1016%2Fj.clim.2016.01.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Btk inhibition treats TLR7/IFN driven murine lupus</span></div><div class="casAuthors">Bender, Andrew T.; Pereira, Albertina; Fu, Kai; Samy, Eileen; Wu, Yin; Liu-Bujalski, Lesley; Caldwell, Richard; Chen, Yi-Ying; Tian, Hui; Morandi, Federica; Head, Jared; Koehler, Ursula; Genest, Melinda; Okitsu, Shinji L.; Xu, Daigen; Grenningloh, Roland</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Immunology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">164</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">65-77</span>CODEN:
                <span class="NLM_cas:coden">CLIIFY</span>;
        ISSN:<span class="NLM_cas:issn">1521-6616</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (Btk) is expressed in a variety of immune cells and previous work has demonstrated that blocking Btk is a promising strategy for treating autoimmune diseases.  Herein, we utilized a tool Btk inhibitor, M7583, to det. the therapeutic efficacy of Btk inhibition in two mouse lupus models driven by TLR7 activation and type I interferon.  In BXSB-Yaa lupus mice, Btk inhibition reduced autoantibodies, nephritis, and mortality.  In the pristane-induced DBA/1 lupus model, Btk inhibition suppressed arthritis, but autoantibodies and the IFN gene signature were not significantly affected; suggesting efficacy was mediated through inhibition of Fc receptors.  In vitro studies using primary human macrophages revealed that Btk inhibition can block activation by immune complexes and TLR7 which contributes to tissue damage in SLE.  Overall, our results provide translational insight into how Btk inhibition may provide benefit to a variety of SLE patients by affecting both BCR and FcR signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA2d9Kk41QULVg90H21EOLACvtfcHk0ljS5qkYlszXUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XivVCrsb4%253D&md5=f926090bf3c6659e31995cc6c4b08be9</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.clim.2016.01.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.clim.2016.01.012%26sid%3Dliteratum%253Aachs%26aulast%3DBender%26aufirst%3DA.%2BT.%26aulast%3DPereira%26aufirst%3DA.%26aulast%3DFu%26aufirst%3DK.%26aulast%3DSamy%26aufirst%3DE.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DLiu-Bujalski%26aufirst%3DL.%26aulast%3DCaldwell%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DY.%2BY.%26aulast%3DTian%26aufirst%3DH.%26aulast%3DMorandi%26aufirst%3DF.%26aulast%3DHead%26aufirst%3DJ.%26aulast%3DKoehler%26aufirst%3DU.%26aulast%3DGenest%26aufirst%3DM.%26aulast%3DOkitsu%26aufirst%3DS.%2BL.%26aulast%3DXu%26aufirst%3DD.%26aulast%3DGrenningloh%26aufirst%3DR.%26atitle%3DBtk%2520Inhibition%2520Treats%2520TLR7%252FIFN%2520Driven%2520Murine%2520Lupus%26jtitle%3DClin.%2520Immunol.%26date%3D2016%26volume%3D164%26spage%3D65%26epage%3D77%26doi%3D10.1016%2Fj.clim.2016.01.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chalmers, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doerner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosanac, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khalil, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harcken, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimock, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Der, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herlitz, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webb, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seccareccia, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fine, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramanujam, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Putterman, C.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Blockade of Immune Complex-Mediated Glomerulonephritis by Highly Selective Inhibition of Bruton’s Tyrosine Kinase</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">26164</span>, <span class="refDoi"> DOI: 10.1038/srep26164</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1038%2Fsrep26164" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=27192942" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BC28Xot1Gqt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=26164&author=S.+A.+Chalmersauthor=J.+Doernerauthor=T.+Bosanacauthor=S.+Khalilauthor=D.+Smithauthor=C.+Harckenauthor=J.+Dimockauthor=E.+Derauthor=L.+Herlitzauthor=D.+Webbauthor=E.+Seccarecciaauthor=D.+Fengauthor=J.+S.+Fineauthor=M.+Ramanujamauthor=E.+Kleinauthor=C.+Putterman&title=Therapeutic+Blockade+of+Immune+Complex-Mediated+Glomerulonephritis+by+Highly+Selective+Inhibition+of+Bruton%E2%80%99s+Tyrosine+Kinase&doi=10.1038%2Fsrep26164"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic Blockade of Immune Complex-Mediated Glomerulonephritis by Highly Selective Inhibition of Bruton's Tyrosine Kinase</span></div><div class="casAuthors">Chalmers, Samantha A.; Doerner, Jessica; Bosanac, Todd; Khalil, Sara; Smith, Dustin; Harcken, Christian; Dimock, Janice; Der, Evan; Herlitz, Leal; Webb, Deborah; Seccareccia, Elise; Feng, Di; Fine, Jay S.; Ramanujam, Meera; Klein, Elliott; Putterman, Chaim</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">26164</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Lupus nephritis (LN) is a potentially dangerous end organ pathol. that affects upwards of 60% of lupus patients.  Bruton's tyrosine kinase (BTK) is important for B cell development, Fc receptor signaling, and macrophage polarization.  In this study, we investigated the effects of a novel, highly selective and potent BTK inhibitor, BI-BTK-1, in an inducible model of LN in which mice receive nephrotoxic serum (NTS) contg. anti-glomerular antibodies.  Mice were treated once daily with vehicle alone or BI-BTK-1, either prophylactically or therapeutically.  When compared with control treated mice, NTS-challenged mice treated prophylactically with BI-BTK-1 exhibited significantly attenuated kidney disease, which was dose dependent.  BI-BTK-1 treatment resulted in decreased infiltrating IBA-1+ cells, as well as C3 deposition within the kidney.  RT-PCR on whole kidney RNA and serum profiling indicated that BTK inhibition significantly decreased levels of LN-relevant inflammatory cytokines and chemokines.  Renal RNA expression profiling by RNA-seq revealed that BI-BTK-1 dramatically modulated pathways related to inflammation and glomerular injury.  Importantly, when administered therapeutically, BI-BTK-1 reversed established proteinuria and improved renal histopathol.  Our results highlight the important role for BTK in the pathogenesis of immune complex-mediated nephritis, and BTK inhibition as a promising therapeutic target for LN.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAplnw9VtL3rVg90H21EOLACvtfcHk0ljS5qkYlszXUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xot1Gqt7o%253D&md5=ce83240c6f4ab86e25b9f17ef0dd32b7</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1038%2Fsrep26164&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep26164%26sid%3Dliteratum%253Aachs%26aulast%3DChalmers%26aufirst%3DS.%2BA.%26aulast%3DDoerner%26aufirst%3DJ.%26aulast%3DBosanac%26aufirst%3DT.%26aulast%3DKhalil%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DHarcken%26aufirst%3DC.%26aulast%3DDimock%26aufirst%3DJ.%26aulast%3DDer%26aufirst%3DE.%26aulast%3DHerlitz%26aufirst%3DL.%26aulast%3DWebb%26aufirst%3DD.%26aulast%3DSeccareccia%26aufirst%3DE.%26aulast%3DFeng%26aufirst%3DD.%26aulast%3DFine%26aufirst%3DJ.%2BS.%26aulast%3DRamanujam%26aufirst%3DM.%26aulast%3DKlein%26aufirst%3DE.%26aulast%3DPutterman%26aufirst%3DC.%26atitle%3DTherapeutic%2520Blockade%2520of%2520Immune%2520Complex-Mediated%2520Glomerulonephritis%2520by%2520Highly%2520Selective%2520Inhibition%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26spage%3D26164%26doi%3D10.1038%2Fsrep26164" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walter, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rule, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyer, M. J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cazin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quittet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutchinson, C. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birkett, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamieson, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Courtenay-Luck, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshizawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharpe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohno, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishimura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cartron, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morschhauser, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fegan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salles, G.</span></span> <span> </span><span class="NLM_article-title">A Phase I Clinical Trial of the Selective Btk Inhibitor ONO/GS-4059 in Relapsed and Refractory Mature B-cell Malignancies,</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>127</i></span>,  <span class="NLM_fpage">411</span>– <span class="NLM_lpage">419</span>, <span class="refDoi"> DOI: 10.1182/blood-2015-08-664086</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1182%2Fblood-2015-08-664086" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2016&pages=411-419&author=H.+S.+Walterauthor=S.+A.+Ruleauthor=M.+J.+S.+Dyerauthor=L.+Karlinauthor=C.+Jonesauthor=B.+Cazinauthor=P.+Quittetauthor=N.+Shahauthor=C.+V.+Hutchinsonauthor=H.+Hondaauthor=K.+Duffyauthor=J.+Birkettauthor=V.+Jamiesonauthor=N.+Courtenay-Luckauthor=T.+Yoshizawaauthor=J.+Sharpeauthor=T.+Ohnoauthor=S.+Abeauthor=A.+Nishimuraauthor=G.+Cartronauthor=F.+Morschhauserauthor=C.+Feganauthor=G.+Salles&title=A+Phase+I+Clinical+Trial+of+the+Selective+Btk+Inhibitor+ONO%2FGS-4059+in+Relapsed+and+Refractory+Mature+B-cell+Malignancies%2C&doi=10.1182%2Fblood-2015-08-664086"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1182%2Fblood-2015-08-664086&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2015-08-664086%26sid%3Dliteratum%253Aachs%26aulast%3DWalter%26aufirst%3DH.%2BS.%26aulast%3DRule%26aufirst%3DS.%2BA.%26aulast%3DDyer%26aufirst%3DM.%2BJ.%2BS.%26aulast%3DKarlin%26aufirst%3DL.%26aulast%3DJones%26aufirst%3DC.%26aulast%3DCazin%26aufirst%3DB.%26aulast%3DQuittet%26aufirst%3DP.%26aulast%3DShah%26aufirst%3DN.%26aulast%3DHutchinson%26aufirst%3DC.%2BV.%26aulast%3DHonda%26aufirst%3DH.%26aulast%3DDuffy%26aufirst%3DK.%26aulast%3DBirkett%26aufirst%3DJ.%26aulast%3DJamieson%26aufirst%3DV.%26aulast%3DCourtenay-Luck%26aufirst%3DN.%26aulast%3DYoshizawa%26aufirst%3DT.%26aulast%3DSharpe%26aufirst%3DJ.%26aulast%3DOhno%26aufirst%3DT.%26aulast%3DAbe%26aufirst%3DS.%26aulast%3DNishimura%26aufirst%3DA.%26aulast%3DCartron%26aufirst%3DG.%26aulast%3DMorschhauser%26aufirst%3DF.%26aulast%3DFegan%26aufirst%3DC.%26aulast%3DSalles%26aufirst%3DG.%26atitle%3DA%2520Phase%2520I%2520Clinical%2520Trial%2520of%2520the%2520Selective%2520Btk%2520Inhibitor%2520ONO%252FGS-4059%2520in%2520Relapsed%2520and%2520Refractory%2520Mature%2520B-cell%2520Malignancies%252C%26jtitle%3DBlood%26date%3D2016%26volume%3D127%26spage%3D411%26epage%3D419%26doi%3D10.1182%2Fblood-2015-08-664086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Byrd, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrington, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devereux, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaves, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wierda, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awan, F. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillmen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghia, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrientos, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagel, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woyach, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaptein, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lannutti, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Covey, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fardis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGreivy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamdy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothbaum, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izumi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diacovo, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, R. R.</span></span> <span> </span><span class="NLM_article-title">Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>374</i></span>,  <span class="NLM_fpage">323</span>– <span class="NLM_lpage">332</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1509981</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1056%2FNEJMoa1509981" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=26641137" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlOlur%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=374&publication_year=2016&pages=323-332&author=J.+C.+Byrdauthor=B.+Harringtonauthor=S.+O%E2%80%99Brienauthor=J.+A.+Jonesauthor=A.+Schuhauthor=S.+Devereuxauthor=J.+Chavesauthor=W.+G.+Wierdaauthor=F.+T.+Awanauthor=J.+R.+Brownauthor=P.+Hillmenauthor=D.+M.+Stephensauthor=P.+Ghiaauthor=J.+C.+Barrientosauthor=J.+M.+Pagelauthor=J.+Woyachauthor=D.+Johnsonauthor=J.+Huangauthor=X.+Wangauthor=A.+Kapteinauthor=B.+J.+Lannuttiauthor=T.+Coveyauthor=M.+Fardisauthor=J.+McGreivyauthor=A.+Hamdyauthor=W.+Rothbaumauthor=R.+Izumiauthor=T.+G.+Diacovoauthor=A.+J.+Johnsonauthor=R.+R.+Furman&title=Acalabrutinib+%28ACP-196%29+in+Relapsed+Chronic+Lymphocytic+Leukemia&doi=10.1056%2FNEJMoa1509981"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia</span></div><div class="casAuthors">Byrd, John C.; Harrington, Bonnie; O'Brien, Susan; Jones, Jeffrey A.; Schuh, Anna; Devereux, Steve; Chaves, Jorge; Wierda, William G.; Awan, Farrukh T.; Brown, Jennifer R.; Hillmen, Peter; Stephens, Deborah M.; Ghia, Paolo; Barrientos, Jacqueline C.; Pagel, John M.; Woyach, Jennifer; Johnson, Dave; Huang, Jane; Wang, Xiaolin; Kaptein, Allard; Lannutti, Brian J.; Covey, Todd; Fardis, Maria; McGreivy, Jesse; Hamdy, Ahmed; Rothbaum, Wayne; Izumi, Raquel; Diacovo, Thomas G.; Johnson, Amy J.; Furman, Richard R.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">374</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">323-332</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Irreversible inhibition of Bruton's tyrosine kinase (BTK) by ibrutinib represents an important therapeutic advance for the treatment of chronic lymphocytic leukemia (CLL).  However, ibrutinib also irreversibly inhibits alternative kinase targets, which potentially compromises its therapeutic index.  Acalabrutinib (ACP-196) is a more selective, irreversible BTK inhibitor that is specifically designed to improve on the safety and efficacy of first-generation BTK inhibitors.  In this uncontrolled, phase 1-2, multicenter study, we administered oral acalabrutinib to 61 patients who had relapsed CLL to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of acalabrutinib.  Patients were treated with acalabrutinib at a dose of 100 to 400 mg once daily in the dose-escalation (phase 1) portion of the study and 100 mg twice daily in the expansion (phase 2) portion.  The median age of the patients was 62 years, and patients had received a median of three previous therapies for CLL; 31% had chromosome 17p13.1 deletion, and 75% had unmutated Ig heavy-chain variable genes.  No dose-limiting toxic effects occurred during the dose-escalation portion of the study.  The most common adverse events obsd. were headache (in 43% of the patients), diarrhea (in 39%), and in- creased wt. (in 26%).  Most adverse events were of grade 1 or 2.  At a median follow- up of 14.3 mo, the overall response rate was 95%, including 85% with a partial response and 10% with a partial response with lymphocytosis; the remaining 5% of patients had stable disease.  Among patients with chromosome 17p13.1 deletion, the overall response rate was 100%.  No cases of Richter's transformation (CLL that has evolved into large-cell lymphoma) and only one case of CLL progression have occurred.  In this study, the selective BTK inhibitor acalabrutinib had promising safety and efficacy profiles in patients with relapsed CLL, including those with chromosome 17p13.1 deletion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGHCPciF9hPrVg90H21EOLACvtfcHk0ljwutiq_ZRpCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlOlur%252FI&md5=d20e0158f9ea308b9d06fa668154516e</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1509981&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1509981%26sid%3Dliteratum%253Aachs%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DHarrington%26aufirst%3DB.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DS.%26aulast%3DJones%26aufirst%3DJ.%2BA.%26aulast%3DSchuh%26aufirst%3DA.%26aulast%3DDevereux%26aufirst%3DS.%26aulast%3DChaves%26aufirst%3DJ.%26aulast%3DWierda%26aufirst%3DW.%2BG.%26aulast%3DAwan%26aufirst%3DF.%2BT.%26aulast%3DBrown%26aufirst%3DJ.%2BR.%26aulast%3DHillmen%26aufirst%3DP.%26aulast%3DStephens%26aufirst%3DD.%2BM.%26aulast%3DGhia%26aufirst%3DP.%26aulast%3DBarrientos%26aufirst%3DJ.%2BC.%26aulast%3DPagel%26aufirst%3DJ.%2BM.%26aulast%3DWoyach%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DD.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DKaptein%26aufirst%3DA.%26aulast%3DLannutti%26aufirst%3DB.%2BJ.%26aulast%3DCovey%26aufirst%3DT.%26aulast%3DFardis%26aufirst%3DM.%26aulast%3DMcGreivy%26aufirst%3DJ.%26aulast%3DHamdy%26aufirst%3DA.%26aulast%3DRothbaum%26aufirst%3DW.%26aulast%3DIzumi%26aufirst%3DR.%26aulast%3DDiacovo%26aufirst%3DT.%2BG.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26aulast%3DFurman%26aufirst%3DR.%2BR.%26atitle%3DAcalabrutinib%2520%2528ACP-196%2529%2520in%2520Relapsed%2520Chronic%2520Lymphocytic%2520Leukemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2016%26volume%3D374%26spage%3D323%26epage%3D332%26doi%3D10.1056%2FNEJMoa1509981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabnis, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buhrlage, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Developing Irreversible Inhibitors of the Protein Kinase Cysteinome</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">146</span>– <span class="NLM_lpage">159</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2012.12.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1016%2Fj.chembiol.2012.12.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=23438744" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtFWitbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=146-159&author=Q.+Liuauthor=Y.+Sabnisauthor=Z.+Zhaoauthor=T.+Zhangauthor=S.+J.+Buhrlageauthor=L.+H.+Jonesauthor=N.+S.+Gray&title=Developing+Irreversible+Inhibitors+of+the+Protein+Kinase+Cysteinome&doi=10.1016%2Fj.chembiol.2012.12.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Developing Irreversible Inhibitors of the Protein Kinase Cysteinome</span></div><div class="casAuthors">Liu, Qingsong; Sabnis, Yogesh; Zhao, Zheng; Zhang, Tinghu; Buhrlage, Sara J.; Jones, Lyn H.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">146-159</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Protein kinases are a large family of approx. 530 highly conserved enzymes that transfer a γ-phosphate group from ATP to a variety of amino acid residues, such as tyrosine, serine, and threonine, that serves as a ubiquitous mechanism for cellular signal transduction.  The clin. success of a no. of kinase-directed drugs and the frequent observation of disease causing mutations in protein kinases suggest that a large no. of kinases may represent therapeutically relevant targets.  To date, the majority of clin. and preclin. kinase inhibitors are ATP competitive, noncovalent inhibitors that achieve selectivity through recognition of unique features of particular protein kinases.  Recently, there has been renewed interest in the development of irreversible inhibitors that form covalent bonds with cysteine or other nucleophilic residues in the ATP-binding pocket.  Irreversible kinase inhibitors have a no. of potential advantages including prolonged pharmacodynamics, suitability for rational design, high potency, and ability to validate pharmacol. specificity through mutation of the reactive cysteine residue.  Here, we review recent efforts to develop cysteine-targeted irreversible protein kinase inhibitors and discuss their modes of recognizing the ATP-binding pocket and their biol. activity profiles.  In addn., we provided an informatics assessment of the potential "kinase cysteinome" and discuss strategies for the efficient development of new covalent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVGD7TX3oIeLVg90H21EOLACvtfcHk0lgsUyg8U4y69Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtFWitbs%253D&md5=cef80823123bae88362e816a0a638133</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2012.12.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2012.12.006%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DSabnis%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DBuhrlage%26aufirst%3DS.%2BJ.%26aulast%3DJones%26aufirst%3DL.%2BH.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDeveloping%2520Irreversible%2520Inhibitors%2520of%2520the%2520Protein%2520Kinase%2520Cysteinome%26jtitle%3DChem.%2520Biol.%26date%3D2013%26volume%3D20%26spage%3D146%26epage%3D159%26doi%3D10.1016%2Fj.chembiol.2012.12.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Erickson, R. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schutt, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarrant, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDowell, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewin-Koh, S.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedehus, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carano, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staflin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katewa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dambach, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misner, D. L.</span></span> <span> </span><span class="NLM_article-title">Bruton’s Tyrosine Kinase Small Molecule Inhibitors Induce a Distinct Pancreatic Toxicity in Rats</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>360</i></span>,  <span class="NLM_fpage">226</span>– <span class="NLM_lpage">238</span>, <span class="refDoi"> DOI: 10.1124/jpet.116.236224</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1124%2Fjpet.116.236224" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=27821712" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BC2sXptVOjtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=360&publication_year=2017&pages=226-238&author=R.+I.+Ericksonauthor=L.+K.+Schuttauthor=J.+M.+Tarrantauthor=M.+McDowellauthor=L.+Liuauthor=A.+R.+Johnsonauthor=S.-C.+Lewin-Kohauthor=M.+Hedehusauthor=J.+Rossauthor=R.+A.+Caranoauthor=K.+Staflinauthor=F.+Zhongauthor=J.+J.+Crawfordauthor=S.+Zhongauthor=K.+Reifauthor=A.+Katewaauthor=H.+Wongauthor=W.+B.+Youngauthor=D.+M.+Dambachauthor=D.+L.+Misner&title=Bruton%E2%80%99s+Tyrosine+Kinase+Small+Molecule+Inhibitors+Induce+a+Distinct+Pancreatic+Toxicity+in+Rats&doi=10.1124%2Fjpet.116.236224"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Bruton's tyrosine kinase small molecule inhibitors induce a distinct pancreatic toxicity in rats</span></div><div class="casAuthors">Erickson, Rebecca I.; Schutt, Leah K.; Tarrant, Jacqueline M.; McDowell, Michelle; Liu, Lichuan; Johnson, Adam R.; Lewin-Koh, Sock-Cheng; Hedehus, Maj; Ross, Jed; Carano, Richard A. D.; Staflin, Karin; Zhong, Fiona; Crawford, James J.; Zhong, Shelly; Reif, Karin; Katewa, Arna; Wong, Harvey; Young, Wendy B.; Dambach, Donna M.; Misner, Dinah L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">360</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">226-238</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK) is a member of the Tec family of cytoplasmic tyrosine kinases involved in B-cell and myeloid cell signaling.  Small mol. inhibitors of BTK are being investigated for treatment of several hematol. cancers and autoimmune diseases.  GDC-0853 ((S)-2-(3'-(hydroxymethyl)-1-methyl-5-((5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)-6-oxo-1,6-dihydro-[3,4'-bipyridin]-2'-yl)-7,7-dimethyl-3,4,7,8-tetrahydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1(6H)-one) is a selective and reversible oral small-mol. BTK inhibitor in development for the treatment of rheumatoid arthritis and systemic lupus erythematosus.  In Sprague-Dawley (SD) rats, administration of GDC-0853 and other structurally diverse BTK inhibitors for 7 days or longer caused pancreatic lesions consisting of multifocal islet-centered hemorrhage, inflammation, fibrosis, and pigment-laden macrophages with adjacent lobular exocrine acinar cell atrophy, degeneration, and inflammation.  Similar findings were not obsd. in mice or dogs at much higher exposures.  Hemorrhage in the peri-islet vasculature emerged between four and seven daily doses of GDC-0853 and was histol. similar to spontaneously occurring changes in aging SD rats.  This suggests that GDC-0853 could exacerbate a background finding in younger animals.  Glucose homeostasis was dysregulated following a glucose challenge; however, this occurred only after 28 days of administration and was not directly assocd. with onset or severity of pancreatic lesions.  There were no changes in other common serum biomarkers assessing endocrine and exocrine pancreatic function.  Addnl., these lesions were not readily detectable via Doppler ultrasound, computed tomog., or magnetic resonance imaging.  Our results indicate that pancreatic lesions in rats are likely a class effect of BTK inhibitors, which may exacerbate an islet-centered pathol. that is unlikely to be relevant to humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgiBmsDhUKIbVg90H21EOLACvtfcHk0lgsUyg8U4y69Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXptVOjtLo%253D&md5=15b2ef2030ed978d81cec5be5e0a74c8</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1124%2Fjpet.116.236224&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.116.236224%26sid%3Dliteratum%253Aachs%26aulast%3DErickson%26aufirst%3DR.%2BI.%26aulast%3DSchutt%26aufirst%3DL.%2BK.%26aulast%3DTarrant%26aufirst%3DJ.%2BM.%26aulast%3DMcDowell%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DLewin-Koh%26aufirst%3DS.-C.%26aulast%3DHedehus%26aufirst%3DM.%26aulast%3DRoss%26aufirst%3DJ.%26aulast%3DCarano%26aufirst%3DR.%2BA.%26aulast%3DStaflin%26aufirst%3DK.%26aulast%3DZhong%26aufirst%3DF.%26aulast%3DCrawford%26aufirst%3DJ.%2BJ.%26aulast%3DZhong%26aufirst%3DS.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DKatewa%26aufirst%3DA.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DYoung%26aufirst%3DW.%2BB.%26aulast%3DDambach%26aufirst%3DD.%2BM.%26aulast%3DMisner%26aufirst%3DD.%2BL.%26atitle%3DBruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520Small%2520Molecule%2520Inhibitors%2520Induce%2520a%2520Distinct%2520Pancreatic%2520Toxicity%2520in%2520Rats%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2017%26volume%3D360%26spage%3D226%26epage%3D238%26doi%3D10.1124%2Fjpet.116.236224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pai, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">French, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hotzel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plise, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salphati, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Setchell, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ware, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lauriault, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schutt, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartley, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dambach, D.</span></span> <span> </span><span class="NLM_article-title">Antibody-Mediated Inhibition of Fibroblast Growth Factor 19 Results in Increased Bile Acids Synthesis and Ileal Malabsorption of Bile Acids in Cynomolgus Monkeys</span>. <i>Toxicol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">446</span>– <span class="NLM_lpage">456</span>, <span class="refDoi"> DOI: 10.1093/toxsci/kfs011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1093%2Ftoxsci%2Fkfs011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=22268002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BC38Xks1SitbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2012&pages=446-456&author=R.+Paiauthor=D.+Frenchauthor=N.+Maauthor=K.+Hotzelauthor=E.+Pliseauthor=L.+Salphatiauthor=K.+D.+Setchellauthor=J.+Wareauthor=V.+Lauriaultauthor=L.+Schuttauthor=D.+Hartleyauthor=D.+Dambach&title=Antibody-Mediated+Inhibition+of+Fibroblast+Growth+Factor+19+Results+in+Increased+Bile+Acids+Synthesis+and+Ileal+Malabsorption+of+Bile+Acids+in+Cynomolgus+Monkeys&doi=10.1093%2Ftoxsci%2Fkfs011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Antibody-Mediated Inhibition of Fibroblast Growth Factor 19 Results in Increased Bile Acids Synthesis and Ileal Malabsorption of Bile Acids in Cynomolgus Monkeys</span></div><div class="casAuthors">Pai, Rama; French, Dorothy; Ma, Ning; Hotzel, Kathy; Plise, Emile; Salphati, Laurent; Setchell, Kenneth D. R.; Ware, Joseph; Lauriault, Veronique; Schutt, Leah; Hartley, Dylan; Dambach, Donna</div><div class="citationInfo"><span class="NLM_cas:title">Toxicological Sciences</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">446-456</span>CODEN:
                <span class="NLM_cas:coden">TOSCF2</span>;
        ISSN:<span class="NLM_cas:issn">1096-0929</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Fibroblast growth factor 19 (FGF19) represses cholesterol 7α-hydroxylase (Cyp7α1) and inhibits bile acid synthesis in vitro and in vivo.  Previous studies have shown that anti-FGF19 antibody treatment reduces growth of colon tumor xenografts and prevents hepatocellular carcinomas in FGF19 transgenic mice and thus may be a useful cancer target.  In a repeat dose safety study in cynomolgus monkeys, anti-FGF19 treatment (3-100 mg/kg) demonstrated dose-related liver toxicity accompanied by severe diarrhea and low food consumption.  The mechanism of anti-FGF19 toxicity was investigated using in vitro and in vivo approaches.  The authors' results show that anti-FGF19 antibody had no direct cytotoxic effect on monkey hepatocytes.  Anti-FGF19 increased Cyp7α1, as expected, but also increased bile acid efflux transporter gene (bile salt export pump, multidrug resistant protein 2 [MRP2], and MRP3) expression and reduced sodium taurocholate cotransporting polypeptide and org. anion transporter 2 expression in liver tissues from treated monkeys and in primary hepatocytes.  In addn., anti-FGF19 treatment increased solute transporter gene (ileal bile acid-binding protein, org. solute transporter α [OST-α], and OST-β) expression in ileal tissues from treated monkeys but not in Caco-2 cells.  However, deoxycholic acid (a secondary bile acid) increased expression of FGF19 and these solute transporter genes in Caco-2 cells.  Gas chromatog.-mass spectrometry anal. of monkey feces showed an increase in total bile acids and cholic acid derivs.  These findings suggest that high doses of anti-FGF19 increase Cyp7α1 expression and bile acid synthesis and alter the expression of bile transporters in the liver resulting in enhanced bile acid efflux and reduced uptake.  Increased bile acids alter expression of solute transporters in the ileum causing diarrhea and the enhanced enterohepatic recirculation of bile acids leading to liver toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqORkYjNAK2bLVg90H21EOLACvtfcHk0lgrFHUoiQFz7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xks1SitbY%253D&md5=b70cb6104a023ef79adda0cea34fc8a4</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1093%2Ftoxsci%2Fkfs011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Ftoxsci%252Fkfs011%26sid%3Dliteratum%253Aachs%26aulast%3DPai%26aufirst%3DR.%26aulast%3DFrench%26aufirst%3DD.%26aulast%3DMa%26aufirst%3DN.%26aulast%3DHotzel%26aufirst%3DK.%26aulast%3DPlise%26aufirst%3DE.%26aulast%3DSalphati%26aufirst%3DL.%26aulast%3DSetchell%26aufirst%3DK.%2BD.%26aulast%3DWare%26aufirst%3DJ.%26aulast%3DLauriault%26aufirst%3DV.%26aulast%3DSchutt%26aufirst%3DL.%26aulast%3DHartley%26aufirst%3DD.%26aulast%3DDambach%26aufirst%3DD.%26atitle%3DAntibody-Mediated%2520Inhibition%2520of%2520Fibroblast%2520Growth%2520Factor%252019%2520Results%2520in%2520Increased%2520Bile%2520Acids%2520Synthesis%2520and%2520Ileal%2520Malabsorption%2520of%2520Bile%2520Acids%2520in%2520Cynomolgus%2520Monkeys%26jtitle%3DToxicol.%2520Sci.%26date%3D2012%26volume%3D126%26spage%3D446%26epage%3D456%26doi%3D10.1093%2Ftoxsci%2Fkfs011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pai, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortwine, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misner, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dambach, D.</span></span> <span> </span><span class="NLM_article-title">Application of an In Silico Approach to Predict Intrinsic In Vitro Cytotoxicity for Compounds in Primary Human Hepatocytes During Preclinical Development</span>. <i>Toxicologist</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>132</i></span>,  <span class="NLM_fpage">189</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2013&pages=189&author=R.+Paiauthor=B.+Weiauthor=P.+Changauthor=J.+J.+Crawfordauthor=W.+Youngauthor=D.+F.+Ortwineauthor=D.+L.+Misnerauthor=D.+Dambach&title=Application+of+an+In+Silico+Approach+to+Predict+Intrinsic+In+Vitro+Cytotoxicity+for+Compounds+in+Primary+Human+Hepatocytes+During+Preclinical+Development"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPai%26aufirst%3DR.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DChang%26aufirst%3DP.%26aulast%3DCrawford%26aufirst%3DJ.%2BJ.%26aulast%3DYoung%26aufirst%3DW.%26aulast%3DOrtwine%26aufirst%3DD.%2BF.%26aulast%3DMisner%26aufirst%3DD.%2BL.%26aulast%3DDambach%26aufirst%3DD.%26atitle%3DApplication%2520of%2520an%2520In%2520Silico%2520Approach%2520to%2520Predict%2520Intrinsic%2520In%2520Vitro%2520Cytotoxicity%2520for%2520Compounds%2520in%2520Primary%2520Human%2520Hepatocytes%2520During%2520Preclinical%2520Development%26jtitle%3DToxicologist%26date%3D2013%26volume%3D132%26spage%3D189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aliagas, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergeron, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaney, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradley, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koehler, M. F. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortwine, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsui, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gobbi, A.</span></span> <span> </span><span class="NLM_article-title">An Integrated Suite of Modeling Tools That Empower Scientists in Structure- and Property-Based Drug Design</span>. <i>J. Comput.-Aided Mol. Des.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">511</span>– <span class="NLM_lpage">523</span>, <span class="refDoi"> DOI: 10.1007/s10822-015-9845-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1007%2Fs10822-015-9845-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2015&pages=511-523&author=J.+A.+Fengauthor=I.+Aliagasauthor=P.+Bergeronauthor=J.+M.+Blaneyauthor=E.+K.+Bradleyauthor=M.+F.+T.+Koehlerauthor=M.+L.+Leeauthor=D.+F.+Ortwineauthor=V.+Tsuiauthor=J.+Wuauthor=A.+Gobbi&title=An+Integrated+Suite+of+Modeling+Tools+That+Empower+Scientists+in+Structure-+and+Property-Based+Drug+Design&doi=10.1007%2Fs10822-015-9845-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1007%2Fs10822-015-9845-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10822-015-9845-4%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DJ.%2BA.%26aulast%3DAliagas%26aufirst%3DI.%26aulast%3DBergeron%26aufirst%3DP.%26aulast%3DBlaney%26aufirst%3DJ.%2BM.%26aulast%3DBradley%26aufirst%3DE.%2BK.%26aulast%3DKoehler%26aufirst%3DM.%2BF.%2BT.%26aulast%3DLee%26aufirst%3DM.%2BL.%26aulast%3DOrtwine%26aufirst%3DD.%2BF.%26aulast%3DTsui%26aufirst%3DV.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DGobbi%26aufirst%3DA.%26atitle%3DAn%2520Integrated%2520Suite%2520of%2520Modeling%2520Tools%2520That%2520Empower%2520Scientists%2520in%2520Structure-%2520and%2520Property-Based%2520Drug%2520Design%26jtitle%3DJ.%2520Comput.-Aided%2520Mol.%2520Des.%26date%3D2015%26volume%3D29%26spage%3D511%26epage%3D523%26doi%3D10.1007%2Fs10822-015-9845-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuglstatter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondru, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, Z. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntosh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Litman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kocer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frauchiger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dewdney, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zecic, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taygerly, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarma, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabriel, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, T. D.</span></span> <span> </span><span class="NLM_article-title">Structure-Based Drug Design of RN486, a Potent and Selective Bruton’s Tyrosine Kinase (BTK) Inhibitor, for the Treatment of Rheumatoid Arthritis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">512</span>– <span class="NLM_lpage">516</span>, <span class="refDoi"> DOI: 10.1021/jm500305p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500305p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlsl2qtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=512-516&author=Y.+Louauthor=X.+Hanauthor=A.+Kuglstatterauthor=R.+K.+Kondruauthor=Z.+K.+Sweeneyauthor=M.+Sothauthor=J.+McIntoshauthor=R.+Litmanauthor=J.+Suhauthor=B.+Kocerauthor=D.+Davisauthor=J.+Parkauthor=S.+Frauchigerauthor=N.+Dewdneyauthor=H.+Zecicauthor=J.+P.+Taygerlyauthor=K.+Sarmaauthor=J.+Hongauthor=R.+J.+Hillauthor=T.+Gabrielauthor=D.+M.+Goldsteinauthor=T.+D.+Owens&title=Structure-Based+Drug+Design+of+RN486%2C+a+Potent+and+Selective+Bruton%E2%80%99s+Tyrosine+Kinase+%28BTK%29+Inhibitor%2C+for+the+Treatment+of+Rheumatoid+Arthritis&doi=10.1021%2Fjm500305p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Drug Design of RN486, a Potent and Selective Bruton's Tyrosine Kinase (BTK) Inhibitor, for the Treatment of Rheumatoid Arthritis</span></div><div class="casAuthors">Lou, Yan; Han, Xiaochun; Kuglstatter, Andreas; Kondru, Rama K.; Sweeney, Zachary K.; Soth, Michael; McIntosh, Joel; Litman, Renee; Suh, Judy; Kocer, Buelent; Davis, Dana; Park, Jaehyeon; Frauchiger, Sandra; Dewdney, Nolan; Zecic, Hasim; Taygerly, Joshua P.; Sarma, Keshab; Hong, Junbae; Hill, Ronald J.; Gabriel, Tobias; Goldstein, David M.; Owens, Timothy D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">512-516</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Structure-based drug design was used to guide the optimization of a series of selective BTK inhibitors as potential treatments for Rheumatoid arthritis.  Highlights include the introduction of a benzyl alc. group and a fluorine substitution, each of which resulted in over 10-fold increase in activity.  Concurrent optimization of drug-like properties led to compd. I (RN486) (J. Pharmacol. Exp. Ther. 2012, 341, 90), which was selected for advanced preclin. characterization based on its favorable properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMdHX9-PE5I7Vg90H21EOLACvtfcHk0lhqA3xNNVYQIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlsl2qtb8%253D&md5=dc3c069b0e876f44846a30e3aa6a894a</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fjm500305p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500305p%26sid%3Dliteratum%253Aachs%26aulast%3DLou%26aufirst%3DY.%26aulast%3DHan%26aufirst%3DX.%26aulast%3DKuglstatter%26aufirst%3DA.%26aulast%3DKondru%26aufirst%3DR.%2BK.%26aulast%3DSweeney%26aufirst%3DZ.%2BK.%26aulast%3DSoth%26aufirst%3DM.%26aulast%3DMcIntosh%26aufirst%3DJ.%26aulast%3DLitman%26aufirst%3DR.%26aulast%3DSuh%26aufirst%3DJ.%26aulast%3DKocer%26aufirst%3DB.%26aulast%3DDavis%26aufirst%3DD.%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DFrauchiger%26aufirst%3DS.%26aulast%3DDewdney%26aufirst%3DN.%26aulast%3DZecic%26aufirst%3DH.%26aulast%3DTaygerly%26aufirst%3DJ.%2BP.%26aulast%3DSarma%26aufirst%3DK.%26aulast%3DHong%26aufirst%3DJ.%26aulast%3DHill%26aufirst%3DR.%2BJ.%26aulast%3DGabriel%26aufirst%3DT.%26aulast%3DGoldstein%26aufirst%3DD.%2BM.%26aulast%3DOwens%26aufirst%3DT.%2BD.%26atitle%3DStructure-Based%2520Drug%2520Design%2520of%2520RN486%252C%2520a%2520Potent%2520and%2520Selective%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520%2528BTK%2529%2520Inhibitor%252C%2520for%2520the%2520Treatment%2520of%2520Rheumatoid%2520Arthritis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D512%26epage%3D516%26doi%3D10.1021%2Fjm500305p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pease, J. H.</span></span> <span> </span><span class="NLM_article-title">A Novel Method for High Throughput Lipophilicity Determination by Microscale Shake Flask and Liquid Chromatography Tandem Mass Spectrometry</span>. <i>Comb. Chem. High Throughput Screening</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">817</span>– <span class="NLM_lpage">825</span>, <span class="refDoi"> DOI: 10.2174/1386207311301010007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.2174%2F1386207311301010007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=24168238" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFWktLbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2013&pages=817-825&author=B.+Linauthor=J.+H.+Pease&title=A+Novel+Method+for+High+Throughput+Lipophilicity+Determination+by+Microscale+Shake+Flask+and+Liquid+Chromatography+Tandem+Mass+Spectrometry&doi=10.2174%2F1386207311301010007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">A Novel Method for High Throughput Lipophilicity Determination by Microscale Shake Flask and Liquid Chromatography Tandem Mass Spectrometry</span></div><div class="casAuthors">Lin, Baiwei; Pease, Joseph H.</div><div class="citationInfo"><span class="NLM_cas:title">Combinatorial Chemistry & High Throughput Screening</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">817-825</span>CODEN:
                <span class="NLM_cas:coden">CCHSFU</span>;
        ISSN:<span class="NLM_cas:issn">1386-2073</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Modern small mol. drug design requires the optimization of not only the binding characteristics of the mol. but also its physicochem. properties for ADMET performance.  A key phys. property is lipophilicity and medicinal chemists need rapid access to high quality data in order to drive their decision making.  Traditionally lipophilicity (log D) measurements are performed with a shake flask method and UV detn.  This method suffers from low sensitivity and is not easily converted to a high throughput format.  Over the past decade, several groups have taken different approaches to improve this assay, including replacing the shake flask method with one that utilizes reverse phase HPLC.  Here we describe a new microscale shake flask method that utilizes UPLC-MS/MS to achieve increased throughput, sensitivity and accuracy.  Approaches for assessing data quality are also described.  This platform technol. only requires micrograms of compd. and is routinely used by most small mol. drug discovery project teams at Genentech.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoS0kv3IN4lnLVg90H21EOLACvtfcHk0lhqA3xNNVYQIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFWktLbO&md5=1d863747144615780be712cc329ab344</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.2174%2F1386207311301010007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1386207311301010007%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DB.%26aulast%3DPease%26aufirst%3DJ.%2BH.%26atitle%3DA%2520Novel%2520Method%2520for%2520High%2520Throughput%2520Lipophilicity%2520Determination%2520by%2520Microscale%2520Shake%2520Flask%2520and%2520Liquid%2520Chromatography%2520Tandem%2520Mass%2520Spectrometry%26jtitle%3DComb.%2520Chem.%2520High%2520Throughput%2520Screening%26date%3D2013%26volume%3D16%26spage%3D817%26epage%3D825%26doi%3D10.2174%2F1386207311301010007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leach, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hann, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffen, E. J.</span></span> <span> </span><span class="NLM_article-title">Fragment Screening: An Introduction</span>. <i>Mol. BioSyst.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">429</span>– <span class="NLM_lpage">446</span>, <span class="refDoi"> DOI: 10.1039/b610069b</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1039%2Fb610069b" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVCks7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2006&pages=429-446&author=A.+R.+Leachauthor=M.+M.+Hannauthor=J.+N.+Burrowsauthor=E.+J.+Griffen&title=Fragment+Screening%3A+An+Introduction&doi=10.1039%2Fb610069b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Fragment screening: an introduction</span></div><div class="casAuthors">Leach, Andrew R.; Hann, Michael M.; Burrows, Jeremy N.; Griffen, Ed J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular BioSystems</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">429-446</span>CODEN:
                <span class="NLM_cas:coden">MBOIBW</span>;
        ISSN:<span class="NLM_cas:issn">1742-206X</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpttvt8xGGyL7Vg90H21EOLACvtfcHk0liQJZcDrYv70g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVCks7vE&md5=66d60d107405d7e87e90f5d2d29355ed</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1039%2Fb610069b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb610069b%26sid%3Dliteratum%253Aachs%26aulast%3DLeach%26aufirst%3DA.%2BR.%26aulast%3DHann%26aufirst%3DM.%2BM.%26aulast%3DBurrows%26aufirst%3DJ.%2BN.%26aulast%3DGriffen%26aufirst%3DE.%2BJ.%26atitle%3DFragment%2520Screening%253A%2520An%2520Introduction%26jtitle%3DMol.%2520BioSyst.%26date%3D2006%26volume%3D2%26spage%3D429%26epage%3D446%26doi%3D10.1039%2Fb610069b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leeson, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Springthorpe, B.</span></span> <span> </span><span class="NLM_article-title">The Influence of Drug-Like Concepts on Decision-Making in Medicinal Chemistry,</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">881</span>– <span class="NLM_lpage">890</span>, <span class="refDoi"> DOI: 10.1038/nrd2445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1038%2Fnrd2445" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=881-890&author=P.+D.+Leesonauthor=B.+Springthorpe&title=The+Influence+of+Drug-Like+Concepts+on+Decision-Making+in+Medicinal+Chemistry%2C&doi=10.1038%2Fnrd2445"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1038%2Fnrd2445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2445%26sid%3Dliteratum%253Aachs%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DSpringthorpe%26aufirst%3DB.%26atitle%3DThe%2520Influence%2520of%2520Drug-Like%2520Concepts%2520on%2520Decision-Making%2520in%2520Medicinal%2520Chemistry%252C%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D881%26epage%3D890%26doi%3D10.1038%2Fnrd2445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, Z. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuglstatter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldstein, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kocer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kondru, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Litman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntosh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarma, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taygerly, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, T. D.</span></span> <span> </span><span class="NLM_article-title">Finding the Perfect Spot for Fluorine: Improving Potency Up To 40-Fold During a Rational Fluorine Scan of a Bruton’s Tyrosine Kinase (BTK) Inhibitor Scaffold</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">367</span>– <span class="NLM_lpage">371</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.11.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1016%2Fj.bmcl.2014.11.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=25466710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitValtrvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=367-371&author=Y.+Louauthor=Z.+K.+Sweeneyauthor=A.+Kuglstatterauthor=D.+Davisauthor=D.+M.+Goldsteinauthor=X.+Hanauthor=J.+Hongauthor=B.+Kocerauthor=R.+K.+Kondruauthor=R.+Litmanauthor=J.+McIntoshauthor=K.+Sarmaauthor=J.+Suhauthor=J.+Taygerlyauthor=T.+D.+Owens&title=Finding+the+Perfect+Spot+for+Fluorine%3A+Improving+Potency+Up+To+40-Fold+During+a+Rational+Fluorine+Scan+of+a+Bruton%E2%80%99s+Tyrosine+Kinase+%28BTK%29+Inhibitor+Scaffold&doi=10.1016%2Fj.bmcl.2014.11.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Finding the perfect spot for fluorine: Improving potency up to 40-fold during a rational fluorine scan of a Bruton's Tyrosine Kinase (BTK) inhibitor scaffold</span></div><div class="casAuthors">Lou, Yan; Sweeney, Zachary K.; Kuglstatter, Andreas; Davis, Dana; Goldstein, David M.; Han, Xiaochun; Hong, Junbae; Kocer, Buelent; Kondru, Rama K.; Litman, Renee; McIntosh, Joel; Sarma, Keshab; Suh, Judy; Taygerly, Joshua; Owens, Timothy D.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">367-371</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A rational fluorine scan based on co-crystal structures was explored to increase the potency of a series of selective BTK inhibitors.  While fluorine substitution on a satd. bicyclic ring system yields no apparent benefit, the same operation on an unsatd. bicyclic ring can increase HWB activity by up to 40-fold.  Comparison of co-crystal structures of parent mols. and fluorinated counterparts revealed the importance of placing fluorine at the optimal position to achieve favorable interactions with protein side chains.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnBQYbDM1CNbVg90H21EOLACvtfcHk0liQJZcDrYv70g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitValtrvF&md5=e1f4815a0df9e91ce9150eacf196fc07</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.11.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.11.030%26sid%3Dliteratum%253Aachs%26aulast%3DLou%26aufirst%3DY.%26aulast%3DSweeney%26aufirst%3DZ.%2BK.%26aulast%3DKuglstatter%26aufirst%3DA.%26aulast%3DDavis%26aufirst%3DD.%26aulast%3DGoldstein%26aufirst%3DD.%2BM.%26aulast%3DHan%26aufirst%3DX.%26aulast%3DHong%26aufirst%3DJ.%26aulast%3DKocer%26aufirst%3DB.%26aulast%3DKondru%26aufirst%3DR.%2BK.%26aulast%3DLitman%26aufirst%3DR.%26aulast%3DMcIntosh%26aufirst%3DJ.%26aulast%3DSarma%26aufirst%3DK.%26aulast%3DSuh%26aufirst%3DJ.%26aulast%3DTaygerly%26aufirst%3DJ.%26aulast%3DOwens%26aufirst%3DT.%2BD.%26atitle%3DFinding%2520the%2520Perfect%2520Spot%2520for%2520Fluorine%253A%2520Improving%2520Potency%2520Up%2520To%252040-Fold%2520During%2520a%2520Rational%2520Fluorine%2520Scan%2520of%2520a%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520%2528BTK%2529%2520Inhibitor%2520Scaffold%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D367%26epage%3D371%26doi%3D10.1016%2Fj.bmcl.2014.11.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohli, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katewa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gogol, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belmont, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penuel, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burton, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortwine, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franke, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estevez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mortara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergeron, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, W. B.</span></span> <span> </span><span class="NLM_article-title">Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">2897</span>– <span class="NLM_lpage">2907</span>, <span class="refDoi"> DOI: 10.1021/acschembio.6b00480</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.6b00480" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVWltr3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=2897-2907&author=A.+R.+Johnsonauthor=P.+B.+Kohliauthor=A.+Katewaauthor=E.+Gogolauthor=L.+Belmontauthor=R.+Choyauthor=E.+Penuelauthor=L.+Burtonauthor=C.+Eigenbrotauthor=C.+Yuauthor=D.+F.+Ortwineauthor=K.+Bowmanauthor=Y.+Frankeauthor=C.+Tamauthor=A.+Estevezauthor=K.+Mortaraauthor=J.+Wuauthor=H.+Liauthor=M.+Linauthor=P.+Bergeronauthor=J.+J.+Crawfordauthor=W.+B.+Young&title=Battling+Btk+Mutants+With+Noncovalent+Inhibitors+That+Overcome+Cys481+and+Thr474+Mutations&doi=10.1021%2Facschembio.6b00480"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations</span></div><div class="casAuthors">Johnson, Adam R.; Kohli, Pawan Bir; Katewa, Arna; Gogol, Emily; Belmont, Lisa D.; Choy, Regina; Penuel, Elicia; Burton, Luciana; Eigenbrot, Charles; Yu, Christine; Ortwine, Daniel F.; Bowman, Krista; Franke, Yvonne; Tam, Christine; Estevez, Alberto; Mortara, Kyle; Wu, Jiansheng; Li, Hong; Lin, May; Bergeron, Philippe; Crawford, James J.; Young, Wendy B.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2897-2907</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The Bruton's tyrosine kinase (Btk) inhibitor ibrutinib has shown impressive clin. efficacy in a range of B-cell malignancies, however acquired resistance has emerged and second generation therapies are now being sought.  Ibrutinib is a covalent, irreversible inhibitor that modifies Cys481 in the ATP binding site of Btk and renders the enzyme inactive, thereby blocking B-cell receptor signal transduction.  Not surprisingly, Cys481 is the most commonly mutated Btk residue in cases of acquired resistance to ibrutinib.  Mutations at other sites, including Thr474, a gatekeeper residue, have also been detected.  Herein the authors describe noncovalent Btk inhibitors that differ from covalent inhibitors like ibrutinib in that they do not interact with Cys481, they potently inhibit the ibrutinib-resistant Btk C481S mutant in vitro and in cells, and they are exquisitely selective for Btk.  Noncovalent inhibitors such as GNE-431 also show excellent potency against the C481R, T474I, and T474M mutants.  X-ray crystallog. anal. of Btk provides insight into the unique mode of binding of these inhibitors that explains their high selectivity for Btk and their retained activity against mutant forms of Btk.  This class of noncovalent Btk inhibitors may provide a treatment option to patients, esp. those who have acquired resistance to ibrutinib by mutation of Cys481 or Thr474.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkuzaMmxhJ67Vg90H21EOLACvtfcHk0livcpxo28bouA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVWltr3E&md5=1e0458160f967ed01c259751cc2118e1</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Facschembio.6b00480&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.6b00480%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DKohli%26aufirst%3DP.%2BB.%26aulast%3DKatewa%26aufirst%3DA.%26aulast%3DGogol%26aufirst%3DE.%26aulast%3DBelmont%26aufirst%3DL.%26aulast%3DChoy%26aufirst%3DR.%26aulast%3DPenuel%26aufirst%3DE.%26aulast%3DBurton%26aufirst%3DL.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DOrtwine%26aufirst%3DD.%2BF.%26aulast%3DBowman%26aufirst%3DK.%26aulast%3DFranke%26aufirst%3DY.%26aulast%3DTam%26aufirst%3DC.%26aulast%3DEstevez%26aufirst%3DA.%26aulast%3DMortara%26aufirst%3DK.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DLin%26aufirst%3DM.%26aulast%3DBergeron%26aufirst%3DP.%26aulast%3DCrawford%26aufirst%3DJ.%2BJ.%26aulast%3DYoung%26aufirst%3DW.%2BB.%26atitle%3DBattling%2520Btk%2520Mutants%2520With%2520Noncovalent%2520Inhibitors%2520That%2520Overcome%2520Cys481%2520and%2520Thr474%2520Mutations%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2016%26volume%3D11%26spage%3D2897%26epage%3D2907%26doi%3D10.1021%2Facschembio.6b00480" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catlett, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adamczyk, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffies, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murthy, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nowak, M.</span></span> <span> </span><span class="NLM_article-title">Safety, Pharmacokinetics, and Pharmacodynamics of BMS-986142, a Novel Reversible BTK Inhibitor, in Healthy Participants</span>. <i>Eur. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">689</span>– <span class="NLM_lpage">698</span>, <span class="refDoi"> DOI: 10.1007/s00228-017-2226-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1007%2Fs00228-017-2226-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=28265691" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjvVahs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2017&pages=689-698&author=S.+K.+Leeauthor=J.+Xingauthor=I.+M.+Catlettauthor=R.+Adamczykauthor=A.+Griffiesauthor=A.+Liuauthor=B.+Murthyauthor=M.+Nowak&title=Safety%2C+Pharmacokinetics%2C+and+Pharmacodynamics+of+BMS-986142%2C+a+Novel+Reversible+BTK+Inhibitor%2C+in+Healthy+Participants&doi=10.1007%2Fs00228-017-2226-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Safety, pharmacokinetics, and pharmacodynamics of BMS-986142, a novel reversible BTK inhibitor, in healthy participants</span></div><div class="casAuthors">Lee, Sun Ku; Xing, Jun; Catlett, Ian M.; Adamczyk, Robert; Griffies, Amber; Liu, Ang; Murthy, Bindu; Nowak, Miroslawa</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">689-698</span>CODEN:
                <span class="NLM_cas:coden">EJCPAS</span>;
        ISSN:<span class="NLM_cas:issn">0031-6970</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">BMS-986142 is an oral, small-mol. reversible inhibitor of Bruton's tyrosine kinase.  The main objectives of our phase I studies were to characterize the safety and tolerability, pharmacokinetics, and pharmacodynamics of BMS-986142 in healthy participants, and to investigate the potential for the effect of BMS-986142 on the PK of methotrexate (MTX) in combination.  In a combined single ascending dose and multiple ascending dose study, the safety, pharmacokinetics, and pharmacodynamics of BMS-986142 were assessed in healthy non-Japanese participants following administration of a single dose (5-900 mg) or multiple doses (25-350 mg, once daily for 14 days).  In a drug-drug interaction study, the effect of BMS-986142 (350 mg, once daily for 5 days) on the single-dose pharmacokinetics of MTX (7.5 mg) was assessed in healthy participants.  Results: BMS-986142 was generally well tolerated, alone and in combination with MTX.  BMS-986142 was rapidly absorbed with peak concns. occurring within 2 h, and was eliminated with a mean half-life ranging from 7 to 11 h.  Exposure of BMS-986142 appeared dose proportional within the dose ranges tested.  A dose- and concn.-dependent inhibition of CD69 expression was obsd. following administration of BMS-986142.  BMS-986142 did not affect the pharmacokinetics of MTX.  BMS-986142 was well tolerated at the doses tested, had pharmacokinetic and pharmacodynamic profiles which support once-daily dosing, and can be coadministered with MTX without the pharmacokinetic interaction of BMS-986142 on MTX.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkY5ZXpICJWrVg90H21EOLACvtfcHk0livcpxo28bouA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjvVahs70%253D&md5=d1435ec2479d5a50d0a5b863cc98d803</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1007%2Fs00228-017-2226-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00228-017-2226-2%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DS.%2BK.%26aulast%3DXing%26aufirst%3DJ.%26aulast%3DCatlett%26aufirst%3DI.%2BM.%26aulast%3DAdamczyk%26aufirst%3DR.%26aulast%3DGriffies%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DA.%26aulast%3DMurthy%26aufirst%3DB.%26aulast%3DNowak%26aufirst%3DM.%26atitle%3DSafety%252C%2520Pharmacokinetics%252C%2520and%2520Pharmacodynamics%2520of%2520BMS-986142%252C%2520a%2520Novel%2520Reversible%2520BTK%2520Inhibitor%252C%2520in%2520Healthy%2520Participants%26jtitle%3DEur.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2017%26volume%3D73%26spage%3D689%26epage%3D698%26doi%3D10.1007%2Fs00228-017-2226-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goutopoulos, A.</span></span> <i>Abstracts of Papers, 254th ACS National Meeting & Exposition</i>, Washington, DC, August 20–24, 2017; <span class="NLM_publisher-name">American Chemical Society</span>: <span class="NLM_publisher-loc">Washington, DC</span>, <span class="NLM_year">2017</span>;  <span class="NLM_fpage">MEDI-268</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&pages=MEDI-268&author=A.+Goutopoulos&title=Abstracts+of+Papers%2C+254th+ACS+National+Meeting+%26+Exposition"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DGoutopoulos%26aufirst%3DA.%26jtitle%3DAbstracts%2520of%2520Papers%252C%2520254th%2520ACS%2520National%2520Meeting%2520%2526%2520Exposition%26pub%3DAmerican%2520Chemical%2520Society%26date%3D2017%26spage%3DMEDI-268" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Musumeci, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanna, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greco, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giacchello, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fallacara, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amato, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schenone, S.</span></span> <span> </span><span class="NLM_article-title">Pyrrolo[2,3-d]pyrimidines Active as Btk Inhibitors</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">1305</span>– <span class="NLM_lpage">1318</span>, <span class="refDoi"> DOI: 10.1080/13543776.2017.1355908</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1080%2F13543776.2017.1355908" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=28705083" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1Sgt7vK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=1305-1318&author=F.+Musumeciauthor=M.+Sannaauthor=C.+Grecoauthor=I.+Giacchelloauthor=A.+L.+Fallacaraauthor=R.+Amatoauthor=S.+Schenone&title=Pyrrolo%5B2%2C3-d%5Dpyrimidines+Active+as+Btk+Inhibitors&doi=10.1080%2F13543776.2017.1355908"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors</span></div><div class="casAuthors">Musumeci, Francesca; Sanna, Monica; Greco, Chiara; Giacchello, Ilaria; Fallacara, Anna Lucia; Amato, Rosario; Schenone, Silvia</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1305-1318</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Introduction: Btk is a tyrosine kinase dysregulated in several B-cell malignancies and autoimmune diseases, and this has given rise to a search for Btk inhibitors.  Nevertheless, only one Btk inhibitor, ibrutinib, has been approved to date, although other compds. are currently being evaluated in clin. trials or in preclinal stages.  Area covered: This review, after a brief introduction on Btk and its inhibitors already in clin. trials, focusses on pyrrolo[2,3-d]pyrimidine derivs. patented in the last five years as Btk inhibitors.  Indeed, the pyrrolo[2,3-d]pyrimidine scaffold, being a deaza-isostere of adenine, the nitrogenous base of ATP, is an actively pursued target for Btk inhibitors.  The patent literature since 2012 have been extensively investigated, pointing out the general features of the patented compds. and, when it is possible, their mechanism of action.  Expert opinion: The recently patented pyrrolo[2,3-d]pyrimidines, acting as reversible or irreversible inhibitors, showed a very interesting in vitro activity.  For this reason, the development of compds. endowed with this scaffold could afford a significant impact in the search for drug candidates for the treatment of immune diseases or B-cell malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPT0s7eVqXebVg90H21EOLACvtfcHk0lhoTNrLS1orLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1Sgt7vK&md5=294c9b8bcafe6f7831187cb963f2f072</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1080%2F13543776.2017.1355908&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2017.1355908%26sid%3Dliteratum%253Aachs%26aulast%3DMusumeci%26aufirst%3DF.%26aulast%3DSanna%26aufirst%3DM.%26aulast%3DGreco%26aufirst%3DC.%26aulast%3DGiacchello%26aufirst%3DI.%26aulast%3DFallacara%26aufirst%3DA.%2BL.%26aulast%3DAmato%26aufirst%3DR.%26aulast%3DSchenone%26aufirst%3DS.%26atitle%3DPyrrolo%255B2%252C3-d%255Dpyrimidines%2520Active%2520as%2520Btk%2520Inhibitors%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2017%26volume%3D27%26spage%3D1305%26epage%3D1318%26doi%3D10.1080%2F13543776.2017.1355908" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pompliano, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meek, T. D.</span></span> <span> </span><span class="NLM_article-title">Drug-Target Residence Time and its Implications for Lead Optimization</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">730</span>– <span class="NLM_lpage">739</span>, <span class="refDoi"> DOI: 10.1038/nrd2082</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1038%2Fnrd2082" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=16888652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BD28XptVCltro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=730-739&author=R.+A.+Copelandauthor=D.+L.+Pomplianoauthor=T.+D.+Meek&title=Drug-Target+Residence+Time+and+its+Implications+for+Lead+Optimization&doi=10.1038%2Fnrd2082"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-target residence time and its implications for lead optimization</span></div><div class="casAuthors">Copeland, Robert A.; Pompliano, David L.; Meek, Thomas D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">730-739</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Much of drug discovery today is predicated on the concept of selective targeting of particular bioactive macromols. by low-mol.-mass drugs.  The binding of drugs to their macromol. targets is therefore seen as paramount for pharmacol. activity.  In vitro assessment of drug-target interactions is classically quantified in terms of binding parameters such as IC50 or Kd.  This article presents an alternative perspective on drug optimization in terms of drug-target binary complex residence time, as quantified by the dissociative half-life of the drug-target binary complex.  We describe the potential advantages of long residence time in terms of duration of pharmacol. effect and target selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGry6SJrMlrrTbVg90H21EOLACvtfcHk0lhoTNrLS1orLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XptVCltro%253D&md5=60ede2301584b10ac4e8fa18e1e6d107</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1038%2Fnrd2082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2082%26sid%3Dliteratum%253Aachs%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26aulast%3DPompliano%26aufirst%3DD.%2BL.%26aulast%3DMeek%26aufirst%3DT.%2BD.%26atitle%3DDrug-Target%2520Residence%2520Time%2520and%2520its%2520Implications%2520for%2520Lead%2520Optimization%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D730%26epage%3D739%26doi%3D10.1038%2Fnrd2082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, R.
A.</span></span> <span> </span><span class="NLM_article-title">The Drug-Target Residence Time Model: a 10-year Retrospective,</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">87</span>– <span class="NLM_lpage">95</span>, <span class="refDoi"> DOI: 10.1038/nrd.2015.18</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1038%2Fnrd.2015.18" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=87-95&author=R.%0AA.+Copeland&title=The+Drug-Target+Residence+Time+Model%3A+a+10-year+Retrospective%2C&doi=10.1038%2Fnrd.2015.18"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2015.18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2015.18%26sid%3Dliteratum%253Aachs%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26atitle%3DThe%2520Drug-Target%2520Residence%2520Time%2520Model%253A%2520a%252010-year%2520Retrospective%252C%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2016%26volume%3D15%26spage%3D87%26epage%3D95%26doi%3D10.1038%2Fnrd.2015.18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, J. F.</span>; <span class="NLM_string-name">Walsh, C. T.</span></span> The Behavior and Significance of Slow-Binding Enzyme Inhibitors. In  <i>Advances in Enzymology and Related Areas of Molecular Biology</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meister, A.</span></span>, Ed.; <span class="NLM_publisher-name">Wiley</span>: <span class="NLM_publisher-loc">New York</span>, <span class="NLM_year">1988</span>; Vol.  <span class="NLM_volume">61</span>, pp  <span class="NLM_fpage">201</span>– <span class="NLM_lpage">301</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1002%2F9780470123072.ch5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1988&pages=201-301&author=J.+F.+Morrison&author=C.+T.+Walshauthor=A.+Meister&title=Advances+in+Enzymology+and+Related+Areas+of+Molecular+Biology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1002%2F9780470123072.ch5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9780470123072.ch5%26sid%3Dliteratum%253Aachs%26aulast%3DMorrison%26aufirst%3DJ.%2BF.%26btitle%3DAdvances%2520in%2520Enzymology%2520and%2520Related%2520Areas%2520of%2520Molecular%2520Biology%26aulast%3DMeister%26aufirst%3DA.%26pub%3DWiley%26date%3D1988%26volume%3D61%26spage%3D201%26epage%3D301" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schutt, L.</span>; <span class="NLM_string-name">Erickson, R.</span>; <span class="NLM_string-name">Tarrant, J.</span>; <span class="NLM_string-name">McDowell, M.</span>; <span class="NLM_string-name">Katewa, A.</span>; <span class="NLM_string-name">Wang, Y.</span>; <span class="NLM_string-name">Huang, T.</span>; <span class="NLM_string-name">Kennedy, W.</span>; <span class="NLM_string-name">Misner, D.</span>; <span class="NLM_string-name">Reif, K.</span></span> BTK Knockout Rat Model Demonstrates Rat-Specific BTK Inhibitor-Related Pancreatic Pathology is On-Target and Unlikely to be Relevant for Humans. Presented at  <i>35th Annual Symposium of the Society of Toxicologic Pathology</i>, San Diego, CA, June 26–29, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=L.+Schutt&author=R.+Erickson&author=J.+Tarrant&author=M.+McDowell&author=A.+Katewa&author=Y.+Wang&author=T.+Huang&author=W.+Kennedy&author=D.+Misner&author=K.+Reif&title=35th+Annual+Symposium+of+the+Society+of+Toxicologic+Pathology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DSchutt%26aufirst%3DL.%26jtitle%3D35th%2520Annual%2520Symposium%2520of%2520the%2520Society%2520of%2520Toxicologic%2520Pathology%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bender, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pereira, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grenningloh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Head, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morandi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haselmayer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu-Bujalski, L.</span></span> <span> </span><span class="NLM_article-title">Ability of Bruton’s Tyrosine Kinase Inhibitors to Sequester Y551 and Prevent Phosphorylation Determines Potency for Inhibition of Fc Receptor but not B-cell Receptor Signaling</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>91</i></span>,  <span class="NLM_fpage">208</span>– <span class="NLM_lpage">219</span>, <span class="refDoi"> DOI: 10.1124/mol.116.107037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1124%2Fmol.116.107037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=28062735" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpsFajtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2017&pages=208-219&author=A.+T.+Benderauthor=A.+Gardbergauthor=A.+Pereiraauthor=T.+Johnsonauthor=Y.+Wuauthor=R.+Grenninglohauthor=J.+Headauthor=F.+Morandiauthor=P.+Haselmayerauthor=L.+Liu-Bujalski&title=Ability+of+Bruton%E2%80%99s+Tyrosine+Kinase+Inhibitors+to+Sequester+Y551+and+Prevent+Phosphorylation+Determines+Potency+for+Inhibition+of+Fc+Receptor+but+not+B-cell+Receptor+Signaling&doi=10.1124%2Fmol.116.107037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Ability of Bruton's tyrosine kinase inhibitors to sequester Y551 and prevent phosphorylation determines potency for inhibition of Fc receptor but not B-cell receptor signaling</span></div><div class="casAuthors">Bender, Andrew T.; Gardberg, Anna; Pereira, Albertina; Johnson, Theresa; Wu, Yin; Grenningloh, Roland; Head, Jared; Morandi, Federica; Haselmayer, Philipp; Liu-Bujalski, Lesley</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">208-219</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (Btk) is expressed in a variety of hematopoietic cells.  Btk has been demonstrated to regulate signaling downstream of the B-cell receptor (BCR), Fc receptors (FcRs), and toll-like receptors.  It has become an attractive drug target because its inhibition may provide significant efficacy by simultaneously blocking multiple disease mechanisms.  Consequently, a large no. of Btk inhibitors have been developed.  These compds. have diverse binding modes, and both reversible and irreversible inhibitors have been developed.  Reported herein, we have tested nine Btk inhibitors and characterized on a mol. level how their interactions with Btk define their ability to block different signaling pathways.  By solving the crystal structures of Btk inhibitors bound to the enzyme, we discovered that the compds. can be classified by their ability to trigger sequestration of Btk residue Y551.  In cells, we found that sequestration of Y551 renders it inaccessible for phosphorylation.  The ability to sequester Y551 was an important determinant of potency against FcγR signaling as Y551 sequestering compds. were more potent for inhibiting basophils and mast cells.  This result was true for the inhibition of FcγR signaling as well.  In contrast, Y551 sequestration was less a factor in detg. potency against BCR signaling.  We also found that Btk activity is regulated differentially in basophils and B cells.  These results elucidate important determinants for Btk inhibitor potency against different signaling pathways and provide insight for designing new compds. with a broader inhibitory profile that will likely result in greater efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrN8F--ON3M7Vg90H21EOLACvtfcHk0lj7-tVUcEgVzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpsFajtr8%253D&md5=f869d52d6bc1aabf352988787ff1cbcf</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1124%2Fmol.116.107037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.116.107037%26sid%3Dliteratum%253Aachs%26aulast%3DBender%26aufirst%3DA.%2BT.%26aulast%3DGardberg%26aufirst%3DA.%26aulast%3DPereira%26aufirst%3DA.%26aulast%3DJohnson%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DGrenningloh%26aufirst%3DR.%26aulast%3DHead%26aufirst%3DJ.%26aulast%3DMorandi%26aufirst%3DF.%26aulast%3DHaselmayer%26aufirst%3DP.%26aulast%3DLiu-Bujalski%26aufirst%3DL.%26atitle%3DAbility%2520of%2520Bruton%25E2%2580%2599s%2520Tyrosine%2520Kinase%2520Inhibitors%2520to%2520Sequester%2520Y551%2520and%2520Prevent%2520Phosphorylation%2520Determines%2520Potency%2520for%2520Inhibition%2520of%2520Fc%2520Receptor%2520but%2520not%2520B-cell%2520Receptor%2520Signaling%26jtitle%3DMol.%2520Pharmacol.%26date%3D2017%26volume%3D91%26spage%3D208%26epage%3D219%26doi%3D10.1124%2Fmol.116.107037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chang, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zapatka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrientos, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steggerda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckert, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Francesco, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woyach, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Versele, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byrd, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stilgenbauer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buggy, J. J.</span></span> <span> </span><span class="NLM_article-title">Use of Tumor Genomic Profiling to Reveal Mechanisms of Resistance to the Btk Inhibitor Ibrutinib in Chronic Lymphocytic Leukemia (CLL)</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">7014</span>, <span class="refDoi"> DOI: 10.1200/jco.2013.31.15_suppl.7014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;key=10.1200%2Fjco.2013.31.15_suppl.7014" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=7014&author=B.+Y.+Changauthor=R.+R.+Furmanauthor=M.+Zapatkaauthor=J.+C.+Barrientosauthor=D.+Liauthor=S.+Steggerdaauthor=K.+Eckertauthor=M.+Francescoauthor=J.+A.+Woyachauthor=A.+J.+Johnsonauthor=D.+F.+Jamesauthor=M.+Verseleauthor=J.+C.+Byrdauthor=S.+Stilgenbauerauthor=J.+J.+Buggy&title=Use+of+Tumor+Genomic+Profiling+to+Reveal+Mechanisms+of+Resistance+to+the+Btk+Inhibitor+Ibrutinib+in+Chronic+Lymphocytic+Leukemia+%28CLL%29&doi=10.1200%2Fjco.2013.31.15_suppl.7014"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1200%2Fjco.2013.31.15_suppl.7014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252Fjco.2013.31.15_suppl.7014%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DB.%2BY.%26aulast%3DFurman%26aufirst%3DR.%2BR.%26aulast%3DZapatka%26aufirst%3DM.%26aulast%3DBarrientos%26aufirst%3DJ.%2BC.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DSteggerda%26aufirst%3DS.%26aulast%3DEckert%26aufirst%3DK.%26aulast%3DFrancesco%26aufirst%3DM.%26aulast%3DWoyach%26aufirst%3DJ.%2BA.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26aulast%3DJames%26aufirst%3DD.%2BF.%26aulast%3DVersele%26aufirst%3DM.%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DStilgenbauer%26aufirst%3DS.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26atitle%3DUse%2520of%2520Tumor%2520Genomic%2520Profiling%2520to%2520Reveal%2520Mechanisms%2520of%2520Resistance%2520to%2520the%2520Btk%2520Inhibitor%2520Ibrutinib%2520in%2520Chronic%2520Lymphocytic%2520Leukemia%2520%2528CLL%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D31%26spage%3D7014%26doi%3D10.1200%2Fjco.2013.31.15_suppl.7014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, J. J.</span>; <span class="NLM_string-name">Ortwine, D. F.</span>; <span class="NLM_string-name">Wei, B.</span>; <span class="NLM_string-name">Young, W.
B.</span></span> <i>Heteroaryl Pyridone and Aza-pyridone Compounds as Inhibitors of Btk Activity</i>. PCT International Application <span class="NLM_patent">WO 2013/067274</span>, May 10, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=J.+J.+Crawford&author=D.+F.+Ortwine&author=B.+Wei&author=W.%0AB.+Young&title=Heteroaryl+Pyridone+and+Aza-pyridone+Compounds+as+Inhibitors+of+Btk+Activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCrawford%26aufirst%3DJ.%2BJ.%26jtitle%3DHeteroaryl%2520Pyridone%2520and%2520Aza-pyridone%2520Compounds%2520as%2520Inhibitors%2520of%2520Btk%2520Activity%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span> <i>RA: Safety and Efficacy Study of GDC-0853 Compared With Placebo and
Adalimumab in Participants With Rheumatoid Arthritis (RA)</i>; ClinicalTrials.gov Identifier: NCT02833350, <a href="https://clinicaltrials.gov/ct2/show/NCT02833350" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02833350</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+RA%3A+Safety+and+Efficacy+Study+of+GDC-0853+Compared+With+Placebo+and%0AAdalimumab+in+Participants+With+Rheumatoid+Arthritis+%28RA%29%3B+ClinicalTrials.gov+Identifier%3A+NCT02833350%2C+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02833350."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DRA%253A%2520Safety%2520and%2520Efficacy%2520Study%2520of%2520GDC-0853%2520Compared%2520With%2520Placebo%2520and%250AAdalimumab%2520in%2520Participants%2520With%2520Rheumatoid%2520Arthritis%2520%2528RA%2529" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span> <i>Lupus: A Study of the Safety and Efficacy of GDC-0853
in Participants
With Moderate to Severe Active Systemic Lupus Erythematosus</i>; ClinicalTrials.gov Identifier: NCT02908100, <a href="https://clinicaltrials.gov/ct2/show/NCT02908100" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02908100</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Lupus%3A+A+Study+of+the+Safety+and+Efficacy+of+GDC-0853%0Ain+Participants%0AWith+Moderate+to+Severe+Active+Systemic+Lupus+Erythematosus%3B+ClinicalTrials.gov+Identifier%3A+NCT02908100%2C+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02908100."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DLupus%253A%2520A%2520Study%2520of%2520the%2520Safety%2520and%2520Efficacy%2520of%2520GDC-0853%250Ain%2520Participants%250AWith%2520Moderate%2520to%2520Severe%2520Active%2520Systemic%2520Lupus%2520Erythematosus" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span> <i>CSU: Efficacy and Safety of GDC-0853 in Participants
With Refractory
Chronic Spontaneous Urticaria (CSU)</i>; ClinicalTrials.gov Identifier:
NCT03137069, <a href="https://clinicaltrials.gov/ct2/show/NCT03137069" class="extLink">https://clinicaltrials.gov/ct2/show/NCT03137069</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+CSU%3A+Efficacy+and+Safety+of+GDC-0853+in+Participants%0AWith+Refractory%0AChronic+Spontaneous+Urticaria+%28CSU%29%3B+ClinicalTrials.gov+Identifier%3A%0ANCT03137069%2C+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03137069."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DCSU%253A%2520Efficacy%2520and%2520Safety%2520of%2520GDC-0853%2520in%2520Participants%250AWith%2520Refractory%250AChronic%2520Spontaneous%2520Urticaria%2520%2528CSU%2529" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5VFI" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5VFI','PDB','5VFI'); return false;">PDB: 5VFI</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-NOTES-d49e3412-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i30"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b01712">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_30018"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.7b01712">10.1021/acs.jmedchem.7b01712</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b01712/suppl_file/jm7b01712_si_001.csv">CSV</a>)</p></li><li><p class="inline">Chemistry; assay conditions; metabolic stability assays; biochemical potency of inhibitors against WT Btk and the C481S, C481R, T474I, and T474M mutants; kinase selectivity of Btk inhibitors; GDC-0853 residence time assay; developing rat collagen induced arthritis study (CIA); cytotoxicity prediction computational model; quantum torsion scan of the GDC-0853 piperazine-to-pyridyl bond; physicochemical properties of GDC-0853; <i>in vitro</i> safety profiling methods; protein purification, crystallographic methods, and crystallographic parameters of X-ray structure of <b>29</b>, GDC-0853, bound to Btk) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b01712/suppl_file/jm7b01712_si_002.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01712/suppl_file/jm7b01712_si_001.csv">jm7b01712_si_001.csv (3.03 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b01712/suppl_file/jm7b01712_si_002.pdf">jm7b01712_si_002.pdf (945.63 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">The authors will release the coordinates and experimental data upon article publication, PDB accession code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5VFI">5VFI</a></p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2018.61.issue-6%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.7b01712" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.7b01712" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                5MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67998febf85425a5","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
